FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Ribeiro, CRD
   Martinelli, KG
   de Mello, VD
   Baptista, BD
   Dias, NST
   Paiva, IA
   Lewis-Ximenez, LL
   Pinto, LMD
   de Paula, VS
AF Ribeiro, Camilla Rodrigues de Almeida
   Martinelli, Katrini Guidolini
   de Mello, Vinicius da Motta
   Baptista, Bruna da Silva
   Dias, Natalia Spitz Toledo
   Paiva, Iury Amancio
   Lewis-Ximenez, Lia Laura
   Pinto, Luzia Maria de Oliveira
   de Paula, Vanessa Salete
TI Cytokine, Genotype, and Viral Load Profile in the Acute and Chronic
   Hepatitis B
SO VIRAL IMMUNOLOGY
LA English
DT Article; Early Access
DE hepatitis B; cytokines; immune response
ID NATURAL-HISTORY; DISEASE PROGRESSION; GENE-EXPRESSION; IMMUNE-RESPONSE;
   VIRUS GENOTYPES; T-CELLS; HBV; INFECTION; INTERLEUKIN-35; CIRRHOSIS
AB Several hepatitis B virus (HBV) factors, including viral load, genotype, genome mutations, and cytokine production, have been reported to be associated with different risks of progression of liver disease. The aim of this study was to verify if there is an association among the levels of cytokines (interleukin [IL]-35, IL-6, IL-17A, interferon [IFN]-gamma) in the plasma, viral load, and the different genotypes of HBV in patients with acute or chronic hepatitis B. Methods: 49 serum samples, 20 from acute and 29 from chronic cases, were submitted to a real-time and nested-polymerase chain reaction to quantify, detect, and genotype HBV DNA. The cytokines IL-35, IL-6, IL-17A, and IFN-gamma were detected by an enzyme-linked immunosorbent assay (ELISA). The median viral load was 3.15 log(10)IU DNA/mL and 2.90 log(10)IU DNA/mL for acute and chronic patients, respectively. Genotype A, D, E, and F were identified in chronic carriers of HBV infection, while only genotype A and F were identified in individuals with acute infection. IFN-gamma(p = 0.024) and IL-17A (p = 0.046) levels were significantly increased in chronic patients and IL-6 and IL-35 were higher in patients with acute infection, however, without statistical difference. IL-17A and IFN-gamma can be modulating proinflammatory effects and inducing hepatocellular damage, in chronic patients, and IL-6 and IL-35 may be involved in viral elimination and protection against chronicity during the acute phase of infection. These results can contribute to understanding of the complex regulatory mechanisms of the host antiviral response related to cytokine production during acute and chronic HBV infection.
C1 [Ribeiro, Camilla Rodrigues de Almeida; Dias, Natalia Spitz Toledo; de Paula, Vanessa Salete] Fundacao Oswaldo Cruz, Oswaldo Cruz Inst, Lab Mol Virol, 4365 Brasil Ave, BR-21040360 Manguinho, RJ, Brazil.
   [Martinelli, Katrini Guidolini] Univ Fed Espirito Santo, Dept Social Med, Espirito Santo, Brazil.
   [de Mello, Vinicius da Motta; Baptista, Bruna da Silva; Lewis-Ximenez, Lia Laura] Fundacao Oswaldo Cruz, Oswaldo Cruz Inst, Lab Viral Hepatitis, Rio De Janeiro, Brazil.
   [Paiva, Iury Amancio; Pinto, Luzia Maria de Oliveira] Fundacao Oswaldo Cruz, Oswaldo Cruz Inst, Lab Viral Immunol, Rio De Janeiro, Brazil.
RP de Paula, VS (corresponding author), Fundacao Oswaldo Cruz, Oswaldo Cruz Inst, Lab Mol Virol, 4365 Brasil Ave, BR-21040360 Manguinho, RJ, Brazil.
EM vdepaula@ioc.fiocruz.br
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brasil
   (CAPES)CAPES [001]; Fundacao de Amparo a Pesquisa do Estado do Rio de
   Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research Support of
   the State of Rio de Janeiro (FAPERJ); Oswaldo Cruz Institute
FX This study was financed by the Coordenacao de Aperfeicoamento de Pessoal
   de Nivel Superior-Brasil (CAPES)-Finance Code 001, Fundacao de Amparo a
   Pesquisa do Estado do Rio de Janeiro (FAPERJ) and Oswaldo Cruz Institute
   who approved the project and funded the research with scholarship and
   grants.
CR Abara WE, 2017, ANN INTERN MED, V167, P794, DOI 10.7326/M17-1106
   Abbas AK, 2007, CELL MOL IMMUNOL, P251
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Bao SX, 2017, MOL MED REP, V16, P3713, DOI 10.3892/mmr.2017.7044
   Bertoletti A, 2006, J GEN VIROL, V87, P1439, DOI 10.1099/vir.0.81920-0
   Bertoletti A, 2012, GUT, V61, P1754, DOI 10.1136/gutjnl-2011-301073
   Bouezzedine F, 2015, VIROLOGY, V481, P34, DOI 10.1016/j.virol.2015.02.026
   Butler EK, 2018, HEPATOLOGY, V68, P2106, DOI 10.1002/hep.30082
   Chang JJ, 2005, J VIROL, V79, P3038, DOI 10.1128/JVI.79.5.3038-3051.2005
   Cho HJ, 2017, CYTOKINE, V95, P118, DOI 10.1016/j.cyto.2017.02.020
   Du WJ, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-40
   Elkhawaga Amal A, 2019, Egypt J Immunol, V26, P55
   European Assoc Study Liver, 2017, J HEPATOL, V67, P370, DOI 10.1016/j.jhep.2017.03.021
   Fenoglio D, 2012, AUTOIMMUN REV, V12, P300, DOI 10.1016/j.autrev.2012.05.004
   FERRARI C, 1990, J IMMUNOL, V145, P3442
   Fields BN, 2013, FIELDS VIROLOGY, P2456
   Gao YH, 2017, J CLIN MICROBIOL, V55, P2972, DOI 10.1128/JCM.00760-17
   Gomes SA, 2008, INTRO VIROLOGIA HUMA
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Hosel M, 2009, HEPATOLOGY, V50, P1773, DOI 10.1002/hep.23226
   Huang ZM, 2012, LIVER INT, V32, P894, DOI 10.1111/j.1478-3231.2012.02764.x
   Jung MC, 1999, VIROLOGY, V261, P165, DOI 10.1006/viro.1999.9833
   LAGO BV, 2019, VIRUSES-BASEL, V11, DOI DOI 10.3390/v11090860
   Lamontagne R Jason, 2016, Hepatoma Res, V2, P163, DOI 10.20517/2394-5079.2016.05
   Lampe E, 2017, J GEN VIROL, V98, P1389, DOI 10.1099/jgv.0.000789
   Li H, 2020, ADV EXP MED BIOL, V1179, P1, DOI 10.1007/978-981-13-9151-4_1
   Lian JQ, 2014, HEPAT MON, V14, DOI 10.5812/hepatmon.18892
   Liaw YF, 1997, VIRAL HEP REV, V3, P143
   Lin CL, 2017, BEST PRACT RES CL GA, V31, P249, DOI 10.1016/j.bpg.2017.04.010
   Lin FC, 2014, CYTOKINE GROWTH F R, V25, P369, DOI 10.1016/j.cytogfr.2014.07.015
   Liu SQ, 2017, INT IMMUNOPHARMACOL, V50, P87, DOI 10.1016/j.intimp.2017.06.015
   Lopes T. G. S. L., 2011, Revista de Ciencias Medicas e Biologicas, V10, P337
   Manno M, 2004, GASTROENTEROLOGY, V127, P756, DOI 10.1053/j.gastro.2004.06.021
   McMahon Brian J, 2008, Medscape J Med, V10, P91
   Mello FCA, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-103
   Nita ME, 2009, ANN HEPATOL, V8, P339
   Pungpapong S, 2007, MAYO CLIN PROC, V82, P967, DOI 10.4065/82.8.967
   Sarkar N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141741
   Schaefer S, 2007, WORLD J GASTROENTERO, V13, P14, DOI 10.3748/wjg.v13.i1.14
   Shao X, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00472
   Shi M, 2015, MOL MED REP, V11, P121, DOI 10.3892/mmr.2014.2681
   Shimizu I, 2007, WORLD J GASTROENTERO, V13, P4295, DOI 10.3748/wjg.v13.i32.4295
   Sobao Y, 2002, J HEPATOL, V36, P105, DOI 10.1016/S0168-8278(01)00264-1
   Stein Lance L., 2009, Infectious Disorders - Drug Targets, V9, P105
   Sunbul M, 2014, WORLD J GASTROENTERO, V20, P5427, DOI 10.3748/wjg.v20.i18.5427
   Tang LSY, 2018, JAMA-J AM MED ASSOC, V319, P1802, DOI 10.1001/jama.2018.3795
   Terrault Norah A, 2018, Clin Liver Dis (Hoboken), V12, P33, DOI 10.1002/cld.728
   Valaydon ZS, 2017, BEST PRACT RES CL GA, V31, P257, DOI 10.1016/j.bpg.2017.04.013
   Valente F, 2010, MEM I OSWALDO CRUZ, V105, P970, DOI 10.1590/S0074-02762010000800004
   Villar Livia Melo, 2015, World J Virol, V4, P323, DOI 10.5501/wjv.v4.i4.323
   Wang J, 2016, J HEPATOL, V65, P700, DOI 10.1016/j.jhep.2016.05.029
   Wang L, 2016, J BIOL CHEM, V291, P16863, DOI 10.1074/jbc.M115.693101
   World Health Organization, 2017, GLOBAL HEPATITIS REP
   Wu W, 2010, J GASTROEN HEPATOL, V25, P750, DOI 10.1111/j.1440-1746.2009.06154.x
   Xia YC, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9010018
   Yang J, 2007, J MED VIROL, V79, P1741, DOI 10.1002/jmv.20983
   Zhang JY, 2010, HEPATOLOGY, V51, P81, DOI 10.1002/hep.23273
   Zu Siederdissen CH, 2018, J VIRAL HEPATITIS, V25, P1226, DOI 10.1111/jvh.12993
NR 58
TC 0
Z9 0
U1 2
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0882-8245
EI 1557-8976
J9 VIRAL IMMUNOL
JI Viral Immunol.
DI 10.1089/vim.2020.0176
EA OCT 2020
PG 8
WC Immunology; Virology
SC Immunology; Virology
GA OJ4KI
UT WOS:000583932100001
PM 33090087
DA 2020-11-30
ER

PT J
AU Henss, L
   Yue, C
   Von Rhein, C
   Tschismarov, R
   Lewis-Ximenez, LL
   Dolle, A
   Baylis, SA
   Schnierle, BS
AF Henss, Lisa
   Yue, Constanze
   Von Rhein, Christine
   Tschismarov, Roland
   Lewis-Ximenez, Lia Laura
   Doelle, Albert
   Baylis, Sally A.
   Schnierle, Barbara S.
TI Analysis of Humoral Immune Responses in Chikungunya Virus
   (CHIKV)-Infected Patients and Individuals Vaccinated With a Candidate
   CHIKV Vaccine
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE alphavirus; antibody; chikungunya; neutralization
ID MONOCLONAL-ANTIBODIES; EPITOPE; E2; PROTEINS; ENTRY
AB Background. Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes severe flu-like symptoms. The acute symptoms disappear after 1 week, but chronic arthralgia can persist for years. In this study, humoral immune responses in CHIKV-infected patients and vaccinees were analyzed.
   Methods. Alphavirus neutralization activity was analyzed with pseudotyped lentiviral vectors, and antibody epitope mapping was performed with a peptide array.
   Results. The greatest CHIKV neutralization activity was observed 60-92 days after onset of symptoms. The amount of CHIKV-specific antibodies and their binding avidity and cross-reactivity with other alphaviruses increased over time. Chikungunya virus and o'nyong-nyong virus (ONNV) were both neutralized to a similar extent. Linear antibody binding epitopes were mainly found in E2 domain B and the acid-sensitive regions (ASRs). In addition, serum samples from healthy volunteers vaccinated with a measles-vectored chikungunya vaccine candidate, MV-CHIK, were analyzed. Neutralization activity in the samples from the vaccine cohort was 2- to 6-fold lower than in samples from CHIKV-infected patients. In contrast to infection, vaccination only induced cross-neutralization with ONNV, and the E2 ASR1 was the major antibody target.
   Conclusions. These data could assist vaccine design and enable the identification of correlates of protection necessary for vaccine efficacy.
C1 [Henss, Lisa; Yue, Constanze; Von Rhein, Christine; Baylis, Sally A.; Schnierle, Barbara S.] Paul Ehrlich Inst, Dept Virol, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.
   [Tschismarov, Roland] Themis Biosci GmbH, Vienna, Austria.
   [Lewis-Ximenez, Lia Laura] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
RP Schnierle, BS (corresponding author), Paul Ehrlich Inst, Dept Virol, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.
EM barbara.schnierle@pei.de
FU German Ministry of Health (Bundesministerium fur Gesundheit) [ZMV
   I1-2517 FSB 413]
FX This work was funded by the German Ministry of Health (Bundesministerium
   fur Gesundheit) (ZMV I1-2517 FSB 413) by a grant to S. A. B. and B. S.
   S.
CR Acres B, 2008, EXPERT REV VACCINES, V7, P889, DOI 10.1586/14760584.7.7.889
   Basore K, 2019, CELL, V177, P1725, DOI 10.1016/j.cell.2019.04.006
   BLACKBURN NK, 1995, RES VIROLOGY, V146, P69, DOI 10.1016/0923-2516(96)80591-7
   Brehin AC, 2008, VIROLOGY, V371, P185, DOI 10.1016/j.virol.2007.09.028
   Broeckel R, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005637
   Burt FJ, 2017, LANCET INFECT DIS, V17, pE107, DOI 10.1016/S1473-3099(16)30385-1
   Chua CL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171989
   DIETZGEN RG, 1987, J VIROL METHODS, V15, P159, DOI 10.1016/0166-0934(87)90059-0
   Fong RH, 2014, J VIROL, V88, P14364, DOI 10.1128/JVI.01943-14
   Fox JM, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aav5062
   Fox JM, 2015, CELL, V163, P1095, DOI 10.1016/j.cell.2015.10.050
   Hallengard D, 2014, J VIROL, V88, P13333, DOI 10.1128/JVI.01926-14
   Hasan SS, 2018, CELL REP, V25, P3136, DOI 10.1016/j.celrep.2018.11.067
   Henss L, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010082
   Itoh M, 2002, J CLIN MICROBIOL, V40, P1733, DOI 10.1128/JCM.40.5.1733-1738.2002
   Jin J, 2015, CELL REP, V13, P2553, DOI 10.1016/j.celrep.2015.11.043
   Kam YW, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003445
   Kam YW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095647
   Kam YW, 2012, J VIROL, V86, P13005, DOI 10.1128/JVI.01780-12
   Kam YW, 2012, EMBO MOL MED, V4, P330, DOI 10.1002/emmm.201200213
   Kam YW, 2012, J INFECT DIS, V205, P1147, DOI 10.1093/infdis/jis033
   Kielian M, 2015, CELL, V163, P1053, DOI 10.1016/j.cell.2015.11.006
   Li L, 2010, NATURE, V468, P705, DOI 10.1038/nature09546
   Lum FM, 2013, J IMMUNOL, V190, P6295, DOI 10.4049/jimmunol.1300304
   Martins KA, 2019, AM J TROP MED HYG, V100, P1541, DOI 10.4269/ajtmh.18-0756
   Milligan GN, 2019, VACCINE, V37, P7427, DOI 10.1016/j.vaccine.2018.10.033
   Miner JJ, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah3438
   Pal P, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003312
   Partidos CD, 2012, VACCINE, V30, P4638, DOI 10.1016/j.vaccine.2012.04.099
   Prat CM, 2014, EMERG INFECT DIS, V20, P2129, DOI 10.3201/eid2012.141269
   Reisinger EC, 2018, LANCET, V392, P2718, DOI 10.1016/S0140-6736(18)32488-7
   Remoli ME, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftu002
   Rossi SL, 2019, J INFECT DIS, V220, P735, DOI 10.1093/infdis/jiz202
   Schwartz O, 2010, NAT REV MICROBIOL, V8, P491, DOI 10.1038/nrmicro2368
   Selvarajah S, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002423
   Smith JL, 2018, MSPHERE, V3, DOI [10.1128/mSphere.00003-18, 10.1128/msphere.00003-18]
   Smith SA, 2015, CELL HOST MICROBE, V18, P86, DOI 10.1016/j.chom.2015.06.009
   Song H, 2019, CELL, V177, P1714, DOI 10.1016/j.cell.2019.04.008
   Voss JE, 2010, NATURE, V468, P709, DOI 10.1038/nature09555
   Weber C, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003684
   Yoon IK, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003764
NR 41
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAY 15
PY 2020
VL 221
IS 10
BP 1713
EP 1723
DI 10.1093/infdis/jiz658
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA LU0FK
UT WOS:000537439000018
PM 31828322
DA 2020-11-30
ER

PT J
AU Cruz, HM
   de Paula, VS
   Cruz, JCM
   do O, KMR
   Milagres, FAP
   Bastos, FI
   Mota, JC
   Cruz, MS
   de Andrade, TM
   Pollo-Flores, P
   Leal, E
   Motta-Castro, ARC
   Ivantes, CAP
   Bezerra, CS
   Barbosa, JR
   Cruz, JNM
   Lewis-Ximenez, LL
   Villar, LM
AF Cruz, Helena Medina
   de Paula, Vanessa Salete
   Miguel Cruz, Juliana Custodio
   Rodrigues do O, Kycia Maria
   Padua Milagres, Flavio Augusto
   Bastos, Francisco Inacio
   Mota, Jurema Correa
   Cruz, Marcelo Santos
   de Andrade, Tarcisio Matos
   Pollo-Flores, Priscila
   Leal, Erotildes
   Coimbra Motta-Castro, Ana Rita
   Pontes Ivantes, Claudia Alexandra
   Bezerra, Cristianne Sousa
   Barbosa, Jakeline Ribeiro
   Monte Cruz, Jose Napoleao
   Lewis-Ximenez, Lia Laura
   Villar, Livia Melo
TI Evaluation of accuracy of hepatitis B virus antigen and antibody
   detection and relationship between epidemiological factors using dried
   blood spot
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE Dried blood spot; Diagnosis; Hepatitis B; Enzyme immunoassay
ID SAMPLES; ASSAYS; HBSAG
AB Dried blood spots (DBS) testing might increase the access for Hepatitis B virus (HBV) diagnosis, but little is known about the performance of these assays in real life conditions. This study aims to evaluate the diagnostic accuracy of HBsAg, anti-HBc and anti-HBs detection in DBS in clinical settings and field studies and to evaluate demographic and risk behaviour according the presence of HBsAg and anti-HBc. Paired sera and DBS samples were obtained from 2309 individuals from 3 groups, defined as follows: G1: clinical setting (n = 5-19), G2: general population (n = 1305) and G3: vulnerable individuals that could be more exposed to blood contact (n = 485). Sera and DBS were tested using commercial enzyme immunoassay (EIA), with some modifications added. Using DBS samples, the specificity values were above 90 % for HBsAg and anti-HBc in all groups and for anti-HBs range from 58.6%-85%. HBsAg testing had the best performance in GI (sensitivity = 84.4 %) and among those samples that the paired serum also presented anti-HBc marker (sensitivity = 91.6 %). High sensitivity of anti-HBc testing in DBS samples was observed in GI (80.8 %) and among HBV active cases (HBsAg + /anti-HBc +) (98.4 %). Testing of anti-HBs in DBS showed the highest sensitivity in GIII (65.5 %), in previous HBV exposed and cured individuals and when serum titers were above 100 IU/mL (86.7 %). DBS samples could be used for screening and prevalence studies for HBsAg and anti-HBc, particularly in clinical settings and among HBV active cases in field studies.
C1 [Cruz, Helena Medina; Miguel Cruz, Juliana Custodio; Bezerra, Cristianne Sousa; Barbosa, Jakeline Ribeiro; Lewis-Ximenez, Lia Laura; Villar, Livia Melo] Fiocruz MS, Lab Viral Hepatitis, Oswaldo Cruz Inst, Rio De Janeiro, Brazil.
   [de Paula, Vanessa Salete] Fiocruz MS, Mol Virol Lab, Oswaldo Cruz Inst, Rio De Janeiro, Brazil.
   [Rodrigues do O, Kycia Maria] Sao Lucas Hosp, Petropolis, RJ, Brazil.
   [Padua Milagres, Flavio Augusto] Fed Univ Tocantins, Med Fac, Palmas, Brazil.
   [Bastos, Francisco Inacio; Mota, Jurema Correa] Fundacao Oswaldo Cruz, Inst Commun & Sci Informat & Technol Hlth, Rio De Janeiro, Brazil.
   [Cruz, Marcelo Santos] Univ Fed Rio de Janeiro, Inst Psychiat, Rio De Janeiro, Brazil.
   [de Andrade, Tarcisio Matos] Univ Fed Bahia, Med Fac, Salvador, BA, Brazil.
   [Pollo-Flores, Priscila] Fed Fluminense Univ, Antonio Pedro Univ Hosp, Rio De Janeiro, Brazil.
   [Leal, Erotildes] Univ Fed Rio de Janeiro, Fac Med, Rio De Janeiro, Brazil.
   [Coimbra Motta-Castro, Ana Rita] Univ Fed Mato Grosso do Sul, Campo Grande, MS, Brazil.
   [Coimbra Motta-Castro, Ana Rita] FIOCRUZ MS, Campo Grande, MS, Brazil.
   [Pontes Ivantes, Claudia Alexandra] Orientat & Counselling Ctr, Curitiba, Parana, Brazil.
   [Bezerra, Cristianne Sousa] Inst Fed Ciencia & Tecnol Ceara, Fortaleza, Ceara, Brazil.
   [Barbosa, Jakeline Ribeiro] Fiocruz MS, Brasilia, DF, Brazil.
   [Monte Cruz, Jose Napoleao] Cent Lab Publ Hlth Ceara, Fortaleza, Ceara, Brazil.
RP Villar, LM (corresponding author), Fiocruz MS, Lab Viral Hepatitis, Oswaldo Cruz Inst, Rio De Janeiro, Brazil.
EM liviafiocruz@gmail.com
RI Barbosa, Jakeline/AAC-9805-2020; de Paula, Vanessa S/I-8037-2016
OI Barbosa, Jakeline/0000-0001-6238-7173; de Paula, Vanessa
   S/0000-0002-6314-754X; Mota, Jurema/0000-0002-5007-1590; Milagres,
   Flavio/0000-0002-6889-8772; Motta-Castro, Ana Rita/0000-0003-3070-1337
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Brazilian National Counsel of Technological and
   Scientific Development (CNPq)National Council for Scientific and
   Technological Development (CNPq); Higher Education Personnel Improvement
   Coordination (CAPES)CAPES
FX The authors wish to thank, Elisangela Ferreira da Silva, Leticia de
   Paula Scalioni, Renata Tourinho dos Santos, Jaqueline Correia de
   Oliveira for technical assistance in the sample collection. We would
   like to thank financial support by the Fundacao de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ), Brazilian National Counsel of
   Technological and Scientific Development (CNPq), and Higher Education
   Personnel Improvement Coordination (CAPES).
CR Dokubo EK, 2014, J CLIN VIROL, V59, P223, DOI 10.1016/j.jcv.2014.01.014
   Flores GL, 2017, J VIROL METHODS, V247, P32, DOI 10.1016/j.jviromet.2017.05.004
   Forbi JC, 2010, ANN AFR MED, V9, P44, DOI 10.4103/1596-3519.62625
   Gruner N, 2015, JOVE-J VIS EXP, DOI 10.3791/52619
   Kania D, 2013, CLIN MICROBIOL INFEC, V19, pE533, DOI 10.1111/1469-0691.12292
   Lee CE, 2011, ANN ACAD MED SINGAP, V40, P448
   Marques BLC, 2012, J MED VIROL, V84, P1600, DOI 10.1002/jmv.23379
   Mason LMK, 2019, J VIRAL HEPATITIS, V26, P1431, DOI 10.1111/jvh.13182
   Mayer TK, 2012, BMC CLIN PATHOL, V12, DOI 10.1186/1472-6890-12-8
   Mohamed S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061077
   Mossner BK, 2016, WORLD J GASTROENTERO, V22, P7604, DOI 10.3748/wjg.v22.i33.7604
   Nazzal Zaher, 2014, BMC Res Notes, V7, P190, DOI 10.1186/1756-0500-7-190
   Ross RS, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-72
   Stene-Johansen K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166201
   United Nations, 2015, TRANSF OUR WORLD 203
   Villar Livia Melo, 2019, BMC Res Notes, V12, P523, DOI 10.1186/s13104-019-4547-y
   Villar LM, 2019, CAN J GASTROENTEROL, V2019, DOI 10.1155/2019/5672795
   Villar Livia Melo, 2015, World J Virol, V4, P323, DOI 10.5501/wjv.v4.i4.323
   Villar LM, 2011, J MED VIROL, V83, P1522, DOI 10.1002/jmv.22138
   World Health Organization, 2018, HEP B
   World Health Organization, 2017, GUID HEP B C TEST
   Pereira VRZB, 2017, MEM I OSWALDO CRUZ, V112, P544, DOI 10.1590/0074-02760170043
NR 22
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD MAR
PY 2020
VL 277
AR 113798
DI 10.1016/j.jviromet.2019.113798
PG 9
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA KM6NT
UT WOS:000514255500005
PM 31837375
DA 2020-11-30
ER

PT J
AU Chen, DY
   Wolski, D
   Aneja, J
   Matsubara, L
   Robilotti, B
   Hauck, G
   de Sousa, PSF
   Subudhi, S
   Fernandes, CA
   Hoogeveen, RC
   Kim, AY
   Lewis-Ximenez, L
   Lauer, GM
AF Chen, Diana Y.
   Wolski, David
   Aneja, Jasneet
   Matsubara, Lyndon
   Robilotti, Brandon
   Hauck, Garrett
   Fonseca de Sousa, Paulo Sergio
   Subudhi, Sonu
   Fernandes, Carlos Augusto
   Hoogeveen, Ruben C.
   Kim, Arthur Y.
   Lewis-Ximenez, Lia
   Lauer, Georg M.
TI Hepatitis C virus specific CD4(+) T cell phenotype and function in
   different infection outcomes
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID PD-1 EXPRESSION; CD8(+); ASSOCIATION; DYSFUNCTION; RESPONSES; SURVIVAL
AB CD4(+) T cell failure is a hallmark of chronic hepatitis C virus (HCV) infection. However, the mechanisms underlying the impairment and loss of virus-specific CD4(+) T cells in persisting HCV infection remain unclear. Here we examined HCV-specific CD4(+) T cells longitudinally during acute infection with different infection outcomes. We found that HCV-specific CD4(+) T cells are characterized by expression of a narrower range of T cell inhibitory receptors compared with CD8(+) T cells, with initially high expression levels of PD-1 and CTLA-4 that were associated with negative regulation of proliferation in all patients, irrespective of outcome. In addition, HCV-specific CD4(+) T cells were phenotypically similar during early resolving and persistent infection and secreted similar levels of cytokines. However, upon viral control, CD4(+) T cells quickly downregulated inhibitory receptors and differentiated into long-lived memory cells. In contrast, persisting viremia continued to drive T cell activation and PD-1 and CTLA-4 expression, and blocked T cell differentiation, until the cells quickly disappeared from the circulation. Our data support an important and physiological role for inhibitory receptor-mediated regulation of CD4(+) T cells in early HCV infection, irrespective of outcome, with persistent HCV viremia leading to sustained upregulation of PD-1 and CTLA-4.
C1 [Chen, Diana Y.; Wolski, David; Aneja, Jasneet; Matsubara, Lyndon; Robilotti, Brandon; Hauck, Garrett; Subudhi, Sonu; Hoogeveen, Ruben C.; Lauer, Georg M.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
   [Aneja, Jasneet; Kim, Arthur Y.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
   [Aneja, Jasneet; Kim, Arthur Y.] Harvard Med Sch, Boston, MA 02115 USA.
   [Fonseca de Sousa, Paulo Sergio; Lewis-Ximenez, Lia] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Viral Hepatitis Lab, Rio De Janeiro, Brazil.
   [Fernandes, Carlos Augusto] Noel Nutels Cent Publ Hlth Lab, Rio De Janeiro, Brazil.
RP Lauer, GM (corresponding author), 55 Fruit St, Boston, MA 02114 USA.
EM glauer@mgh.harvard.edu
RI Subudhi, Sonu/L-8509-2019
OI Subudhi, Sonu/0000-0002-5937-1880
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01 AI105035, U01 AI131314, U19
   AI066345, U19 AI082630, R01 DA046277]
FX This work was funded by NIH grants R01 AI105035 (to GML), U01 AI131314
   and U19 AI066345 (to AYK, LLX, and GML), and U19 AI082630 and R01
   DA046277 (to AYK and GML).
CR Abdel-Hakeem MS, 2014, GASTROENTEROLOGY, V147, P870, DOI 10.1053/j.gastro.2014.07.005
   Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444
   Bengsch B, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000947
   Crawford A, 2014, IMMUNITY, V40, P289, DOI 10.1016/j.immuni.2014.01.005
   Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115
   Duggal P, 2013, ANN INTERN MED, V158, P235, DOI 10.7326/0003-4819-158-4-201302190-00003
   Gerlach JT, 1999, GASTROENTEROLOGY, V117, P933, DOI 10.1016/S0016-5085(99)70353-7
   Grakoui A, 2003, SCIENCE, V302, P659, DOI 10.1126/science.1088774
   Gruener NH, 2001, J VIROL, V75, P5550, DOI 10.1128/JVI.75.12.5550-5558.2001
   Kared H, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003422
   Kasprowicz V, 2008, J VIROL, V82, P3154, DOI 10.1128/JVI.02474-07
   Kaufmann DE, 2007, NAT IMMUNOL, V8, P1246, DOI 10.1038/ni1515
   Petrovas C, 2007, BLOOD, V110, P928, DOI 10.1182/blood-2007-01-069112
   Petrovas C, 2006, J EXP MED, V203, P2281, DOI 10.1084/jem.20061496
   Petrovas C, 2009, J IMMUNOL, V183, P1120, DOI 10.4049/jimmunol.0900182
   Raziorrouh B, 2011, GASTROENTEROLOGY, V141, P1422, DOI 10.1053/j.gastro.2011.07.004
   Schlaphoff V, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002045
   zur Wiesch JS, 2005, J IMMUNOL, V175, P3603, DOI 10.4049/jimmunol.175.6.3603
   zur Wiesch JS, 2012, J EXP MED, V209, P61, DOI 10.1084/jem.20100388
NR 19
TC 6
Z9 5
U1 0
U2 1
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD FEB 3
PY 2020
VL 130
IS 2
BP 768
EP 773
DI 10.1172/JCI126277
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA KK0BS
UT WOS:000512418100027
PM 31904582
OA Green Published
DA 2020-11-30
ER

PT J
AU Tonnerre, P
   Melgaco, JG
   Torres-Cornejo, A
   Pinto, MA
   Yue, C
   Blumel, J
   de Sousa, PSF
   de Mello, VD
   Moran, J
   de Filippis, AMB
   Wolski, D
   Grifoni, A
   Sette, A
   Barouch, DH
   Hoogeveen, RC
   Baylis, SA
   Lauer, GM
   Lewis-Ximenez, LL
AF Tonnerre, Pierre
   Melgaco, Juliana G.
   Torres-Cornejo, Almudena
   Pinto, Marcelo A.
   Yue, Constanze
   Bluemel, Johannes
   Fonseca de Sousa, Paulo Sergio
   de Mello, Vinicius da Motta
   Moran, Julio
   Bispo de Filippis, Ana M.
   Wolski, David
   Grifoni, Alba
   Sette, Alessandro
   Barouch, Dan H.
   Hoogeveen, Ruben C.
   Baylis, Sally A.
   Lauer, Georg M.
   Lewis-Ximenez, Lia L.
TI Evolution of the innate and adaptive immune response in women with acute
   Zika virus infection
SO NATURE MICROBIOLOGY
LA English
DT Article
ID ANTIBODY-DEPENDENT ENHANCEMENT; T-CELL RESPONSES; CROSS-REACTIVITY;
   DENGUE VIRUS; TRANSMISSION; RHESUS; MONOCYTES; TARGET; BRAZIL
AB Zika virus (ZIKV) is a flavivirus that is closely related to other human pathogens, such as dengue virus (DENV)(1). Primary transmission usually involves Aedes aegypti, which has expanded its distribution range considerably(2), although rarer infection routes, including mother-to-fetus transmission, sexual contact and blood transfusion, have also been observed(3-7). Primary ZIKV infection is usually asymptomatic or mild in adults, with quickly resolved blood viraemia, but ZIKV might persist for months in saliva, urine, semen, breast milk and the central nervous system(8-12). During a recent ZIKV outbreak in South America, substantial numbers of neurological complications, such as Guillain-Barre syndrome, were reported(13,14) together with cases of microcephaly and associated developmental problems in infants born to women infected with ZIKV during pregnancy(15-20), highlighting the clinical importance of this infection. Analyses of the human immune response to ZIKV are lacking(21-28), but the recent outbreak has provided an opportunity to assess ZIKV immunity using current immunological methods. Here, we comprehensively assess the acute innate and adaptive immune response to ZIKV infection in ten women who were recruited during early infection and followed through reconvalescence. We define a cascade of events that lead to immunological control of ZIKV, with previous exposure to DENV impacting some, but not all, mediators of antiviral immunity.
C1 [Tonnerre, Pierre; Melgaco, Juliana G.; Torres-Cornejo, Almudena; Wolski, David; Hoogeveen, Ruben C.; Lauer, Georg M.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
   [Melgaco, Juliana G.; Pinto, Marcelo A.; Fonseca de Sousa, Paulo Sergio; de Mello, Vinicius da Motta; Bispo de Filippis, Ana M.; Lewis-Ximenez, Lia L.] Harvard Med Sch, Boston, MA 02115 USA.
   [Yue, Constanze; Bluemel, Johannes; Lewis-Ximenez, Lia L.] Fiocruz MS, Oswaldo Cruz Inst, Rio De Janeiro, Brazil.
   [Moran, Julio] Paul Ehrlich Inst, Div Virol, Langen, Germany.
   [Grifoni, Alba; Sette, Alessandro] Dr Julio Moran Labs, Zurich, Switzerland.
   [Sette, Alessandro] La Jolla Inst Immunol, Div Vaccine Discovery, La Jolla, CA USA.
   [Barouch, Dan H.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
   [Barouch, Dan H.] Ragon Inst MGH MIT & Harvard, Cambridge, MA USA.
   [Barouch, Dan H.] Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02215 USA.
   [Tonnerre, Pierre] Inst Pasteur, Biodivers & Epidemiol Bacterial Pathogens, Paris, France.
   [Melgaco, Juliana G.] Fiocruz MS, Immunobiol Technol Inst, Biomanguinhos, Rio De Janeiro, Brazil.
RP Lauer, GM (corresponding author), Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.; Lewis-Ximenez, LL (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Lewis-Ximenez, LL (corresponding author), Fiocruz MS, Oswaldo Cruz Inst, Rio De Janeiro, Brazil.
EM glauer@mgh.harvard.edu; lialewis.fiocruz@gmail.com
RI Melgaco, Juliana/AAQ-6084-2020; Tonnerre, Pierre/AAA-1631-2020
OI Melgaco, Juliana/0000-0003-0087-6531; Tonnerre,
   Pierre/0000-0002-1719-9736; Mello, Vinicius/0000-0001-7705-5921
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [U01 AI131314, U19
   AI066345, HHSN27220140045C, 1PO1AI106695-01A1, U19AI118626-01,
   75N9301900065]; EUEuropean Union (EU) [734584]; Conselho Nacional de
   Desenvolvimento TecnologicoNational Council for Scientific and
   Technological Development (CNPq) [CNPq 470092/2014-9, 200099/2016-7];
   Fundacao de Amparo a Pesquisa do Estado do Rio de JaneiroCarlos Chagas
   Filho Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ) [Faperj E-26/202.930/2016]; 'Sicherheit von Blut(produkten) und
   Geweben hinsichtlich der Abwesenheit von Zikaviren' from the German
   Ministry of Health
FX We thank the patients as well as the physicians and medical staff of the
   Viral Hepatitis Clinic in Brazil who provided care to the patients; the
   Flavivirus Laboratory staff at FIOCRUZ as well as J. Quick and N. Loman
   from the University of Birmingham for their assistance in analysing
   patient samples for ZIKV; B. da Silva Baptista as well as the
   Massachusetts General Hospital HSCI CRM flow cytometry core facility
   members for their technical assistance. This work was supported in part
   by National Institutes of Health grants U01 AI131314 (to G.M.L. and
   L.L.L.-X.), U19 AI066345 (to G.M.L. and L.L.L.-X.), HHSN27220140045C (to
   A.S.), 1PO1AI106695-01A1 (to A.S.), U19AI118626-01 (to A.S.),
   75N9301900065 (to A.S.), the EU grant 734584 (to A.S.), Conselho
   Nacional de Desenvolvimento Tecnologico (CNPq 470092/2014-9;
   200099/2016-7), Fundacao de Amparo a Pesquisa do Estado do Rio de
   Janeiro (Faperj E-26/202.930/2016) and 'Sicherheit von Blut(produkten)
   und Geweben hinsichtlich der Abwesenheit von Zikaviren' from the German
   Ministry of Health.
CR Abbink P, 2016, SCIENCE, V353, P1129, DOI 10.1126/science.aah6157
   Aid M, 2017, CELL, V169, P610, DOI 10.1016/j.cell.2017.04.008
   Bardina SV, 2017, SCIENCE, V356, P175, DOI 10.1126/science.aal4365
   Barouch DH, 2017, IMMUNITY, V46, P176, DOI 10.1016/j.immuni.2017.02.005
   Baylis SA, 2017, TRANSFUSION, V57, P748, DOI 10.1111/trf.14026
   Terzian ACB, 2017, CLIN INFECT DIS, V65, P1260, DOI 10.1093/cid/cix558
   Bonaldo MC, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004816
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Brasil P, 2016, LANCET, V387, P1482, DOI 10.1016/S0140-6736(16)30058-7
   Carlin AF, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0007053
   Costa F, 2016, ANN INTERN MED, V164, P689, DOI 10.7326/M16-0332
   Crosby EJ, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003970
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Delgado FG, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10090480
   Duangchinda T, 2010, P NATL ACAD SCI USA, V107, P16922, DOI 10.1073/pnas.1010867107
   Everett H, 1999, TRENDS MICROBIOL, V7, P160, DOI 10.1016/S0966-842X(99)01487-0
   Foo SS, 2017, NAT MICROBIOL, V2, P1558, DOI 10.1038/s41564-017-0016-3
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Franca GVA, 2016, LANCET, V388, P891, DOI 10.1016/S0140-6736(16)30902-3
   George J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10901-1
   Grifoni A, 2017, J VIROL, V91, DOI [10.1128/JVI.01469-17, 10.1128/jvi.01469-17]
   Hazin AN, 2016, NEW ENGL J MED, V374, P2193, DOI 10.1056/NEJMc1603617
   Honein MA, 2017, JAMA-J AM MED ASSOC, V317, P59, DOI 10.1001/jama.2016.19006
   Ishikawa T, 2014, VACCINE, V32, P1326, DOI 10.1016/j.vaccine.2014.01.040
   Kim J, 2018, IMMUNITY, V48, P161, DOI 10.1016/j.immuni.2017.11.025
   Kraemer MUG, 2015, ELIFE, V4, DOI 10.7554/eLife.08347
   Lai LL, 2018, CLIN INFECT DIS, V66, P1, DOI 10.1093/cid/cix732
   Lannuzel A, 2019, NEUROLOGY, V92, pE2406, DOI 10.1212/WNL.0000000000007536
   Larocca RA, 2016, NATURE, V536, P474, DOI 10.1038/nature18952
   Maini MK, 2000, J EXP MED, V191, P1269, DOI 10.1084/jem.191.8.1269
   Meaney-Delman D, 2016, MMWR-MORBID MORTAL W, V65, P211, DOI 10.15585/mmwr.mm6508e1
   Michlmayr D, 2017, NAT MICROBIOL, V2, P1462, DOI 10.1038/s41564-017-0035-0
   Motta IJF, 2016, NEW ENGL J MED, V375, P1101, DOI 10.1056/NEJMc1607262
   Musso D, 2015, EMERG INFECT DIS, V21, P359, DOI 10.3201/eid2102.141363
   Ngono AE, 2017, CELL HOST MICROBE, V21, P35, DOI 10.1016/j.chom.2016.12.010
   Nguyen TPD, 2010, J IMMUNOL, V184, P7281, DOI 10.4049/jimmunol.0903262
   Osuna CE, 2016, NAT MED, V22, P1448, DOI 10.1038/nm.4206
   Pantoja P, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15674
   Petersen LR, 2016, NEW ENGL J MED, V374, P1552, DOI 10.1056/NEJMra1602113
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Ricciardi MJ, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006000
   Robbiani DF, 2017, CELL, V169, P597, DOI 10.1016/j.cell.2017.04.024
   Rogers TF, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan6809
   Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070
   Simeone RM, 2016, MMWR-MORBID MORTAL W, V65, P514, DOI 10.15585/mmwr.mm6520e1
   Sotelo JR, 2017, EMERG INFECT DIS, V23, P854, DOI 10.3201/eid2305.161538
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Sun XM, 2017, CELL REP, V21, P3471, DOI 10.1016/j.celrep.2017.11.087
   Tian Y, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00531
   Trosemeier J. H., 2016, GENOME ANNOUNC, V4, P00917
   Wang C, 2017, J IMMUNOL, V199, P3094, DOI 10.4049/jimmunol.1700671
   Wang QH, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aai8336
   Wen JS, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.36
   Ye Q, 2016, INFECT GENET EVOL, V43, P43, DOI 10.1016/j.meegid.2016.05.004
NR 54
TC 3
Z9 3
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2058-5276
J9 NAT MICROBIOL
JI NAT. MICROBIOL
PD JAN
PY 2020
VL 5
IS 1
BP 76
EP +
DI 10.1038/s41564-019-0618-z
PG 18
WC Microbiology
SC Microbiology
GA KQ8GL
UT WOS:000517158800015
PM 31792427
OA Green Accepted
DA 2020-11-30
ER

PT J
AU Baylis, SA
   Hanschmann, KMO
   Matsubayashi, K
   Sakata, H
   Roque-Afonso, AM
   Kaiser, M
   Corman, VM
   Kamili, S
   Aggarwal, R
   Trehanpati, N
   Gartner, T
   Thomson, EC
   Davis, CA
   Filipe, AD
   Abdelrahman, TT
   Blumel, J
   Terao, E
   Pullirsch, D
   Hottowy, B
   Lewis-Ximenez, LL
   Pinto, MA
   Wang, YC
   Huang, WJ
   Zhao, CY
   Zheng, ZZ
   Shih, JWK
   Tang, ZM
   Ji, WF
   Izopet, J
   Lhomme, S
   Dubois, M
   Schonborn, M
   Beckort, C
   Hess, M
   Tillack, M
   Brischke, D
   Vollmer, T
   Dreier, J
   Wenzel, J
   Klein, J
   O'Riordan, J
   Murphy, J
   Boland, F
   Pacini, B
   Pisani, G
   Simeoni, M
   Fabi, S
   Mizusawa, S
   Uchida, S
   Ekvarn, E
   Hogema, B
   Schuurman, T
   Schar, O
   Ijaz, S
   Dicks, S
   Haywood, B
   Mixson-Hayden, T
   Linnen, J
   Ong, E
   Cory, R
AF Baylis, Sally A.
   Hanschmann, Kay-Martin O.
   Matsubayashi, Keiji
   Sakata, Hidekatsu
   Roque-Afonso, Anne-Marie
   Kaiser, Marco
   Corman, Victor M.
   Kamili, Saleem
   Aggarwal, Rakesh
   Trehanpati, Nirupma
   Gaertner, Thomas
   Thomson, Emma C.
   Davis, Christopher A.
   Filipe, Ana da Silva
   Abdelrahman, Tamer T.
   Bluemel, Johannes
   Terao, Eriko
   Pullirsch, Dieter
   Hottowy, Brigitte
   Lewis-Ximenez, Lia Laura
   Pinto, Marcelo Alves
   Wang, Youchun
   Huang, Weijin
   Zhao, Chenyan
   Zheng, Zizheng
   Shih, James Wai Kuo
   Tang, Zi-Min
   Ji, Wen-Fang
   Izopet, Jacques
   Lhomme, Sebastien
   Dubois, Martine
   Schoenborn, Maike
   Beckort, Christiane
   Hess, Markus
   Tillack, Manuela
   Brischke, Daniel
   Vollmer, Tanja
   Dreier, Jens
   Wenzel, Juergen
   Klein, Jasmin
   O'Riordan, Joan
   Murphy, Jessica
   Boland, Fiona
   Pacini, Barbara
   Pisani, Giulio
   Simeoni, Matteo
   Fabi, Sara
   Mizusawa, Saeko
   Uchida, Shigeharu
   Ekvarn, Elisabet
   Hogema, Boris
   Schuurman, Tim
   Schaer, Oliver
   Ijaz, Samreen
   Dicks, Steven
   Haywood, Becky
   Mixson-Hayden, Tonya
   Linnen, Jeffrey
   Ong, Edgar
   Cory, Robin
CA HEV Collaborative Study Grp
TI Development of a World Health Organization International Reference Panel
   for different genotypes of hepatitis E virus for nucleic acid
   amplification testing
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE Hepatitis E virus; HEV; NAT; NAAT; Standardization; Genotype; World
   Health Organization
ID RT-PCR; BLOOD; HEV
AB Background: Globally, hepatitis E virus (HEV) is a major cause of acute viral hepatitis. Epidemiology and clinical presentation of hepatitis E vary greatly by location and are affected by the HEV genotype. Nucleic acid amplification technique (NAT)-based assays are important for the detection of acute HEV infection as well for monitoring chronic cases of hepatitis E.
   Objectives: The aim of the study was to evaluate a panel of samples containing different genotypes of HEV for use in nucleic NAT-based assays.
   Study design: The panel of samples comprises eleven different members including HEV genotype 1a (2 strains), 1e, 2a, 3b, 3c, 3e, 3f, 4c, 4g as well as a human isolate related to rabbit HEV. Each laboratory assayed the panel members directly against the 1st World Health Organization (WHO) International Standard (IS) for HEV RNA (6329/10) which is based upon a genotype 3 a strain.
   Results: The samples for evaluation were distributed to 24 laboratories from 14 different countries and assayed on three separate days. Of these, 23 participating laboratories returned a total of 32 sets of data; 17 from quantitative assays and 15 from qualitative assays. The assays used consisted of a mixture of in-house developed and commercially available assays. The results showed that all samples were detected consistently by the majority of participants, although in some cases, some samples were detected less efficiently.
   Conclusions: Based on the results of the collaborative study the panel (code number 8578/13) was established as the "1st International Reference Panel (IRP) for all HEV genotypes for NAT-based assays" by the WHO Expert Committee on Biological Standardization. This IRP will be important for assay validation and ensuring adequate detection of different genotypes and clinically important sub-genotypes of HEV.
C1 [Baylis, Sally A.; Hanschmann, Kay-Martin O.; Bluemel, Johannes] Paul Ehrlich Inst, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.
   [Matsubayashi, Keiji; Aggarwal, Rakesh; Uchida, Shigeharu] Japanese Red Cross Soc, Cent Blood Inst, Tokyo, Japan.
   [Matsubayashi, Keiji; Sakata, Hidekatsu] Japanese Red Cross Hokkaido Block Blood Ctr, Sapporo, Hokkaido, Japan.
   [Roque-Afonso, Anne-Marie] Hop Paul Brousse, AP HP, Virol, Villejuif, France.
   [Kaiser, Marco] GenExpress Gesell Prot Design mbH, Berlin, Germany.
   [Corman, Victor M.] Charite Univ Med Berlin, Berlin, Germany.
   [Corman, Victor M.] Free Univ Berlin, Berlin, Germany.
   [Corman, Victor M.] Humboldt Univ, Berlin, Germany.
   [Corman, Victor M.] Berlin Inst Hlth, Inst Virol, Berlin, Germany.
   [Corman, Victor M.] German Ctr Infect Res DZIF, Berlin, Germany.
   [Kamili, Saleem] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA.
   [Aggarwal, Rakesh] Sanjay Gandhi Postgrad Inst Med Sci, Lucknow, Uttar Pradesh, India.
   [Trehanpati, Nirupma] Inst Liver & Biliary Sci, New Delhi, India.
   [Gaertner, Thomas; Schoenborn, Maike; Beckort, Christiane; Ekvarn, Elisabet] Octapharma, Frankfurt, Germany.
   [Thomson, Emma C.; Davis, Christopher A.; Filipe, Ana da Silva; Abdelrahman, Tamer T.] Univ Glasgow, Ctr Virus Res, Glasgow, Lanark, Scotland.
   [Abdelrahman, Tamer T.] King Fahad Med City, Microbiol Dept, Riyadh, Saudi Arabia.
   [Terao, Eriko] European Directorate Qual Med & HealthCare, Strasbourg, France.
   [Pullirsch, Dieter; Hottowy, Brigitte] AGES PharmMed, Vienna, Austria.
   [Lewis-Ximenez, Lia Laura; Pinto, Marcelo Alves] Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Wang, Youchun; Huang, Weijin; Zhao, Chenyan] Natl Inst Food & Drug Control, Beijing, Peoples R China.
   [Zheng, Zizheng; Shih, James Wai Kuo; Tang, Zi-Min; Ji, Wen-Fang] Xiamen Univ, Xiamen, Fujian, Peoples R China.
   [Izopet, Jacques; Lhomme, Sebastien; Dubois, Martine] Inst Federatif Biol Purpan, Toulouse, France.
   [Hess, Markus; Tillack, Manuela; Brischke, Daniel] Altona Diagnost, Hamburg, Germany.
   [Vollmer, Tanja; Dreier, Jens] Herz & Diabeteszentrum Nordrhein Westfalen, Inst Lab & Transfusionsmed, Bad Oeynhausen, Germany.
   [Wenzel, Juergen; Klein, Jasmin] Univ Regensburg, Regensburg, Germany.
   [O'Riordan, Joan; Murphy, Jessica; Boland, Fiona] Irish Blood Transfus Serv, Dublin, Ireland.
   [Pacini, Barbara] Kedrion Biopharmaceut, Bolognana, Lucca, Italy.
   [Pisani, Giulio; Simeoni, Matteo; Fabi, Sara] Ist Super Sanita, Rome, Italy.
   [Mizusawa, Saeko] Natl Inst Infect Dis, Tokyo, Japan.
   [Hogema, Boris] Sanquin Blood Supply Fdn, Amsterdam, Netherlands.
   [Schuurman, Tim] Univ Med Ctr Groningen, Groningen, Netherlands.
   [Schaer, Oliver] Roche Diagnost Int Ltd, Rotkreuz, Switzerland.
   [Ijaz, Samreen; Dicks, Steven; Haywood, Becky] Publ Hlth England, London, England.
   [Kamili, Saleem; Mixson-Hayden, Tonya] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Linnen, Jeffrey; Ong, Edgar; Cory, Robin] Hologic Inc, San Diego, CA USA.
RP Baylis, SA (corresponding author), Paul Ehrlich Inst, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.
EM sally.baylis@pei.de
RI Corman, Victor Max/K-1319-2019; huang, weijin/AAY-5028-2020; Thomson,
   Emma C/M-8690-2017; Aggarwal, Rakesh/D-1583-2009; Roque-Afonso,
   Anne-Marie/D-5737-2014
OI Corman, Victor Max/0000-0002-3605-0136; Thomson, Emma
   C/0000-0003-1482-0889; Ijaz, Samreen/0000-0001-6658-3542; Aggarwal,
   Rakesh/0000-0001-9689-494X; Roque-Afonso,
   Anne-Marie/0000-0002-6612-2030; da Silva Filipe, Ana
   Cristina/0000-0002-9442-2903; Abdelrahman, Tamer/0000-0003-0381-9524
CR Abravanel F, 2012, J CLIN MICROBIOL, V50, P897, DOI 10.1128/JCM.05942-11
   Adlhoch C, 2009, VOX SANG, V97, P303, DOI 10.1111/j.1423-0410.2009.01211.x
   Baylis SA, 2019, J CLIN MICROBIOL, V57, DOI 10.1128/JCM.01056-18
   Baylis S A, 2017, Pharmeur Bio Sci Notes, V2017, P12
   Baylis SA, 2013, EMERG INFECT DIS, V19, P729, DOI 10.3201/eid1905.121845
   Baylis SA, 2011, J CLIN MICROBIOL, V49, P1234, DOI 10.1128/JCM.02578-10
   Drexler JF, 2012, J VIROL, V86, P9134, DOI 10.1128/JVI.00800-12
   European Assoc Study Liver, 2018, J HEPATOL, V68, P1256, DOI 10.1016/j.jhep.2018.03.005
   Garson JA, 2012, J VIROL METHODS, V186, P157, DOI 10.1016/j.jviromet.2012.07.027
   Jothikumar N, 2006, J VIROL METHODS, V131, P65, DOI 10.1016/j.jviromet.2005.07.004
   Matsubayashi K, 2008, TRANSFUSION, V48, P1368, DOI 10.1111/j.1537-2995.2008.01722.x
   Purdy MA, 2017, J GEN VIROL, V98, P2645, DOI 10.1099/jgv.0.000940
   Smith DB, 2016, J GEN VIROL, V97, P537, DOI 10.1099/jgv.0.000393
   Takahashi M, 2010, J CLIN MICROBIOL, V48, P1112, DOI 10.1128/JCM.02002-09
   Tanaka T, 2007, J GEN VIROL, V88, P903, DOI 10.1099/vir.0.82535-0
   Wenzel JJ, 2011, J CLIN VIROL, V52, P50, DOI 10.1016/j.jcv.2011.06.006
   Zhao CY, 2007, J MED VIROL, V79, P1966, DOI 10.1002/jmv.21040
NR 17
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD OCT
PY 2019
VL 119
BP 60
EP 67
DI 10.1016/j.jcv.2019.05.006
PG 8
WC Virology
SC Virology
GA IW5QR
UT WOS:000485033500011
PM 31431408
OA Other Gold, Green Accepted
DA 2020-11-30
ER

PT J
AU Lago, BV
   do Espirito-Santo, MP
   Costa, VD
   Marques, VA
   Villar, LM
   Lewis-Ximenez, LL
   Lampe, E
   Mello, FCA
AF Lago, Barbara, V
   do Espirito-Santo, Marcia P.
   Costa, Vanessa D.
   Marques, Vanessa A.
   Villar, Livia M.
   Lewis-Ximenez, Lia L.
   Lampe, Elisabeth
   Mello, Francisco C. A.
TI Genetic Diversity of the Hepatitis B Virus Subgenotypes in Brazil
SO VIRUSES-BASEL
LA English
DT Article
DE hepatitis B virus; subgenotypes; Brazil
ID MOLECULAR EPIDEMIOLOGY; HBV GENOTYPES; SOUTHERN BRAZIL; HIGH PREVALENCE;
   INFECTION; EVOLUTION; ORIGIN; CLASSIFICATION; POPULATION; REVEALS
AB Hepatitis B virus (HBV) subgenotypes may be related to clinical outcomes and response to antiviral therapy. Most Brazilian studies on HBV subgenotypes are restricted to some regions and to specific population groups. Here, we provide an insight about genetic diversity of HBV subgenotypes in 321 serum samples from all five geographical regions, providing a representative overview of their circulation among chronic carriers. Overall, HBV/A1 was the most prevalent subgenotype, being found as the major one in all regions except in South Brazil. Among HBV/D samples, subgenotype D3 was the most prevalent, found in 51.5%, followed by D2 (27.3%) and D4 (21.2%). D2 and D3 were the most prevalent subgenotypes in South region, with high similarity with European strains. D4 was found in North and Northeast region and clustered with strains from Cape Verde and India. For HBV/F, the most frequent subgenotype was F2 (84.1%), followed by F4 (10.1%) and F1 (5.8%), closely related with strains from Venezuela, Argentina and Chile, respectively. Phylogeographic analyses were performed using an HBV full-length genome obtained from samples infected with genotypes rarely found in Brazil (B, C, and E). According to Bayesian inference, HBV/B2 and HBV/C2 were probably introduced in Brazil through China, and HBV/E from Guinea, all of them mostly linked to recent events of human migration. In conclusion, this study provided a comprehensive overview of the current circulation of HBV subgenotypes in Brazil. Our findings might contribute to a better understand of the dynamics of viral variants, to establish a permanent molecular surveillance on the introduction and dispersion patterns of new strains and, thus, to support public policies to control HBV dissemination in Brazil.
C1 [Lago, Barbara, V; Costa, Vanessa D.; Marques, Vanessa A.; Villar, Livia M.; Lewis-Ximenez, Lia L.; Lampe, Elisabeth; Mello, Francisco C. A.] Fiocruz MS, Inst Oswaldo Cruz, Lab Hepatites Virais, BR-21040900 Rio De Janeiro, RJ, Brazil.
   [Lago, Barbara, V; do Espirito-Santo, Marcia P.] Fiocruz MS, Inst Tecnol Imunobiol Biomanguinhos, BR-21040900 Rio De Janeiro, RJ, Brazil.
RP Lago, BV; Mello, FCA (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab Hepatites Virais, BR-21040900 Rio De Janeiro, RJ, Brazil.; Lago, BV (corresponding author), Fiocruz MS, Inst Tecnol Imunobiol Biomanguinhos, BR-21040900 Rio De Janeiro, RJ, Brazil.
EM barbaravlago@gmail.com; paschoalms@gmail.com; v.duarte391@gmail.com;
   vmarques@ioc.fiocruz.br; liviafiocruz@gmail.com;
   lialewis.fiocruz@gmail.com; elampe@ioc.fiocruz.br; fcamello@gmail.com
RI MELO VILLAR, LIVIA/F-7811-2012
OI MELO VILLAR, LIVIA/0000-0001-7644-8969; Costa, Vanessa Duarte
   da/0000-0003-4490-2658; Lago, Barbara/0000-0002-9173-6309
FU 'Ministerio da Saude, Fundo Nacional de Saude, Departamento de DST/AIDS
   e Hepatites Virais', CNPq [25000.214350/2012-24]
FX This study was supported by funding from the 'Ministerio da Saude, Fundo
   Nacional de Saude, Departamento de DST/AIDS e Hepatites Virais',
   approved in process number 25000.214350/2012-24., CNPq.
CR Mora MVA, 2010, J GEN VIROL, V91, P501, DOI 10.1099/vir.0.015958-0
   Alvarado-Mora MV, 2013, ANTIVIR THER, V18, P459, DOI 10.3851/IMP2599
   Andernach IE, 2009, EMERG INFECT DIS, V15, P1222, DOI 10.3201/eid1508.081642
   Araujo NM, 2011, INFECT GENET EVOL, V11, P1199, DOI 10.1016/j.meegid.2011.04.017
   Araujo NM, 2004, ARCH VIROL, V149, P1383, DOI 10.1007/s00705-003-0269-4
   Banerjee P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109425
   Becker Carlos Eduardo, 2010, Arq. Gastroenterol., V47, P13, DOI 10.1590/S0004-28032010000100003
   Bertolini DA, 2012, INFECT GENET EVOL, V12, P1295, DOI 10.1016/j.meegid.2012.04.009
   Ribeiro NRC, 2006, LIVER INT, V26, P636, DOI 10.1111/j.1478-3231.2006.01280.x
   Campos Rodolfo H, 2005, J Clin Virol, V34 Suppl 2, pS8, DOI 10.1016/S1386-6532(05)80028-9
   Carrilho FJ, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-13
   Carvalho-Silva DR, 2001, AM J HUM GENET, V68, P281, DOI 10.1086/316931
   Chudy M, 2006, HEPATOLOGY, V44, P99, DOI 10.1002/hep.21220
   Clemente CM, 2009, J GASTROENTEROL, V44, P568, DOI 10.1007/s00535-009-0044-8
   Cruz-Santos MD, 2018, ANN HEPATOL, V17, P54, DOI 10.5604/01.3001.0010.7535
   De Amorim M., 2016, CAD GEOGR, V26, P15, DOI [10.5752/p.2318-2962.2016v26, DOI 10.5752/P.2318-2962.2016V26]
   De Maddalena C, 2007, VIROLOGY, V365, P113, DOI 10.1016/j.virol.2007.03.015
   de Paoli J, 2018, BRAZ J INFECT DIS, V22, P294, DOI 10.1016/j.bjid.2018.06.006
   de Sousa DD, 2018, REV INST MED TROP SP, V60, DOI [10.1590/S1678-9946201860035, 10.1590/s1678-9946201860035]
   Devesa M, 2008, J MED VIROL, V80, P20, DOI 10.1002/jmv.21024
   Chacha SGF, 2017, BRAZ J INFECT DIS, V21, P424, DOI 10.1016/j.bjid.2017.01.011
   Barros LMF, 2014, INFECT GENET EVOL, V24, P68, DOI 10.1016/j.meegid.2014.03.007
   GUNTHER S, 1995, J VIROL, V69, P5437
   Gusatti CS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135816
   Hannoun C, 2005, J GEN VIROL, V86, P2163, DOI 10.1099/vir.0.80972-0
   Hannoun C, 2000, J GEN VIROL, V81, P75, DOI 10.1099/0022-1317-81-1-75
   Kostaki EG, 2018, ELIFE, V7, DOI 10.7554/eLife.36709
   Kowalec K, 2013, J VIRAL HEPATITIS, V20, P122, DOI 10.1111/j.1365-2893.2012.01632.x
   Kramvis A, 2007, HEPATOL RES, V37, pS9, DOI 10.1111/j.1872-034X.2007.00098.x
   Kramvis A, 2014, INTERVIROLOGY, V57, P141, DOI 10.1159/000360947
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   Lago BV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105317
   Lago BV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092223
   Lampe E, 2017, J GEN VIROL, V98, P1389, DOI 10.1099/jgv.0.000789
   Livingston SE, 2007, J INFECT DIS, V195, P5, DOI 10.1086/509894
   Locarnini S, 2013, SEMIN CANCER BIOL, V23, P561, DOI 10.1016/j.semcancer.2013.08.006
   Loureiro CL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118959
   Mallory MA, 2011, J VIROL METHODS, V177, P31, DOI 10.1016/j.jviromet.2011.06.009
   Marinho TA, 2014, REV SOC BRAS MED TRO, V47, P18, DOI 10.1590/0037-8682-0177-2013
   Martinez AA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134850
   de Mello FMMA, 2014, REV SOC BRAS MED TRO, V47, P701, DOI 10.1590/0037-8682-0158-2014
   Mello FCA, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-103
   Mello FCA, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-236
   Menegol D, 2013, BRAZ J MICROBIOL, V44, P1237, DOI 10.1590/S1517-83822014005000013
   Motta-Castro A, 2008, ARCH VIROL, V153, P2197, DOI 10.1007/s00705-008-0237-0
   Mulders MN, 2004, J INFECT DIS, V190, P400, DOI 10.1086/421502
   Mojsiejczuk LN, 2016, INFECT GENET EVOL, V44, P34, DOI 10.1016/j.meegid.2016.06.032
   Norder H, 2004, INTERVIROLOGY, V47, P289, DOI 10.1159/000080872
   ORITO E, 1989, P NATL ACAD SCI USA, V86, P7059, DOI 10.1073/pnas.86.18.7059
   Osiowy C, 2006, J VIROL, V80, P10307, DOI 10.1128/JVI.00996-06
   Panduro A, 2013, ANTIVIR THER, V18, P475, DOI 10.3851/IMP2605
   Parana R, 2005, J CLIN VIROL, V34, pS130, DOI 10.1016/S1386-6532(05)80022-8
   Paraskevis D, 2013, HEPATOLOGY, V57, P908, DOI 10.1002/hep.26079
   Patterson Ross Zoe, 2018, PLoS Pathog, V14, pe1006887, DOI 10.1371/journal.ppat.1006887
   Pourkarim MR, 2014, WORLD J GASTROENTERO, V20, P7152, DOI 10.3748/wjg.v20.i23.7152
   Sagnelli C, 2014, J MED VIROL, V86, P1683, DOI 10.1002/jmv.24005
   Sant' Anna CD, 2018, J MED VIROL, V90, P1063, DOI 10.1002/jmv.25051
   Schaefer S, 2007, HEPATOL RES, V37, pS20, DOI 10.1111/j.1872-034X.2007.00099.x
   Spitz N, 2015, MEM I OSWALDO CRUZ, V110, P151, DOI 10.1590/0074-02760140426
   Suchard MA, 2018, VIRUS EVOL, V4, DOI 10.1093/ve/vey016
   Sunbul M, 2014, WORLD J GASTROENTERO, V20, P5427, DOI 10.3748/wjg.v20.i18.5427
   Tatematsu K, 2009, J VIROL, V83, P10538, DOI 10.1128/JVI.00462-09
   Valente F, 2010, MEM I OSWALDO CRUZ, V105, P970, DOI 10.1590/S0074-02762010000800004
   Zaaijer HL, 2011, J VIRAL HEPATITIS, V18, P815, DOI 10.1111/j.1365-2893.2010.01397.x
   Zehender G, 2015, INFECT GENET EVOL, V32, P361, DOI 10.1016/j.meegid.2015.03.009
   Zhou Y, 2007, J MOL EVOL, V65, P197, DOI 10.1007/s00239-007-0054-1
NR 66
TC 1
Z9 1
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD SEP
PY 2019
VL 11
IS 9
AR 860
DI 10.3390/v11090860
PG 16
WC Virology
SC Virology
GA JA6OT
UT WOS:000487962400112
PM 31540166
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Cruz, HM
   de Paula, VS
   da Silva, EF
   do O, KMR
   Milagres, FAP
   Cruz, MS
   Bastos, FI
   da Mota, JC
   Pollo-Flores, P
   Leal, E
   Motta-Castro, ARC
   Lewis-Ximenez, LL
   Lampe, E
   Villar, LM
AF Cruz, Helena Medina
   de Paula, Vanessa Salete
   da Silva, Elisangela Ferreira
   Rodrigues do O, Kycia Maria
   Padua Milagres, Flavio Augusto
   Cruz, Marcelo Santos
   Bastos, Francisco Inacio
   da Mota, Jurema Correa
   Pollo-Flores, Priscila
   Leal, Erotildes
   Coimbra Motta-Castro, Ana Rita
   Lewis-Ximenez, Lia Laura
   Lampe, Elisabeth
   Villar, Livia Melo
TI Utility of oral fluid samples for hepatitis B antibody detection in real
   life conditions
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Hepatitis B virus; Oral fluid; Enzyme immunoassay; Prevalence; Diagnosis
ID C VIRUS; COLLECTION METHODS; SALIVA; PREVALENCE; INFECTION; DIAGNOSIS;
   HIV; ASSAYS; TESTS; HBSAG
AB BackgroundHepatitis B virus (HBV) testing in oral fluid samples may provide advantages in diagnosis, screening or prevalence studies, especially among individuals with venous access difficulties. This study aims to optimize one commercially available assay for detecting total anti-HBc marker in oral fluid samples and to evaluate its utility under real life conditions in different settings for the purposes of prevalence and diagnostic studies.MethodsOral fluid was collected using a Salivette device and some parameters were initially evaluated: type of elution buffer and sample volume. Thereafter, the utility of oral fluid samples for detection of anti-HBc was evaluated in real life conditions in which, 1296 individuals gave serum and oral fluid samples. All serum samples were submitted to commercial EIAs to detect total anti-HBc, according to the manufacturer's instructions and oral fluid samples according to previous optimization.ResultsIn optimization evaluation, PBS/BSA 0.5% and 100 mu L of oral fluid (volume was two-fold increased compared to serum in EIA) were chosen as transport buffer and sample volume. In the field study, anti-HBc was detected in 211 out of 1296 serum samples giving overall oral fluid sensitivity of 52.6% and specificity of 96%. Concordance was higher in ambulatory setting (67.7) compared to general population (31.8). Meanstandard deviation values of optical density/cutoff (OD/CO) in serum samples were higher in false-negative oral fluid samples than those seen in true positive samples. Sensitivity was higher in those presenting active infection compared to anti-HBc isolate and past infection. Sensitivity also increased in the ambulatory group when HCV individuals were excluded.Conclusions It was possible to optimize a commercial EIA for detecting anti-HBc in oral fluid samples and where the highest concordance was found in ambulatory settings and among individuals with active infection.
C1 [Cruz, Helena Medina; da Silva, Elisangela Ferreira; Lewis-Ximenez, Lia Laura; Lampe, Elisabeth; Villar, Livia Melo] Fiocruz MS, Lab Viral Hepatitis, Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
   [de Paula, Vanessa Salete] Fiocruz MS, Mol Virol Lab, Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Rodrigues do O, Kycia Maria] Sao Lucas Hosp, Rio De Janeiro, Brazil.
   [Padua Milagres, Flavio Augusto] Fed Univ Tocantins, Fac Med, Palmas, Brazil.
   [Cruz, Marcelo Santos] Univ Fed Rio de Janeiro, Inst Psychiat, Rio De Janeiro, Brazil.
   [Bastos, Francisco Inacio; da Mota, Jurema Correa] Fundacao Oswaldo Cruz, Inst Commun & Sci Informat & Technol Hlth, Rio De Janeiro, Brazil.
   [Pollo-Flores, Priscila] Fed Fluminense Univ, Antonio Pedro Univ Hosp, Rio De Janeiro, Brazil.
   [Leal, Erotildes] Univ Fed Rio de Janeiro, Fac Med, Rio De Janeiro, Brazil.
   [Coimbra Motta-Castro, Ana Rita] Univ Fed Mato Grosso do Sul, Campo Grande, MS, Brazil.
   [Coimbra Motta-Castro, Ana Rita] Fiocruz MS, Campo Grande, MS, Brazil.
RP Villar, LM (corresponding author), Fiocruz MS, Lab Viral Hepatitis, Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
EM liviafiocruz@gmail.com
RI Cruz, Marcelo Santos/AAH-5963-2020; Cruz, Helena Medina/U-4780-2019; de
   Paula, Vanessa S/I-8037-2016
OI Cruz, Marcelo Santos/0000-0003-0057-2095; Cruz, Helena
   Medina/0000-0003-2088-7705; de Paula, Vanessa S/0000-0002-6314-754X;
   Milagres, Flavio/0000-0002-6889-8772; Motta-Castro, Ana
   Rita/0000-0003-3070-1337; Mota, Jurema/0000-0002-5007-1590
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Brazilian National Counsel of Technological and
   Scientific Development (CNPq)National Council for Scientific and
   Technological Development (CNPq); CAPESCAPES; Oswaldo Cruz Foundation
   (FIOCRUZ)
FX This research was supported by the Fundacao de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ), Brazilian National Counsel of
   Technological and Scientific Development (CNPq), CAPES and the Oswaldo
   Cruz Foundation (FIOCRUZ). These agencies were not responsible for the
   design of the study and collection, analysis, and interpretation of data
   and in writing the manuscript.
CR Altman D.G., 1991, PRACTICAL STAT MED R
   Amado LA, 2006, MEM I OSWALDO CRUZ, V101, P149, DOI 10.1590/S0074-02762006000200006
   Leon LAA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145454
   Leon LAA, 2013, FUTURE VIROL, V8, P575, DOI 10.2217/FVL.13.41
   Belza MJ, 2012, SEX TRANSM INFECT, V88, P218, DOI 10.1136/sextrans-2011-050131
   BRANDTZAEG P, 1970, SCAND J HAEMAT     S, V12, P1
   CROWTHER JR, 2001, METHODS MOL BIOL
   Cruz HM, 2012, J ORAL PATHOL MED, V41, P793, DOI 10.1111/j.1600-0714.2012.01176.x
   Cruz HM, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1249-5
   Cruz HM, 2011, J CLIN LAB ANAL, V25, P134, DOI 10.1002/jcla.20447
   Cruz MS, 2013, INT J DRUG POLICY, V24, P432, DOI 10.1016/j.drugpo.2013.03.012
   de Oliveira ACDS, 2010, BRAZ J INFECT DIS, V14, P502, DOI 10.1590/S1413-86702010000500013
   Fisker N, 2002, J MED VIROL, V68, P500, DOI 10.1002/jmv.10242
   Flores GL, 2017, J VIROL METHODS, V247, P32, DOI 10.1016/j.jviromet.2017.05.004
   Gerlich WH, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-239
   Hutse V, 2005, J MED VIROL, V77, P53, DOI 10.1002/jmv.20413
   Judd A, 2003, J MED VIROL, V71, P49, DOI 10.1002/jmv.10463
   Khadse SV, 2016, J CLIN DIAGN RES, V10, pBC12, DOI 10.7860/JCDR/2016/17319.7107
   Lackner A, 2010, J MED VIROL, V82, P1582, DOI 10.1002/jmv.21849
   LeFevre ML, 2014, ANN INTERN MED, V161, P58, DOI 10.7326/M14-1018
   Ministry of Health Brazil, 2018, B EP HEP VIR
   Mortimer P P, 1994, Clin Diagn Virol, V2, P231, DOI 10.1016/0928-0197(94)90048-5
   Nokes DJ, 2001, B WORLD HEALTH ORGAN, V79, P588
   Noppornpanth Suwanna, 2000, Southeast Asian Journal of Tropical Medicine and Public Health, V31, P419
   PARRY JV, 1993, ANN NY ACAD SCI, V694, P216, DOI 10.1111/j.1749-6632.1993.tb18355.x
   PARRY JV, 1989, J MED VIROL, V28, P255, DOI 10.1002/jmv.1890280410
   PARRY JV, 1987, LANCET, V2, P72, DOI 10.1016/S0140-6736(87)92737-1
   Portilho M, 2017, ORAL DIS, V23, P1072, DOI 10.1111/odi.12692
   Quoilin S, 2007, EUR J EPIDEMIOL, V22, P195, DOI 10.1007/s10654-007-9105-6
   Richards Allen L., 1996, Southeast Asian Journal of Tropical Medicine and Public Health, V27, P80
   Roitt I, 1983, IMMUNOLOGY ORAL DIS, P279
   Scalioni LD, 2013, J CLIN LAB ANAL, V27, P186, DOI 10.1002/jcla.21582
   Soderling E, 1989, HUMAN SALIVA CLIN CH, P1
   Talukder Y, 2005, J VIROL METHODS, V128, P162, DOI 10.1016/j.jviromet.2005.04.013
   Tourinho RS, 2011, J VIROL METHODS, V173, P169, DOI 10.1016/j.jviromet.2011.01.014
   VANDERSCHOUW YT, 1992, FAM PRACT, V9, P506, DOI 10.1093/fampra/9.4.506
   Villar LM, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3279-2
   Villar Livia Melo, 2015, World J Virol, V4, P323, DOI 10.5501/wjv.v4.i4.323
   Villar LM, 2014, J MED VIROL, V86, P1515, DOI 10.1002/jmv.23993
   World Health Organization, 2017, HEP B
   Santos RLX, 2015, J INFECT PUBLIC HEAL, V8, P474, DOI 10.1016/j.jiph.2015.04.025
   Zhevachevsky NG, 2000, J MED VIROL, V61, P433, DOI 10.1002/1096-9071(200008)61:4&lt;433::AID-JMV4&gt;3.0.CO;2-5
NR 42
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD JUL 17
PY 2019
VL 19
AR 632
DI 10.1186/s12879-019-4183-0
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA IJ5DD
UT WOS:000475922100002
PM 31315573
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Hoogeveen, RC
   Robidoux, MP
   Schwarz, T
   Heydmann, L
   Cheney, JA
   Kvistad, D
   Aneja, J
   Melgaco, JG
   Fernandes, CA
   Chung, RT
   Boonstra, A
   Kim, AY
   Baumert, TF
   Timm, J
   Lewis-Ximenez, LL
   Tonnerre, P
   Lauer, GM
AF Hoogeveen, Ruben C.
   Robidoux, Maxwell P.
   Schwarz, Tatjana
   Heydmann, Laura
   Cheney, James A.
   Kvistad, Daniel
   Aneja, Jasneet
   Melgaco, Juliana G.
   Fernandes, Carlos A.
   Chung, Raymond T.
   Boonstra, Andre
   Kim, Arthur Y.
   Baumert, Thomas F.
   Timm, Joerg
   Lewis-Ximenez, Lia L.
   Tonnerre, Pierre
   Lauer, Georg M.
TI Phenotype and function of HBV-specific T cells is determined by the
   targeted epitope in addition to the stage of infection
SO GUT
LA English
DT Article
ID HEPATITIS-B-VIRUS; PROGRAMMED DEATH-1; PD-1 EXPRESSION; VIRAL CONTROL;
   RESPONSES; DIFFERENTIATION; DYSFUNCTION; ADAPTATION; ACTIVATION;
   BLOCKADE
AB Objective Chronic HBV infection affects more than 250 million people worldwide and remains a global healthcare problem in part because we lack curative treatment. Sustained viral control requires HBV-specific T cells, but these become functionally impaired in chronic infection. Clinical evidence indicates that functional cure of HBV infection by the host immune response is feasible. Developing T cell-based therapies able to achieve functional cure will require identification of the requirements for a successful T cell response against HBV and the relative contribution of individual T cell specificities to HBV control.
   Design The phenotype and function of HBV-specific T cells were studied directly ex vivo using fluorochrome-labelled multimers. We studied multiple HBV-specific T cell specificities targeting different HBV proteins in individuals with either an acute self-limiting or chronic HBV infection.
   Results We detected strong T cell responses targeting multiple HBV viral proteins in acute selflimiting and low-frequency core and polymerasespecific T cells in chronic infection. Expression of the T cell inhibitory receptor PD-1, as well as T cell differentiation, T cell function and T cell regulation differed by stages and outcomes of infection. In addition, these features differed significantly between T cells targeting different HBV specificities.
   Conclusion HBV-specific T cells with different target specificities are characterised by distinct phenotypical and functional profiles. These results have direct implications for the design of immunological studies in HBV infection, and are potentially relevant for informing immunotherapeutic approaches to induce functional cure.
C1 [Hoogeveen, Ruben C.; Robidoux, Maxwell P.; Cheney, James A.; Kvistad, Daniel; Aneja, Jasneet; Chung, Raymond T.; Tonnerre, Pierre; Lauer, Georg M.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
   [Hoogeveen, Ruben C.; Robidoux, Maxwell P.; Cheney, James A.; Kvistad, Daniel; Aneja, Jasneet; Chung, Raymond T.; Kim, Arthur Y.; Tonnerre, Pierre; Lauer, Georg M.] Harvard Med Sch, Boston, MA 02115 USA.
   [Hoogeveen, Ruben C.; Boonstra, Andre] Erasmus MC, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands.
   [Schwarz, Tatjana; Timm, Joerg] Heinrich Heine Univ, Univ Hosp, Inst Virol, Dusseldorf, Germany.
   [Heydmann, Laura; Baumert, Thomas F.] INSERM, U1110, Inst Rech Malad Virales & Hepat, Strasbourg, France.
   [Melgaco, Juliana G.; Lewis-Ximenez, Lia L.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Fernandes, Carlos A.] Lab Cent Saude Publ Noel Nutels, Rio De Janeiro, Brazil.
   [Kim, Arthur Y.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
RP Lauer, GM (corresponding author), Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.; Lauer, GM (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.
EM glauer@mgh.harvard.edu
RI Tonnerre, Pierre/AAA-1631-2020; Melgaco, Juliana/AAQ-6084-2020; Lauer,
   Georg/J-1467-2018
OI Tonnerre, Pierre/0000-0002-1719-9736; Melgaco,
   Juliana/0000-0003-0087-6531; Lauer, Georg/0000-0002-9792-4271
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [U01 AI131314, U19 AI082630]; Dutch
   Royal Academy of Arts and Sciences; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [U19AI082630, U19AI082630,
   U01AI131314, U19AI082630, U19AI082630, U19AI082630, U19AI082630,
   U19AI082630, U19AI082630, U19AI082630, U19AI082630, U19AI082630,
   U19AI082630, U19AI082630, U19AI082630, U19AI082630, U19AI082630,
   U19AI082630, U19AI082630, U19AI082630, U19AI082630, U19AI082630,
   U19AI082630, U19AI082630, U19AI082630, U19AI082630, U19AI082630,
   U19AI082630, U19AI082630, U19AI082630, U19AI082630, U01AI131314,
   U19AI082630, U19AI082630, U19AI082630, U19AI082630, U19AI082630] Funding
   Source: NIH RePORTER
FX This work was supported in parts by NIH U01 AI131314 (to GML, AYK and
   LLLX) and U19 AI082630 (to GML, RTC and AYK). RCH received a Ter Meulen
   Fonds Fellowship by the Dutch Royal Academy of Arts and Sciences.
CR Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379
   Bengsch B, 2014, J HEPATOL, V61, P1212, DOI 10.1016/j.jhep.2014.07.005
   Bengsch B, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000947
   Bertoletti A, 2016, J HEPATOL, V64, pS71, DOI 10.1016/j.jhep.2016.01.026
   Boettler T, 2006, J VIROL, V80, P3532, DOI 10.1128/JVI.80.7.3532-3540.2006
   Boni C, 2001, HEPATOLOGY, V33, P963, DOI 10.1053/jhep.2001.23045
   Boni C, 2007, J VIROL, V81, P4215, DOI 10.1128/JVI.02844-06
   Boni C, 2012, GASTROENTEROLOGY, V143, P963, DOI 10.1053/j.gastro.2012.07.014
   Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118
   Das A, 2008, J EXP MED, V205, P2111, DOI 10.1084/jem.20072076
   Desmond CP, 2012, J VIROL, V86, P1181, DOI 10.1128/JVI.05308-11
   FERRARI C, 1990, J IMMUNOL, V145, P3442
   Fisicaro P, 2017, NAT MED, V23, P327, DOI 10.1038/nm.4275
   Fisicaro P, 2012, GASTROENTEROLOGY, V143, P1576, DOI 10.1053/j.gastro.2012.08.041
   Fisicaro P, 2010, GASTROENTEROLOGY, V138, P682, DOI 10.1053/j.gastro.2009.09.052
   Gehring AJ, 2007, J VIROL, V81, P2940, DOI 10.1128/JVI.02415-06
   Greenough TC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012926
   Kakimi K, 2002, J VIROL, V76, P8609, DOI 10.1128/JVI.76.17.8609-8620.2002
   Kasprowicz V, 2010, J VIROL, V84, P1656, DOI 10.1128/JVI.01499-09
   Kefalakes H, 2015, HEPATOLOGY, V62, P47, DOI 10.1002/hep.27771
   Kurktschiev PD, 2014, J EXP MED, V211, P2047, DOI 10.1084/jem.20131333
   Lopes AR, 2008, J CLIN INVEST, V118, P1835, DOI 10.1172/JCI33402
   Maini MK, 2000, J EXP MED, V191, P1269, DOI 10.1084/jem.191.8.1269
   Maini MK, 1999, GASTROENTEROLOGY, V117, P1386, DOI 10.1016/S0016-5085(99)70289-1
   Marraco SAF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3700
   Nassal M, 2015, GUT, V64, P1972, DOI 10.1136/gutjnl-2015-309809
   Nebbia G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047648
   Ott JJ, 2012, VACCINE, V30, P2212, DOI 10.1016/j.vaccine.2011.12.116
   Pallett LJ, 2017, J EXP MED, V214, P1567, DOI 10.1084/jem.20162115
   Pallett LJ, 2015, NAT MED, V21, P591, DOI 10.1038/nm.3856
   Papatheodoridis G, 2016, HEPATOLOGY, V63, P1481, DOI 10.1002/hep.28438
   Peppa D, 2013, J EXP MED, V210, P99, DOI 10.1084/jem.20121172
   Raziorrouh B, 2010, HEPATOLOGY, V52, P1934, DOI 10.1002/hep.23936
   REHERMANN B, 1995, J EXP MED, V181, P1047, DOI 10.1084/jem.181.3.1047
   Rehermann B, 2005, NAT REV IMMUNOL, V5, P215, DOI 10.1038/nri1573
   Rivino L, 2018, J CLIN INVEST, V128, P668, DOI [10.1172/JCI92812, 10.1172/jci92812]
   Sandalova E, 2012, GASTROENTEROLOGY, V143, P78, DOI 10.1053/j.gastro.2012.03.041
   Sauce D, 2007, AIDS, V21, P2005, DOI 10.1097/QAD.0b013e3282eee548
   Schurich A, 2011, HEPATOLOGY, V53, P1494, DOI 10.1002/hep.24249
   Sen DR, 2016, SCIENCE, V354, P1165, DOI 10.1126/science.aae0491
   Sharpe AH, 2018, NAT REV IMMUNOL, V18, P153, DOI 10.1038/nri.2017.108
   Thimme R, 2003, J VIROL, V77, P68, DOI 10.1128/JVI.77.1.68-76.2003
   Webster GJM, 2004, J VIROL, V78, P5707, DOI 10.1128/JVI.78.11.5707-5719.2004
   Webster GJM, 2000, HEPATOLOGY, V32, P1117, DOI 10.1053/jhep.2000.19324
   World Health Organization, 2017, GLOB HEP REP
   Zhang Z, 2009, J HEPATOL, V50, P1163, DOI 10.1016/j.jhep.2009.01.026
NR 46
TC 19
Z9 20
U1 0
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD MAY
PY 2019
VL 68
IS 5
BP 893
EP 904
DI 10.1136/gutjnl-2018-316644
PG 12
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA ID6ZS
UT WOS:000471831400016
PM 30580250
DA 2020-11-30
ER

PT J
AU Mello, VM
   Lago, BV
   Sousa, PSF
   Mello, FCA
   Souza, CB
   Pinto, LCM
   Ginuino, CF
   Fernandes, CAS
   Aguiar, SF
   Villar, LM
   Lampe, E
   Melgaco, JG
   Lewis-Ximenez, LL
AF Mello, Vinicius M.
   Lago, Barbara V.
   Sousa, Paulo S. F.
   Mello, Francisco C. A.
   Souza, Caroline B.
   Pinto, Laura C. M.
   Ginuino, Cleber F.
   Fernandes, Carlos A. S.
   Aguiar, Shirlei F.
   Villar, Livia M.
   Lampe, Elisabeth
   Melgaco, Juliana G.
   Lewis-Ximenez, Lia L.
TI Hepatitis A Strain Linked to the European Outbreaks During Gay Events
   between 2016 and 2017, Identified in a Brazilian Homosexual Couple in
   2017
SO VIRUSES-BASEL
LA English
DT Article
DE Hepatitis A virus (HAV); European strain; HAV in Brazilian MSM
ID VIRUS; MEN
AB Hepatitis A virus (HAV) outbreaks among men who have sex with men (MSM) have been reported worldwide and associated primarily with sexual transmission through oral-anal sex. Here, we provide the molecular and evolutionary description of a European strain, linked to HAV outbreaks among MSM, detected in a Brazilian homosexual couple. Bayesian analysis provided evidence that the viral isolates were introduced in Brazil from Spain between the end of 2016 and the beginning of 2017.
C1 [Mello, Vinicius M.; Lago, Barbara V.; Sousa, Paulo S. F.; Mello, Francisco C. A.; Souza, Caroline B.; Pinto, Laura C. M.; Ginuino, Cleber F.; Villar, Livia M.; Lampe, Elisabeth; Melgaco, Juliana G.; Lewis-Ximenez, Lia L.] Fundacao Oswaldo Cruz, Viral Hepatitis Lab, Oswaldo Cruz Inst, BR-21040900 Rio De Janeiro, RJ, Brazil.
   [Lago, Barbara V.] Fundacao Oswaldo Cruz, Inst Technol Immunobiol Biomanguinhos, BR-21040900 Rio De Janeiro, RJ, Brazil.
   [Fernandes, Carlos A. S.; Aguiar, Shirlei F.] Cent Publ Hlth Lab Noel Nutels, Hepatitis Div, BR-20231092 Rio De Janeiro, RJ, Brazil.
RP Mello, VM; Lago, BV (corresponding author), Fundacao Oswaldo Cruz, Viral Hepatitis Lab, Oswaldo Cruz Inst, BR-21040900 Rio De Janeiro, RJ, Brazil.; Lago, BV (corresponding author), Fundacao Oswaldo Cruz, Inst Technol Immunobiol Biomanguinhos, BR-21040900 Rio De Janeiro, RJ, Brazil.
EM vinicius.mello@ioc.fiocruz.br; barbaravlago@gmail.com;
   paulosfsousa@gmail.com; fcamello@gmail.com; carolinebaldin@uol.com.br;
   lauracmpinto@gmail.com; cleber@ioc.fiocruz.br; cas.fernandes@gmail.com;
   shirleideaguiar@gmail.com; liviafiocruz@gmail.com;
   elisabeth.fiocruz@gmail.com; juliana.melgaco@gmail.com;
   lialewis.fiocruz@gmail.com
RI Melgaco, Juliana/AAQ-6084-2020; MELO VILLAR, LIVIA/F-7811-2012
OI Melgaco, Juliana/0000-0003-0087-6531; Lago, Barbara/0000-0002-9173-6309;
   MELO VILLAR, LIVIA/0000-0001-7644-8969; Mello,
   Vinicius/0000-0001-7705-5921
FU Oswaldo Cruz Institute (IOC)/Oswaldo Cruz Foundation (FIOCRUZ)/Ministry
   of Health, Brazil; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico of Brazil-CNPqNational Council for Scientific and
   Technological Development (CNPq); Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior of Brasil-CAPES [001]
FX Oswaldo Cruz Institute (IOC)/Oswaldo Cruz Foundation (FIOCRUZ)/Ministry
   of Health, Brazil; and the Brazilian national funding agencies (Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico of Brazil-CNPq and
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior of
   Brasil-CAPES, finance code 001).
CR Aloise R, 2008, INT J STD AIDS, V19, P321, DOI 10.1258/ijsa.2007.007100
   Bordi L, 2012, J CLIN VIROL, V54, P26, DOI 10.1016/j.jcv.2012.01.009
   Cella E, 2018, J MED VIROL, V90, P1493, DOI 10.1002/jmv.25220
   Centers for Disease Control and Prevention (CDC), 2017, HEP INF
   Centers for Disease Control (CDC), 1992, MMWR Morb Mortal Wkly Rep, V41, P161
   Chen GJ, 2017, J INFECT DIS, V215, P1339, DOI 10.1093/infdis/jix123
   CHRISTENSON B, 1982, AM J EPIDEMIOL, V116, P599, DOI 10.1093/oxfordjournals.aje.a113442
   COREY L, 1980, NEW ENGL J MED, V302, P435, DOI 10.1056/NEJM198002213020804
   European Centre for Disease Prevention and Control, 2017, EP UPD HEP OUTBR EU
   European Centre for Disease Prevention and Control, 2017, HEP OUTBR EU EEA MOS
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Federal Government of Brazil, 2016, MED GUID RIO 2016 OL
   Governo Federal do Brasil Ministerio da Saude, 102018 GOV FED BRAS
   Governo Federal do Brasil Ministerio da Saude, 2018, B EP HEP VIR 2018
   Gozlan Y, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.29.30575
   HENNING KJ, 1995, AM J MED, V99, P132, DOI 10.1016/S0002-9343(99)80132-6
   Lanini S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185428
   LEENTVAARKUIJPERS A, 1995, INT J EPIDEMIOL, V24, P218, DOI 10.1093/ije/24.1.218
   Rivas V, 2018, EUROSURVEILLANCE, V23, P14, DOI 10.2807/1560-7917.ES.2018.23.9.18-00060
   Shire NJ, 2006, VACCINE, V24, P272, DOI 10.1016/j.vaccine.2005.07.102
   Wang H, 2015, INT J INFECT DIS, V33, P156, DOI 10.1016/j.ijid.2015.01.022
   World Health Organization, 2017, HEP OUTBR MOSTL AFF
NR 22
TC 2
Z9 2
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD MAR 20
PY 2019
VL 11
IS 3
AR 281
DI 10.3390/v11030281
PG 7
WC Virology
SC Virology
GA HT2ML
UT WOS:000464396700001
PM 30897727
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Yue, C
   Teitz, S
   Miyabashi, T
   Boller, K
   Lewis-Ximenez, LL
   Baylis, SA
   Blumel, J
AF Yue, Constanze
   Teitz, Sebastian
   Miyabashi, Tomoyuki
   Boller, Klaus
   Lewis-Ximenez, Lia Laura
   Baylis, Sally A.
   Bluemel, Johannes
TI Inactivation and Removal of Chikungunya Virus and Mayaro Virus from
   Plasma-derived Medicinal Products
SO VIRUSES-BASEL
LA English
DT Article
DE alphaviruses; inactivation; heat treatment; S; D treatment;
   plasma-derived medicinal products; chikungunya virus; Mayaro virus;
   virus retentive filtration; nanofiltration
ID WEST-NILE-VIRUS; ZIKA VIRUS; SOLVENT/DETERGENT TREATMENT; HEAT
   INACTIVATION; VACCINIA VIRUS; TREATED PLASMA; EPIDEMIC; THERMOSTABILITY;
   NANOFILTRATION; PASTEURIZATION
AB Background: Chikungunya virus (CHIKV) and Mayaro virus (MAYV) are closely related members of the Semliki Forest complex within the genus alphavirus and are transmitted by arthropods, causing acute febrile illness in humans. CHIKV has spread to almost all continents, whereas autochthonous MAYV infections have been reported in South America and in the Caribbean. Nevertheless, there was concern about potential spread of MAYV to other regions similar to CHIKV in the past. The risk for transmission of emerging viruses by blood transfusion and the safety of plasma-derived medicinal products (PDMPs) are constant concerns. The manufacturing processes of PDMPs include procedures to inactivate/remove viruses. Methods: In this study, we investigated the reduction of MAYV and CHIKV by heat inactivation in various matrices, solvent/detergent treatment and nanofiltration. Results: Unexpectedly, MAYV was significantly more resistant to heat and solvent/detergent treatment compared to CHIKV. However, being similar in size, both MAYV and CHIKV were removed below the detection limit by 35 nm virus filters. Conclusions: The inactivation profiles of different alphavirus members vary considerably, even within the Semliki Forest Complex. However, robust dedicated viral inactivation/removal procedures commonly used in the plasma product industry are effective in inactivating or removing MAYV and CHIKV.
C1 [Yue, Constanze; Boller, Klaus; Baylis, Sally A.; Bluemel, Johannes] Paul Ehrlich Inst, Dept Virol, D-63225 Langen, Germany.
   [Teitz, Sebastian; Miyabashi, Tomoyuki] Asahi Kasei, D-51105 Cologne, Germany.
   [Lewis-Ximenez, Lia Laura] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, BR-21040900 Rio De Janeiro, RJ, Brazil.
RP Yue, C (corresponding author), Paul Ehrlich Inst, Dept Virol, D-63225 Langen, Germany.
EM Constanze.Yue@pei.de; s.teitz@akbio.eu;
   miyabayashi.tb@om.asahi-kasei.co.jp; Klaus.Boller@pei.de;
   lialewis.fiocruz@gmail.com; Sally.Baylis@pei.de; Johannes.Bluemel@pei.de
CR Appassakij H, 2013, TRANSFUSION, V53, P2567, DOI 10.1111/j.1537-2995.2012.03960.x
   Baba M, 2013, J INFECT DEV COUNTR, V7, P51, DOI 10.3855/jidc.2411
   Blumel J, 2017, TRANSFUSION, V57, P790, DOI 10.1111/trf.13873
   Brouard C, 2008, TRANSFUSION, V48, P1333, DOI 10.1111/j.1537-2995.2008.01646.x
   Burnouf T, 2005, CURR NANOSCI, V1, P189, DOI 10.2174/157341305774642894
   Cadar D, 2017, EUROSURVEILLANCE, V22, P9, DOI [10.2807/1560-7917.ES.2017.22.14.30501, 10.2807/1560-7917.es.2017.22.14.30501]
   Cardone F, 2012, TRANSFUSION, V52, P953, DOI 10.1111/j.1537-2995.2011.03425.x
   Cella E, 2018, ASIAN PAC J TROP MED, V11, P194, DOI 10.4103/1995-7645.228433
   Centers for Diease Control and Prevention, 2018, GEOGR DISTR CHIK VIR
   Dichtelmuller HO, 2009, TRANSFUSION, V49, P1931, DOI 10.1111/j.1537-2995.2009.02222.x
   Dodd RY, 2015, TRANSFUS MED REV, V29, P153, DOI 10.1016/j.tmrv.2015.03.001
   Espindola OM, 2006, J VIROL METHODS, V134, P171, DOI 10.1016/j.jviromet.2006.01.001
   Fang Y, 2009, AM J TROP MED HYG, V80, P862, DOI 10.4269/ajtmh.2009.80.862
   Farcet MR, 2017, TRANSFUSION, V57, P797, DOI 10.1111/trf.13953
   HARRISON SC, 1971, J MOL BIOL, V60, P523, DOI 10.1016/0022-2836(71)90186-0
   Hassing RJ, 2010, EUROSURVEILLANCE, V15, P22
   Henss L, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010082
   HOROWITZ B, 1992, BLOOD, V79, P826
   Huang YJS, 2015, VECTOR-BORNE ZOONOT, V15, P674, DOI 10.1089/vbz.2015.1795
   Huangfu CJ, 2017, BIOLOGICALS, V46, P139, DOI 10.1016/j.biologicals.2017.01.009
   Johnson BW, 2016, AM J TROP MED HYG, V95, P182, DOI 10.4269/ajtmh.16-0013
   Karber G, 1931, N-S ARCH EX PATH PH, V162, P480, DOI 10.1007/BF01863914
   KNEVELMAN A, 1994, VOX SANG, V66, P89, DOI 10.1111/j.1423-0410.1994.tb00288.x
   Kre<ss> J.A., 2017, COLLABORATIVE STUDY
   Leydold SM, 2012, TRANSFUSION, V52, P2122, DOI 10.1111/j.1537-2995.2012.03565.x
   Liumbruno GM, 2008, BLOOD TRANSFUS-ITALY, V6, P199, DOI 10.2450/2008.0016-08
   Long KC, 2011, AM J TROP MED HYG, V85, P750, DOI 10.4269/ajtmh.2011.11-0359
   Mackay IM, 2016, MICROBES INFECT, V18, P724, DOI 10.1016/j.micinf.2016.10.007
   Musso D, 2016, LANCET, V387, P1993, DOI 10.1016/S0140-6736(16)30428-7
   PAREDES AM, 1993, P NATL ACAD SCI USA, V90, P9095, DOI 10.1073/pnas.90.19.9095
   Park SL, 2016, J VIROL METHODS, V234, P152, DOI 10.1016/j.jviromet.2016.04.004
   Pisani G, 2016, TRANSFUS MED HEMOTH, V43, P158, DOI 10.1159/000446219
   Rabenau HF, 2016, BUNDESGESUNDHEITSBLA, V59, P540, DOI 10.1007/s00103-016-2325-8
   Remington KM, 2004, VOX SANG, V87, P10, DOI 10.1111/j.1423-0410.2004.00530.x
   Rezvan H, 2006, MED J ISLAM REPUB IR, V20, P86
   Roberts P, 2000, BIOLOGICALS, V28, P29, DOI 10.1006/biol.1999.0236
   Roberts P, 2002, BIOLOGICALS, V30, P255, DOI 10.1006/biol.2002.0340
   Roberts P, 1999, BIOLOGICALS, V27, P263, DOI 10.1006/biol.1999.0178
   Ruppach H, 2014, BIOPROCESS J, V12, P24, DOI DOI 10.12665/J124.RUPPACH
   Seitz H, 2002, BIOLOGICALS, V30, P197, DOI 10.1006/biol.2002.0328
   Spearman C, 1908, BRIT J PSYCHOL, V2, P227, DOI 10.1111/j.2044-8295.1908.tb00176.x
   STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994
   Tesh RB, 1999, CLIN INFECT DIS, V28, P67, DOI 10.1086/515070
   UEMURA Y, 1994, VOX SANG, V67, P246, DOI 10.1111/j.1423-0410.1994.tb01246.x
   Venturi G, 2017, EUROSURVEILLANCE, V22, P11, DOI 10.2807/1560-7917.ES.2017.22.39.17-00646
   Weidmann M, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-81
NR 46
TC 2
Z9 2
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD MAR 7
PY 2019
VL 11
IS 3
AR 234
DI 10.3390/v11030234
PG 13
WC Virology
SC Virology
GA HT2RD
UT WOS:000464409200005
PM 30866548
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Ribeiro, CRD
   Amado, LA
   Tourinho, RS
   Lima, LRP
   Melgaco, JG
   de Almeida, AJ
   Bastos, LS
   Lewis-Ximenez, LL
   de Paula, VS
AF de Almeida Ribeiro, Camilla R.
   Amado, Luciane A.
   Tourinho, Renata S.
   Pinto Lima, Lyana R.
   Melgaco, Juliana G.
   de Almeida, Adilson J.
   Bastos, Leonardo S.
   Lewis-Ximenez, Lia L.
   de Paula, Vanessa S.
TI Accuracy of rapid test for diagnosis of hepatitis A with different
   infection rate settings and with predictive modeling
SO FUTURE MICROBIOLOGY
LA English
DT Article
DE hepatitis A antibodies; outbreak; rapid immunochromatographic test;
   seroepidemiology studies; vaccine
ID PERFORMANCE; PREVALENCE; ANTIBODIES; ASSAYS
AB Aim: We evaluated the accuracy of a commercial rapid immunochromatographic test (rapid test [RT]) for hepatitis A (HA) diagnosis and epidemiological studies. Materials & methods: The accuracy of a RT was evaluated in laboratory and in field conditions. Predictive modeling estimated the test performance in a hypothetical population. Results: The RT showed sensitivities of 66-86%, and specificities of 21-100%, depending on the antibody isotype (IgM or IgG) analyzed and prevalence of infection. Conclusion: The RT is a good alternative for diagnostic in HA outbreaks. The predictive model indicates that it should not be used alone for HA diagnosis in low prevalence populations. These data can be used in the future to strengthen decision-making during the implementation of rapid diagnostic methods in health services.
C1 [de Almeida Ribeiro, Camilla R.; Pinto Lima, Lyana R.; de Paula, Vanessa S.] Fundacao Oswaldo Cruz, Oswaldo Cruz Inst, Lab Mol Virol, Rio De Janeiro, Brazil.
   [Amado, Luciane A.; Tourinho, Renata S.; Melgaco, Juliana G.] Fundacao Oswaldo Cruz, Oswaldo Cruz Inst, Lab Dev Technol Virol, Rio De Janeiro, Brazil.
   [de Almeida, Adilson J.] Fed Univ State Rio de Janeiro, Sch Med & Surg, Gaffree & Guinle Univ Hosp, Dept Gen Med, Rio De Janeiro, Brazil.
   [Bastos, Leonardo S.] Fundacao Oswaldo Cruz, Sci Comp Program, Rio De Janeiro, Brazil.
   [Lewis-Ximenez, Lia L.] Fundacao Oswaldo Cruz, Oswaldo Cruz Inst, Viral Hepatitis Lab, Ambulatory Clin Viral Hepatitis, Rio De Janeiro, Brazil.
RP Amado, LA (corresponding author), Fundacao Oswaldo Cruz, Oswaldo Cruz Inst, Lab Dev Technol Virol, Rio De Janeiro, Brazil.
EM l_amado@ioc.fiocruz.br
RI Bastos, Leonardo Soares/AAD-5335-2019; Melgaco, Juliana/AAQ-6084-2020;
   de Paula, Vanessa S/I-8037-2016
OI Bastos, Leonardo Soares/0000-0002-1406-0122; Melgaco,
   Juliana/0000-0003-0087-6531; de Paula, Vanessa S/0000-0002-6314-754X
FU Oswaldo Cruz Foundation
FX This study was supported by Oswaldo Cruz Foundation. The authors have no
   other relevant affiliations or financial involvement with any
   organization or entity with a financial interest in or financial
   conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR ALTMAN DG, 1991, STAT MED, V10, P1897, DOI 10.1002/sim.4780101206
   Amado LA, 2010, INT J EXP PATHOL, V91, P87, DOI 10.1111/j.1365-2613.2009.00699.x
   Bower WA, 2000, J INFECT DIS, V182, P12, DOI 10.1086/315701
   Brasil MS, 2017, B HEPATITES, V48, P9
   Centeno Monica A., 2002, Pediatr Crit Care Med, V3, P227, DOI 10.1097/00130478-200207000-00004
   Cha YJ, 2013, ANN LAB MED, V33, P184, DOI 10.3343/alm.2013.33.3.184
   Ciocca M, 2008, ARCH DIS CHILD, V93, P48, DOI 10.1136/adc.2006.115113
   Ciocca M, 2007, PEDIATR INFECT DIS J, V26, P711, DOI 10.1097/INF.0b013e3180f60bed
   Cruz HM, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1249-5
   Ximenes RAD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094622
   Ximenes RAD, 2010, CAD SAUDE PUBLICA, V26, P1693, DOI 10.1590/S0102-311X2010000900003
   Lee HJ, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-164
   Lemon SM, 2018, J HEPATOL, V68, P167, DOI 10.1016/j.jhep.2017.08.034
   Lima LR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102925
   Mcknight KL, 2018, COLD SPRING HARB PER, V8
   Murphy TV, 2016, MMWR-MORBID MORTAL W, V65, P29, DOI 10.15585/mmwr.su6501a6
   Naz A, 2014, PAK J MED SCI, V30, P166, DOI 10.12669/pjms.301.4173
   Organization WH, 2012, WEEKL EP REC, V87, P261
   Platform SDK, 2017, SUSTAINABLE DEV GOAL
   PROVOST PJ, 1975, P SOC EXP BIOL MED, V148, P532
   Scalioni LD, 2014, J CLIN VIROL, V60, P200, DOI 10.1016/j.jcv.2014.04.001
   Scheiblauer H, 2006, TRANSFUSION, V46, P708, DOI 10.1111/j.1537-2995.2006.00789.x
   Shin EC, 2018, COLD SPRING HARB PER, V8
   Standard Diagnostics, 2013, SD BIOLINE HAV IGG I
   Vitral CL, 2012, MEM I OSWALDO CRUZ, V107, P652, DOI 10.1590/S0074-02762012000500012
   Walker Barbara Wyand, 2018, Nursing, V48, P66, DOI 10.1097/01.NURSE.0000531014.78460.95
   World Health Organization, 2016, GLOB HLTH SECT STRAT
   Yong H. T., 2009, INT FOOD RES J, V16, P455
NR 28
TC 1
Z9 1
U1 0
U2 0
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746-0913
EI 1746-0921
J9 FUTURE MICROBIOL
JI Future Microbiol.
PD FEB
PY 2019
VL 14
IS 3
BP 247
EP 258
DI 10.2217/fmb-2018-0211
PG 12
WC Microbiology
SC Microbiology
GA HN7ET
UT WOS:000460352400009
PM 30663895
DA 2020-11-30
ER

PT J
AU Henss, L
   Yue, C
   Kandler, J
   Faddy, HM
   Simmons, G
   Panning, M
   Lewis-Ximenez, LL
   Baylis, SA
   Schnierle, BS
AF Henss, Lisa
   Yue, Constanze
   Kandler, Joshua
   Faddy, Helen M.
   Simmons, Graham
   Panning, Marcus
   Lewis-Ximenez, Lia Laura
   Baylis, Sally A.
   Schnierle, Barbara S.
TI Establishment of an Alphavirus-Specific Neutralization Assay to
   Distinguish Infections with Different Members of the Semliki Forest
   Complex
SO VIRUSES-BASEL
LA English
DT Article
DE alphavirus; neutralization assay; lentiviral vector; pseudotyping
ID ROSS RIVER VIRUS; MAYARO-VIRUS; CHIKUNGUNYA; HISTORY; DISEASE;
   GLYCOPROTEINS; PATHOGENESIS; OUTBREAK
AB Background: Alphaviruses are transmitted by arthropod vectors and can be found worldwide. Alphaviruses of the Semliki Forest complex such as chikungunya virus (CHIKV), Mayaro virus (MAYV) or Ross River virus (RRV) cause acute febrile illness and long-lasting arthralgia in humans, which cannot be clinically discriminated from a dengue virus or Zika virus infection. Alphaviruses utilize a diverse array of mosquito vectors for transmission and spread. For instance, adaptation of CHIKV to transmission by Aedes albopictus has increased its spread and resulted in large outbreaks in the Indian Ocean islands. For many alphaviruses commercial diagnostic tests are not available or show cross-reactivity among alphaviruses. Climate change and globalization will increase the spread of alphaviruses and monitoring of infections is necessary and requires virus-specific methods. Method: We established an alphavirus neutralization assay in a 384-well format by using pseudotyped lentiviral vectors. Results: MAYV-specific reactivity could be discriminated from CHIKV reactivity. Human plasma from blood donors infected with RRV could be clearly identified and did not cross-react with other alphaviruses. Conclusion: This safe and easy to use multiplex assay allows the discrimination of alphavirus-specific reactivity within a single assay and has potential for epidemiological surveillance. It might also be useful for the development of a pan-alphavirus vaccine.
C1 [Henss, Lisa; Yue, Constanze; Kandler, Joshua; Baylis, Sally A.; Schnierle, Barbara S.] Paul Ehrlich Inst, Dept Virol, D-63225 Langen, Germany.
   [Faddy, Helen M.] Australian Red Cross Blood Serv, Brisbane, Qld 4000, Australia.
   [Simmons, Graham] Vitalant Res Inst, San Francisco, CA 94118 USA.
   [Panning, Marcus] Univ Freiburg, Fac Med, Inst Virol, Med Ctr, D-79106 Freiburg, Germany.
   [Lewis-Ximenez, Lia Laura] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, BR-21040900 Rio De Janeiro, RJ, Brazil.
RP Schnierle, BS (corresponding author), Paul Ehrlich Inst, Dept Virol, D-63225 Langen, Germany.
EM Lisa.Henss@pei.de; Constanze.Yue@pei.de; jdkandler@gmail.com;
   hFaddy@redcrossblood.org.au; gsimmons@vitalant.org;
   marcus.panning@uniklinik-freiburg.de; lialewis.fiocruz@gmail.com;
   Sally.Baylis@pei.de; Barbara.Schnierle@pei.de
RI Panning, Marcus/I-7889-2016; Simmons, Graham/G-3523-2012; Schnierle,
   Barbara/AAG-8108-2019
OI Simmons, Graham/0000-0002-9615-7023; 
FU German Ministry of Health (BMG); NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [R01 AI119056];
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI119056, R01AI119056, R01AI119056, R01AI119056] Funding Source: NIH
   RePORTER
FX This research was funded by the German Ministry of Health (BMG) by a
   grant to S.A.B. and B.S.S and the NIH grant R01 AI119056 to G.S.
CR Adam A, 2016, VECTOR-BORNE ZOONOT, V16, P290, DOI 10.1089/vbz.2015.1897
   Agarwal A, 2016, VIROLOGY, V497, P59, DOI 10.1016/j.virol.2016.06.025
   ANDERSON CR, 1957, AM J TROP MED HYG, V6, P1012, DOI 10.4269/ajtmh.1957.6.1012
   ATKINS GJ, 1985, J GEN VIROL, V66, P395, DOI 10.1099/0022-1317-66-3-395
   Auguste AJ, 2015, EMERG INFECT DIS, V21, P1742, DOI 10.3201/eid2110.141660
   Claflin SB, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005070
   Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998
   Flies EJ, 2018, BIOSCIENCE, V68, P288, DOI 10.1093/biosci/biy011
   Forrester NL, 2012, J VIROL, V86, P2729, DOI 10.1128/JVI.05591-11
   Fox JM, 2015, CELL, V163, P1095, DOI 10.1016/j.cell.2015.10.050
   Mourao MPG, 2012, VECTOR-BORNE ZOONOT, V12, P42, DOI 10.1089/vbz.2011.0669
   Gratz NG, 2004, MED VET ENTOMOL, V18, P215, DOI 10.1111/j.0269-283X.2004.00513.x
   Jacups SP, 2008, VECTOR-BORNE ZOONOT, V8, P283, DOI 10.1089/vbz.2007.0152
   Kahl CA, 2005, MOL THER, V11, P470, DOI 10.1016/j.ymthe.2004.08.032
   Kahl CA, 2004, J VIROL, V78, P1421, DOI 10.1128/JVI.78.3.1421-1430.2004
   Kam YW, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003445
   Kishishita N, 2013, J CLIN MICROBIOL, V51, P1389, DOI 10.1128/JCM.03109-12
   Lednicky J, 2016, EMERG INFECT DIS, V22, P2000, DOI 10.3201/eid2211.161015
   Liu X, 2017, MICROBES INFECT, V19, P496, DOI 10.1016/j.micinf.2017.07.001
   Long KC, 2011, AM J TROP MED HYG, V85, P750, DOI 10.4269/ajtmh.2011.11-0359
   Lum FM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20305-4
   Mackay IM, 2016, MICROBES INFECT, V18, P724, DOI 10.1016/j.micinf.2016.10.007
   Marano G, 2017, BLOOD TRANSFUS-ITALY, V15, P489, DOI 10.2450/2017.0215-17
   Moreira J, 2018, CLIN MICROBIOL INFEC, V24, P827, DOI 10.1016/j.cmi.2018.05.001
   Partidos CD, 2012, VACCINE, V30, P4638, DOI 10.1016/j.vaccine.2012.04.099
   Possas C, 2016, EPIDEMIOL HEALTH, V38, DOI 10.4178/epih.e2016023
   Prat CM, 2014, EMERG INFECT DIS, V20, P2129, DOI 10.3201/eid2012.141269
   Salvador B, 2009, VIROLOGY, V393, P33, DOI 10.1016/j.virol.2009.07.013
   Schwartz O, 2010, NAT REV MICROBIOL, V8, P491, DOI 10.1038/nrmicro2368
   Seaman MS, 2010, J VIROL, V84, P1439, DOI 10.1128/JVI.02108-09
   Siegert Sandra, 2005, AIDS Res Ther, V2, P7, DOI 10.1186/1742-6405-2-7
   Smith JL, 2018, MSPHERE, V3, DOI [10.1128/mSphere.00003-18, 10.1128/msphere.00003-18]
   SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628
   Tesh RB, 1999, CLIN INFECT DIS, V28, P67, DOI 10.1086/515070
   Theilacker C, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-369
   Weber C, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005318
   Weber C, 2014, J VIROL METHODS, V201, P7, DOI 10.1016/j.jviromet.2014.02.001
   World Health Organization (WHO), 2014, ANN EMERG MED, V64, P552, DOI DOI 10.1016/J.ANNEMERGMED.2014.08.002
   Zeller H, 2016, J INFECT DIS, V214, pS436, DOI 10.1093/infdis/jiw391
NR 39
TC 5
Z9 5
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD JAN
PY 2019
VL 11
IS 1
AR 82
DI 10.3390/v11010082
PG 13
WC Virology
SC Virology
GA HM0IW
UT WOS:000459132000081
PM 30669393
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Flores, GL
   Cruz, HM
   Miguel, JC
   Potsch, DV
   Pilotto, JH
   Lewis-Ximenez, LL
   Lampe, E
   Villar, LM
AF Flores, Geane Lopes
   Cruz, Helena Medina
   Miguel, Juliana Custodio
   Potsch, Denise Vigo
   Pilotto, Jose Henrique
   Lewis-Ximenez, Lia Laura
   Lampe, Elisabeth
   Villar, Livia Melo
TI Assessing hepatitis B immunity using dried blood spot samples from HIV
   plus individuals
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE diagnosis; dried blood spot; hepatitis B; immunodeficiency virus;
   immunity
ID INFECTED PATIENTS; VACCINATION COVERAGE; MARKERS; VIRUS
AB This study aims to evaluate the utility of an optimized enzyme immunoassay (EIA) to detect and quantify antibodies against hepatitis B surface antibody (anti-HBs) in dried blood spots (DBSs) within the context of human immunodeficiency virus (HIV) status. Serum and DBS samples were obtained from 56 HIV+ and 99 HIV- patients and subjected to EIA for the detection of anti-HBs, where sample volume and cut off value were modified for DBS testing. Sensitivities of anti-HBs detection in DBS were 79.8% and 76.8% in HIV- and HIV+ subjects, respectively. Concordant results for anti-HBs in serum and DBS presented high mean CD8 cell counts, HIV viral load and optical density (OD) values of anti-HBs. Anti-HBs titers were significantly higher in serum, whether or not anti-HBs titers were detected in DBS. It was possible to detect anti-HBs in DBS as low as 17.4 and 27.3IU/mL among HIV+ and HIV- subjects, respectively. In conclusion, DBS can be used to detect and quantify anti-HBs in HIV-infected individuals, which could increase access to diagnosis and vaccination.
   Highlights Evaluation of anti-HBs detection in DBS according to HIV status.Similar performance of anti-HBs detection from DBS independent of HIV status.Detection of anti-HBs in concentration up to 17 IU / mL in DBS.DBS could be a potential tool to increase identification of hepatitis B immunity.
C1 [Flores, Geane Lopes; Cruz, Helena Medina; Miguel, Juliana Custodio; Lewis-Ximenez, Lia Laura; Lampe, Elisabeth; Villar, Livia Melo] Fiocruz MS, Oswaldo Cruz Inst, Viral Hepatitis Lab, Helio & Peggy Pereira Pavill,Ground Floor,Off B09, BR-21036004 Rio De Janeiro, Brazil.
   [Potsch, Denise Vigo] Univ Fed Rio de Janeiro, Clementino Fraga Filho Hosp, Infect Dis Ambulatory, Rio De Janeiro, Brazil.
   [Pilotto, Jose Henrique] Nova Iguacu Gen Hosp, Dept Sexual Transmitted Dis, Nova Iguacu, RJ, Brazil.
   [Pilotto, Jose Henrique] Fiocruz MS, Oswaldo Cruz Inst, Mol Immunol Lab, Rio De Janeiro, Brazil.
RP Villar, LM (corresponding author), Fiocruz MS, Oswaldo Cruz Inst, Viral Hepatitis Lab, Helio & Peggy Pereira Pavill,Ground Floor,Off B09, BR-21036004 Rio De Janeiro, Brazil.
EM liviafiocruz@gmail.com
RI Cruz, Helena Medina/U-4780-2019; Pilotto, Jose Henrique/AAD-9773-2019;
   MELO VILLAR, LIVIA/F-7811-2012
OI Cruz, Helena Medina/0000-0003-2088-7705; Pilotto, Jose
   Henrique/0000-0003-0521-8597; MELO VILLAR, LIVIA/0000-0001-7644-8969
FU State Research Foundation in Rio de Janeiro (FAPERJ); Brazilian National
   Council of Technological and Scientific Development (CNPq)National
   Council for Scientific and Technological Development (CNPq); Brazilian
   Ministry of Health; Coordination of Personal Improvement of Higher
   Education (CAPES); Oswaldo Cruz Foundation (FIOCRUZ)
FX State Research Foundation in Rio de Janeiro (FAPERJ); Brazilian National
   Council of Technological and Scientific Development (CNPq); Brazilian
   Ministry of Health; Coordination of Personal Improvement of Higher
   Education (CAPES); Oswaldo Cruz Foundation (FIOCRUZ)
CR Barbosa JR, 2017, J VIROL METHODS, V248, P244, DOI 10.1016/j.jviromet.2017.08.001
   Chaiklang K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080409
   Flores GL, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13030314
   Fuster F, 2016, VACCINE, V34, P1889, DOI 10.1016/j.vaccine.2016.02.055
   Haban H, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4776-8
   Lee CE, 2011, ANN ACAD MED SINGAP, V40, P448
   Martins S, 2015, BRAZ J INFECT DIS, V19, P181, DOI 10.1016/j.bjid.2014.12.002
   Mena G, 2015, HUM VACC IMMUNOTHER, V11
   Mohamed S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061077
   Mossner BK, 2016, WORLD J GASTROENTERO, V22, P7604, DOI 10.3748/wjg.v22.i33.7604
   Potsch DV, 2012, VACCINE, V30, P5973, DOI 10.1016/j.vaccine.2012.07.028
   Ross RS, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-72
   Snijdewind IJM, 2012, ANTIVIR RES, V93, P309, DOI 10.1016/j.antiviral.2011.12.011
   Tengan FM, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2695-z
   Valour F, 2014, VACCINE, V32, P4558, DOI 10.1016/j.vaccine.2014.06.015
   Villar LM, 2011, J MED VIROL, V83, P1522, DOI 10.1002/jmv.22138
   World Health Organization, 2017, HEP B
   Ximenes RAA, 2015, AM J TROP MED HYG, V93, P1341, DOI 10.4269/ajtmh.15-0216
NR 18
TC 1
Z9 1
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD DEC
PY 2018
VL 90
IS 12
BP 1863
EP 1867
DI 10.1002/jmv.25275
PG 5
WC Virology
SC Virology
GA GX0PG
UT WOS:000447412600012
PM 30085359
DA 2020-11-30
ER

PT J
AU Cruz, HM
   Barbosa, JR
   Colares, JKB
   Neto, AHAD
   Alencar, MDL
   Bastos, FI
   da Mota, JC
   Carvalho-Costa, FA
   Ivantes, CAP
   Lewis-Ximenez, LL
   Villar, LM
AF Cruz, Helena Medina
   Barbosa, Jakeline Ribeiro
   Baima Colares, Jeova Keny
   Almeida de Moraes Neto, Antonio Henrique
   Leal Alencar, Maria de Fatima
   Bastos, Francisco Inacio
   da Mota, Jurema Correa
   Carvalho-Costa, Filipe Anibal
   Pontes Ivantes, Claudia Alexandra
   Lewis-Ximenez, Lia Laura
   Villar, Livia Melo
TI Cross-sectional study to determine viral hepatitis knowledge in
   different urban populations in Brazil
SO WORLD JOURNAL OF HEPATOLOGY
LA English
DT Article
DE Viral hepatitis; Knowledge; Perception; Urban population; Brazil
ID VIRUS-INFECTION; HBV INFECTION; PREVALENCE; ATTITUDES; MARKERS
AB AIM
   To evaluate viral hepatitis knowledge among individuals from different resource areas and health conditions to identify possible gaps.
   METHODS
   A cross-sectional, descriptive study was carried out among 447 individuals from five distinct populations in Brazil: Southeast Viral Hepatitis Ambulatory (n = 100), South (n = 89) and Northeast (n = 114) Health Center, Southeast (n = 77) and Northeast (n = 67) low resource areas. All individuals answered a questionnaire assessing sociodemographic characteristics and viral hepatitis awareness. The perception was scored based on the average number of correct answers of all participants and categorized as "low" (0-28 correct answers) or "desirable" (29-46 correct answers). Associations between sociodemographic characteristics and perception were also evaluated.
   RESULTS
   A low level of knowledge was observed in individuals from Northeast Health Center, Northeast and Southeast low resource areas while desirable knowledge was observed in individuals from Viral Hepatitis Ambulatory and South Health Center. According to sociodemographic characteristics, desirable scores were more common among those with secondary education (47.1%), those who declared themselves as white (46.3%), and those who lived in houses with three individuals (25.5%). Multivariate analysis showed an association between viral hepatitis perception and type of population.
   CONCLUSION
   The results demonstrated high level of knowledge among study participants from health clinics from the Southeast region of Brazil and the importance of education programs in increasing the level of knowledge in low resource areas.
C1 [Cruz, Helena Medina; Barbosa, Jakeline Ribeiro; Lewis-Ximenez, Lia Laura; Villar, Livia Melo] Fiocruz MS, Lab Viral Hepatitis, Oswaldo Cruz Inst, BR-21040360 Rio De Janeiro, Brazil.
   [Barbosa, Jakeline Ribeiro; Baima Colares, Jeova Keny] Univ Fed Ceara, Postgrad Program Pathol, BR-60020181 Fortaleza, Ceara, Brazil.
   [Baima Colares, Jeova Keny] Univ Fortaleza, Postgrad Program Med Sci, BR-60430160 Fortaleza, Ceara, Brazil.
   [Almeida de Moraes Neto, Antonio Henrique; Leal Alencar, Maria de Fatima] Fiocruz MS, Oswaldo Cruz Inst, Lab Innovat Therapies Teaching & Bioprod, BR-21040360 Rio De Janeiro, Brazil.
   [Bastos, Francisco Inacio; da Mota, Jurema Correa] Fundacao Oswaldo Cruz, Inst Commun & Sci Informat & Technol Hlth, BR-21040900 Rio De Janeiro, Brazil.
   [Carvalho-Costa, Filipe Anibal] Fiocruz MS, Oswaldo Cruz Inst, Lab Epidemiol & Mol Systemat, BR-21040900 Rio De Janeiro, Brazil.
   [Pontes Ivantes, Claudia Alexandra] Orientat & Counselling Ctr, BR-80810070 Curitiba, Parana, Brazil.
RP Villar, LM (corresponding author), Oswaldo Cruz Inst, Viral Hepatitis Lab, Helio & Peggy Pereira Pavill,Ground Floor, BR-21036004 Manguinho, RJ, Brazil.
EM lvillar@ioc.fiocruz.br
RI Colares, Jeova Keny Baima/C-5257-2014; Cruz, Helena Medina/U-4780-2019;
   Barbosa, Jakeline/AAC-9805-2020; MELO VILLAR, LIVIA/F-7811-2012
OI Colares, Jeova Keny Baima/0000-0003-1367-6272; Cruz, Helena
   Medina/0000-0003-2088-7705; Barbosa, Jakeline/0000-0001-6238-7173; Mota,
   Jurema/0000-0002-5007-1590; MELO VILLAR, LIVIA/0000-0001-7644-8969
FU CAPESCAPES; CNPqNational Council for Scientific and Technological
   Development (CNPq); FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ)
FX The authors would like to acknowledge the financial support of CAPES,
   CNPq and FAPERJ, and the volunteers who agreed to participate in this
   study.
CR Abdela Abdnur, 2016, BMC Res Notes, V9, P410, DOI 10.1186/s13104-016-2216-y
   Ataei B, 2013, HEPAT MON, V13, DOI 10.5812/hepatmon.6215
   Brouard C, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-576
   Centers for Disease Control and Prevention (CDC), 2012, EPIDEMIOLOGY PREVENT
   Chemaitelly H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069803
   Cruz HM, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15020189
   Cui WH, 2016, INT J INFECT DIS, V49, P62, DOI 10.1016/j.ijid.2016.05.028
   Debing Y, 2016, J HEPATOL, V65, P200, DOI 10.1016/j.jhep.2016.02.045
   dos Santos DCM, 2002, MEM I OSWALDO CRUZ, V97, P637, DOI 10.1590/S0074-02762002000500007
   Focaccia R, 2013, TRATADO HEPATITES VI
   Ganczak M, 2016, J COMMUN HEALTH, V41, P635, DOI 10.1007/s10900-015-0139-5
   Ghahramani F., 2006, Hepatitis Monthly, V6, P59
   Instituto Brasileiro de Geografia e Etatistica, PORT IBGE
   Joukar F, 2012, WORLD J GASTROENTERO, V18, P2238, DOI 10.3748/wjg.v18.i18.2238
   Komatsu H, 2012, J INFECT DIS, V206, P478, DOI 10.1093/infdis/jis293
   Lyra AC, 2005, BRAZ J MED BIOL RES, V38, P767, DOI 10.1590/S0100-879X2005000500015
   Maniero VC, 2012, J NURS UFPE LINE, V6, P831
   Ogholikhan S, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4010006
   PANG L, 1995, AM J TROP MED HYG, V52, P347, DOI 10.4269/ajtmh.1995.52.347
   Parana R, 1999, HEPATOLOGY, V30, P289, DOI 10.1002/hep.510300143
   Pereira LMMB, 2009, AM J TROP MED HYG, V81, P240
   Polo D, 2015, INT J FOOD MICROBIOL, V193, P43, DOI 10.1016/j.ijfoodmicro.2014.10.007
   Sood A, 2002, Trop Gastroenterol, V23, P198
   Trinta KS, 2001, MEM I OSWALDO CRUZ, V96, P25, DOI 10.1590/S0074-02762001000100004
   ul Haq N, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-448
   ul Haq N, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-692
   Villar Livia Melo, 2015, World J Virol, V4, P323, DOI 10.5501/wjv.v4.i4.323
   Villar LM, 2014, J MED VIROL, V86, P1515, DOI 10.1002/jmv.23993
   World Health Organization, 2017, HLTH TOP HEP
   Wu E, 2015, HEPATOL INT, V9, P58, DOI 10.1007/s12072-014-9559-z
   Zhang XS, 2016, HUM VACC IMMUNOTHER, V12, P2322, DOI 10.1080/21645515.2015.1134069
NR 31
TC 2
Z9 3
U1 0
U2 0
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1948-5182
J9 WORLD J HEPATOL
JI World J. Hepatol.
PD NOV 27
PY 2018
VL 10
IS 11
BP 867
EP 876
DI 10.4254/wjh.v10.i11.867
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA HD0XO
UT WOS:000452232900010
PM 30533187
OA Green Published, Other Gold
DA 2020-11-30
ER

PT J
AU Villar, LM
   Bezerra, CS
   Portilho, MM
   Mendonca, ACF
   Frota, CC
   Carvalho-Costa, FA
   Da Cruz, JNM
   Lewis-Ximenez, LL
   Lago, BV
   Lampe, E
AF Villar, Livia Melo
   Bezerra, Cristianne Sousa
   Portilho, Moyra Machado
   Fonseca Mendonca, Ana Carolina
   Frota, Cristiane Cunha
   Carvalho-Costa, Filipe Anibal
   Monte Da Cruz, Jose Napoleao
   Lewis-Ximenez, Lia Laura
   Lago, Barbara Vieira
   Lampe, Elisabeth
TI Dried Blood Spot Samples As Alternative to Serum for Hepatitis B Virus
   Molecular Detection.
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver
   Meeting
CY NOV 09-13, 2018
CL San Francisco, CA
SP Amer Assoc Study Liver Dis
C1 [Villar, Livia Melo; Bezerra, Cristianne Sousa; Portilho, Moyra Machado; Fonseca Mendonca, Ana Carolina; Lewis-Ximenez, Lia Laura; Lago, Barbara Vieira; Lampe, Elisabeth] Fiocruz MS, Oswaldo Cruz Inst, Viral Hepatitis Lab, Rio De Janeiro, Brazil.
   [Bezerra, Cristianne Sousa] Inst Fed Ciencia Tecnol Ceara, Fortaleza, Ceara, Brazil.
   [Frota, Cristiane Cunha] Univ Fed Ceara, Fortaleza, Ceara, Brazil.
   [Carvalho-Costa, Filipe Anibal] Fiocruz MS, Inst Oswaldo Cruz, Lab Epidemiol & Sistemat Mol, Rio De Janeiro, Brazil.
   [Monte Da Cruz, Jose Napoleao] Lab Cent Saude Publ, Brasilia, DF, Brazil.
RI , Cristiane/M-7424-2018
OI , Cristiane/0000-0003-0018-7736
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2018
VL 68
SU 1
MA 2105
BP 1200A
EP 1200A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA GV3TU
UT WOS:000446020503333
DA 2020-11-30
ER

PT J
AU Barbosa, JR
   Cortes, VF
   Portilho, MM
   Miguel, JC
   Marques, VA
   Bezerra, CS
   de Souza, NV
   Lima, DM
   Colares, JKB
   Lewis-Ximenez, LL
   Lampe, E
   Villar, LM
AF Barbosa, Jakeline Ribeiro
   Cortes, Vanessa Faria
   Portilho, Moyra Machado
   Miguel, Juliana Custodio
   Marques, Vanessa Alves
   Bezerra, Cristianne Sousa
   de Souza, Natalia Vasconcelos
   Lima, Danielle Malta
   Baima Colares, Jeova Keny
   Lewis-Ximenez, Lia Laura
   Lampe, Elisabeth
   Villar, Livia Melo
TI Performance of point of care assays for hepatitis B and C viruses in
   chronic kidney disease patients
SO JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Article
ID DIAGNOSTIC-TESTS; SURFACE-ANTIGEN; RAPID TESTS; HEMODIALYSIS; INFECTION;
   HBSAG
AB Aims Point of care testing (POCT) has been used for hepatitis B and C diagnosis in general population, but little is known about the influence of clinical conditions in the accuracy of these assays. This study aims to evaluate the performance of POCTs for detection of hepatitis B virus surface antigen (HBsAg) and antibodies to Hepatitis C Virus (anti-HCV) in Chronic Kidney Disease (CKD) patients.
   Methods A total of 286 subjects were included in this study. HBsAg and anti-HCV were detected using commercial EIAs and four POCTs: HBsAg (WAMA ImunoRapido HBsAg and VIKIA HBsAg) and anti-HCV (DOLES HCV teste rapido and WAMA Imuno-Rapido anti-HCV) in serum and whole blood.
   Results Using EIA, HBsAg and anti-HCV prevalence was 4.5% and 16.1% in CKD patients. HBsAg and anti-HCV POCTs had sensitivities from 92.3% to 100% and 84.8% to 89.1% while specificities were 99.3% to 100% and 99.2% to 99.6%, respectively. POCT using serum samples performed well compared with whole blood samples and true positive samples of POCTs had high optical density to cut-off (OD/CO) values compared with EIA.
   Conclusions This study demonstrates good performance of HBsAg and anti-HCV POCTs in CKD patients, especially in serum samples indicating low interference of this disease in the performance of these assays. POCTs could be an important tool for HBV and HCV screening in high-risk populations.
C1 [Barbosa, Jakeline Ribeiro; Cortes, Vanessa Faria; Portilho, Moyra Machado; Miguel, Juliana Custodio; Marques, Vanessa Alves; Bezerra, Cristianne Sousa; Lewis-Ximenez, Lia Laura; Lampe, Elisabeth; Villar, Livia Melo] Oswaldo Cruz Inst, Viral Hepatitis Lab, Fiocruz, RJ, Brazil.
   [Barbosa, Jakeline Ribeiro; Lima, Danielle Malta; Baima Colares, Jeova Keny] Univ Fed Ceara, Postgrad Program Pathol, Fortaleza, Ceara, Brazil.
   [Cortes, Vanessa Faria] Fed Univ Sao Joao Del Rey, Campus Divinopolis, Sao Joao Del Rei, MG, Brazil.
   [Bezerra, Cristianne Sousa] Fed Inst Sci Educ & Technol Ceara, Fortaleza, Ceara, Brazil.
   [de Souza, Natalia Vasconcelos] Univ Estadual Ceara, Postgrad Program Northeast Network Biotechnol REN, Fortaleza, Ceara, Brazil.
   [de Souza, Natalia Vasconcelos] Univ Fortaleza, Fortaleza, Ceara, Brazil.
   [Lima, Danielle Malta; Baima Colares, Jeova Keny] Univ Fortaleza, Postgrad Program Med Sci, Fortaleza, Ceara, Brazil.
RP Villar, LM (corresponding author), Fundacao Oswaldo Cruz, Oswaldo Cruz Inst, Viral Hepatitis Lab, BR-21036004 Rio De Janeiro, Brazil.
EM liviafiocruz@gmail.com
RI Barbosa, Jakeline/AAC-9805-2020; Colares, Jeova Keny Baima/C-5257-2014
OI Barbosa, Jakeline/0000-0001-6238-7173; Colares, Jeova Keny
   Baima/0000-0003-1367-6272; Cortes, Vanessa Faria/0000-0002-6464-7634;
   Sousa Bezerra, Cristianne/0000-0002-9389-5186
FU Research Support Foundation of the State of Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); Brazilian National Council of Technological
   and Scientific Development (CNPq)National Council for Scientific and
   Technological Development (CNPq); Brazilian Ministry of Health, the
   Coordination of Improvement of Higher Education Personnel (CAPES);
   Oswaldo Cruz Foundation (FIOCRUZ)
FX This research was supported by the Research Support Foundation of the
   State of Rio de Janeiro (FAPERJ), Brazilian National Council of
   Technological and Scientific Development (CNPq), Brazilian Ministry of
   Health, the Coordination of Improvement of Higher Education Personnel
   (CAPES) and Oswaldo Cruz Foundation (FIOCRUZ).
CR Barbosa JR, 2017, J VIROL METHODS, V248, P244, DOI 10.1016/j.jviromet.2017.08.001
   Barbosa JR, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14070793
   Sette LHBC, 2014, CLINICS, V69, P271, DOI 10.6061/clinics/2014(04)09
   Bottero J, 2013, J HEPATOL, V58, P473, DOI 10.1016/j.jhep.2012.11.016
   Carvalho-Filho RJ, 2015, WORLD J GASTROENTERO, V21, P408, DOI 10.3748/wjg.v21.i2.408
   Chevaliez S, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2016.01.009
   Cohen G, 2012, TOXINS, V4, P962, DOI 10.3390/toxins4110962
   Cruz HM, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1249-5
   Edey M, 2010, NEPHROLOGY, V15, P137, DOI 10.1111/j.1440-1797.2009.01268.x
   Fabrizi F, 2000, AM J KIDNEY DIS, V35, P122, DOI 10.1016/S0272-6386(00)70310-6
   Firdaus R, 2013, J VIRAL HEPATITIS, V20, P290, DOI 10.1111/jvh.12002
   Halle MP, 2016, IRAN J KIDNEY DIS, V10, P304
   Honge BL, 2014, HIV MED, V15, P571, DOI 10.1111/hiv.12158
   Kalantar-Zadeh K, 2005, AM J KIDNEY DIS, V46, P290, DOI 10.1053/j.ajkd.2005.05.006
   Kalinowski P., 2010, APS
   Khuroo MS, 2014, J CLIN EXP HEPATOL, V4, P226, DOI 10.1016/j.jceh.2014.07.008
   Khuroo MS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121450
   Kim MH, 2013, J VIROL METHODS, V193, P379, DOI 10.1016/j.jviromet.2013.07.005
   Lee JH, 2015, J GASTROEN HEPATOL, V30, P696, DOI 10.1111/jgh.12788
   Marinaki S, 2015, WORLD J HEPATOL, V7, P548, DOI 10.4254/wjh.v7.i3.548
   da Silva NMO, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-167
   Pereira LMMB, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-60
   Pereira LMMB, 2009, AM J TROP MED HYG, V81, P240
   Scalioni LD, 2014, J CLIN VIROL, V60, P200, DOI 10.1016/j.jcv.2014.04.001
   Sesso Ricardo Cintra, 2016, J. Bras. Nefrol., V38, P54, DOI 10.5935/0101-2800.20160009
   Sharma M, 2015, UNITED EUR GASTROENT, V3, P364, DOI 10.1177/2050640615580725
NR 26
TC 5
Z9 5
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0021-9746
EI 1472-4146
J9 J CLIN PATHOL
JI J. Clin. Pathol.
PD OCT
PY 2018
VL 71
IS 10
BP 879
EP 884
DI 10.1136/jclinpath-2018-205024
PG 6
WC Pathology
SC Pathology
GA GV4QG
UT WOS:000446084700011
PM 29730611
DA 2020-11-30
ER

PT J
AU Lago, BV
   Mello, FCA
   Barros, TM
   Mello, VM
   Villar, LM
   Lewis-Ximenez, LL
   Pardini, MIMC
   Lampe, E
AF Lago, Barbara V.
   Mello, Francisco C. A.
   Barros, Tairine M.
   Mello, Vinicius M.
   Villar, Livia M.
   Lewis-Ximenez, Lia L.
   Pardini, Maria Ines M. C.
   Lampe, Elisabeth
CA Brazilian Hepatitis B Res Grp
TI Hepatitis D infection in Brazil: Prevalence and geographical
   distribution of anti-Delta antibody
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE Brazil; HDV; seroepidemiology
ID B SURFACE-ANTIGEN; VIRUS-INFECTION; LABREA HEPATITIS; NORTHEAST BRAZIL;
   AMAZONAS STATE; GENOTYPE 8; SERUM; INTERFERENCE; VENEZUELA; CARRIERS
AB In Brazil, the Amazon Basin is endemic for hepatitis D virus (HDV) infection; however, studies in other regions of the country are scarce. This study aims to map the seroepidemiological situation of anti-Delta antibodies in chronic hepatitis B carriers in all five Brazilian geographic regions. Serum samples from 1240 HBsAg positive individuals (55.4% men; mean age 43.1 +/- 13.4 years) from 24 of 26 Brazilian states were tested for the presence of anti-Delta antibodies using a commercial immunoassay. Anti-Delta antibodies were detected in 40 samples (3.2%; 52.5% female; mean age of 38.1 +/- 13.8 years). Age less than 20 years was significantly associated with anti-HDV positivity (P<0.001). The distribution of anti-Delta differed markedly in the diverse regions of the country. The highest prevalence of anti-HDV was found in the North (8.5%; P<0.001), followed by Central West (2.5%), Southeast (1.7%), Northeast (0.8%), and South (0.0%). Anti-Delta antibodies were detected in 12 states, but more than 60% of the positive cases were observed in two states, Amazonas and Acre, located in the western portion of the Amazon region. The overall HDV prevalence of 3.2% emphasizes that HDV is far from being a disease under control in Brazil. Despite the low HDV prevalence in non-endemic regions, this infection persists as a major concern in two states (Acre and Amazonas) in the north of the country, indicating that a continuous epidemiological surveillance program should be implemented in all Brazilian regions.
C1 [Lago, Barbara V.; Mello, Francisco C. A.; Barros, Tairine M.; Mello, Vinicius M.; Villar, Livia M.; Lewis-Ximenez, Lia L.; Lampe, Elisabeth] Fiocruz MS, Inst Oswaldo Cruz, Lab Hepatites Virais, Rio De Janeiro, RJ, Brazil.
   [Lago, Barbara V.] Fiocruz MS, Inst Tecnol Imunobiol Biomanguinhos, Rio De Janeiro, RJ, Brazil.
   [Pardini, Maria Ines M. C.] Univ Estadual Paulista Unesp, Div Hemoctr, Fac Med FMB, Lab Biol Mol, Campus Botucatu, Botucatu, SP, Brazil.
RP Mello, FCA (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab Hepatites Virais, Rio De Janeiro, RJ, Brazil.
EM fcamello@ioc.fiocruz.br
OI Pardini, Maria Ines de Moura Campos/0000-0001-6470-0944; Mello,
   Vinicius/0000-0001-7705-5921
FU Ministerio da Saude, Fundo Nacional de Saude, Departamento de IST/AIDS e
   Hepatites Virais [25000.214350/2012-24]
FX Ministerio da Saude, Fundo Nacional de Saude, Departamento de IST/AIDS e
   Hepatites Virais, Grant number: 25000.214350/2012-24
CR Barros LMF, 2011, VIRUS RES, V160, P333, DOI 10.1016/j.virusres.2011.07.006
   BENSABATH G, 1987, JAMA-J AM MED ASSOC, V258, P479, DOI 10.1001/jama.1987.03400040077025
   Bertolini DA, 2012, INFECT GENET EVOL, V12, P1295, DOI 10.1016/j.meegid.2012.04.009
   Botelho-Souza LF, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0845-y
   Braga W S, 2001, Rev Soc Bras Med Trop, V34, P349, DOI 10.1590/S0037-86822001000400007
   Braga Wornei Silva Miranda, 2004, EPIDEMIOL SERV SAUDE, V13, P35, DOI DOI 10.5123/S1679-49742004000100005
   BUITRAGO B, 1986, HEPATOLOGY, V6, P1285, DOI 10.1002/hep.1840060610
   Casey JL, 1996, J INFECT DIS, V174, P920, DOI 10.1093/infdis/174.5.920
   Chow SK, 2016, CLIN VACCINE IMMUNOL, V23, P732, DOI 10.1128/CVI.00028-16
   Santos MDC, 2016, VIRUS RES, V224, P6, DOI 10.1016/j.virusres.2016.08.003
   Ximenes RAD, 2010, CAD SAUDE PUBLICA, V26, P1693, DOI 10.1590/S0102-311X2010000900003
   Villa DD, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0402-5
   DIAS LB, 1985, REV I MED TROP, V27, P242, DOI 10.1590/S0036-46651985000500003
   Duarte MC, 2010, TROP MED INT HEALTH, V15, P924, DOI 10.1111/j.1365-3156.2010.02560.x
   Souto FJD, 2016, REV SOC BRAS MED TRO, V49, P11, DOI 10.1590/0037-8682-0176-2015
   Crispim MAE, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-94
   Fattovich G, 2000, GUT, V46, P420, DOI 10.1136/gut.46.3.420
   FONSECA JCF, 1988, T ROY SOC TROP MED H, V82, P469, DOI 10.1016/0035-9203(88)90166-6
   HADLER SC, 1984, ANN INTERN MED, V100, P339, DOI 10.7326/0003-4819-100-3-339
   Hughes SA, 2011, LANCET, V378, P73, DOI 10.1016/S0140-6736(10)61931-9
   Jardi R, 2001, HEPATOLOGY, V34, P404, DOI 10.1053/jhep.2001.26511
   Madejon A, 2016, WORLD J GASTROENTERO, V22, P3165, DOI 10.3748/wjg.v22.i11.3165
   Mendes-Correa MC, 2011, INT J INFECT DIS, V15, pE828, DOI 10.1016/j.ijid.2011.08.003
   Ministerio da Saude-Secretaria de Vigilancia em Saude, 2017, B EP HEP VIR, P65
   Braga WSM, 2012, REV SOC BRAS MED TRO, V45, P691, DOI 10.1590/S0037-86822012000600007
   Nunes HM, 2007, CAD SAUDE PUBLICA, V23, P2756, DOI 10.1590/S0102-311X2007001100023
   Pereira LMMB, 2009, AM J TROP MED HYG, V81, P240
   Ribeiro L C, 2000, Rev Soc Bras Med Trop, V33, P599, DOI 10.1590/S0037-86822000000600013
   RIZZETTO M, 1977, GUT, V18, P997, DOI 10.1136/gut.18.12.997
   RIZZETTO M, 1980, P NATL ACAD SCI-BIOL, V77, P6124, DOI 10.1073/pnas.77.10.6124
   Rizzetto M, 2016, LIVER INT, V36, P135, DOI 10.1111/liv.13018
   Rizzetto M, 2013, CLIN LIVER DIS, V17, P475, DOI 10.1016/j.cld.2013.05.007
   SMEDILE A, 1982, LANCET, V2, P945, DOI 10.1016/S0140-6736(82)90156-8
NR 33
TC 4
Z9 4
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD AUG
PY 2018
VL 90
IS 8
BP 1358
EP 1363
DI 10.1002/jmv.25196
PG 6
WC Virology
SC Virology
GA GK0JY
UT WOS:000435797200013
PM 29663457
DA 2020-11-30
ER

PT J
AU Villar, LM
   Scalioni, LP
   Portilho, MM
   dadamendonca, ACF
   Lima, JM
   Fraga, KA
   Lewis-Ximenez, LL
   Lampe, E
AF Villar, L. M.
   Scalioni, L. P.
   Portilho, M. M.
   daDamendonca, A. C. F.
   Lima, J. M.
   Fraga, K. A.
   Lewis-Ximenez, L. L.
   Lampe, E.
TI Vitamin D levels and polymorphism of vitamin D receptor (VDR) were not
   associated to laboratorial data among hepatitis B virus (HBV) patients
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Meeting Abstract
CT 16th International Symposium on Viral Hepatitis and Liver Diseases
   (ISVHLD)
CY JUN 14-17, 2018
CL Toronto, CANADA
C1 [Villar, L. M.; Scalioni, L. P.; Portilho, M. M.; daDamendonca, A. C. F.; Lima, J. M.; Fraga, K. A.; Lewis-Ximenez, L. L.; Lampe, E.] Fiocruz MS, Viral Hepatitis Lab, Rio De Janeiro, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
EI 1365-2893
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD JUN
PY 2018
VL 25
SU 2
SI SI
MA P1-059
BP 53
EP 53
PG 1
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA GJ2LC
UT WOS:000435101000084
DA 2020-11-30
ER

PT J
AU Villar, LM
   Cruz, HM
   dePaula, VS
   da Silva, EF
   do O, KMR
   Milagres, FAP
   Cruz, MS
   Bastos, FI
   Pollo-Flores, P
   Leal, E
   Motta-Castro, ARC
   Lewis-Ximenez, LL
   Lampe, E
AF Villar, L. M.
   Cruz, H. M.
   dePaula, V. S.
   da Silva, E. F.
   do O, K. M. R.
   Milagres, F. A. P.
   Cruz, M. S.
   Bastos, F. I.
   Pollo-Flores, P.
   Leal, E.
   Motta-Castro, A. R. C.
   Lewis-Ximenez, L. L.
   Lampe, E.
TI Evaluation of hepatitis B core antibody detection using oral fluid
   samples according to background prevalence
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Meeting Abstract
CT 16th International Symposium on Viral Hepatitis and Liver Diseases
   (ISVHLD)
CY JUN 14-17, 2018
CL Toronto, CANADA
C1 [Villar, L. M.; Cruz, H. M.; da Silva, E. F.; Lewis-Ximenez, L. L.; Lampe, E.] Viral Hepatitis Lab, Rio De Janeiro, Brazil.
   [dePaula, V. S.] Fiocruz MS, Mol Virol Lab, Rio De Janeiro, Brazil.
   [do O, K. M. R.] Sao Lucas Hosp, Petropolis, Brazil.
   [Milagres, F. A. P.] Fed Univ Tocantins, Palmas, Brazil.
   [Cruz, M. S.] Univ Fed Rio de Janeiro, Inst Psychiat, Rio De Janeiro, Brazil.
   [Bastos, F. I.] Fiocruz MS, Inst Commun & Sci Informat & Technol Hlth, Rio De Janeiro, Brazil.
   [Pollo-Flores, P.] Fed Fluminense Univ, Antonio Pedro Univ Hosp, Rio De Janeiro, Brazil.
   [Leal, E.] Univ Fed Rio de Janeiro, Fac Med, Rio De Janeiro, Brazil.
   [Motta-Castro, A. R. C.] Univ Fed Mato Grosso do Sul, Campo Grande, Brazil.
   [Motta-Castro, A. R. C.] Fiocruz Mato Grosso do Sul, Campo Grande, Brazil.
RI Cruz, Marcelo Santos/AAH-5963-2020; milagres, flavio/Q-2403-2019; Cruz,
   Marcelo Santos/I-5890-2014; de Paula, Vanessa S/I-8037-2016
OI Cruz, Marcelo Santos/0000-0003-0057-2095; de Paula, Vanessa
   S/0000-0002-6314-754X
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
EI 1365-2893
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD JUN
PY 2018
VL 25
SU 2
SI SI
MA P1-150
BP 102
EP 102
PG 1
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA GJ2LC
UT WOS:000435101000167
DA 2020-11-30
ER

PT J
AU Oliveira, JM
   Sousa, PSF
   Souza, CB
   Palma, LDV
   Balassiano, N
   Moura, FM
   Leal, MS
   Rodrigues, BC
   Pereira, GHS
   Pinto, LC
   Mello, VM
   Melgaco, JG
   Lampe, E
   Lewis-Ximenez, LL
AF Oliveira, J. M.
   Sousa, P. S. F.
   Souza, C. B.
   Palma, L. D. V.
   Balassiano, N.
   Moura, F. M.
   Leal, M. S.
   Rodrigues, B. C.
   Pereira, G. H. S.
   Pinto, L. C.
   Mello, V. M.
   Melgaco, J. G.
   Lampe, E.
   Lewis-Ximenez, L. L.
TI Hepatitis B core immunoglobulin G antibody (Anti-HBc IgG) avidity index
   to differentiate acute from chronic hepatitis B virus (HBV) infection in
   cases with persistent anti-HBc immunoglobulin M (Anti-HBc IgM)
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Meeting Abstract
CT 16th International Symposium on Viral Hepatitis and Liver Diseases
   (ISVHLD)
CY JUN 14-17, 2018
CL Toronto, CANADA
C1 [Oliveira, J. M.; Sousa, P. S. F.; Souza, C. B.; Palma, L. D. V.; Balassiano, N.; Moura, F. M.; Leal, M. S.; Rodrigues, B. C.; Pereira, G. H. S.; Pinto, L. C.; Mello, V. M.; Melgaco, J. G.; Lampe, E.; Lewis-Ximenez, L. L.] Fiocruz MS, Inst Oswaldo Cruz, Ambulatorio Lab Hepatites Virais, Rio De Janeiro, Brazil.
RI Melgaco, Juliana/AAQ-6084-2020
OI Melgaco, Juliana/0000-0003-0087-6531
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
EI 1365-2893
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD JUN
PY 2018
VL 25
SU 2
SI SI
MA P1-165
BP 109
EP 109
PG 1
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA GJ2LC
UT WOS:000435101000178
DA 2020-11-30
ER

PT J
AU Villar, LM
   Barbosa, JR
   Cortes, VF
   Portilho, MM
   Miguel, JC
   Marques, VA
   Bezerra, CS
   Lima, DM
   Colares, JKB
   Lewis-Ximenez, LL
   Lampe, E
AF Villar, L. M.
   Barbosa, J. R.
   Cortes, V. F.
   Portilho, M. M.
   Miguel, J. C.
   Marques, V. A.
   Bezerra, C. S.
   Lima, D. M.
   Colares, J. K. B.
   Lewis-Ximenez, L. L.
   Lampe, E.
TI Performance of point of care assays for hepatitis B and C viruses in
   chronic kidney disease patients
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Meeting Abstract
CT 16th International Symposium on Viral Hepatitis and Liver Diseases
   (ISVHLD)
CY JUN 14-17, 2018
CL Toronto, CANADA
C1 [Villar, L. M.; Barbosa, J. R.; Portilho, M. M.; Miguel, J. C.; Marques, V. A.; Bezerra, C. S.; Lewis-Ximenez, L. L.; Lampe, E.] Fiocruz MS, Viral Hepatitis Lab, Rio De Janeiro, Brazil.
   [Cortes, V. F.] Fed Univ Sao Joao Del Rey, Divinopolis, Brazil.
   [Lima, D. M.; Colares, J. K. B.] Univ Fortaleza, Fortaleza, Ceara, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
EI 1365-2893
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD JUN
PY 2018
VL 25
SU 2
SI SI
MA P1-171
BP 111
EP 111
PG 1
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA GJ2LC
UT WOS:000435101000183
DA 2020-11-30
ER

PT J
AU Mello, VM
   Lago, BV
   Melgaco, JG
   Mello, FCA
   Sousa, PSF
   Villar, LM
   Portilho, MM
   Fernandes, CA
   Aguiar, SF
   Lampe, E
   Lewis-Ximenez, LL
AF Mello, V. M.
   Lago, B. V.
   Melgaco, J. G.
   Mello, F. C. A.
   Sousa, P. S. F.
   Villar, L. M.
   Portilho, M. M.
   Fernandes, C. A.
   Aguiar, S. F.
   Lampe, E.
   Lewis-Ximenez, L. L.
TI Circulation of two european hepatitis a genotype IA outbreak strains
   among men who have sex with men in Brazil
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Meeting Abstract
CT 16th International Symposium on Viral Hepatitis and Liver Diseases
   (ISVHLD)
CY JUN 14-17, 2018
CL Toronto, CANADA
C1 [Mello, V. M.; Lago, B. V.; Melgaco, J. G.; Mello, F. C. A.; Sousa, P. S. F.; Villar, L. M.; Portilho, M. M.; Lampe, E.; Lewis-Ximenez, L. L.] Inst Oswaldo Cruz FIOCRUZ, Ambulatorio Lab Hepatites Virais, Rio De Janeiro, Brazil.
   [Fernandes, C. A.; Aguiar, S. F.] Secretaria Estadual Saude, Lab Cent Saude Publ Noel Nutel, Rio De Janeiro, Brazil.
RI Melgaco, Juliana/AAQ-6084-2020
OI Melgaco, Juliana/0000-0003-0087-6531
CR Beebeejaun K, 2017, EURO SURVEILL, V22
   Charre C, 2017, EURO SURVEILL, V22
   European Centre for Disease Prevention and Control, 2016, HEP A OUTBR EU EEA M
   European Centre for Disease Prevention and Control (ECDC), 2017, HEP A OUTBR EU EEA M
   Freidl GS, 2017, EURO SURVEILL, V22
   Lanini S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185428
   WHO, 2017, HEP A OUTBR MOSTL AF
NR 7
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
EI 1365-2893
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD JUN
PY 2018
VL 25
SU 2
SI SI
MA P1-122
BP 88
EP 89
PG 2
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA GJ2LC
UT WOS:000435101000142
DA 2020-11-30
ER

PT J
AU Peliganga, LB
   Mello, VM
   Nunes, JPS
   Sousa, PSF
   Portilho, MM
   Ginuino, CF
   Fernandes, CA
   Aguiar, SF
   Lampe, E
   Lewis-Ximenez, LL
AF Peliganga, L. B.
   Mello, V. M.
   Nunes, J. P. S.
   Sousa, P. S. F.
   Portilho, M. M.
   Ginuino, C. F.
   Fernandes, C. A.
   Aguiar, S. F.
   Lampe, E.
   Lewis-Ximenez, L. L.
TI Molecular detection of Hepatitis B virus (HBV) DNA among Hepatitis B
   Surface antigen (HBsAg) Negative Blood Donors in Angola
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Meeting Abstract
CT 16th International Symposium on Viral Hepatitis and Liver Diseases
   (ISVHLD)
CY JUN 14-17, 2018
CL Toronto, CANADA
C1 [Peliganga, L. B.] Minist Saude Angola, Direcao Nacl Saude Publ, Luanda, Angola, Angola.
   [Mello, V. M.; Nunes, J. P. S.; Sousa, P. S. F.; Portilho, M. M.; Ginuino, C. F.; Lampe, E.; Lewis-Ximenez, L. L.] Inst Oswaldo Cruz Fiocruz, Lab Hepatites Virais, Rio De Janeiro, Brazil.
   [Fernandes, C. A.; Aguiar, S. F.] Secretaria Estadual Saude, Lab Cent Saude Publ Noel Nutels, Rio De Janeiro, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
EI 1365-2893
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD JUN
PY 2018
VL 25
SU 2
SI SI
MA P1-135
BP 95
EP 95
PG 1
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA GJ2LC
UT WOS:000435101000154
DA 2020-11-30
ER

PT J
AU Lewis-Ximenez, LL
   Peliganga, LB
AF Lewis-Ximenez, L. L.
   Peliganga, L. B.
TI Impact of late hepatitis B immunization in Angola
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Meeting Abstract
CT 16th International Symposium on Viral Hepatitis and Liver Diseases
   (ISVHLD)
CY JUN 14-17, 2018
CL Toronto, CANADA
C1 [Lewis-Ximenez, L. L.] Inst Oswaldo Cruz Fiocruz, Lab Hepatites Virais, Rio De Janeiro, Brazil.
   [Peliganga, L. B.] Minist Saude, Direcao Nacl Saude Publ, Luanda, Angola.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
EI 1365-2893
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD JUN
PY 2018
VL 25
SU 2
SI SI
MA P1-141
BP 98
EP 99
PG 2
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA GJ2LC
UT WOS:000435101000160
DA 2020-11-30
ER

PT J
AU Villar, LM
   Bezerra, CS
   Portilho, MM
   Lago, BV
   Barbosa, JR
   Lewis-Ximenez, LL
   Frota, CC
   Lampe, E
AF Villar, L. M.
   Bezerra, C. S.
   Portilho, M. M.
   Lago, B. V.
   Barbosa, J. R.
   Lewis-Ximenez, L. L.
   Frota, C. C.
   Lampe, E.
TI Evaluation of dried blood spot samples for detecting hepatitis B virus
   genotypes
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Meeting Abstract
CT 16th International Symposium on Viral Hepatitis and Liver Diseases
   (ISVHLD)
CY JUN 14-17, 2018
CL Toronto, CANADA
C1 [Villar, L. M.; Bezerra, C. S.; Portilho, M. M.; Lago, B. V.; Barbosa, J. R.; Lewis-Ximenez, L. L.; Lampe, E.] Fiocruz MS, Viral Hepatitis Lab, Rio De Janeiro, Brazil.
   [Frota, C. C.] Univ Fed Ceara, Med Fac, Fortaleza, Ceara, Brazil.
RI , Cristiane/M-7424-2018
OI , Cristiane/0000-0003-0018-7736
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
EI 1365-2893
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD JUN
PY 2018
VL 25
SU 2
SI SI
MA P1-140
BP 98
EP 98
PG 1
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA GJ2LC
UT WOS:000435101000159
DA 2020-11-30
ER

PT J
AU Lago, BV
   Lampe, E
   Espirito-Santo, MP
   Costa, VD
   Lewis-Ximenez, LL
   Mello, FCA
AF Lago, B. V.
   Lampe, E.
   Espirito-Santo, M. P.
   Costa, V. D.
   Lewis-Ximenez, L. L.
   Mello, F. C. A.
TI Genetic diversity of the hepatitis B virus in Brazil
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Meeting Abstract
CT 16th International Symposium on Viral Hepatitis and Liver Diseases
   (ISVHLD)
CY JUN 14-17, 2018
CL Toronto, CANADA
C1 [Lago, B. V.; Lampe, E.; Costa, V. D.; Lewis-Ximenez, L. L.; Mello, F. C. A.] Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Lago, B. V.; Espirito-Santo, M. P.] Fundacao Oswaldo Cruz, Biomanguinhos, Rio De Janeiro, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
EI 1365-2893
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD JUN
PY 2018
VL 25
SU 2
SI SI
MA P1-148
BP 101
EP 101
PG 1
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA GJ2LC
UT WOS:000435101000165
DA 2020-11-30
ER

PT J
AU Costa, VD
   Silva, PC
   Prado, GN
   Mello, CEB
   Nunes, EP
   Lewis-Ximenez, LL
   Mello, FC
   Lampe, E
AF Costa, V. D.
   Silva, P. C.
   Prado, G. N.
   Brandao Mello, C. E.
   Nunes, E. P.
   Lewis-Ximenez, L. L.
   Mello, F. C.
   Lampe, E.
TI Prevalence of baseline NS5A inhibitor resistance-associated variants in
   Brazilian patients infected with genotypes 1 and 3
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Meeting Abstract
CT 16th International Symposium on Viral Hepatitis and Liver Diseases
   (ISVHLD)
CY JUN 14-17, 2018
CL Toronto, CANADA
C1 [Costa, V. D.; Silva, P. C.; Prado, G. N.; Lewis-Ximenez, L. L.; Mello, F. C.; Lampe, E.] Fundacao Oswaldo Cruz, Lab Viral Hepatitis, Rio De Janeiro, Brazil.
   [Brandao Mello, C. E.] Univ Hosp Gaffree Guinle, Ambulatory Gastroenterol, Rio De Janeiro, Brazil.
   [Nunes, E. P.] Fundacao Oswaldo Cruz, Natl Inst Infectol, Rio De Janeiro, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
EI 1365-2893
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD JUN
PY 2018
VL 25
SU 2
SI SI
MA P2-038
BP 127
EP 128
PG 2
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA GJ2LC
UT WOS:000435101000213
DA 2020-11-30
ER

PT J
AU Villar, LM
   da Mendonca, ACF
   Portilho, MM
   Villela-Nogueira, CA
   Lewis-Ximenez, LL
   Lampe, E
AF Villar, L. M.
   da Mendonca, A. C. F.
   Portilho, M. M.
   Villela-Nogueira, C. A.
   Lewis-Ximenez, L. L.
   Lampe, E.
TI Usefulness of saliva samples for HCV RNA detection: important tool to
   increase diagnosis access in low resource areas
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Meeting Abstract
CT 16th International Symposium on Viral Hepatitis and Liver Diseases
   (ISVHLD)
CY JUN 14-17, 2018
CL Toronto, CANADA
C1 [Villar, L. M.; da Mendonca, A. C. F.; Portilho, M. M.; Lewis-Ximenez, L. L.; Lampe, E.] Fiocruz MS, Viral Hepatitis Lab, Rio De Janeiro, Brazil.
   [Villela-Nogueira, C. A.] Univ Fed Rio de Janeiro, Univ Hosp Clementino Fraga Filho, Rio De Janeiro, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
EI 1365-2893
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD JUN
PY 2018
VL 25
SU 2
SI SI
MA P2-054
BP 134
EP 134
PG 1
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA GJ2LC
UT WOS:000435101000226
DA 2020-11-30
ER

PT J
AU Lampe, E
   Mello, FCDA
   Lago, BVD
   Costa, VDD
   Marques, VA
   Nascimento, GPD
   Sousa, PSFD
   Correa, PF
   Mello, V
   Lewis-Ximenez, LL
AF Lampe, E.
   Mello, F. C. D. A.
   Lago, B. V. D.
   Costa, V. D. D.
   Marques, V. A.
   Nascimento, G. P. D.
   Sousa, P. S. F. D.
   Correa, P. F.
   Mello, V.
   Lewis-Ximenez, L. L.
TI Nosocomal transmission of hepatitis C viruses (HCV) in a hemodialysis
   unit: molecular evidence
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Meeting Abstract
CT 16th International Symposium on Viral Hepatitis and Liver Diseases
   (ISVHLD)
CY JUN 14-17, 2018
CL Toronto, CANADA
C1 [Lampe, E.; Mello, F. C. D. A.; Lago, B. V. D.; Costa, V. D. D.; Marques, V. A.; Nascimento, G. P. D.; Sousa, P. S. F. D.; Correa, P. F.; Mello, V.; Lewis-Ximenez, L. L.] Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
EI 1365-2893
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD JUN
PY 2018
VL 25
SU 2
SI SI
MA P2-070
BP 143
EP 144
PG 2
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA GJ2LC
UT WOS:000435101000241
DA 2020-11-30
ER

PT J
AU Lewis-Ximenez, L
   Greaume, S
   M'Bengue, A
   Merieux, Y
   Rafik, M
   Ragab, D
   Soucheleau, J
AF Lewis-Ximenez, L.
   Greaume, S.
   M'Bengue, A.
   Merieux, Y.
   Rafik, M.
   Ragab, D.
   Soucheleau, J.
TI Performance evaluation of VIKIA (R) ANTI-HCV, rapid test for the
   qualitative detection of antibodies anti-HCV in European and
   non-European populations
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Meeting Abstract
CT 16th International Symposium on Viral Hepatitis and Liver Diseases
   (ISVHLD)
CY JUN 14-17, 2018
CL Toronto, CANADA
C1 [Lewis-Ximenez, L.] Fundacao Oswaldo Cruz, Oswaldo Cruz Inst, Viral Hepatitis Ambulatory Viral Hepatitis Lab, Rio De Janeiro, Brazil.
   [Greaume, S.] Etab Francais Sang Normandie, Bois Guillaume, France.
   [M'Bengue, A.] Inst Pasteur Cote Ivoire, Cocody, Cote Ivoire.
   [Merieux, Y.] Etab Francais Sang Auvergne Rhone Alpes, Decines Charpieu, France.
   [Rafik, M.; Ragab, D.] Ain Shams Univ, Dept Clin Pathol, Cairo, Egypt.
   [Soucheleau, J.] Labs Lafayette, Lyon, France.
RI Ragab, Dina/AAK-1726-2020; Rafik, Mona/C-1650-2015
OI Ragab, Dina/0000-0003-4738-9853; Rafik, Mona/0000-0002-8782-5552
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
EI 1365-2893
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD JUN
PY 2018
VL 25
SU 2
SI SI
MA P2-076
BP 145
EP 146
PG 2
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA GJ2LC
UT WOS:000435101000245
DA 2020-11-30
ER

PT J
AU Mello, FC
   Lago, BV
   Mello, V
   Portilho, MM
   Pinto, LCM
   Baldin, C
   Pereira, SA
   Pilotto, JH
   Lampe, E
   Lewis-Ximenez, LL
AF Mello, F. C. A.
   Lago, B. V.
   Mello, V.
   Portilho, M. M.
   Pinto, L. C. M.
   Baldin, C.
   Pereira, S. A.
   Pilotto, J. H.
   Lampe, E.
   Lewis-Ximenez, L. L.
TI Hepatitis C among MSM suggesting sexual transmission and importation of
   a HCV strain previously unreported in Brazil
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Meeting Abstract
CT 16th International Symposium on Viral Hepatitis and Liver Diseases
   (ISVHLD)
CY JUN 14-17, 2018
CL Toronto, CANADA
C1 [Mello, F. C. A.; Lago, B. V.; Mello, V.; Portilho, M. M.; Pinto, L. C. M.; Baldin, C.; Pereira, S. A.; Pilotto, J. H.; Lampe, E.; Lewis-Ximenez, L. L.] Fiocruz MS, Rio De Janeiro, Brazil.
RI Pilotto, Jose Henrique/AAD-9773-2019
OI Pilotto, Jose Henrique/0000-0003-0521-8597
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
EI 1365-2893
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD JUN
PY 2018
VL 25
SU 2
SI SI
MA P2-077
BP 146
EP 146
PG 1
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA GJ2LC
UT WOS:000435101000246
DA 2020-11-30
ER

PT J
AU Sousa, PSF
   Batista, C
   Martins, A
   Ximenez, L
   Peliganga, LB
   Ximenez, N
   Silva, AICD
   Lampe, E
   Lewis-Ximenez, LL
AF Sousa, P. S. F.
   Batista, C.
   Martins, A.
   Ximenez, L.
   Peliganga, L. B.
   Ximenez, N.
   Silva, A. I. C. D.
   Lampe, E.
   Lewis-Ximenez, L. L.
TI Long-term immunity to hepatitis B among Brazilian Amerindians who
   completed 3-dose hepatitis B vaccination
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Meeting Abstract
CT 16th International Symposium on Viral Hepatitis and Liver Diseases
   (ISVHLD)
CY JUN 14-17, 2018
CL Toronto, CANADA
C1 [Sousa, P. S. F.; Ximenez, L.; Silva, A. I. C. D.; Lampe, E.; Lewis-Ximenez, L. L.] Inst Oswaldo Cruz FIOCRUZ, Ambulatorio Lab Hepatites Virais, Rio De Janeiro, Brazil.
   [Batista, C.] DNDi Reg Off Latin Amer, Drugs Neglected Dis Initiat, Rio De Janeiro, Brazil.
   [Martins, A.] Minist Saude, Distr Sanit Indigena Alto Rio Negro DSEI ARN, Sao Gabriel Da Cachoeira, Amazonas, Brazil.
   [Peliganga, L. B.] Minist Saude, Direcao Nacl Saude Publ, Luanda, Angola.
   [Ximenez, N.] Pontificia Univ Catolica Rio de Janeiro, PUC RJ, Rio De Janeiro, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
EI 1365-2893
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD JUN
PY 2018
VL 25
SU 2
SI SI
MA P2-139
BP 175
EP 176
PG 2
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA GJ2LC
UT WOS:000435101000299
DA 2020-11-30
ER

PT J
AU Flores, GL
   Brandao, CE
   Pilotto, JH
   Lewis-Ximenez, LL
   Lampe, E
   Villar, LM
AF Flores, G. L.
   Brandao, C. E.
   Pilotto, J. H.
   Lewis-Ximenez, L. L.
   Lampe, E.
   Villar, L. M.
TI Dried blood spot samples as alternative specimen for hepatitis C
   diagnosis
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Meeting Abstract
CT 16th International Symposium on Viral Hepatitis and Liver Diseases
   (ISVHLD)
CY JUN 14-17, 2018
CL Toronto, CANADA
C1 [Flores, G. L.; Pilotto, J. H.; Lewis-Ximenez, L. L.; Lampe, E.; Villar, L. M.] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Brandao, C. E.] Fed Univ State Rio de Janeiro, Gaffree & Guinle Univ Hosp, Rio De Janeiro, Brazil.
RI Pilotto, Jose Henrique/AAD-9773-2019
OI Pilotto, Jose Henrique/0000-0003-0521-8597
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
EI 1365-2893
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD JUN
PY 2018
VL 25
SU 2
SI SI
MA LBP-017
BP 203
EP 204
PG 2
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA GJ2LC
UT WOS:000435101000343
DA 2020-11-30
ER

PT J
AU Portilho, MM
   Mendonca, ACD
   Bezerra, CS
   do Espirito-Santos, MP
   de Paula, VS
   Nabuco, LC
   Villela-Nogueira, CA
   Lewis-Ximenez, LL
   Lampe, E
   Villar, LM
AF Portilho, Moyra Machado
   da Fonseca Mendonca, Ana Carolina
   Bezerra, Cristianne Sousa
   do Espirito-Santos, Marcia Paschoal
   de Paula, Vanessa Salete
   Nabuco, Leticia Cancella
   Villela-Nogueira, Cristiane Alves
   Lewis-Ximenez, Lia Laura
   Lampe, Elisabeth
   Villar, Livia Melo
TI Usefulness of in-house real time PCR for HBV DNA quantification in serum
   and oral fluid samples
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE HBV DNA quantification; In-house real time PCR; Synthetic curve; Oral
   fluid
ID B-VIRUS DNA; PERFORMANCE-CHARACTERISTICS; DIAGNOSIS; SALIVA;
   ACCEPTABILITY; QUANTITATION; ASSAYS; DETECT; TESTS
AB For quantification of hepatitis B virus DNA (HBV DNA), commercial assays are used with serum or plasma samples, but oral fluid samples could be an alternative for HBV diagnosis due to ease of collection. This study aims to develop in-house real time PCR using synthetic curve for HBV DNA quantification for serum and oral fluid samples. Samples were collected from 103 individuals (55 HBsAg reactive and HBV DNA reactive by commercial assay and 48 without HBV markers) and submitted to two in-house real time PCR assays for HBV pre-S/S region with different standard curves: qPCR plasmidial and qPCR synthetic. A total of 27 serum samples were HBV DNA positive by qPCR plasmidial and 40 with qPCR synthetic (72% and 85% of concordance, respectively). Quantitative PCR synthetic presented efficiency of 99% and sensitivity of 2log10 copies/mL. Among oral fluid samples, five and ten were detected using qPCR plasmidial and synthetic, respectively. This study demonstrated that qPCR synthetic using serum samples could be used as alternative for HBV DNA quantification due to its sensitivity. In addition, it was possible to quantify HBV DNA in oral fluid samples suggesting the potential of this specimen for molecular diagnosis of HBV.
C1 [Portilho, Moyra Machado; da Fonseca Mendonca, Ana Carolina; Bezerra, Cristianne Sousa; do Espirito-Santos, Marcia Paschoal; Lewis-Ximenez, Lia Laura; Lampe, Elisabeth; Villar, Livia Melo] Fiocruz MS, Inst Oswaldo Cruz, Lab Viral Hepatitis, Rio De Janeiro, Brazil.
   [de Paula, Vanessa Salete] Fiocruz MS, Inst Oswaldo Cruz, Mol Virol Lab, Rio De Janeiro, Brazil.
   [Nabuco, Leticia Cancella; Villela-Nogueira, Cristiane Alves] Univ Rio de Janeiro, UFRJ, Clementino Frage Filho Hosp, Rio De Janeiro, Brazil.
RP Villar, LM (corresponding author), Viral Hepatitis Lab, Helio & Peggy Pereira Pavill,Ground Floor, BR-21036004 Rio De Janeiro, RJ, Brazil.
EM lvillar@ioc.fiocruz.br
RI VILLAR, LIVIA M/F-7811-2012; de Paula, Vanessa S/I-8037-2016
OI VILLAR, LIVIA M/0000-0001-7644-8969; de Paula, Vanessa
   S/0000-0002-6314-754X; Sousa Bezerra, Cristianne/0000-0002-9389-5186
FU "Foundation of Research Support of Rio de Janeiro State" (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Brazilian National Council of Technological and
   Scientific Development (CNPq)National Council for Scientific and
   Technological Development (CNPq); Brazilian Ministry of Health;
   Coordination of Improvement of Higher Education Personnel (CAPES)CAPES;
   Oswaldo Cruz Foundation (FIOCRUZ)
FX This work was financially supported by the "Foundation of Research
   Support of Rio de Janeiro State" (FAPERJ), the Brazilian National
   Council of Technological and Scientific Development (CNPq), the
   Brazilian Ministry of Health, the Coordination of Improvement of Higher
   Education Personnel (CAPES) and the Oswaldo Cruz Foundation (FIOCRUZ).
CR Arnado LA, 2008, J VIROL METHODS, V148, P74, DOI 10.1016/j.jviromet.2007.10.020
   Baltazar CS, 2014, J CLIN MICROBIOL, V52, P3544, DOI 10.1128/JCM.01098-14
   Bowers RM, 2011, MOL CELL PROBE, V25, P60, DOI 10.1016/j.mcp.2010.12.002
   Caliendo AM, 2011, J CLIN MICROBIOL, V49, P2854, DOI 10.1128/JCM.00471-11
   Cruz HM, 2012, J ORAL PATHOL MED, V41, P793, DOI 10.1111/j.1600-0714.2012.01176.x
   Cruz HM, 2011, J CLIN LAB ANAL, V25, P134, DOI 10.1002/jcla.20447
   Datta S, 2014, WORLD J GASTROENTERO, V20, P14615, DOI 10.3748/wjg.v20.i40.14615
   dos Santos AD, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-16
   European Assoc Study Liver, 2017, J HEPATOL, V67, P370, DOI 10.1016/j.jhep.2017.03.021
   Heiberg IL, 2010, PEDIATR INFECT DIS J, V29, P465, DOI 10.1097/INF.0b013e3181d8e009
   Ismail AM, 2011, J CLIN MICROBIOL, V49, P3215, DOI 10.1128/JCM.00915-11
   Kania D, 2014, J VIROL METHODS, V201, P24, DOI 10.1016/j.jviromet.2014.01.015
   Kidd-Ljunggren K, 2006, J HOSP INFECT, V64, P352, DOI 10.1016/j.jhin.2006.06.029
   Kim JH, 2014, WORLD J GASTROENTERO, V20, P5708, DOI 10.3748/wjg.v20.i19.5708
   Lin YY, 2009, SCAND J INFECT DIS, V41, P614, DOI 10.1080/00365540902875073
   Naito H, 2001, J CLIN MICROBIOL, V39, P362, DOI 10.1128/JCM.39.1.362-364.2001
   Niesters H. G. M., 2005, EUROPEAN J GASTROENT, V17, P117
   Noppornpanth Suwanna, 2000, Southeast Asian Journal of Tropical Medicine and Public Health, V31, P419
   Paraskevis D, 2002, J VIROL METHODS, V103, P201, DOI 10.1016/S0166-0934(02)00033-2
   Paraskevis D, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-57
   Lima LRP, 2017, MEM I OSWALDO CRUZ, V112, P220, DOI 10.1590/0074-02760160354
   Portilho MM, 2012, J MED MICROBIOL, V61, P844, DOI 10.1099/jmm.0.040238-0
   Rashed-Ul Islam S M, 2015, Euroasian J Hepatogastroenterol, V5, P11, DOI 10.5005/jp-journals-10018-1121
   Shyamala V, 2004, J CLIN MICROBIOL, V42, P5199, DOI 10.1128/JCM.42.11.5199-5204.2004
   Sitnik R, 2010, REV INST MED TROP SP, V52, P119, DOI 10.1590/S0036-46652010000300001
   Takkenberg RB, 2009, J MED VIROL, V81, P988, DOI 10.1002/jmv.21477
   Tourinho R., 2015, J GENET GENOME RES, V2, P13
   Valsamakis A, 2007, CLIN MICROBIOL REV, V20, P426, DOI 10.1128/CMR.00009-07
   Wang W, 2014, CLIN CHIM ACTA, V437, P168, DOI 10.1016/j.cca.2014.07.021
   White B, 2008, DRUG ALCOHOL REV, V27, P666, DOI 10.1080/09595230801956116
   Zhang YL, 2008, CHIN J PREV MED, V42, P696
NR 31
TC 10
Z9 10
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD JUN
PY 2018
VL 256
BP 100
EP 106
DI 10.1016/j.jviromet.2018.03.001
PG 7
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA GE0EZ
UT WOS:000430888200011
PM 29514044
DA 2020-11-30
ER

PT J
AU Costa, V
   Brandao-Mello, C
   Pires, MMA
   Mello, FCDA
   Silva, PGCS
   Nunes, EP
   Lewis-Ximenez, LL
   Lampe, E
AF Costa, V.
   Brandao-Mello, C.
   Pires, M. M. A.
   Mello, F. C. D. A.
   Silva, P. G. C. S.
   Nunes, E. P.
   Lewis-Ximenez, L. L.
   Lampe, E.
TI Resistance analysis of hepatitis C virus NS5A gene in Brazilian patients
   infected with genotypes 1 and 3 treated with Daclatasvir
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress (ILC)
CY APR 11-15, 2018
CL Paris, FRANCE
SP European Assoc Study Liver
C1 [Costa, V.; Mello, F. C. D. A.; Silva, P. G. C. S.; Lewis-Ximenez, L. L.; Lampe, E.] Oswaldo Cruz Inst, Viral Hepatitis Lab, Rio De Janeiro, Brazil.
   [Brandao-Mello, C.] Univ Rio De Janeiro, Internal Med Dept, Rio De Janeiro, Brazil.
   [Pires, M. M. A.] Gaffree & Guinle Univ Hosp, Gastroenterol & Hepatol Div, Rio De Janeiro, Brazil.
   [Nunes, E. P.] Evandro Chagas Inst, Oswaldo Cruz Inst, Rio De Janeiro, Brazil.
EM cedubrandao@gmail.com
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2018
VL 68
SU 1
MA THU-382
BP S301
EP S302
DI 10.1016/S0168-8278(18)30822-5
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA HO6UT
UT WOS:000461068601214
DA 2020-11-30
ER

PT J
AU Portilho, MM
   Mendonca, ACDF
   Lago, B
   Villela-Nogueira, C
   Nabuco, L
   Ivantes, CAP
   Lewis-Ximenez, LL
   Lampe, E
   Villar, L
AF Portilho, M. M.
   Mendonca, A. C. D. F.
   Lago, B.
   Villela-Nogueira, C.
   Nabuco, L.
   Ivantes, C. A. P.
   Lewis-Ximenez, L. L.
   Lampe, E.
   Villar, L.
TI Identification of HBV genotypes and mutations associated to antiviral
   resistance and vaccine escape in serum and oral fluid samples from
   chronic hepatitis B patients
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress (ILC)
CY APR 11-15, 2018
CL Paris, FRANCE
SP European Assoc Study Liver
C1 [Portilho, M. M.; Mendonca, A. C. D. F.; Lago, B.; Lewis-Ximenez, L. L.; Lampe, E.; Villar, L.] Oswaldo Cruz Inst, Lab Viral Hepatitis, Rio De Janeiro, Brazil.
   [Villela-Nogueira, C.; Nabuco, L.] Univ Fed Rio de Janeiro, Clementino Fraga Filho Univ Hosp, Rio De Janeiro, Brazil.
   [Ivantes, C. A. P.] Ctr Orientat & Guidance COA, Curitiba, Parana, Brazil.
EM moyramp@gmail.com
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2018
VL 68
SU 1
MA SAT-358
BP S768
EP S769
DI 10.1016/S0168-8278(18)31803-8
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA HO6UT
UT WOS:000461068603345
DA 2020-11-30
ER

PT J
AU Scalioni, LD
   dos Santos, BR
   Spritzer, PM
   Villela-Nogueira, CA
   Lewis-Ximenez, LL
   Pollo-Flores, P
   Esberard, EBC
   Brandao-Mello, CE
   Lampe, E
   Villar, LM
AF Scalioni, Leticia de Paula
   dos Santos, Betania Rodrigues
   Spritzer, Poli Mara
   Villela-Nogueira, Cristiane Alves
   Lewis-Ximenez, Lia Laura
   Pollo-Flores, Priscila
   Cathala Esberard, Eliane Bordalo
   Brandao-Mello, Carlos Eduardo
   Lampe, Elisabeth
   Villar, Livia Melo
TI Impact of vitamin D receptor and binding protein gene polymorphisms in
   clinical and laboratory data of HCV patients Cross sectional study
SO MEDICINE
LA English
DT Article
DE fibrosis; hepatitis C; polymorphism; vitamin D
ID CHRONIC HEPATITIS-C; GENOME-WIDE ASSOCIATION; VIRUS-INFECTION; D
   DEFICIENCY; PARATHYROID-HORMONE; D SUPPLEMENTATION; PLUS RIBAVIRIN;
   FIBROSIS; THERAPY; IL28B
AB Potential relationship of vitamin D, vitamin D receptor (VDR), and vitamin D binding protein (DBP) have been suggested in the pathophysiology of hepatitis C virus (HCV) infection. The aim of this observational study is to determine vitamin D levels, and VDR and DBP genetic polymorphism according demographic and laboratory data in chronic HCV patients (CHC).
   A total of 148 CHC patients gave serum samples for testing 25-hydroxyvitamin D (25 (OH) D) level by immunochemiluminometric assay (<20ng/mL defined as deficient) and donated blood samples to allelic discrimination analysis using TaqMan assays. Analyzed single nucleotide polymorphisms (SNPs) were: VDR-rs7975232 (ApaI) C>A, rs731236A>G (TaqI), rs1544410 C>T (BsmI), rs10735810 T>C (FokI) and carrier globulin/binding protein (GC)-rs4588 and rs7041 and the haplotype bAt [CCA]. Hepatic fibrosis was assessed using Fib-4 and Forns index.
   Eighty-two (54.40%) patients demonstrated deficiency of vitamin D and this was associated to AST (P=.019 [CI: 1.003-1.034]), total cholesterol (P=.038 [CI: 1.004-1.164]), fibrosis grade (P<. 001 [CI: 0.000-0.844]), and FokI (P=.028) allele T presence. Association was found between VDR polymorphism and fibrosis (BsmI andTaqI), triglycerides (TaqI), and HDL (FokI). DBP polymorphism was associated to HCV genotype (GC rs7041), previous HCV treatment, and GGT (GC rs4588).
   In conclusion, lowfrequency of vitamin D deficiencywas found, but VDR polymorphisms were frequently associated to fibrosis grade suggesting that they could be used as disease evaluation markers to understand the mechanisms underlying the virus-host interaction.
C1 [Scalioni, Leticia de Paula; Lewis-Ximenez, Lia Laura; Lampe, Elisabeth; Villar, Livia Melo] Fiocruz MS, Inst Oswaldo Cruz, Lab Viral Hepatitis, Helio & Peggy Pereira Pavill,Ground Floor, BR-21036004 Rio De Janeiro, RJ, Brazil.
   [dos Santos, Betania Rodrigues; Spritzer, Poli Mara] Univ Fed Rio Grande do Sul, Dept Physiol, Gynecol Endocrinol Unit, Div Endocrinol,Porto Alegre Clin Hosp, Rio De Janeiro, Brazil.
   [Villela-Nogueira, Cristiane Alves] Univ Fed Rio de Janeiro, Hepatol Unit, Med Clin Dept, Clementino Fraga Filho Univ Hosp, Rio de Janeiro, Brazil.
   [Pollo-Flores, Priscila; Cathala Esberard, Eliane Bordalo] Fed Fluminense Univ, Antonio Pedro Univ Hosp, Rio De Janeiro, Brazil.
   [Brandao-Mello, Carlos Eduardo] Univ Fed Estado Rio de Janeiro, Gaffree Guinle Hosp, Rio De Janeiro, Brazil.
RP Villar, LM (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab Viral Hepatitis, Helio & Peggy Pereira Pavill,Ground Floor, BR-21036004 Rio De Janeiro, RJ, Brazil.
EM lvillar@ioc.fiocruz.br
RI Spritzer, Poli/A-3357-2019; VILLAR, LIVIA M/F-7811-2012; Santos, Betania
   R/J-4568-2013; Spritzer, Poli Mara/R-8405-2019
OI VILLAR, LIVIA M/0000-0001-7644-8969; Santos, Betania
   R/0000-0003-3748-0856; Spritzer, Poli Mara/0000-0002-5204-107X
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Brazilian National Counsel of Technological and
   Scientific Development (CNPq)National Council for Scientific and
   Technological Development (CNPq); Oswaldo Cruz Foundation (FIOCRUZ)
FX This study was supported by Fundacao de Amparo a Pesquisa do Estado do
   Rio de Janeiro (FAPERJ), Brazilian National Counsel of Technological and
   Scientific Development (CNPq), and Oswaldo Cruz Foundation (FIOCRUZ).
CR Asselah T, 2010, LIVER INT, V30, P1259, DOI 10.1111/j.1478-3231.2010.02283.x
   Assone T, 2016, VIRUSES-BASEL, V8, DOI [10.1016/J.VIROL.2012.09.028, 10.3390/v8020038]
   Baur K, 2012, ANTIVIR THER, V17, P541, DOI 10.3851/IMP2018
   Bitetto D, 2011, J HEPATOL, V55, P944, DOI 10.1016/j.jhep.2011.01.044
   Bitetto D, 2011, TRANSPL INT, V24, P43, DOI 10.1111/j.1432-2277.2010.01141.x
   D'Avolio A, 2012, THER DRUG MONIT, V34, P722, DOI 10.1097/FTD.0b013e318272e55a
   Eslam M, 2011, J VIRAL HEPATITIS, V18, P675, DOI 10.1111/j.1365-2893.2011.01474.x
   Falleti E, 2012, HEPATOLOGY, V56, P1641, DOI 10.1002/hep.25848
   Fan LY, 2005, J GASTROEN HEPATOL, V20, P249, DOI 10.1111/j.1440-1746.2005.03532.x
   Fattovich G, 2011, ALIMENT PHARM THER, V33, P1162, DOI 10.1111/j.1365-2036.2011.04635.x
   Georgel P, 2010, TRENDS MOL MED, V16, P277, DOI 10.1016/j.molmed.2010.04.003
   Gerova DI, 2014, SCAND J CLIN LAB INV, V74, P665, DOI 10.3109/00365513.2014.930710
   Ginsberg HN, 2005, ARCH MED RES, V36, P232, DOI 10.1016/j.arcmed.2005.01.005
   Gong Yi-Gu, 2010, Zhongguo Dang Dai Er Ke Za Zhi, V12, P544
   Gutierrez OM, 2011, OSTEOPOROSIS INT, V22, P1745, DOI 10.1007/s00198-010-1383-2
   Holmberg SD, 2013, CLIN INFECT DIS, V57, P240, DOI 10.1093/cid/cit245
   Hsia J, 2007, CIRCULATION, V115, P846, DOI 10.1161/CIRCULATIONAHA.106.673491
   Hung CH, 2016, J FORMOS MED ASSOC, V115, P278, DOI 10.1016/j.jfma.2015.11.008
   Jacobson IM, 2012, J VIRAL HEPATITIS, V19, P1, DOI 10.1111/j.1365-2893.2012.01590.x
   Ladero JM, 2013, ANN HEPATOL, V12, P199, DOI 10.1016/S1665-2681(19)31357-2
   Lange CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040159
   Lange CM, 2011, J HEPATOL, V54, P887, DOI 10.1016/j.jhep.2010.08.036
   Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107
   Mastro TD, 2016, J INFECT DIS, V214, P339, DOI 10.1093/infdis/jiw006
   Melo-Villar L, 2015, ANN HEPATOL, V14, P457, DOI 10.1016/S1665-2681(19)31166-4
   Miki D, 2011, NAT GENET, V43, P797, DOI 10.1038/ng.876
   Ochs-Balcom HM, 2011, AM J CLIN NUTR, V93, P5, DOI 10.3945/ajcn.2010.29986
   Petta S, 2010, HEPATOLOGY, V51, P1158, DOI 10.1002/hep.23489
   Rauch A, 2010, GASTROENTEROLOGY, V138, P1338, DOI 10.1053/j.gastro.2009.12.056
   Razavi H, 2013, HEPATOLOGY, V57, P2164, DOI 10.1002/hep.26218
   Ren Y, 2015, WORLD J GASTROENTERO, V21, P11152, DOI 10.3748/wjg.v21.i39.11152
   Rukin NJ, 2007, NUTR REV, V65, pS96, DOI 10.1111/j.1753-4887.2007.tb00350.x
   Santos BR, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-62
   Santos BR, 2013, HORM RES PAEDIAT, V79, P162, DOI 10.1159/000348847
   Sharma S, 2014, WORLD J GASTROENTERO, V20, P16820, DOI 10.3748/wjg.v20.i45.16820
   Shehab H, 2016, INT J BIOMED, V6, P265, DOI 10.21103/Article6(4)_OA3
   Skaaby T, 2014, ENDOCRINE, V47, P213, DOI 10.1007/s12020-013-0107-8
   Uitterlinden AG, 2004, GENE, V338, P143, DOI 10.1016/j.gene.2004.05.014
   Vallet-Pichard A, 2007, HEPATOLOGY, V46, P32, DOI 10.1002/hep.21669
   Valva P, 2016, WORLD J GASTROENTERO, V22, P1367, DOI 10.3748/wjg.v22.i4.1367
   Villar LM, 2013, WORLD J GASTROENTERO, V19, P5917, DOI 10.3748/wjg.v19.i35.5917
   von Essen MR, 2010, NAT IMMUNOL, V11, P344, DOI 10.1038/ni.1851
   Wang TJ, 2010, LANCET, V376, P180, DOI 10.1016/S0140-6736(10)60588-0
   Yilmaz H, 2016, J INFECT DEV COUNTR, V10, P308, DOI 10.3855/jidc.7849
   Zierold C, 2003, J CELL BIOCHEM, V88, P234, DOI 10.1002/jcb.10341
NR 45
TC 8
Z9 8
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD FEB
PY 2018
VL 97
IS 8
AR e9881
DI 10.1097/MD.0000000000009881
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA GA0IW
UT WOS:000427997700040
PM 29465575
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Melgaco, JG
   Gardinali, NR
   de Mello, VD
   Leal, M
   Lewis-Ximenez, LL
   Pinto, MA
AF Melgaco, Juliana Gil
   Gardinali, Noemi Rovaris
   de Mello, Vinicius da Motta
   Leal, Mariana
   Lewis-Ximenez, Lia Laura
   Pinto, Marcelo Alves
TI Hepatitis E: Update on Prevention and Control
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Review
ID E VIRUS-INFECTION; NON-B HEPATITIS; HEV INFECTION; BLOOD-DONORS;
   LIVER-TRANSPLANT; VERTICAL TRANSMISSION; VIRAL-HEPATITIS;
   PREGNANT-WOMEN; GENOTYPE 4; NON-A
AB Hepatitis E virus (HEV) is a common etiology of acute viral hepatitis worldwide. Recombinant HEV vaccines have been developed, but only one is commercially available and licensed in China since 2011. Epidemiological studies have identified genotype 3 as the major cause of chronic infection in immunocompromised individuals. Ribavirin has been shown to be effective as a monotherapy to induce HEV clearance in chronic patients who have undergone solid organ transplant (SOT) under immunosuppressive therapy. Efforts and improvements in prevention and control have been made to reduce the instances of acute and chronic hepatitis E in endemic and nonendemic countries. However, this review shows that further studies are required to demonstrate the importance of preventive vaccination and treatment worldwide, with emphasis on hepatitis E infection in the public health system.
C1 [Melgaco, Juliana Gil; de Mello, Vinicius da Motta; Leal, Mariana; Lewis-Ximenez, Lia Laura] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Ambulatorio Lab Hepatites Virais, Rio De Janeiro, RJ, Brazil.
   [Gardinali, Noemi Rovaris; Pinto, Marcelo Alves] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Desenvolvimento Tecnol Virol, Rio De Janeiro, RJ, Brazil.
RP Melgaco, JG (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Ambulatorio Lab Hepatites Virais, Rio De Janeiro, RJ, Brazil.; Gardinali, NR (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Desenvolvimento Tecnol Virol, Rio De Janeiro, RJ, Brazil.
EM juliana.melgaco@gmail.com; no_rovaris@yahoo.com.br
RI Pinto, Marcelo Alves/ABA-3312-2020; Melgaco, Juliana/AAQ-6084-2020;
   Pinto, Marcelo/G-7503-2012
OI Melgaco, Juliana/0000-0003-0087-6531; Pinto,
   Marcelo/0000-0003-3462-7277; Mello, Vinicius/0000-0001-7705-5921
CR Acharya SK, 2007, J HEPATOL, V46, P387, DOI 10.1016/j.jhep.2006.09.016
   [Anonymous], 2015, Wkly Epidemiol Rec, V90, P185
   [Anonymous], 2017, REV VACCINE PR UNPUB
   [Anonymous], 2017, R A CLIN PRESENTATIO
   [Anonymous], 2010, R A GLOBAL PREVALENC
   Arankalle VA, 1999, J VIRAL HEPATITIS, V6, P161, DOI 10.1046/j.1365-2893.1999.00141.x
   AYE TT, 1992, NUCLEIC ACIDS RES, V20, P3512, DOI 10.1093/nar/20.13.3512
   Barnaud E, 2012, APPL ENVIRON MICROB, V78, P5153, DOI 10.1128/AEM.00436-12
   Bortoliero André Luiz, 2006, Rev. Inst. Med. trop. S. Paulo, V48, P87, DOI 10.1590/S0036-46652006000200006
   Bose PD, 2011, J HEPATOL, V54, P1107, DOI 10.1016/j.jhep.2010.08.037
   Bouamra Y, 2014, INTERVIROLOGY, V57, P43, DOI 10.1159/000354801
   Cheng XS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048968
   Clemente-Casares P, 2009, J WATER HEALTH, V7, P664, DOI 10.2166/wh.2009.120
   Colson P., 2017, TRANSFUSION ASS HEPA
   Dai X, 2013, EMERG INFECT DIS, V19, P1528, DOI 10.3201/eid1909.130013
   Dalton HR, 2007, LANCET, V369, P1260, DOI 10.1016/S0140-6736(07)60595-9
   Dalton HR, 2014, FUTURE MICROBIOL, V9, P1361, DOI 10.2217/fmb.14.89
   Domanovic D, 2017, EUROSURVEILLANCE, V22, P6, DOI 10.2807/1560-7917.ES.2017.22.16.30514
   Fierro NA, 2016, WORLD J GASTROENTERO, V22, P2271, DOI 10.3748/wjg.v22.i7.2271
   FitzSimons David, 2010, Vaccine, V28, P583, DOI 10.1016/j.vaccine.2009.10.136
   Gardinali NR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174070
   Geng YS, 2014, HEPAT MON, V14, DOI 10.5812/hepatmon.15618
   Gerolami R, 2008, NEW ENGL J MED, V358, P859, DOI 10.1056/NEJMc0708687
   Goel A., 2017, ADV HEPATITIS E 2 EP
   Goumba Charles M, 2010, BMC Res Notes, V3, P103, DOI 10.1186/1756-0500-3-103
   Garcia CG, 2012, J MED VIROL, V84, P1025, DOI 10.1002/jmv.23277
   Hewitt P. E., 2017, HEPATITIS E VIRUS BL
   Hewitt PE, 2014, LANCET, V384, P1766, DOI 10.1016/S0140-6736(14)61034-5
   Inagaki Y, 2015, EBIOMEDICINE, V2, P1607, DOI 10.1016/j.ebiom.2015.09.030
   Izopet J, 2015, J CLIN VIROL, V70, P39, DOI 10.1016/j.jcv.2015.06.103
   Jilani N, 2007, J GASTROEN HEPATOL, V22, P676, DOI 10.1111/j.1440-1746.2007.04913.x
   Kamar N, 2008, NEW ENGL J MED, V358, P811, DOI 10.1056/NEJMoa0706992
   Kamar N, 2016, LIVER INT, V36, P467, DOI 10.1111/liv.13037
   Kamar N, 2015, TRANSPLANTATION, V99, P2124, DOI 10.1097/TP.0000000000000850
   Kamar N, 2014, CLIN MICROBIOL REV, V27, P116, DOI 10.1128/CMR.00057-13
   Kamar N, 2012, LANCET, V379, P2477, DOI 10.1016/S0140-6736(11)61849-7
   Kamili S, 2011, VIRUS RES, V161, P93, DOI 10.1016/j.virusres.2011.05.008
   Kang YH, 2017, J MED VIROL, V89, P872, DOI 10.1002/jmv.24693
   Kaushik N, 2017, J VIROL, V91, DOI 10.1128/JVI.00754-17
   Khuroo M. S., 2017, INCIDENCE SEVERITY V
   Khuroo MS, 2016, WORLD J GASTROENTERO, V22, P7030, DOI 10.3748/wjg.v22.i31.7030
   KHUROO MS, 1980, AM J MED, V68, P818, DOI 10.1016/0002-9343(80)90200-4
   KHUROO MS, 1995, LANCET, V345, P1025, DOI 10.1016/S0140-6736(95)90761-0
   Koenecke C, 2014, BONE MARROW TRANSPL, V49, P159, DOI 10.1038/bmt.2013.148
   Kumar A, 2014, CYTOKINE, V65, P95, DOI 10.1016/j.cyto.2013.09.022
   Kumar RM, 2001, EUR J OBSTET GYN R B, V100, P9, DOI 10.1016/S0301-2115(01)00448-1
   Lapa D, 2015, INT J MOL SCI, V16, P25711, DOI 10.3390/ijms161025711
   Lee GH, 2016, GASTROENTEROLOGY, V150, P355, DOI 10.1053/j.gastro.2015.10.048
   Li SW, 2015, HUM VACC IMMUNOTHER, V11, P908, DOI 10.1080/21645515.2015.1008870
   dos Santos DRL, 2010, J CLIN VIROL, V47, P276, DOI 10.1016/j.jcv.2009.12.021
   Wassaf MGM, 2014, J CLIN VIROL, V61, P334, DOI 10.1016/j.jcv.2014.08.016
   Minagi T, 2016, VOX SANG, V111, P242, DOI 10.1111/vox.12425
   Mirazo S, 2018, VET MICROBIOL, V213, P21, DOI 10.1016/j.vetmic.2017.11.013
   Mirazo S, 2014, HEPATIC MED-EVID RES, V6, P45, DOI 10.2147/HMER.S63417
   Mirazo S, 2011, ARCH VIROL, V156, P1451, DOI 10.1007/s00705-011-0991-2
   Miyoshi M, 2016, INTERNAL MED, V55, P2811, DOI 10.2169/internalmedicine.55.7025
   Mushahwar IK, 2008, J MED VIROL, V80, P646, DOI 10.1002/jmv.21116
   NAIDU S S, 1957, Indian J Med Res, V45, P71
   Naik S. R., 2017, LARGE WATERBORNE VIR
   Nelson KE, 2016, CURR OPIN INFECT DIS, V29, P478, DOI 10.1097/QCO.0000000000000294
   Panduro A, 2011, SALUD PUBLICA MEXICO, V53, pS37
   Bin Park S, 2012, NATURE, V491, P21, DOI 10.1038/491021a
   Passos-Castilho AM, 2016, J MED VIROL, V88, P361, DOI 10.1002/jmv.24336
   Peron JM, 2016, LIVER INT, V36, P328, DOI 10.1111/liv.12911
   Pinto M., 2017, HUMAN VIROLOGY LATIN, P119
   Pischke S, 2014, TRANSPL INFECT DIS, V16, P333, DOI 10.1111/tid.12183
   Pischke S, 2013, LIVER INT, V33, P722, DOI 10.1111/liv.12114
   Qu CB, 2017, ARCH VIROL, V162, P2989, DOI 10.1007/s00705-017-3444-8
   Ramos DD, 2016, FEMS MICROBIOL LETT, V363, DOI 10.1093/femsle/fnw021
   Rein DB, 2012, HEPATOLOGY, V55, P988, DOI 10.1002/hep.25505
   Ren FR, 2014, TRANSFUSION, V54, P910, DOI 10.1111/trf.12530
   Rendon J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148417
   RIEDMANN EM, 2012, HUM VACC IMMUNOTHER, V8, P1743
   Riveiro-Barciela M, 2013, ANN HEPATOL, V12, P861, DOI 10.1016/S1665-2681(19)31290-6
   Salam GD, 2013, HEPATOL RES, V43, P826, DOI 10.1111/hepr.12028
   Satake M, 2017, TRANSFUSION, V57, P280, DOI 10.1111/trf.13994
   Schielke A, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-487
   Schlosser B, 2012, J HEPATOL, V56, P500, DOI 10.1016/j.jhep.2011.06.021
   Sharma S, 2017, J VIRAL HEPATITIS, V24, P1067, DOI 10.1111/jvh.12730
   Singh A., 2016, CHRONIC HEPATITIS E
   Smith DB, 2015, J GEN VIROL, V96, P1191, DOI 10.1099/vir.0.000115
   de Souza AJS, 2012, COMP IMMUNOL MICROB, V35, P477, DOI 10.1016/j.cimid.2012.04.004
   Sridhar S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040869
   Su YY, 2017, CLIN MICROBIOL INFEC, V23, DOI 10.1016/j.cmi.2016.10.029
   Teshale E. H., 2017, TRAVELERS HLTH HEPAT
   Teshale EH, 2011, WORLD J HEPATOL, V3, P285, DOI 10.4254/wjh.v3.i12.285
   Trabelsi K, 2014, VACCINE, V32, P2808, DOI 10.1016/j.vaccine.2014.02.041
   TSAREV SA, 1994, P NATL ACAD SCI USA, V91, P10198, DOI 10.1073/pnas.91.21.10198
   Viswanathan R, 2013, NATL MED J INDIA, V26, P362
   Wang X., 2017, PROPHYLAXIS HEPATITI
   Wang Yongxia, 2010, Weishengwu Xuebao, V50, P937
   Wen J., 2017, IMMUNOGENICITY DIFFE
   Who, 2017, HEP E
   WONG DC, 1980, LANCET, V2, P876
   Woo PCY, 2014, EMERG INFECT DIS, V20, P1044, DOI 10.3201/eid2006.140140
   Wu T, 2012, HEPATOLOGY, V55, DOI 10.1002/hep.25522
   Wu X, 2016, AM J TRANSL RES, V8, P1
   Wu X, 2016, HUM VACC IMMUNOTHER, V12, P2603, DOI 10.1080/21645515.2016.1184806
   You SL, 2013, HEPATOL INT, V7, P714, DOI 10.1007/s12072-013-9424-5
   Yugo DM, 2013, INT J ENV RES PUB HE, V10, P4507, DOI 10.3390/ijerph10104507
   Zaki ME, 2011, LIVER INT, V31, P1001, DOI 10.1111/j.1478-3231.2011.02521.x
   Zhang J, 2014, CLIN MICROBIOL INFEC, V20, pO397, DOI 10.1111/1469-0691.12419
   Zhang J, 2015, NEW ENGL J MED, V372, P914, DOI 10.1056/NEJMoa1406011
   Zhang J, 2009, VACCINE, V27, P1869, DOI 10.1016/j.vaccine.2008.12.061
   Zhang LM, 2017, TRANSFUSION, V57, P248, DOI 10.1111/trf.13937
   Zhao CY, 2016, ADV EXP MED BIOL, V948, P191, DOI 10.1007/978-94-024-0942-0_11
   Zhao YY, 2016, HUM VACC IMMUNOTHER, V12, P2003, DOI 10.1080/21645515.2016.1141844
   Zhu FC, 2010, LANCET, V376, P895, DOI 10.1016/S0140-6736(10)61030-6
NR 108
TC 13
Z9 14
U1 0
U2 4
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2018
VL 2018
AR 5769201
DI 10.1155/2018/5769201
PG 9
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA FS1ON
UT WOS:000419546700001
PM 29546064
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Portilho, MM
   Nabuco, LC
   Villela-Nogueira, CA
   Brandao-Mello, CE
   Pilotto, JH
   Flores, GL
   Lewis-Ximenez, LL
   Lampe, E
   Villar, LM
AF Portilho, Moyra Machado
   Nabuco, Leticia Cancella
   Villela-Nogueira, Cristiane Alves
   Brandao-Mello, Carlos Eduardo
   Pilotto, Jose Henrique
   Flores, Geane Lopes
   Lewis-Ximenez, Lia Laura
   Lampe, Elisabeth
   Villar, Livia Melo
TI Detection of occult hepatitis B in serum and oral fluid samples
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE occult hepatitis B; HBV DNA; oral fluid
ID VIRUS-INFECTION; SURFACE-ANTIGEN; DNA
AB In occult hepatitis B infection (OBI), hepatitis B virus DNA (HBV DNA) can be detected in serum samples; however, oral fluid collection for detection of HBV DNA has not yet been explored, despite the availability of collection devices. Serum and oral fluid samples from 45 hepatitis B core antibody (anti-HBc)-positive patients were collected for the amplification of the HBV polymerase gene. HBV DNA was detected in five serum and four oral fluid samples (the detection limit for oral fluid was 1.656 log IU/mL in paired serum). In conclusion, simple methodologies of sample collection and in-house polymerase chain reaction (PCR) allowed detection of HBV DNA, and these could be used to improve the diagnosis of OBI, especially in locations with limited resources.
C1 [Portilho, Moyra Machado; Flores, Geane Lopes; Lewis-Ximenez, Lia Laura; Lampe, Elisabeth; Villar, Livia Melo] Fundacao Oswaldo Cruz Fiocruz, Inst Oswaldo Cruz, Lab Hepatites Virais, Rio De Janeiro, RJ, Brazil.
   [Nabuco, Leticia Cancella; Villela-Nogueira, Cristiane Alves] Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Rio De Janeiro, RJ, Brazil.
   [Brandao-Mello, Carlos Eduardo] Univ Fed Rio de Janeiro, Hosp Univ Gaffree & Guinle, Rio De Janeiro, RJ, Brazil.
   [Pilotto, Jose Henrique] Hosp Geral Nova Iguacu, Nova Iguacu, RJ, Brazil.
   [Pilotto, Jose Henrique] Fundacao Oswaldo Cruz Fiocruz, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Rio De Janeiro, RJ, Brazil.
RP Villar, LM (corresponding author), Fundacao Oswaldo Cruz Fiocruz, Inst Oswaldo Cruz, Lab Hepatites Virais, Rio De Janeiro, RJ, Brazil.
EM lvillar@ioc.fiocruz.br
RI Pilotto, Jose Henrique/AAD-9773-2019; VILLAR, LIVIA M/F-7811-2012
OI Pilotto, Jose Henrique/0000-0003-0521-8597; VILLAR, LIVIA
   M/0000-0001-7644-8969
FU FAPERJCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); CNPqNational Council for Scientific and
   Technological Development (CNPq); Brazilian Ministry of Health;
   CAPESCAPES; FIOCRUZ
FX FAPERJ, CNPq, Brazilian Ministry of Health, CAPES, FIOCRUZ.
CR Brechot C, 2001, HEPATOLOGY, V34, P194, DOI 10.1053/jhep.2001.25172
   Chen HY, 2016, J FORMOS MED ASSOC, V116, P697
   Coppola N, 2015, WORLD J GASTROENTERO, V21, P11931, DOI 10.3748/wjg.v21.i42.11931
   Heiberg IL, 2010, PEDIATR INFECT DIS J, V29, P465, DOI 10.1097/INF.0b013e3181d8e009
   Kidd-Ljunggren K, 2006, J HOSP INFECT, V64, P352, DOI 10.1016/j.jhin.2006.06.029
   Maldonado-Rodriguez A, 2015, WORLD J HEPATOL, V7, P253, DOI 10.4254/wjh.v7.i2.253
   Mallory MA, 2011, J VIROL METHODS, V177, P31, DOI 10.1016/j.jviromet.2011.06.009
   Morsica G, 2009, INFECTION, V37, P445, DOI 10.1007/s15010-008-8194-9
   Niesters H. G. M., 2005, EUROPEAN J GASTROENT, V17, P117
   Noppornpanth Suwanna, 2000, Southeast Asian Journal of Tropical Medicine and Public Health, V31, P419
   Piroth L, 2008, SCAND J INFECT DIS, V40, P835, DOI 10.1080/00365540801918511
   Portilho MM, 2012, J MED MICROBIOL, V61, P844, DOI 10.1099/jmm.0.040238-0
   Raimondo G, 2008, J HEPATOL, V49, P652, DOI 10.1016/j.jhep.2008.07.014
   Larrubia JR, 2011, WORLD J GASTROENTERO, V17, P1529, DOI [10.3748/wjg.v17.i12.1529, 10.3748/wjg.v17.i12. 1529]
   Squadrito G, 2013, J HEPATOL, V59, P696, DOI 10.1016/j.jhep.2013.05.043
   TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]
   Zhang YL, 2008, CHIN J PREV MED, V42, P696
NR 17
TC 2
Z9 2
U1 0
U2 3
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD JAN
PY 2018
VL 113
IS 1
BP 62
EP 65
DI 10.1590/0074-02760170071
PG 4
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA FO8XA
UT WOS:000417170300010
PM 29211108
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Villar, LM
   Caldas, GC
   Scalioni, LD
   Miguel, JC
   da Silva, EF
   Marques, VA
   Villela-Nogueira, CA
   Lewis-Ximenez, LL
   Lampe, E
AF Villar, Livia Melo
   Caldas, Gabriela Cardoso
   Scalioni, Leticia de Paula
   Miguel, Juliana Custodio
   da Silva, Elisangela Ferreira
   Marques, Vanessa Alves
   Villela-Nogueira, Cristiane Alves
   Lewis-Ximenez, Lia Laura
   Lampe, Elisabeth
TI High prevalence of insulin resistance among Brazilian chronic hepatitis
   C patients
SO ARCHIVES OF ENDOCRINOLOGY METABOLISM
LA English
DT Article
DE Hepatitis C; insulin resistance; prevalence
ID SUSTAINED VIROLOGICAL RESPONSE; GENOTYPE 1 INFECTION; METABOLIC
   SYNDROME; PLUS RIBAVIRIN; METAANALYSIS; HOMEOSTASIS; OBESITY; MODEL
AB Objective: This study aims to estimate the prevalence of insulin resistance (IR) among chronic hepatitis C (CHC) patients and their related laboratory and demographic data. Subjects and methods: In this study, non-diabetic CHC patients referred to Viral Hepatitis Ambulatories from Rio de Janeiro (Brazil) donated blood samples. Insulin was measured using a chemiluminescence immunoassay. IR was determined by HOMA-IR, where HOMA-IR > 2 was defined as IR. Results: A total of 214 CHC patients were recruited (123 females aged 53.6 years +/- 10.9 years). IR was present in 133 patients (62.1%) and was associated in bivariate analysis to higher mean values of age (p = 0.040), triglycerides (p = 0.032), glucose (p = 0.000), insulin (p = 0.000), waist circumference (p = 0.001), and body mass index (p = 0.007); however, none of these variables were significant in the multivariate analysis. Conclusions: The high prevalence of IR was observed among CHC patients, and there was no difference in clinical or laboratory parameters when both groups were compared in the multivariate analysis. This high IR prevalence could lead to a high risk for development of cardiovascular disease and metabolic disorders.
C1 [Villar, Livia Melo; Caldas, Gabriela Cardoso; Scalioni, Leticia de Paula; Miguel, Juliana Custodio; da Silva, Elisangela Ferreira; Marques, Vanessa Alves; Lewis-Ximenez, Lia Laura; Lampe, Elisabeth] Fiocruz MS, Inst Oswaldo Cruz, Lab Hepatite Viral, Rio De Janeiro, RJ, Brazil.
   [Villela-Nogueira, Cristiane Alves] Univ Fed Rio de Janeiro, HUCFF, Dept Clin Med, Unidade Hepatol, Rio De Janeiro, RJ, Brazil.
RP Villar, LM (corresponding author), Fundacao Oswaldo Cruz, Lab Hepatite Viral, Pavilhao Helio e Peggy Pereira,Sala B09, BR-21036004 Rio De Janeiro, RJ, Brazil.
EM lvillar@ioc.fiocruz.br
RI VILLAR, LIVIA M/F-7811-2012
OI VILLAR, LIVIA M/0000-0001-7644-8969
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (Faperj)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Brazilian National Counsel of Technological and
   Scientific Development (CNPq)National Council for Scientific and
   Technological Development (CNPq); Oswaldo Cruz Foundation (Fiocruz)
FX this research was supported by the Fundacao de Amparo a Pesquisa do
   Estado do Rio de Janeiro (Faperj), Brazilian National Counsel of
   Technological and Scientific Development (CNPq) and the Oswaldo Cruz
   Foundation (Fiocruz).
CR Bensenor IM, 2015, METAB SYNDR RELAT D, V13, P362, DOI 10.1089/met.2015.0045
   Chang ML, 2016, WORLD J GASTROENTERO, V22, P1461, DOI 10.3748/wjg.v22.i4.1461
   Das GC, 2012, VIROLOGY, V434, P5, DOI 10.1016/j.virol.2012.07.003
   del Campo JA, 2013, ALIMENT PHARM THER, V37, P74, DOI 10.1111/apt.12113
   Eslam M, 2011, J VIRAL HEPATITIS, V18, P675, DOI 10.1111/j.1365-2893.2011.01474.x
   Eslam M, 2011, ALIMENT PHARM THER, V34, P297, DOI 10.1111/j.1365-2036.2011.04716.x
   Eslam M, 2012, J CLIN GASTROENTEROL, V46, P228, DOI 10.1097/MCG.0b013e31822a2dc6
   Fattovich G, 2011, LIVER INT, V31, P66, DOI 10.1111/j.1478-3231.2010.02343.x
   Ghany MG, 2009, HEPATOLOGY, V49, P1335, DOI 10.1002/hep.22759
   Kiran Z, 2013, PAK J MED SCI, V29, P201, DOI 10.12669/pjms.291.2888
   Knobler H, 2016, WORLD J HEPATOL, V8, P131, DOI 10.4254/wjh.v8.i2.131
   Laurito MP, 2013, BRAZ J INFECT DIS, V17, P555, DOI 10.1016/j.bjid.2013.02.009
   Oliveira LPM, 2016, J AM COLL NUTR, V35, P436, DOI 10.1080/07315724.2015.1072756
   Oliveira LPM, 2012, CLINICS, V67, P219, DOI 10.6061/clinics/2012(03)03
   de Souza AFM, 2011, ARQ BRAS ENDOCRINOL, V55, P412, DOI 10.1590/S0004-27302011000600008
   Mello V, 2006, J MED VIROL, V78, P1406, DOI 10.1002/jmv.20712
   Michalczuk MT, 2012, INT J HEPATOL, V2012, DOI 10.1155/2012/576584
   Miyajima I, 2013, J GASTROENTEROL, V48, P93, DOI 10.1007/s00535-012-0610-3
   Oliveira AC, 2009, FREE RADICAL RES, V43, P1187, DOI 10.3109/10715760903247249
   Ramcharran D, 2010, HEPATOLOGY, V52, P854, DOI 10.1002/hep.23796
   Romero-Gomez M, 2005, GASTROENTEROLOGY, V128, P636, DOI 10.1053/j.gastro.2004.12.049
   Peres DPS, 2013, ANN HEPATOL, V12, P871, DOI 10.1016/S1665-2681(19)31291-8
   Serfaty L, 2012, GUT, V61, P1473, DOI 10.1136/gutjnl-2011-300749
   Zhang XQ, 2016, ACTA PHARM SIN B, V6, P26, DOI 10.1016/j.apsb.2015.09.008
NR 24
TC 1
Z9 1
U1 0
U2 0
PU SBEM-SOC BRASIL ENDOCRINOLOGIA & METABOLOGIA
PI RIO DE JANEIRO, RJ
PA RUA HUMAITA, 85 CJ 501, RIO DE JANEIRO, RJ, 22261-000, BRAZIL
SN 2359-3997
EI 2359-4292
J9 ARCH ENDOCRIN METAB
JI Arch. Endocrinol. Metab.
PD DEC
PY 2017
VL 61
IS 6
BP 628
EP 632
DI 10.1590/2359-3997000000315
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA FV2DY
UT WOS:000424375800018
PM 29412389
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Portilho, M
   Mendonca, A
   Marques, V
   Nabuco, L
   Villela-Nogueira, C
   Ivantes, C
   Lewis-Ximenez, L
   Lampe, E
   Villar, L
AF Portilho, M. M.
   Mendonca, A. C. F.
   Marques, V. A.
   Nabuco, L. C.
   Villela-Nogueira, C. A.
   Ivantes, C. A. P.
   Lewis-Ximenez, L. L.
   Lampe, E.
   Villar, L. M.
TI Comparison of oral fluid collection methods for the molecular detection
   of hepatitis B virus
SO ORAL DISEASES
LA English
DT Article
DE hepatitis B; molecular detection; oral fluid
ID SALIVA SPECIMENS; SURFACE-ANTIGEN; DNA; SERUM; TRANSMISSION; INFECTION;
   CHILDREN; CARDS; HBV; HCV
AB BackgroundThis study aims to compare the efficiency of four oral fluid collection methods (Salivette, FTA Card, spitting and DNA-Sal) to detect HBV DNA by qualitative PCR.
   Materials and MethodsSeventy-four individuals (32 HBV reactive and 42 with no HBV markers) donated serum and oral fluid. In-house qualitative PCR to detect HBV was used for both samples and commercial quantitative PCR for serum.
   ResultsHBV DNA was detected in all serum samples from HBV-infected individuals, and it was not detected in control group. HBV DNA from HBV group was detected in 17 samples collected with Salivette device, 16 samples collected by FTA Card device, 16 samples collected from spitting and 13 samples collected by DNA-Sal device. Samples that corresponded to a higher viral load in their paired serum sample could be detected using all oral fluid collection methods, but Salivette collection device yielded the largest numbers of positive samples and had a wide range of viral load that was detected.
   ConclusionIt was possible to detect HBV DNA using all devices tested, but higher number of positive samples was observed when samples were collected using Salivette device, which shows high concordance to viral load observed in the paired serum samples.
C1 [Portilho, M. M.; Mendonca, A. C. F.; Marques, V. A.; Lewis-Ximenez, L. L.; Lampe, E.; Villar, L. M.] Lab Viral Hepatitis Oswaldo Cruz Inst, FIOCRUZ, Rio De Janeiro, Brazil.
   [Nabuco, L. C.; Villela-Nogueira, C. A.] Univ Rio Janeiro, Clementino Fraga Filho Hosp, UFRJ, Rio De Janeiro, Brazil.
   [Ivantes, C. A. P.] Ctr Guidance & Advisor COA, Curitiba, PR, Brazil.
RP Villar, LM (corresponding author), Viral Hepatitis Lab, Correspondence, Livia Melo Villar, Rio De Janeiro, Brazil.
EM lvillar@ioc.fiocruz.br
RI VILLAR, LIVIA M/F-7811-2012
OI VILLAR, LIVIA M/0000-0001-7644-8969
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel SuperiorCAPES;
   Fundacao Oswaldo Cruz; Conselho Nacional de Desenvolvimento Cientifico e
   TecnologicoNational Council for Scientific and Technological Development
   (CNPq); Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do
   Rio de JaneiroCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ)
FX Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior; Fundacao
   Oswaldo Cruz; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico; Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado
   do Rio de Janeiro
CR Abdelwhab EM, 2011, J VIROL METHODS, V174, P120, DOI 10.1016/j.jviromet.2011.03.017
   Amado LA, 2011, J MED VIROL, V83, P768, DOI 10.1002/jmv.22045
   Arnado LA, 2008, J VIROL METHODS, V148, P74, DOI 10.1016/j.jviromet.2007.10.020
   Baltazar CS, 2014, J CLIN MICROBIOL, V52, P3544, DOI 10.1128/JCM.01098-14
   Biswal JK, 2016, MOL CELL PROBE, V30, P225, DOI 10.1016/j.mcp.2016.06.002
   Cruz HM, 2012, J ORAL PATHOL MED, V41, P793, DOI 10.1111/j.1600-0714.2012.01176.x
   Cruz HM, 2011, J CLIN LAB ANAL, V25, P134, DOI 10.1002/jcla.20447
   Datta S, 2012, J CLIN EXP HEPATOL, V2, P353, DOI 10.1016/j.jceh.2012.10.003
   Fei QJ, 2015, ANDROLOGY-US, V3, P506, DOI 10.1111/andr.12021
   Heiberg IL, 2010, PEDIATR INFECT DIS J, V29, P465, DOI 10.1097/INF.0b013e3181d8e009
   Holm-Hansen C, 2004, CLIN DIAGN LAB IMMUN, V11, P909, DOI 10.1128/CDLI.11.5.909-912.2004
   Kao Jia-Horng, 2008, Expert Rev Gastroenterol Hepatol, V2, P553, DOI 10.1586/17474124.2.4.553
   Ke WX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098865
   Kidd-Ljunggren K, 2006, J HOSP INFECT, V64, P352, DOI 10.1016/j.jhin.2006.06.029
   Komatsu H, 2012, J INFECT DIS, V206, P478, DOI 10.1093/infdis/jis293
   Lema C, 2006, GENET TEST, V10, P126, DOI 10.1089/gte.2006.10.126
   Liang X, 2014, J VIROL METHODS, V202, P69, DOI 10.1016/j.jviromet.2014.02.022
   Menezes GBL, 2012, MEM I OSWALDO CRUZ, V107, P680, DOI 10.1590/S0074-02762012000500016
   Mallory MA, 2011, J VIROL METHODS, V177, P31, DOI 10.1016/j.jviromet.2011.06.009
   Ministry of Health from Brazil, 2016, CLIN PROT THER GUID
   Niesters H. G. M., 2005, EUROPEAN J GASTROENT, V17, P117
   Parizad EG, 2016, HEPAT MON, V16, DOI 10.5812/hepatmon.30385
   Pereira CV, 2016, MEM I OSWALDO CRUZ, V111, P252, DOI 10.1590/0074-02760150390
   Portilho MM, 2012, J MED MICROBIOL, V61, P844, DOI 10.1099/jmm.0.040238-0
   Tourinho RS, 2015, INT J ENV RES PUB HE, V12, P7357, DOI 10.3390/ijerph120707357
   Villar Livia Melo, 2015, World J Virol, V4, P323, DOI 10.5501/wjv.v4.i4.323
   White B, 2008, DRUG ALCOHOL REV, V27, P666, DOI 10.1080/09595230801956116
   WHO, 2016, HEP B EP
NR 28
TC 4
Z9 5
U1 2
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1354-523X
EI 1601-0825
J9 ORAL DIS
JI Oral Dis.
PD NOV
PY 2017
VL 23
IS 8
BP 1072
EP 1079
DI 10.1111/odi.12692
PG 8
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA FJ4VR
UT WOS:000412741600009
PM 28544047
DA 2020-11-30
ER

PT J
AU Wolski, D
   Foote, PK
   Chen, DY
   Lewis-Ximenez, LL
   Fauvelle, C
   Aneja, J
   Walker, A
   Tonnerre, P
   Torres-Cornejo, A
   Kvistad, D
   Imam, S
   Waring, MT
   Tully, DC
   Allen, TM
   Chung, RT
   Timm, J
   Haining, WN
   Kim, AY
   Baumert, TF
   Lauer, GM
AF Wolski, David
   Foote, Peter K.
   Chen, Diana Y.
   Lewis-Ximenez, Lia L.
   Fauvelle, Catherine
   Aneja, Jasneet
   Walker, Andreas
   Tonnerre, Pierre
   Torres-Cornejo, Almudena
   Kvistad, Daniel
   Imam, Sabrina
   Waring, Michael T.
   Tully, Damien C.
   Allen, Todd M.
   Chung, Raymond T.
   Timm, Joerg
   Haining, W. Nicholas
   Kim, Arthur Y.
   Baumert, Thomas F.
   Lauer, Georg M.
TI Early Transcriptional Divergence Marks Virus-Specific Primary Human
   CD8(+) T Cells in Chronic versus Acute Infection
SO IMMUNITY
LA English
DT Article
ID HEPATITIS-C INFECTION; IMMUNE-RESPONSES; GENE-EXPRESSION; CLASS-I;
   CLEARANCE; ENCYCLOPEDIA; PERSISTENCE; BINDING; ESCAPE; MODULE
AB Distinct molecular pathways govern the differentiation of CD8(+) effector T cells into memory or exhausted T cells during acute and chronic viral infection, but these are not well studied in humans. Here, we employed an integrative systems immunology approach to identify transcriptional commonalities and differences between virus-specific CD8(+) T cells from patients with persistent and spontaneously resolving hepatitis C virus (HCV) infection during the acute phase. We observed dysregulation of metabolic processes during early persistent infection that was linked to changes in expression of genes related to nucleosomal regulation of transcription, T cell differentiation, and the inflammatory response and correlated with subject age, sex, and the presence of HCV-specific CD4(+) T cell populations. These early changes in HCV-specific CD8(+) T cell transcription preceded the overt establishment of T cell exhaustion, making this signature a prime target in the search for the regulatory origins of T cell dysfunction in chronic viral infection.
C1 [Wolski, David; Foote, Peter K.; Chen, Diana Y.; Aneja, Jasneet; Tonnerre, Pierre; Torres-Cornejo, Almudena; Kvistad, Daniel; Chung, Raymond T.; Lauer, Georg M.] Harvard Med Sch, Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
   [Wolski, David; Foote, Peter K.; Chen, Diana Y.; Aneja, Jasneet; Tonnerre, Pierre; Torres-Cornejo, Almudena; Kvistad, Daniel; Chung, Raymond T.; Lauer, Georg M.] Harvard Med Sch, Massachusetts Gen Hosp, Liver Ctr, Boston, MA 02114 USA.
   [Wolski, David; Fauvelle, Catherine; Baumert, Thomas F.] Inst Rech Malad Virales & Hepat, INSERM, U1110, F-67000 Strasbourg, France.
   [Wolski, David; Fauvelle, Catherine; Baumert, Thomas F.] Univ Strasbourg, F-67081 Strasbourg, France.
   [Lewis-Ximenez, Lia L.] Fiocruz MS, Oswaldo Cruz Inst, Lab Viral Hepatitis, BR-21040 Rio De Janeiro, Brazil.
   [Walker, Andreas; Timm, Joerg] Heinrich Heine Univ, Univ Hosp Dusseldorf, Inst Virol, D-40225 Dusseldorf, Germany.
   [Imam, Sabrina; Haining, W. Nicholas] Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
   [Waring, Michael T.; Tully, Damien C.; Allen, Todd M.] Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA.
   [Waring, Michael T.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
   [Kim, Arthur Y.] Harvard Med Sch, Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
   [Baumert, Thomas F.] Nouvel Hop Civil, Inst Hosp Univ, Pole Hepato Digestif, F-67000 Strasbourg, France.
RP Lauer, GM (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.; Lauer, GM (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Liver Ctr, Boston, MA 02114 USA.
EM glauer@mgh.harvard.edu
RI Tonnerre, Pierre/AAA-1631-2020; Allen, Todd/F-5473-2011; Timm,
   Jorg/P-7652-2019; Lauer, Georg/J-1467-2018
OI Tonnerre, Pierre/0000-0002-1719-9736; Allen, Todd/0000-0002-6609-1318;
   Timm, Jorg/0000-0001-7799-3045; Tully, Damien/0000-0002-7620-9340;
   Walker, Andreas/0000-0002-8736-0863; Lauer, Georg/0000-0002-9792-4271
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [U19 AI066345/U01 AI131314, U19
   AI082630, R01 AI105035/R01 DA016017]; ARC, Paris; IHU
   Strasbourg/TheraHCC IHUARC [IHU201301187]; European UnionEuropean Union
   (EU) [ERC-AdG-2014-671231-HEPCIR]; EUEuropean Union (EU)
   [H2020-667273HEPCAR, FP7 HEPAMAB GAN 305600]; ANR/LABEXFrench National
   Research Agency (ANR) [ANR-10-LABX-0028_HEPSYS]; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [U19AI082630,
   U19AI082630, U19AI082630, U19AI082630, U19AI082630, U19AI082630,
   U19AI066345, U01AI131314, R01AI105035, U19AI082630, U19AI082630,
   U19AI082630, U19AI082630, U19AI066345, U19AI082630, U19AI066345,
   U19AI082630, U19AI082630, U19AI082630, U19AI082630, U19AI066345,
   U19AI082630, U19AI082630, U19AI082630, U19AI082630, U19AI082630,
   U19AI082630, U19AI066345, U19AI082630, U19AI082630, U19AI082630,
   U19AI082630, U19AI082630, U19AI082630, U19AI066345, U19AI066345,
   R01AI105035, U19AI066345, U19AI082630, U19AI066345, U19AI082630,
   U19AI066345, U19AI066345, U19AI082630, U19AI082630, U19AI066345,
   U19AI066345, U19AI082630, U19AI082630, U19AI082630, U19AI082630,
   U19AI082630, R01AI105035, U19AI066345, U19AI082630, U19AI082630,
   U19AI082630, U19AI082630, U19AI082630, U19AI066345, U01AI131314,
   U19AI066345, U19AI082630, U19AI066345, U19AI082630, U19AI066345,
   U19AI066345, U19AI082630, U19AI066345, U19AI082630, U19AI082630,
   U19AI082630, U19AI066345, U19AI082630, U19AI066345, U19AI082630,
   U19AI066345, U19AI082630, U19AI082630, U19AI082630, U19AI066345,
   U19AI066345, U19AI082630, U19AI066345, U19AI066345, R01AI105035,
   U19AI066345, U19AI082630, U19AI082630, U19AI082630, U19AI066345,
   U19AI066345, U19AI082630, U19AI082630, U19AI066345, U19AI066345,
   U19AI082630, U19AI082630, U19AI082630, U19AI066345, U19AI066345,
   U19AI066345, U19AI082630, U19AI066345, U19AI066345, U19AI082630,
   U19AI066345, U19AI066345, U19AI082630, U19AI082630, U19AI082630,
   U19AI066345, U01AI131314, U19AI082630, U19AI082630, U19AI066345,
   U19AI082630, U19AI066345, U19AI066345, U01AI131314, U19AI082630,
   U19AI082630, U19AI082630, U19AI082630, U19AI066345, U19AI066345,
   U19AI082630, U19AI082630, U19AI082630, U19AI082630, U19AI066345,
   U19AI066345, U19AI082630, U19AI066345, U19AI082630, U19AI082630,
   U19AI082630, U19AI082630, U19AI066345, U19AI082630, U19AI082630,
   U19AI066345, U19AI082630, U19AI082630, U19AI066345, U19AI066345,
   U19AI082630, U19AI082630, R01AI105035, U19AI082630, U19AI082630,
   U19AI082630, U19AI082630, U19AI082630, U19AI082630, U19AI066345,
   U19AI082630, U19AI082630, U19AI082630, U19AI082630, U19AI066345,
   U19AI082630, U19AI066345, U19AI082630, U19AI082630, U19AI082630,
   U19AI082630, U19AI082630, U19AI066345, U19AI066345, U19AI066345,
   U19AI082630, U19AI082630, U19AI066345, U19AI082630, U19AI066345,
   U19AI066345, U19AI082630, U19AI066345, U19AI082630, U19AI082630,
   U19AI066345, U19AI082630, U19AI082630] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK) [P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Drug Abuse (NIDA) [R01DA016017,
   R01DA016017, R01DA016017, R01DA016017, R01DA016017, R01DA016017,
   R01DA016017, R01DA016017, R01DA016017, R01DA016017, R01DA016017,
   R01DA016017, R01DA016017, R01DA016017, R01DA016017, R01DA016017,
   R01DA016017, R01DA016017] Funding Source: NIH RePORTER
FX We thank Drs. Brad Rosenberg, Naglaa Shoukry, Paul Klenerman, and Kate
   Jeffrey for constructive discussions. This work was funded by the NIH
   through U19 AI066345/U01 AI131314 (G.M.L., L.L. L.-X., A.Y.K.), U19
   AI082630 (G.M.L., A.Y.K., R.T.C., W.N.H.), and R01 AI105035/R01 DA016017
   (G.M.L.) and by ARC, Paris, IHU Strasbourg/TheraHCC IHUARC IHU201301187
   and the European Union/ERC-AdG-2014-671231-HEPCIR, EU
   H2020-667273HEPCAR, FP7 HEPAMAB GAN 305600, and ANR/LABEX
   ANR-10-LABX-0028_HEPSYS (all to T.F.B.).
CR Alexa A, 2006, BIOINFORMATICS, V22, P1600, DOI 10.1093/bioinformatics/btl140
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bakr I, 2006, GUT, V55, P1183, DOI [10.1136/gut.2005.078147, 10.1136/gut.2006.078147]
   Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272
   Bengsch B, 2016, IMMUNITY, V45, P358, DOI 10.1016/j.immuni.2016.07.008
   Berkers CR, 2013, CELL METAB, V18, P617, DOI 10.1016/j.cmet.2013.06.019
   Blondel VD, 2008, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2008/10/P10008
   Bowen DG, 2005, NATURE, V436, P946, DOI 10.1038/nature04079
   Brodin P, 2017, NAT REV IMMUNOL, V17, P21, DOI 10.1038/nri.2016.125
   Cox AL, 2005, J EXP MED, V201, P1741, DOI 10.1084/jem.20050121
   Cox AL, 2005, HEPATOLOGY, V42, P104, DOI 10.1002/hep.20749
   Csardi Gabor, 2006, INT J COMPLEX SYST, P1695, DOI DOI 10.3724/SP.J.1087.2009.02191
   Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179
   Doering TA, 2012, IMMUNITY, V37, P1130, DOI 10.1016/j.immuni.2012.08.021
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Durinck S, 2009, NAT PROTOC, V4, P1184, DOI 10.1038/nprot.2009.97
   ERNST P, 1995, IMMUNITY, V2, P311, DOI 10.1016/1074-7613(95)90139-6
   Fafi-Kremer S, 2010, J EXP MED, V207, P2019, DOI 10.1084/jem.20090766
   Gaiha GD, 2014, IMMUNITY, V41, P1001, DOI 10.1016/j.immuni.2014.12.011
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Giefing-Kroll C, 2015, AGING CELL, V14, P309, DOI 10.1111/acel.12326
   Grakoui A, 2003, SCIENCE, V302, P659, DOI 10.1126/science.1088774
   Han H, 2015, SCI REP-UK, V5, DOI 10.1038/srep11432
   Kahan SM, 2015, VIROLOGY, V479, P180, DOI 10.1016/j.virol.2014.12.033
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kasprowicz V, 2010, J VIROL, V84, P1656, DOI 10.1128/JVI.01499-09
   Kauffmann Audrey, 2009, Bioinformatics, V25, P415, DOI 10.1093/bioinformatics/btn647
   Komai-Koma M, 2004, P NATL ACAD SCI USA, V101, P3029, DOI 10.1073/pnas.0400171101
   Kuniholm MH, 2010, HEPATOLOGY, V51, P1514, DOI 10.1002/hep.23515
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559
   Leek JT, 2007, PLOS GENET, V3, P1724, DOI 10.1371/journal.pgen.0030161
   Liu ZP, 2015, DATABASE-OXFORD, DOI 10.1093/database/bav095
   Major ME, 2004, HEPATOLOGY, V39, P1709, DOI 10.1002/hep.20239
   Marbach D, 2016, NAT METHODS, V13, P366, DOI [10.1038/NMETH.3799, 10.1038/nmeth.3799]
   Mathelier A, 2014, NUCLEIC ACIDS RES, V42, pD142, DOI 10.1093/nar/gkt997
   Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143
   Munoz-Fontela C, 2016, NAT REV IMMUNOL, V16, P741, DOI 10.1038/nri.2016.99
   O'Shea JJ, 2012, IMMUNITY, V36, P542, DOI 10.1016/j.immuni.2012.03.014
   Osburn WO, 2014, HEPATOLOGY, V59, P2140, DOI 10.1002/hep.27013
   Oytam Y, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1212-5
   Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239
   Pestka JM, 2007, P NATL ACAD SCI USA, V104, P6025, DOI 10.1073/pnas.0607026104
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Rouillard AD, 2016, DATABASE-OXFORD, DOI 10.1093/database/baw100
   Shiroishi M, 2003, P NATL ACAD SCI USA, V100, P8856, DOI 10.1073/pnas.1431057100
   Shoukry NH, 2003, J EXP MED, V197, P1645, DOI 10.1084/jem.20030239
   Singer M, 2016, CELL, V166, P1500, DOI 10.1016/j.cell.2016.08.052
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Swadling L, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009185
   Timm J, 2004, J EXP MED, V200, P1593, DOI 10.1084/jem.20041006
   Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862
   Wu D, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks461
   Zhang HM, 2015, NUCLEIC ACIDS RES, V43, pD76, DOI 10.1093/nar/gku887
   zur Wiesch JS, 2005, J IMMUNOL, V175, P3603, DOI 10.4049/jimmunol.175.6.3603
   zur Wiesch JS, 2012, J EXP MED, V209, P61, DOI 10.1084/jem.20100388
NR 55
TC 12
Z9 12
U1 0
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1074-7613
EI 1097-4180
J9 IMMUNITY
JI Immunity
PD OCT 17
PY 2017
VL 47
IS 4
BP 648
EP +
DI 10.1016/j.immuni.2017.09.006
PG 24
WC Immunology
SC Immunology
GA FJ9JE
UT WOS:000413091600011
PM 29045899
OA Green Accepted, Bronze
DA 2020-11-30
ER

PT J
AU Flores, GL
   Cruz, HM
   Potsch, DV
   May, SB
   Brandao-Mello, CE
   Pires, MMA
   Pilotto, JH
   Lewis-Ximenez, LL
   Lampe, E
   Villar, LM
AF Flores, Geane Lopes
   Cruz, Helena Medina
   Potsch, Denise Vigo
   May, Silvia Beatriz
   Brandao-Mello, Carlos Eduardo
   Amendola Pires, Marcia Maria
   Pilotto, Jose Henrique
   Lewis-Ximenez, Lia Laura
   Lampe, Elisabeth
   Villar, Livia Melo
TI Evaluation of HBsAg and anti-HBc assays in saliva and dried blood spot
   samples according HIV status
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE HIV; HBV; Dried blood spot; Saliva; Enzyme immunoassay
ID HEPATITIS-C VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; ORAL FLUID; B-VIRUS;
   STABILITY; HCV
AB Influence of HIV status in HBV markers detection in saliva and dried blood spots (DBS) was not well established. This study aims to evaluate the performance of optimized commercial immunoassay for identifying HBsAg and anti-HBc in saliva and DBS according HIV status. A sum of 535 individuals grouped as HIV+, HBV+, HIV/HBV+ and HIV/HBV- were recruited where 347 and 188 were included for HBsAg and anti-HBc evaluation, respectively. Serum, DBS collected in Whatman 903 paper and saliva obtained using salivette device were analyzed using EIA. Increased sample volume and ROC curve analysis for cut off determination were used for DBS and saliva testing. HBsAg detection in saliva and DBS exhibited sensitivities of 80.9% and 85.6% and specificities of 86.8% and 96.3%. Sensitivity of anti-HBc in saliva and DBS were 82.4% and 76.9% and specificities in saliva and DBS were 96.9% and 91.7%. Low sensitivities were observed for HBsAg (62%) and anti-HBc (47%) detection in saliva of HIV/HBV + individuals. OD values were also lower for HBsAg detection in DBS and saliva of HIV/HBV + individuals compared to their serum samples. Statistical significance was found for sensitivities in HBsAg detection between saliva and DBS demonstrating high sensitivity for DBS specimens. In conclusion, HIV status or antiretroviral treatment appears to interfere in the performance of HBsAg and anti-HBc detection in DBS and saliva samples using the adapted commercial EIA.
C1 [Flores, Geane Lopes; Cruz, Helena Medina; Lewis-Ximenez, Lia Laura; Lampe, Elisabeth; Villar, Livia Melo] Fiocruz MS, Viral Hepatitis Lab, Oswaldo Cruz Inst, Rio De Janeiro, Brazil.
   [Potsch, Denise Vigo; May, Silvia Beatriz] Univ Fed Rio de Janeiro, Clementino Fraga Filho Hosp, Rio De Janeiro, Brazil.
   [Brandao-Mello, Carlos Eduardo; Amendola Pires, Marcia Maria] Univ Fed Estado Rio de Janeiro, Gaffree & Guinle Hosp, Rio De Janeiro, Brazil.
   [Pilotto, Jose Henrique] Nova Iguacu Gen Hosp, Rio De Janeiro, Brazil.
   [Pilotto, Jose Henrique] Fiocruz MS, AIDS & Mol Immunol Lab, Oswaldo Cruz Inst, Rio De Janeiro, Brazil.
RP Villar, LM (corresponding author), Fiocruz MS, Viral Hepatitis Lab, Helio & Peggy Pereira Pavill,Ground Floor, BR-21036004 Rio De Janeiro, RJ, Brazil.
EM liviafiocruz@gmail.com
RI Pilotto, Jose Henrique/AAD-9773-2019; Cruz, Helena Medina/U-4780-2019;
   VILLAR, LIVIA M/F-7811-2012
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Cruz, Helena
   Medina/0000-0003-2088-7705; VILLAR, LIVIA M/0000-0001-7644-8969
CR Altman D.G., 1991, PRACTICAL STAT MED R
   Amado LA, 2006, MEM I OSWALDO CRUZ, V101, P149, DOI 10.1590/S0074-02762006000200006
   Arora Gagandeep, 2012, Compend Contin Educ Dent, V33, P174
   Brazilian Health Ministry Department of STD AIDS and Viral Hepatitis, 2015, TECHN MAN DIAGN VIR
   Cruz HM, 2011, J CLIN LAB ANAL, V25, P134, DOI 10.1002/jcla.20447
   de Oliveira SB, 2014, CAD SAUDE PUBLICA, V30, P433, DOI 10.1590/0102-311X00010413
   Drummer Olaf H, 2006, Clin Biochem Rev, V27, P147
   Flores G.L., 2016, INT J ENV RES PUBLIC, V13
   Forbi JC, 2010, ANN AFR MED, V9, P44, DOI 10.4103/1596-3519.62625
   Hutse V, 2005, J MED VIROL, V77, P53, DOI 10.1002/jmv.20413
   Kao Jia-Horng, 2008, Expert Rev Gastroenterol Hepatol, V2, P553, DOI 10.1586/17474124.2.4.553
   Komada K, 2015, INT J INFECT DIS, V36, P21, DOI 10.1016/j.ijid.2015.04.020
   Lacombe K, 2012, GUT, V61, P47, DOI 10.1136/gutjnl-2012-302062
   Lee CE, 2011, ANN ACAD MED SINGAP, V40, P448
   McAllister G, 2015, J CLIN VIROL, V71, P10, DOI 10.1016/j.jcv.2015.07.303
   Mohamed S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061077
   Mossner BK, 2016, WORLD J GASTROENTERO, V22, P7604, DOI 10.3748/wjg.v22.i33.7604
   Parizad EG, 2016, HEPAT MON, V16, DOI 10.5812/hepatmon.30385
   Quoilin S, 2007, EUR J EPIDEMIOL, V22, P195, DOI 10.1007/s10654-007-9105-6
   Ross RS, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-72
   Scalioni LD, 2013, J CLIN LAB ANAL, V27, P186, DOI 10.1002/jcla.21582
   Snijdewind IJM, 2012, ANTIVIR RES, V93, P309, DOI 10.1016/j.antiviral.2011.12.011
   Villar Livia Melo, 2015, World J Virol, V4, P323, DOI 10.5501/wjv.v4.i4.323
   Villar LM, 2011, J MED VIROL, V83, P1522, DOI 10.1002/jmv.22138
   Wagner M, 2016, MASS SPECTROM REV, V35, P361, DOI 10.1002/mas.21441
   WHO, 2016, GUID HEP B C TEST
   Yang RR, 2011, J MED VIROL, V83, P1159, DOI 10.1002/jmv.22102
NR 27
TC 6
Z9 6
U1 0
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD SEP
PY 2017
VL 247
BP 32
EP 37
DI 10.1016/j.jviromet.2017.05.004
PG 6
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA FA0VC
UT WOS:000405153700006
PM 28506632
DA 2020-11-30
ER

PT J
AU Flores, GL
   Cruz, HM
   Marques, VA
   Villela-Nogueira, CA
   Potsch, DV
   May, SB
   Brandao-Mello, CE
   Pires, MMA
   Pilotto, JH
   Pollo-Flores, P
   Esberard, EBC
   Ivantes, C
   Lewis-Ximenez, LL
   Lampe, E
   Villar, LM
AF Flores, Geane Lopes
   Cruz, Helena Medina
   Marques, Vanessa Alves
   Villela-Nogueira, Cristiane Alves
   Potsch, Denise Vigo
   May, Silvia Beatriz
   Brandao-Mello, Carlos Eduardo
   Amendola Pires, Marcia Maria
   Pilotto, Jose Henrique
   Pollo-Flores, Priscila
   Cathala Esberard, Eliane Bordalo
   Ivantes, Claudia
   Lewis-Ximenez, Lia Laura
   Lampe, Elisabeth
   Villar, Livia Melo
TI Performance of ANTI-HCV testing in dried blood spots and saliva
   according to HIV status
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE dried blood spot; enzyme immunoassay; hepatitis C virus; human
   immunodeficiency virus; saliva
ID HEPATITIS-C-VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; ORAL FLUID; ANTIBODIES;
   PREVALENCE; INFECTION; SAMPLES; ASSAY; RNA
AB The use of saliva and dried blood spots (DBS) could increase access to HCV diagnosis for high-risk populations, such as HIV-infected individuals, but the performance of these assays has not been well established in this group. This study aims to evaluate HIV status, particularly TCD4(+) cell count and viral load, in the performance of anti-HCV testing using DBS and saliva. A total of 961 individuals classified as HCV+, HIV+, or HIV/HCV+, as well as negative controls, donated serum, DBS, and saliva samples for anti-HCV testing using a commercial enzyme immunoassay. Sample volume was modified for DBS and saliva, and an ROC curve was used for cut-off determination in saliva. Anti-HCV sensitivities were greater than 93% using DBS and saliva in the HCV+ group, while they were 83.3% and 95.6% for HCV/HIV+ individuals for DBS and saliva assays, respectively. Specificity varied from 91.7% to 100% using saliva and DBS in HIV monoinfected and control subjects. When only anti-HCV/HCV RNA+ serum samples, that is, true positives, were considered, the sensitivities were 98.3% and 100% for DBS and saliva, respectively, in the HCV+ group and 91.6% and 94.8% for DBS and saliva, respectively, in the HIV/HCV+ group. High absorbance values were observed among those presenting with HCV RNA in serum and low HIV viral load (less than 50 copies/mL). In conclusion, DBS and saliva samples could be used for anti-HCV detection, particularly to identify active HCV cases, but low sensitivity was observed for anti-HCV testing using DBS in the HIV/HCV+ group.
C1 [Flores, Geane Lopes; Cruz, Helena Medina; Marques, Vanessa Alves; Lewis-Ximenez, Lia Laura; Lampe, Elisabeth; Villar, Livia Melo] Fiocruz MS, Viral Hepatitis Lab, Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Villela-Nogueira, Cristiane Alves; Potsch, Denise Vigo; May, Silvia Beatriz] Univ Fed Rio de Janeiro, Clementino Fraga Filho Hosp, Rio De Janeiro, Brazil.
   [Brandao-Mello, Carlos Eduardo; Amendola Pires, Marcia Maria] Univ Fed Rio de Janeiro, Gaffree & Guinle Hosp, Rio De Janeiro, Brazil.
   [Pilotto, Jose Henrique] Fiocruz MS, Inst Oswaldo Cruz, Nova Iguacu Gen Hosp, Rio De Janeiro, Brazil.
   [Pilotto, Jose Henrique] Fiocruz MS, Inst Oswaldo Cruz, AIDS & Mol Immunol Lab, Rio De Janeiro, Brazil.
   [Pollo-Flores, Priscila] Brasilia Univ, Brasilia, DF, Brazil.
   [Cathala Esberard, Eliane Bordalo] Fluminense Fed Univ, Antonio Pedro Univ Hosp, Rio De Janeiro, Brazil.
   [Ivantes, Claudia] Ctr Guidance & Advisor COA, Curitiba, PR, Brazil.
RP Villar, LM (corresponding author), Fiocruz MS, Viral Hepatitis Lab, Helio & Peggy Pereira Pavil Ground Floor Off 309, BR-21036004 Rio De Janeiro, RJ, Brazil.
EM lvillar@ioc.fiocruz.br
RI VILLAR, LIVIA M/F-7811-2012; Cruz, Helena Medina/U-4780-2019; Pilotto,
   Jose Henrique/AAD-9773-2019
OI VILLAR, LIVIA M/0000-0001-7644-8969; Cruz, Helena
   Medina/0000-0003-2088-7705; Pilotto, Jose Henrique/0000-0003-0521-8597
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Brazilian National Council of Technological and
   Scientific Development (CNPq)National Council for Scientific and
   Technological Development (CNPq); Brazilian Ministry of Health;
   Coordination of Improvement of Higher Education Personnel (CAPES)CAPES;
   Oswaldo Cruz Foundation (FIOCRUZ)
FX Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ);
   Brazilian National Council of Technological and Scientific Development
   (CNPq); Brazilian Ministry of Health; Coordination of Improvement of
   Higher Education Personnel (CAPES); Oswaldo Cruz Foundation (FIOCRUZ)
CR Allwright S, 2000, BRIT MED J, V321, P78, DOI 10.1136/bmj.321.7253.78
   Amado LA, 2006, MEM I OSWALDO CRUZ, V101, P149, DOI 10.1590/S0074-02762006000200006
   Bello PY, 1998, EUR J CLIN MICROBIOL, V17, P570, DOI 10.1007/BF01708621
   Cameron SO, 1999, J VIRAL HEPATITIS, V6, P141, DOI 10.1046/j.1365-2893.1999.00142.x
   Coats JT, 2015, INT J DRUG POLICY, V26, P1050, DOI 10.1016/j.drugpo.2015.05.001
   Cruz HM, 2012, J ORAL PATHOL MED, V41, P793, DOI 10.1111/j.1600-0714.2012.01176.x
   Dokubo EK, 2014, J CLIN VIROL, V59, P223, DOI 10.1016/j.jcv.2014.01.014
   Elsana S, 1998, J MED VIROL, V55, P24, DOI 10.1002/(SICI)1096-9071(199805)55:1&lt;24::AID-JMV5&gt;3.0.CO;2-Q
   Flores GL, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13030314
   Freitas SZ, 2014, REV INST MED TROP SP, V56, P517, DOI 10.1590/S0036-46652014000600011
   Judd A, 2003, J MED VIROL, V71, P49, DOI 10.1002/jmv.10463
   Lacombe K, 2012, GUT, V61, P47, DOI 10.1136/gutjnl-2012-302062
   Lucidarme D, 2007, GASTROEN CLIN BIOL, V31, P480, DOI 10.1016/S0399-8320(07)89415-2
   Mahboobi N, 2012, J ORAL PATHOL MED, V41, P505, DOI 10.1111/j.1600-0714.2011.01123.x
   Mallet V, 2011, LIVER INT, V31, P135, DOI 10.1111/j.1478-3231.2010.02394.x
   Marques BLC, 2012, J MED VIROL, V84, P1600, DOI 10.1002/jmv.23379
   McCarron B, 1999, J VIRAL HEPATITIS, V6, P453, DOI 10.1046/j.1365-2893.1999.00197.x
   McIntyre PG, 1996, EUR J CLIN MICROBIOL, V15, P882, DOI 10.1007/BF01691223
   Mossner BK, 2016, WORLD J GASTROENTERO, V22, P7604, DOI 10.3748/wjg.v22.i33.7604
   Peters L, 2015, CURR OPIN HIV AIDS, V10, P297, DOI 10.1097/COH.0000000000000183
   Rafik M, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0572-9
   Ross RS, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-72
   Snijdewind IJM, 2012, ANTIVIR RES, V93, P309, DOI 10.1016/j.antiviral.2011.12.011
   Soulier A, 2016, J INFECT DIS, V213, P1087, DOI 10.1093/infdis/jiv423
   Stankovic-Djordjevic D, 2007, BIOTECHNOL BIOTEC EQ, V21, P83, DOI 10.1080/13102818.2007.10817420
   Tejada-Strop A, 2015, J VIROL METHODS, V212, P66, DOI 10.1016/j.jviromet.2014.10.018
   Tuaillon E, 2010, HEPATOLOGY, V51, P752, DOI 10.1002/hep.23407
   van de Laar TJ, 2016, SEX TRANSM INFECT, V27
   VANDERPOEL CL, 1991, LANCET, V337, P317, DOI 10.1016/0140-6736(91)90942-I
   Villar LM, 2015, BRAZ J INFECT DIS, V19, P285, DOI 10.1016/j.bjid.2015.02.002
   Villar Livia Melo, 2015, World J Virol, V4, P323, DOI 10.5501/wjv.v4.i4.323
   Villar LM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/324638
   Villar LM, 2011, J MED VIROL, V83, P1522, DOI 10.1002/jmv.22138
   Visseaux B, 2013, J CLIN VIROL, V58, P385, DOI 10.1016/j.jcv.2013.07.015
NR 34
TC 5
Z9 5
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD AUG
PY 2017
VL 89
IS 8
BP 1435
EP 1441
DI 10.1002/jmv.24777
PG 7
WC Virology
SC Virology
GA FA2UA
UT WOS:000405295100016
PM 28165155
DA 2020-11-30
ER

PT J
AU Scalioni, LD
   da Silva, AP
   Miguel, JC
   Santo, MPD
   Marques, VA
   Brandao-Mello, CE
   Villela-Nogueira, CA
   Lewis-Ximenez, LL
   Lampe, E
   Villar, LM
AF Scalioni, Leticia de Paula
   da Silva, Allan Peres
   Miguel, Juliana Custodio
   do Espirito Santo, Marcia Paschoal
   Marques, Vanessa Alves
   Brandao-Mello, Carlos Eduardo
   Villela-Nogueira, Cristiane Alves
   Lewis-Ximenez, Lia Laura
   Lampe, Elisabeth
   Villar, Livia Melo
TI Lack of Association between Hepatitis C Virus core Gene Variation
   70/91aa and Insulin Resistance
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE amino acid; core mutation; insulin resistance; hepatitis C
ID AMINO-ACID SUBSTITUTIONS; GENOTYPE 1B; IMPORTANT PREDICTOR; SIGNALING
   PATHWAY; VITAMIN-D; REGION; PEGINTERFERON; PROTEIN
AB The role of hepatitis C virus (HCV) in insulin resistance (IR) is not fully understood. The aim of this study was to determine the impact of amino acid (aa) substitutions in the core region of HCV according to IR and to identify clinical and laboratory associations. Ninety-two treatment-naive HCV patients were recruited to determine laboratory data and blood cell count. IR was determined using Homeostasis Model Assessment (HOMA) index where IR was defined as HOMA >= 2. HCV RNA load and genotype were determined by Abbott Real time HCV. HCV core region was determined by direct nucleotide sequencing. Bivariate analysis was conducted using HOMA IR >= 2 as a dependent factor. IR prevalence was 43.5% (n = 40), vitamin D sufficiency was found in 76.1% (n = 70) and 72.8% (n = 67) had advanced liver fibrosis. In the bivariate analyses, elevated values of gamma GT (p = 0.024) and fibrosis staging (p = 0.004) were associated with IR, but IR was not related to core mutations. The presence of glutamine in position 70 was associated with low vitamin D concentration (p = 0.005). In the multivariate analysis, no variable was independently associated with HOMA-IR. In conclusion, lack of association between IR and HCV core mutations in positions 70 and 91 suggests that genetic variability of this region has little impact on IR.
C1 [Scalioni, Leticia de Paula; da Silva, Allan Peres; Miguel, Juliana Custodio; do Espirito Santo, Marcia Paschoal; Marques, Vanessa Alves; Lewis-Ximenez, Lia Laura; Lampe, Elisabeth; Villar, Livia Melo] Livia Melo Villar, Viral Hepatitis Lab, Helio & Peggy Pereira Pavil,Ground Floor,Room B09, BR-21036004 Rio De Janeiro, RJ, Brazil.
   [Brandao-Mello, Carlos Eduardo] Univ Fed Estado Rio de Janeiro, Gaffree & Guinle Univ Hosp, BR-20270001 Rio De Janeiro, RJ, Brazil.
   [Villela-Nogueira, Cristiane Alves] Univ Fed Rio de Janeiro, Sch Med, Univ Hosp Clementino Fraga Filho, BR-21941913 Rio De Janeiro, RJ, Brazil.
RP Villar, LM (corresponding author), Livia Melo Villar, Viral Hepatitis Lab, Helio & Peggy Pereira Pavil,Ground Floor,Room B09, BR-21036004 Rio De Janeiro, RJ, Brazil.
EM le_scali@hotmail.com; allan@ioc.fiocruz.br; julicm@ioc.fiocruz.br;
   paschoalms@gmail.com; vmarques@ioc.fiocruz.br; cedubrandao@gmail.com;
   crisvillelanog@gmail.com; llewis@ioc.fiocruz.br; elampe@ioc.fiocruz.br;
   liviafiocruz@gmail.com
RI VILLAR, LIVIA M/F-7811-2012
OI VILLAR, LIVIA M/0000-0001-7644-8969
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Brazilian National Counsel of Technological and
   Scientific Development (CNPq)National Council for Scientific and
   Technological Development (CNPq); Oswaldo Cruz Foundation (FIOCRUZ)
FX This research was supported by Fundacao de Amparo a Pesquisa do Estado
   do Rio de Janeiro (FAPERJ), Brazilian National Counsel of Technological
   and Scientific Development (CNPq), and Oswaldo Cruz Foundation
   (FIOCRUZ).
CR Akuta N, 2007, HEPATOLOGY, V46, P1357, DOI 10.1002/hep.21836
   Akuta N, 2012, INTERVIROLOGY, V55, P231, DOI 10.1159/000328327
   Akuta N, 2012, INTERVIROLOGY, V55, P417, DOI 10.1159/000323526
   Akuta N, 2010, J MED VIROL, V82, P575, DOI 10.1002/jmv.21741
   Akuta N, 2009, INTERVIROLOGY, V52, P301, DOI 10.1159/000235909
   Akuta N, 2009, J MED VIROL, V81, P1032, DOI 10.1002/jmv.21473
   Alter MJ, 1998, INFECT DIS CLIN N AM, V12, P13, DOI 10.1016/S0891-5520(05)70405-0
   Banerjee A, 2010, J VIROL, V84, P5936, DOI 10.1128/JVI.02344-09
   Banerjee S, 2008, J VIROL, V82, P2606, DOI 10.1128/JVI.01672-07
   Bland R, 2004, J STEROID BIOCHEM, V89-90, P121, DOI 10.1016/j.jsbmb.2004.03.115
   Bose SK, 2012, J VIROL, V86, P6315, DOI 10.1128/JVI.00050-12
   Cannon CP, 2008, AM J CARDIOL, V102, p5L, DOI 10.1016/j.amjcard.2008.09.067
   CDC, 2008, INF HLTH PROF
   Hung CH, 2011, EXPERT REV ANTI-INFE, V9, P525, DOI [10.1586/eri.11.33, 10.1586/ERI.11.33]
   Dai CY, 2009, J HEPATOL, V50, P712, DOI 10.1016/j.jhep.2008.12.017
   El-Shamy A, 2013, HEPATOLOGY, V58, P555, DOI 10.1002/hep.26205
   Everhart JE, 2013, HEPATOLOGY, V57, P1725, DOI 10.1002/hep.26203
   Hori M., 2016, J ATHEROSCLER THROMB
   Lavanchy D, 2009, LIVER INT, V29, P74, DOI 10.1111/j.1478-3231.2008.01934.x
   Martins PP, 2013, CLIN LAB, V59, P1031, DOI 10.7754/Clin.Lab.2013.120903
   Melo-Villar L., 2016, ANN HEPATOL, V15, P139
   Nakamoto S, 2010, J HEPATOL, V52, P72, DOI 10.1016/j.jhep.2009.10.001
   Parvaiz F, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-474
   Schuch NJ, 2009, ARQ BRAS ENDOCRINOL, V53, P625, DOI 10.1590/S0004-27302009000500015
   Silva Clarice Siqueira, 2016, Indian J Endocrinol Metab, V20, P228, DOI 10.4103/2230-8210.176364
   Sumida Y, 2011, J GASTROEN HEPATOL, V26, P836, DOI 10.1111/j.1440-1746.2010.06568.x
   Uraki S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131346
   Wong Robert J, 2016, Gastroenterol Hepatol (N Y), V12, P293
   Zeitz U, 2003, FASEB J, V17, P509, DOI 10.1096/fj.02-0424fje
NR 29
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUL
PY 2017
VL 18
IS 7
AR 1444
DI 10.3390/ijms18071444
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA FF2SJ
UT WOS:000408746800114
PM 28753979
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU de Almeida, RW
   Mello, FCD
   Menegoy, IV
   Santo, MPD
   Ginuino, CF
   de Sousa, PSF
   Villar, LM
   Lampe, E
   Lewis-Ximenez, LL
AF de Almeida, Ricardo Wagner
   do Amaral Mello, Francisco Campello
   Menegoy, Isabelle Vasconcelos
   do Espirito Santo, Marcia Paschoal
   Ginuino, Cleber Ferreira
   Fonseca de Sousa, Paulo Sergio
   Villar, Livia Melo
   Lampe, Elisabeth
   Lewis-Ximenez, Lia Laura
TI Detection and molecular characterisation of a diagnosis escape variant
   associated with occult hepatitis B virus in Brazil
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE occult hepatitis B infection; HbsAg; genotype; mutation
ID PATTERN ANTI-HBC; INFECTED PATIENTS; SURFACE-ANTIGEN; BLOOD-DONORS;
   C-VIRUS; PREVALENCE; MUTATIONS; REGION; MUTANTS
AB BACKGROUND Many studies have identified mutations in the hepatitis B surface antigen (HBsAg) as important factors limiting the ability of commercial serological assays to detect this viral antigen. However, an association between mutations in the HBsAg gene and the occurrence of occult HBV infection (OBI) in patients has not been established.
   OBJECTIVES To detect hepatitis B virus (HBV) DNA in patients with anti-HBc as a unique serological marker, a previously published, cost-effective TaqMan-based real-time polymerase chain reaction (PCR) test with minor groove binding probes was adapted for use in this study. The current study also aimed to investigate HBsAg mutations and genotypes of HBV in OBI at the Viral Hepatitis Ambulatory Clinic in Rio de Janeiro to determine any possible association.
   METHODS Intra-assay and inter-assay reproducibility were determined, and the mean coefficient of variation values obtained were 2.07 and 3.5, respectively. Probit analysis indicated that the 95% detection level was 25 IU/mL. The prevalence of OBI was investigated in 35 serum samples with an `anti-HBc alone' profile from individuals who attended our clinic between 2011 and 2013.
   FINDINGS HBV DNA was detected in only one sample, resulting in an OBI rate of 2.9%. Nucleotide sequencing of the pre-S/S region was performed to genotype and analyse mutations within the HBsAg gene of this HBV DNA. The HBV in the OBI case was classified as sub-genotype A1, and a sequence analysis of the small S gene revealed 12 mutations in the major hydrophilic region compared to the consensus A1 sequence. Most of these mutations occurred in amino acid residues that have been reported as clinically relevant because they have been implicated in vaccine escape and/or inability to detect HBsAg by commercial serological assays. MAIN
   CONCLUSIONS Our study suggests the importance of specific HBsAg mutations, different from those in D, B, and C genotypes, in sub-genotype Al HBV associated with OBI.
C1 [de Almeida, Ricardo Wagner; do Amaral Mello, Francisco Campello; Menegoy, Isabelle Vasconcelos; do Espirito Santo, Marcia Paschoal; Ginuino, Cleber Ferreira; Fonseca de Sousa, Paulo Sergio; Villar, Livia Melo; Lampe, Elisabeth; Lewis-Ximenez, Lia Laura] Fundacao Oswaldo Cruz Fiocruz, Inst Oswaldo Cruz, Lab Hepatites Virais, Rio De Janeiro, RJ, Brazil.
RP de Almeida, RW (corresponding author), Fundacao Oswaldo Cruz Fiocruz, Inst Oswaldo Cruz, Lab Hepatites Virais, Rio De Janeiro, RJ, Brazil.
EM ricardo.almeida@bio.fiocruz.br
RI VILLAR, LIVIA M/F-7811-2012
OI VILLAR, LIVIA M/0000-0001-7644-8969
CR Alencar RSM, 2008, BRAZ J MED BIOL RES, V41, P235, DOI 10.1590/S0100-879X2006005000197
   Baclig MO, 2014, J MED VIROL, V86, P209, DOI 10.1002/jmv.23717
   Baleriola C, 2011, J CLIN MICROBIOL, V49, P3163, DOI 10.1128/JCM.02447-10
   Barros GM, 2008, REV SOC BRAS MED TRO, V41, P596, DOI 10.1590/S0037-86822008000600010
   CARMAN WF, 1990, LANCET, V336, P325, DOI 10.1016/0140-6736(90)91874-A
   Cheng HR, 2014, LIVER INT, V34, pE71, DOI 10.1111/liv.12324
   Chong-Jin O, 1999, J INFECT DIS, V179, P259, DOI 10.1086/314553
   de Matos MAD, 2013, MEM I OSWALDO CRUZ, V108, P386, DOI 10.1590/S0074-02762013000300019
   Franz C, 2013, MEM I OSWALDO CRUZ, V108, P657, DOI 10.1590/0074-0276108052013019
   Grob P, 2000, J MED VIROL, V62, P450, DOI 10.1002/1096-9071(200012)62:4&lt;450::AID-JMV9&gt;3.0.CO;2-Y
   Hollinger FB, 2010, J VIRAL HEPATITIS, V17, P1, DOI 10.1111/j.1365-2893.2009.01245.x
   KARTHIGESU VD, 1994, J GEN VIROL, V75, P443, DOI 10.1099/0022-1317-75-2-443
   Knoll A, 2006, WORLD J GASTROENTERO, V12, P1255
   Kwak MS, 2014, WORLD J HEPATOL, V6, P860, DOI 10.4254/wjh.v6.i12.860
   Lacombe K, 2013, HEPATOLOGY, V58, P912, DOI 10.1002/hep.26374
   Lazarevic I, 2014, WORLD J GASTROENTERO, V20, P7653, DOI 10.3748/wjg.v20.i24.7653
   Lee KM, 2001, J KOREAN MED SCI, V16, P359, DOI 10.3346/jkms.2001.16.3.359
   Liaw YF, 2009, LANCET, V373, P582, DOI 10.1016/S0140-6736(09)60207-5
   Lledo JL, 2011, WORLD J GASTROENTERO, V17, P1563, DOI [10.3748/wjg.v17.i12. 1563, 10.3748/wjg.v17.i12.1563]
   Ma Q, 2012, J MED VIROL, V84, P198, DOI 10.1002/jmv.23183
   Mello FCA, 2012, BMC MICROBIOL, V12, DOI 10.1186/1471-2180-12-96
   Moresco MND, 2014, VOX SANG, V107, P19, DOI 10.1111/vox.12125
   Parekh S, 2003, J VIROL, V77, P6601, DOI 10.1128/JVI.77.12.6601-6612.2003
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Reddy PB, 2011, J GEN MOL VIROL, V3, P43
   Said ZNA, 2011, WORLD J GASTROENTERO, V17, P1927, DOI 10.3748/wjg.v17.i15.1927
   Svicher V, 2012, ANTIVIR RES, V93, P86, DOI 10.1016/j.antiviral.2011.10.022
   Weinberger KM, 2000, J VIROL METHODS, V85, P75, DOI 10.1016/S0166-0934(99)00154-8
   Xie Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133393
   Yuan Q, 2010, J CLIN MICROBIOL, V48, P357, DOI 10.1128/JCM.01781-09
NR 30
TC 4
Z9 6
U1 0
U2 2
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD JUL
PY 2017
VL 112
IS 7
BP 485
EP 491
DI 10.1590/0074-02760160477
PG 7
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA EX5HL
UT WOS:000403270100003
PM 28591309
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Faria, NR
   Quick, J
   Claro, IM
   Theze, J
   de Jesus, JG
   Giovanetti, M
   Kraemer, MUG
   Hill, SC
   Black, A
   da Costa, AC
   Franco, LC
   Silva, SP
   Wu, CH
   Raghwani, J
   Cauchemez, S
   du Plessis, L
   Verotti, MP
   de Oliveira, WK
   Carmo, EH
   Coelho, GE
   Santelli, ACFS
   Vinhal, LC
   Henriques, CM
   Simpson, JT
   Loose, M
   Andersen, KG
   Grubaugh, ND
   Somasekar, S
   Chiu, CY
   Munoz-Medina, JE
   Gonzalez-Bonilla, CR
   Arias, CF
   Lewis-Ximenez, LL
   Baylis, SA
   Chieppe, AO
   Aguiar, SF
   Fernandes, CA
   Lemos, PS
   Nascimento, BLS
   Monteiro, HAO
   Siqueira, IC
   de Queiroz, MG
   de Souza, TR
   Bezerra, JF
   Lemos, MR
   Pereira, GF
   Loudal, D
   Moura, LC
   Dhalia, R
   Franca, RF
   Magalhaes, T
   Marques, ET
   Jaenisch, T
   Wallau, GL
   de Lima, MC
   Nascimento, V
   de Cerqueira, EM
   de Lima, MM
   Mascarenhas, DL
   Neto, JPM
   Levin, AS
   Tozetto-Mendoza, TR
   Fonseca, SN
   Mendes-Correa, MC
   Milagres, FP
   Segurado, A
   Holmes, EC
   Rambaut, A
   Bedford, T
   Nunes, MRT
   Sabino, EC
   Alcantara, LCJ
   Loman, NJ
   Pybus, OG
AF Faria, N. R.
   Quick, J.
   Claro, I. M.
   Theze, J.
   de Jesus, J. G.
   Giovanetti, M.
   Kraemer, M. U. G.
   Hill, S. C.
   Black, A.
   da Costa, A. C.
   Franco, L. C.
   Silva, S. P.
   Wu, C. -H.
   Raghwani, J.
   Cauchemez, S.
   du Plessis, L.
   Verotti, M. P.
   de Oliveira, W. K.
   Carmo, E. H.
   Coelho, G. E.
   Santelli, A. C. F. S.
   Vinhal, L. C.
   Henriques, C. M.
   Simpson, J. T.
   Loose, M.
   Andersen, K. G.
   Grubaugh, N. D.
   Somasekar, S.
   Chiu, C. Y.
   Munoz-Medina, J. E.
   Gonzalez-Bonilla, C. R.
   Arias, C. F.
   Lewis-Ximenez, L. L.
   Baylis, S. A.
   Chieppe, A. O.
   Aguiar, S. F.
   Fernandes, C. A.
   Lemos, P. S.
   Nascimento, B. L. S.
   Monteiro, H. A. O.
   Siqueira, I. C.
   de Queiroz, M. G.
   de Souza, T. R.
   Bezerra, J. F.
   Lemos, M. R.
   Pereira, G. F.
   Loudal, D.
   Moura, L. C.
   Dhalia, R.
   Franca, R. F.
   Magalhaes, T.
   Marques, E. T., Jr.
   Jaenisch, T.
   Wallau, G. L.
   de Lima, M. C.
   Nascimento, V.
   de Cerqueira, E. M.
   de Lima, M. M.
   Mascarenhas, D. L.
   Moura Neto, J. P.
   Levin, A. S.
   Tozetto-Mendoza, T. R.
   Fonseca, S. N.
   Mendes-Correa, M. C.
   Milagres, F. P.
   Segurado, A.
   Holmes, E. C.
   Rambaut, A.
   Bedford, T.
   Nunes, M. R. T.
   Sabino, E. C.
   Alcantara, L. C. J.
   Loman, N. J.
   Pybus, O. G.
TI Establishment and cryptic transmission of Zika virus in Brazil and the
   Americas
SO NATURE
LA English
DT Article
ID PHYLOGENETIC ANALYSIS; EVOLUTION; TIME; EMERGENCE; MODELS; DENGUE;
   BAHIA; RECOMBINATION; SEQUENCES; SELECTION
AB Transmission of Zika virus (ZIKV) in the Americas was first confirmed in May 2015 in northeast Brazil(1). Brazil has had the highest number of reported ZIKV cases worldwide (more than 200,000 by 24 December 20162) and the most cases associated with microcephaly and other birth defects (2,366 confirmed by 31 December 20162). Since the initial detection of ZIKV in Brazil, more than 45 countries in the Americas have reported local ZIKV transmission, with 24 of these reporting severe ZIKV-associated disease(3). However, the origin and epidemic history of ZIKV in Brazil and the Americas remain poorly understood, despite the value of this information for interpreting observed trends in reported microcephaly. Here we address this issue by generating 54 complete or partial ZIKV genomes, mostly from Brazil, and reporting data generated by a mobile genomics laboratory that travelled across northeast Brazil in 2016. One sequence represents the earliest confirmed ZIKV infection in Brazil. Analyses of viral genomes with ecological and epidemiological data yield an estimate that ZIKV was present in northeast Brazil by February 2014 and is likely to have disseminated from there, nationally and internationally, before the first detection of ZIKV in the Americas. Estimated dates for the international spread of ZIKV from Brazil indicate the duration of pre-detection cryptic transmission in recipient regions. The role of northeast Brazil in the establishment of ZIKV in the Americas is further supported by geographic analysis of ZIKV transmission potential and by estimates of the basic reproduction number of the virus.
C1 [Faria, N. R.; Theze, J.; Kraemer, M. U. G.; Hill, S. C.; Raghwani, J.; du Plessis, L.; Pybus, O. G.] Univ Oxford, Dept Zool, Oxford OX1 3SY, England.
   [Faria, N. R.; Franco, L. C.; Silva, S. P.; Lemos, P. S.; Nascimento, B. L. S.; Monteiro, H. A. O.; Nunes, M. R. T.] Minist Hlth, Evandro Chagas Inst, Ananindeua, Brazil.
   [Quick, J.; Loman, N. J.] Univ Birmingham, Inst Microbiol & Infect, Birmingham, W Midlands, England.
   [Claro, I. M.; da Costa, A. C.; Levin, A. S.; Tozetto-Mendoza, T. R.; Mendes-Correa, M. C.; Segurado, A.; Sabino, E. C.] Univ Sao Paulo, Sch Med, Dept Infect Dis, Sao Paulo, Brazil.
   [Claro, I. M.; da Costa, A. C.; Levin, A. S.; Tozetto-Mendoza, T. R.; Mendes-Correa, M. C.; Segurado, A.; Sabino, E. C.] Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
   [de Jesus, J. G.; Giovanetti, M.; Siqueira, I. C.; Alcantara, L. C. J.] Fiocruz MS, Fundacao Oswaldo Cruz, Salvador, BA, Brazil.
   [Giovanetti, M.] Univ Roma Tor Vergata, Rome, Italy.
   [Kraemer, M. U. G.] Harvard Med Sch, Boston, MA USA.
   [Kraemer, M. U. G.] Boston Childrens Hosp, Boston, MA USA.
   [Black, A.; Bedford, T.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.
   [Black, A.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
   [Wu, C. -H.] Univ Oxford, Dept Stat, Oxford OX1 3LB, England.
   [Cauchemez, S.] Inst Pasteur, Math Modelling Infect Dis, Paris, France.
   [Cauchemez, S.] Inst Pasteur, Ctr Bioinformat Biostat & Integrat Biol, Paris, France.
   [Cauchemez, S.] Ctr Natl Rech Sci, URA3012, Paris, France.
   [Verotti, M. P.] Minist Hlth, Coordena Lab Saude CGLAB DEVIT SVS, Brasilia, DF, Brazil.
   [de Oliveira, W. K.] Minist Hlth, Coordena Geral Vigilincia & Resposta Emergencias, Brasilia, DF, Brazil.
   [de Oliveira, W. K.] Fundacao Oswaldo Cruz FIOCRUZ, Ctr Data & Knowledge Integrat Hlth CIDACS, Salvador, BA, Brazil.
   [Carmo, E. H.; Henriques, C. M.] Minist Hlth, Dept Vigilincia Doencas Transmissiveis, Brasilia, DF, Brazil.
   [Coelho, G. E.; Santelli, A. C. F. S.; Vinhal, L. C.] Minist Hlth, Coordena Geral Programas Controle & Preven Malari, Brasilia, DF, Brazil.
   [Coelho, G. E.] PAHO, Buenos Aires, DF, Argentina.
   [Santelli, A. C. F. S.] Fundacao Oswaldo Cruz FIOCRUZ, Rio De Janeiro, Brazil.
   [Simpson, J. T.] Ontario Inst Canc Res, Toronto, ON, Canada.
   [Loose, M.] Univ Nottingham, Nottingham, England.
   [Andersen, K. G.; Grubaugh, N. D.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.
   [Somasekar, S.; Chiu, C. Y.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.
   [Somasekar, S.; Chiu, C. Y.] Univ Calif San Francisco, Dept Med Infect & Dis, San Francisco, CA 94143 USA.
   [Munoz-Medina, J. E.; Gonzalez-Bonilla, C. R.] Inst Mexicano Seguro Social, Div Labs Vigilancia & Invest Epidemiol, Mexico City, DF, Mexico.
   [Arias, C. F.] Univ Nacl Autonoma Mexico, Inst Biotecnol, Cuernavaca, Morelos, Mexico.
   [Lewis-Ximenez, L. L.] Inst Oswaldo Cruz FIOCRUZ, Rio De Janeiro, Brazil.
   [Baylis, S. A.] Paul Ehrlich Inst, Langen, Germany.
   [Chieppe, A. O.; Aguiar, S. F.; Fernandes, C. A.] Lab Cent Saude Publ Noel Nutels, Rio De Janeiro, Brazil.
   [de Queiroz, M. G.; de Souza, T. R.; Bezerra, J. F.] Labo Cent Saude Publ Estado Rio Grande Norte, Natal, RN, Brazil.
   [de Souza, T. R.] Univ Potiguar Rio Grande Norte, Natal, RN, Brazil.
   [Bezerra, J. F.] Fundacao Natalense Ensino & Cultura, Natal, RN, Brazil.
   [Lemos, M. R.; Pereira, G. F.; Loudal, D.; Moura, L. C.] Lab Cent Saude Publ Estado Paraiba, Joao Pessoa, Paraiba, Brazil.
   [Dhalia, R.; Franca, R. F.; Magalhaes, T.; Marques, E. T., Jr.; Wallau, G. L.] Fundacao Oswaldo Cruz FIOCRUZ, Recife, PE, Brazil.
   [Magalhaes, T.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.
   Univ Pittsburgh, Grad Sch Publ Hlth, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Jaenisch, T.] Univ Heidelberg Hosp, Dept Infect Dis, Sect Clin Trop Med, Heidelberg, Germany.
   [de Lima, M. C.; Nascimento, V.; de Cerqueira, E. M.] Lab Cent Saude Publ Estado Alagoas, Maceio, Brazil.
   [de Lima, M. M.] Univ Estadual Feira de Santana, Feira Santana, Bahia, Argentina.
   [Mascarenhas, D. L.] Secretaria Saude Feira Santana, Feira De Santana, Bahia, Brazil.
   [Moura Neto, J. P.] Univ Fed Amazonas, Manaus, Amazonas, Brazil.
   [Fonseca, S. N.] Hosp Sao Francisco, Ribeirao Preto, Brazil.
   [Milagres, F. P.] Univ Fed Tocantins, Palmas, Brazil.
   [Holmes, E. C.] Univ Sydney, Sydney, NSW, Australia.
   [Rambaut, A.] Univ Edinburgh, Inst Evolutionary Biol, Edinburgh EH9 3FL, Midlothian, Scotland.
   [Rambaut, A.] NIH, Fogarty Int Ctr, Bldg 10, Bethesda, MD 20892 USA.
   [Nunes, M. R. T.] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA.
   [Pybus, O. G.] Metabiota, San Francisco, CA 94104 USA.
RP Pybus, OG (corresponding author), Univ Oxford, Dept Zool, Oxford OX1 3SY, England.; Loman, NJ (corresponding author), Univ Birmingham, Inst Microbiol & Infect, Birmingham, W Midlands, England.; Sabino, EC (corresponding author), Univ Sao Paulo, Sch Med, Dept Infect Dis, Sao Paulo, Brazil.; Sabino, EC (corresponding author), Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.; Alcantara, LCJ (corresponding author), Fiocruz MS, Fundacao Oswaldo Cruz, Salvador, BA, Brazil.; Pybus, OG (corresponding author), Metabiota, San Francisco, CA 94104 USA.
EM sabinoec@usp.br; lalcan@bahia.fiocruz.br; n.j.loman@bham.ac.uk;
   oliver.pybus@zoo.ox.ac.uk
RI milagres, flavio/Q-2403-2019; Bezerrra, Joao/C-8867-2017; Oliveira,
   Claudia DL/G-8618-2011; Sabino, Ester Cerdeira/F-7750-2010; Arias,
   Carlos/O-4036-2019; de Siqueira, Isadora Cristina/R-9953-2016; Esteban,
   Munoz Medina Jose/B-6186-2015; Rambaut, Andrew/B-2481-2009; Pybus,
   Oliver G/B-2640-2012; Wallau, Gabriel Luz/B-5911-2008; Segurado, Aluisio
   C/K-2229-2012; Loman, Nicholas/Z-1573-2019; Giovanetti,
   Marta/AAK-7408-2020; da-Costa, Antonio Charlys/G-1548-2010; Magalhaes,
   Tereza/V-6632-2019; Marques, Ernesto T. A/L-4967-2013; Faria, Nuno
   R/I-2975-2012; Dhalia, Rafael/AAD-5432-2020; Levin, Anna S/C-8831-2012;
   Bezerra, Joao Felipe/AAE-2500-2020
OI Bezerrra, Joao/0000-0002-9978-628X; Sabino, Ester
   Cerdeira/0000-0003-2623-5126; Arias, Carlos/0000-0003-3130-4501; de
   Siqueira, Isadora Cristina/0000-0002-2520-4099; Esteban, Munoz Medina
   Jose/0000-0002-1289-4457; Rambaut, Andrew/0000-0003-4337-3707; Pybus,
   Oliver G/0000-0002-8797-2667; Wallau, Gabriel Luz/0000-0002-1419-5713;
   Segurado, Aluisio C/0000-0002-6311-8036; da-Costa, Antonio
   Charlys/0000-0001-5516-5177; Marques, Ernesto T. A/0000-0003-3826-9358;
   Faria, Nuno R/0000-0001-8839-2798; Levin, Anna S/0000-0003-2427-8368;
   Raghwani, Jayna/0000-0001-8538-4995; Grubaugh,
   Nathan/0000-0003-2031-1933; Alcantara, Luiz/0000-0002-6769-9931; Holmes,
   Edward/0000-0001-9596-3552; Hill, Sarah/0000-0002-2995-2596; Wu,
   Chieh-Hsi/0000-0001-9386-725X; Vinhal Frutuoso, Livia
   Carla/0000-0001-7926-1075; Black, Allison/0000-0002-6618-4127; Loose,
   Matthew/0000-0002-5264-0929; Loman, Nicholas/0000-0002-9843-8988;
   Freitas de Oliveira Franca, Rafael/0000-0002-1846-6007; Giovanetti,
   Marta/0000-0002-5849-7326; Theze, Julien/0000-0001-8188-9494
FU MRC/Wellcome Trust/Newton Fund Zika Rapid Response grant
   [MC_PC_15100/ZK/16-078]; USAID Emerging Pandemic Threats Program-2
   PREDICT-2United States Agency for International Development (USAID)
   [AID-OAA-A-14-00102]; MRC Bioinformatics Fellowship; Sir Henry Dale
   Fellowship [204311/Z/16/Z]; CNPqNational Council for Scientific and
   Technological Development (CNPq) [457480/2014-9, 302584/2015-3,
   439975/2016-6]; FAPESPFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) [2012/03417-7]; NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [R35 GM119774,
   R01 HL105704]; NSFNational Science Foundation (NSF) [DGE-1256082];
   Abbott Laboratories, Inc.Abbott Laboratories; National Health and
   Medical Research CouncilNational Health and Medical Research Council of
   Australia [GNT1037231]; MRCMedical Research Council UK (MRC); CRUKCancer
   Research UK [ANR00310]; Wellcome TrustWellcome Trust; Royal SocietyRoyal
   Society of London [101237/Z/13/Z]; ERCEuropean Research Council (ERC)
   [614725-PATHPHYLODYN, 278433-PREDEMICS]; EUEuropean Union (EU)
   [643476-COMPARE, 734548-ZIKAlliance]; IDAMS; DENFREE; DengueTools;
   PPSUSFACEPE [APQ-0302-4.01/13]; FACEPE [APQ-0044.2.11/16,
   APQ-0055.2.11/16]; German Ministry of Health; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [R01HL105704, R01HL105704, R01HL105704,
   R01HL105704, R01HL105704, R01HL105704, R01HL105704, R01HL105704,
   R01HL105704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [T32AI007244, T32AI007244,
   T32AI007244, T32AI007244, T32AI007244, T32AI007244, T32AI007244,
   T32AI007244, T32AI007244, T32AI007244, T32AI007244, T32AI007244,
   T32AI007244, R33AI120977, T32AI007244, R21AI120977, T32AI007244,
   T32AI007244, T32AI007244, T32AI007244, T32AI007244, T32AI007244,
   T32AI007244, T32AI007244, T32AI007244, T32AI007244, T32AI007244,
   T32AI007244, T32AI007244, R21AI120977, T32AI007244, T32AI007244,
   R33AI120977, T32AI007244, T32AI007244, T32AI007244, T32AI007244,
   T32AI007244, T32AI007244, T32AI007244] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [R35GM119774,
   R35GM119774, R35GM119774, R35GM119774, R35GM119774] Funding Source: NIH
   RePORTER; Medical Research CouncilMedical Research Council UK (MRC)
   [MC_PC_15100, MR/M501621/1, MR/L015080/1] Funding Source: researchfish
FX We thank Fundacao Oswaldo Cruz in Bahia and Pernambuco states,
   University of Sao Paulo, Instituto Evandro Chagas, and the Brazilian
   Zika virus surveillance network for their essential contributions. We
   thank the following for giving us permission to use their unpublished
   genomes available on GenBank: R. Lanciotti, J. Lednicky, A. Enfissi, F.
   Baldanti, R. Shabman, B. Picket, R. Schinazi, M. Bonaldo, M. Gale, M.
   Capobianchi and C. Concetta, M. Leguia, J. Alberto Diaz, E.
   Sevilla-Reyes, A. Franz, M. GarciaBlanco and M. J. van Hemert. We thank
   P. Fernando da Costa Vasconcelos, S. Guerreiro Rodrigues, J. Cardoso, J.
   Vasconcelos, J. Vianez Jr, J. Gil Melgaco, J. Blumel, M. C. Brito
   Lobato, L. Nunes Fava, C. Ayres, L. Abade and F. Campos. L. C. J. A.
   thanks QIAGEN for reagents and equipment and M. R. T. N. thanks FERPEL
   for consumables. We thank Oxford Nanopore for technical support,
   particularly R. Dokos, Z. McDougall, S. Cowan, G. Sanghera, and O.
   Hartwell. This work was supported by an MRC/Wellcome Trust/Newton Fund
   Zika Rapid Response grant (MC_PC_15100/ZK/16-078) and by the USAID
   Emerging Pandemic Threats Program-2 PREDICT-2 (Cooperative Agreement
   AID-OAA-A-14-00102). N. J. L. is supported by an MRC Bioinformatics
   Fellowship. N. R. F. is funded by a Sir Henry Dale Fellowship (grant
   204311/Z/16/Z). CNPq contributed to trip expenses (grant 457480/2014-9).
   A.C.d.C. was supported by FAPESP # 2012/03417-7 and M. R. T. N. by CNPq
   grant no. 302584/2015-3. A. B. and T. B. were supported by NIH award R35
   GM119774. A. B. is supported by the NSF Graduate Research Fellowship
   Program (grant DGE-1256082). T. B. is a Pew Biomedical Scholar. C.Y.C.
   is partially supported by NIH grant R01 HL105704 and an award from
   Abbott Laboratories, Inc. E. C. H. is supported by a National Health and
   Medical Research Council Australia Fellowship (GNT1037231). C.- H. W. is
   supported by the MRC and CRUK (ANR00310) and by the Wellcome Trust and
   Royal Society (grant 101237/Z/13/Z). S. C. H. is supported by the
   Wellcome Trust. This research received funding from the ERC under grant
   agreements 614725-PATHPHYLODYN and 278433-PREDEMICS, and from EU Horizon
   2020 under agreements 643476-COMPARE and 734548-ZIKAlliance. T. J. and
   E. T. M. acknowledge funding from IDAMS, DENFREE, DengueTools, and
   PPSUSFACEPE (project APQ-0302-4.01/13). R. F. F. received funding from
   FACEPE (APQ-0044.2.11/16 and APQ-0055.2.11/16) and from CNPq
   (439975/2016-6). S. A. B. was supported by the Sicherheit von Blut und
   Geweben hinsichtlich der Abwesenheit von Zikaviren from the German
   Ministry of Health.
CR [Anonymous], 2014, R LANG ENV COMP
   Baele G, 2013, MOL BIOL EVOL, V30, P239, DOI 10.1093/molbev/mss243
   Bogoch II, 2016, LANCET INFECT DIS, V16, P1237, DOI 10.1016/S1473-3099(16)30270-5
   Bogoch II, 2016, LANCET, V387, P335, DOI 10.1016/S0140-6736(16)00080-5
   Bouckaert R, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003537
   Bruen TC, 2006, GENETICS, V172, P2665, DOI 10.1534/genetics.105.048975
   Caminade C, 2017, P NATL ACAD SCI USA, V114, P119, DOI 10.1073/pnas.1614303114
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Cori A, 2013, AM J EPIDEMIOL, V178, P1505, DOI 10.1093/aje/kwt133
   Corman VM, 2016, B WORLD HEALTH ORGAN, V94, P880, DOI 10.2471/BLT.16.175950
   Darriba D, 2012, NAT METHODS, V9, P772, DOI 10.1038/nmeth.2109
   De Maio N, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005421
   Drummond AJ, 2012, MOL BIOL EVOL, V29, P1969, DOI 10.1093/molbev/mss075
   Edwards CJ, 2011, CURR BIOL, V21, P1251, DOI 10.1016/j.cub.2011.05.058
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Faye O, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002636
   Ferguson NM, 2016, SCIENCE, V353, P353, DOI 10.1126/science.aag0219
   Ferreira MAR, 2008, CAN J STAT, V36, P355, DOI 10.1002/cjs.5550360302
   Gharbi M, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-166
   Giovanetti M, 2016, INFECT GENET EVOL, V41, P142, DOI 10.1016/j.meegid.2016.03.030
   Grubaugh N. D., 2017, NATURE
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694
   Cuong HQ, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001322
   Holmes EC, 2003, J VIROL, V77, P11296, DOI 10.1128/JVI.77.20.11296-11298.2003
   Holmes EC, 2016, NATURE, V538, P193, DOI 10.1038/nature19790
   Huson DH, 2006, MOL BIOL EVOL, V23, P254, DOI 10.1093/molbev/msj030
   Kindhauser MK, 2016, B WORLD HEALTH ORGAN, V94, P675, DOI 10.2471/BLT.16.171082
   Kozlov AM, 2015, BIOINFORMATICS, V31, P2577, DOI 10.1093/bioinformatics/btv184
   Kraemer MUG, 2015, ELIFE, V4, DOI 10.7554/eLife.08347
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520
   Lessler J, 2016, SCIENCE, V353, DOI 10.1126/science.aaf8160
   Lessler J, 2016, B WORLD HEALTH ORGAN, V94, P841, DOI 10.2471/BLT.16.174540
   Liu H, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.109
   Liu-Helmersson J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089783
   Martin DP, 2015, VIRUS EVOL, V1, DOI 10.1093/ve/vev003
   Metsky HC, 2017, NATURE
   Minin VN, 2008, PHILOS T R SOC B, V363, P3985, DOI 10.1098/rstb.2008.0176
   Ministerio da Saade, 2017, B EP SECR VIG SAUD
   Naccache SN, 2016, EMERG INFECT DIS, V22, P1788, DOI 10.3201/eid2210.160663
   O'Brien JD, 2009, MOL BIOL EVOL, V26, P801, DOI 10.1093/molbev/msp003
   Pacheco O., 2016, NEW ENGL J MED
   PAHO/WHO, 2016, PAHO WHO ZIK EP UPD
   Park DJ, 2015, CELL, V161, P1516, DOI 10.1016/j.cell.2015.06.007
   Paules CI, 2017, NEW ENGL J MED, V376, P1397, DOI 10.1056/NEJMp1702172
   Perkins TA, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.126, 10.1038/nmicrobiol.2016.126]
   Pettersson JHO, 2016, MBIO, V7, DOI [10.1128/mBio.01239-16, 10.1128/mbio.01239-16]
   Pond SLK, 2005, MOL BIOL EVOL, V22, P1208, DOI 10.1093/molbev/msi105
   Pond SLK, 2005, BIOINFORMATICS, V21, P676, DOI 10.1093/bioinformatics/bti079
   Quick J., 2017, NAT PROTOCOLS
   Quick J, 2016, NATURE, V530, P228, DOI 10.1038/nature16996
   Rambaut A, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew007
   Rocklov J, 2016, EBIOMEDICINE, V9, P250, DOI 10.1016/j.ebiom.2016.06.009
   Schierup MH, 2000, GENETICS, V156, P879
   Shapiro B, 2006, MOL BIOL EVOL, V23, P7, DOI 10.1093/molbev/msj021
   Trosemeier J-H, 2016, GENOME ANNOUNC, V4
   Vasconcelos PFC, 2016, VECTOR-BORNE ZOONOT, V16, P295, DOI 10.1089/vbz.2016.1952
   Vogel G, 2016, SCIENCE, V354, P1088, DOI 10.1126/science.354.6316.1088
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1
   World Health Organization, 2017, SIT REP ZIK VIR MICR
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 62
TC 226
Z9 230
U1 6
U2 80
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD JUN 15
PY 2017
VL 546
IS 7658
BP 406
EP +
DI 10.1038/nature22401
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EX5BK
UT WOS:000403250900035
PM 28538727
OA Green Accepted, Green Published
DA 2020-11-30
ER

PT J
AU Quick, J
   Grubaugh, ND
   Pullan, ST
   Claro, IM
   Smith, AD
   Gangavarapu, K
   Oliveira, G
   Robles-Sikisaka, R
   Rogers, TF
   Beutler, NA
   Burton, DR
   Lewis-Ximenez, LL
   de Jesus, JG
   Giovanetti, M
   Hill, SC
   Black, A
   Bedford, T
   Carroll, MW
   Nunes, M
   Alcantara, LC
   Sabino, EC
   Baylis, SA
   Faria, NR
   Loose, M
   Simpson, JT
   Pybus, OG
   Andersen, KG
   Loman, NJ
AF Quick, Joshua
   Grubaugh, Nathan D.
   Pullan, Steven T.
   Claro, Ingra M.
   Smith, Andrew D.
   Gangavarapu, Karthik
   Oliveira, Glenn
   Robles-Sikisaka, Refugio
   Rogers, Thomas F.
   Beutler, Nathan A.
   Burton, Dennis R.
   Lewis-Ximenez, Lia Laura
   de Jesus, Jaqueline Goes
   Giovanetti, Marta
   Hill, Sarah C.
   Black, Allison
   Bedford, Trevor
   Carroll, Miles W.
   Nunes, Marcio
   Alcantara, Luiz Carlos, Jr.
   Sabino, Ester C.
   Baylis, Sally A.
   Faria, Nuno R.
   Loose, Matthew
   Simpson, Jared T.
   Pybus, Oliver G.
   Andersen, Kristian G.
   Loman, Nicholas J.
TI Multiplex PCR method for MinION and Illumina sequencing of Zika and
   other virus genomes directly from clinical samples
SO NATURE PROTOCOLS
LA English
DT Article
ID SURESELECT TARGET ENRICHMENT; REAL-TIME; EBOLA; SURVEILLANCE;
   AMPLIFICATION; EVOLUTION; INSIGHTS; PASSAGES; ROBUST; LASSA
AB Genome sequencing has become a powerful tool for studying emerging infectious diseases; however, genome sequencing directly from clinical samples (i.e., without isolation and culture) remains challenging for viruses such as Zika, for which metagenomic sequencing methods may generate insufficient numbers of viral reads. Here we present a protocol for generating coding-sequence-complete genomes, comprising an online primer design tool, a novel multiplex PCR enrichment protocol, optimized library preparation methods for the portable MinION sequencer (Oxford Nanopore Technologies) and the Illumina range of instruments, and a bioinformatics pipeline for generating consensus sequences. The MinION protocol does not require an Internet connection for analysis, making it suitable for field applications with limited connectivity. Our method relies on multiplex PCR for targeted enrichment of viral genomes from samples containing as few as 50 genome copies per reaction. Viral consensus sequences can be achieved in 1-2 d by starting with clinical samples and following a simple laboratory workflow. This method has been successfully used by several groups studying Zika virus evolution and is facilitating an understanding of the spread of the virus in the Americas. The protocol can be used to sequence other viral genomes using the online Primal Scheme primer designer software. It is suitable for sequencing either RNA or DNA viruses in the field during outbreaks or as an inexpensive, convenient method for use in the lab.
C1 [Quick, Joshua; Smith, Andrew D.; Loman, Nicholas J.] Univ Birmingham, Sch Biosci, Inst Microbiol & Infect, Birmingham, W Midlands, England.
   [Grubaugh, Nathan D.; Gangavarapu, Karthik; Robles-Sikisaka, Refugio; Rogers, Thomas F.; Beutler, Nathan A.; Burton, Dennis R.; Andersen, Kristian G.] Scripps Res Inst, La Jolla, CA 92037 USA.
   [Pullan, Steven T.; Carroll, Miles W.; Andersen, Kristian G.] Publ Hlth England, Natl Infect Serv, Salisbury, Wilts, England.
   [Claro, Ingra M.; Sabino, Ester C.] Univ Sao Paulo, Dept Infect Dis, Sao Paulo, Brazil.
   [Claro, Ingra M.; Sabino, Ester C.] Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
   [Oliveira, Glenn; Andersen, Kristian G.] Scripps Translat Sci Inst, La Jolla, CA USA.
   [Rogers, Thomas F.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
   [Lewis-Ximenez, Lia Laura] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
   [de Jesus, Jaqueline Goes; Giovanetti, Marta; Alcantara, Luiz Carlos, Jr.] Fiocruz MS, Fundacao Oswaldo Cruz, Salvador, BA, Brazil.
   [Giovanetti, Marta] Univ Rome, Tor Vergata, Italy.
   [Hill, Sarah C.; Faria, Nuno R.; Pybus, Oliver G.] Univ Oxford, Dept Zool, Oxford, England.
   [Black, Allison; Bedford, Trevor] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.
   [Black, Allison] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
   [Carroll, Miles W.] Univ Southampton, South Gen Hosp, Southampton, Hants, England.
   [Nunes, Marcio] Inst Evandro Chagas, Belem, Para, Brazil.
   [Baylis, Sally A.] Paul Ehrlich Inst, Langen, Germany.
   [Loose, Matthew] Univ Nottingham, Sch Life Sci, DeepSeq, Nottingham, England.
   [Simpson, Jared T.] OICR, Toronto, ON, Canada.
RP Loman, NJ (corresponding author), Univ Birmingham, Sch Biosci, Inst Microbiol & Infect, Birmingham, W Midlands, England.
EM n.j.loman@bham.ac.uk
RI Giovanetti, Marta/AAK-7408-2020; Faria, Nuno R/I-2975-2012; Loman,
   Nicholas/Z-1573-2019; Pybus, Oliver G/B-2640-2012; Sabino, Ester
   Cerdeira/F-7750-2010
OI Faria, Nuno R/0000-0001-8839-2798; Pybus, Oliver G/0000-0002-8797-2667;
   Sabino, Ester Cerdeira/0000-0003-2623-5126; Giovanetti,
   Marta/0000-0002-5849-7326; Grubaugh, Nathan/0000-0003-2031-1933; Loman,
   Nicholas/0000-0002-9843-8988; Hill, Sarah/0000-0002-2995-2596; Loose,
   Matthew/0000-0002-5264-0929; Black, Allison/0000-0002-6618-4127;
   Alcantara, Luiz/0000-0002-6769-9931; Beutler,
   Nathan/0000-0003-3240-9524; Pullan, Steven/0000-0002-8983-599X
FU Brazilian Ministry of Health and the Latin American Community Engagement
   Networks (LACENs); Medical Research Council/Wellcome Trust/Newton Fund
   Zika Rapid Response Initiative [ZK/16-078]; Medical Research Council
   Bioinformatics Fellowship as part of the Cloud Infrastructure for
   Microbial Bioinformatics (CLIMB) project; National Institutes of Health
   (NIH)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [5T32AI007244-33]; NIH National Center
   for Advancing Translational Studies Clinical and Translational Science
   Award [UL1TR001114]; National Institute of Allergy and Infectious
   Diseases (NIAID)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [HHSN272201400048C]; NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [R35 GM119774, U54 GM111274]; National Science
   Foundation Graduate Research Fellowship ProgramNational Science
   Foundation (NSF) [DGE-1256082]; Sir Henry Dale Fellowship (Wellcome
   Trust/Royal Society) [204311/Z/16/Z]; grant ('Sicherheit von
   Blut(produkten) und Geweben hinsichtlich der Abwesenheit von Zikaviren')
   from the German Ministry of Health; USAID Emerging Pandemic Threats
   Program-2 PREDICT-2United States Agency for International Development
   (USAID) [AID-OAA-A-14-00102]; Medical Research CouncilMedical Research
   Council UK (MRC) [MR/L015080/1, MR/M501621/1, MC_PC_15100] Funding
   Source: researchfish; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [T32AI007244, T32AI007244, T32AI007244,
   T32AI007244, T32AI007244, T32AI007244, T32AI007244, T32AI007244,
   T32AI007244, T32AI007244, T32AI007244, T32AI007244, T32AI007244,
   T32AI007244, T32AI007244, T32AI007244, T32AI007244, T32AI007244,
   T32AI007244, T32AI007244, T32AI007244, T32AI007244, T32AI007244,
   T32AI007244, T32AI007244, T32AI007244, T32AI007244, T32AI007244,
   T32AI007244, T32AI007244, T32AI007244, T32AI007244, T32AI007244,
   T32AI007244, T32AI007244, T32AI007244, T32AI007244] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of General Medical Sciences (NIGMS)
   [U54GM111274, U54GM111274, U54GM111274, R35GM119774, U54GM111274,
   U54GM111274, U54GM111274, U54GM111274, U54GM111274, U54GM111274,
   U54GM111274, U54GM111274, U54GM111274, U54GM111274, U54GM111274,
   U54GM111274, U54GM111274, R35GM119774, U54GM111274, U54GM111274,
   U54GM111274, U54GM111274, R35GM119774, U54GM111274, U54GM111274,
   U54GM111274, U54GM111274, U54GM111274, U54GM111274, R35GM119774,
   U54GM111274, U54GM111274, U54GM111274, U54GM111274] Funding Source: NIH
   RePORTER
FX The authors thank the Brazilian Ministry of Health and the Latin
   American Community Engagement Networks (LACENs) of Natal, Joao Pessoa,
   Recife, Maceio and Salvador for their support. We thank T. Fredeking
   from Antibody Systems for providing the Zika virus samples from
   Colombia. We thank K. Brunker for testing the Primal Scheme software.
   The Zika in Brazil Real-time Analysis (ZiBRA) project
   (http://www.zibraproject.org) is supported by the Medical Research
   Council/Wellcome Trust/Newton Fund Zika Rapid Response Initiative (grant
   no, ZK/16-078), which also provides J.Q.'s salary. N.J.L. is supported
   by a Medical Research Council Bioinformatics Fellowship as part of the
   Cloud Infrastructure for Microbial Bioinformatics (CLIMB) project.
   Primal Scheme is hosted on the CLIMB platform, where pipeline
   development and MinION data analysis was performed<SUP>59</SUP>. N.D.G.
   is supported by National Institutes of Health (NIH) training grant
   5T32AI007244-33. K.G.A. is a PEW Biomedical Scholar, and his work is
   supported by NIH National Center for Advancing Translational Studies
   Clinical and Translational Science Award UL1TR001114 and National
   Institute of Allergy and Infectious Diseases (NIAID) contract
   HHSN272201400048C. A.B. and T.B. were supported by NIH awards R35
   GM119774 and U54 GM111274. T.B. is a Pew Biomedical Scholar. A.B. is
   supported by the National Science Foundation Graduate Research
   Fellowship Program under Grant no. DGE-1256082. N.R.F. was funded by a
   Sir Henry Dale Fellowship (Wellcome Trust/Royal Society grant
   204311/Z/16/Z). Work at the Paul-Ehrlich-Institut was supported by a
   grant ('Sicherheit von Blut(produkten) und Geweben hinsichtlich der
   Abwesenheit von Zikaviren') from the German Ministry of Health. This
   study was supported by USAID Emerging Pandemic Threats Program-2
   PREDICT-2 (cooperative agreement AID-OAA-A-14-00102). The contents of
   this article are the responsibility of the authors and do not
   necessarily reflect the views of USAID or the US government.
CR Andersen KG, 2015, CELL, V162, P738, DOI 10.1016/j.cell.2015.07.020
   Arias A, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew016
   Atkinson B, 2016, MICROBIOL RESOUR ANN, V4, DOI 10.1128/genomeA.01116-16
   Bankevich A, 2012, J COMPUT BIOL, V19, P455, DOI 10.1089/cmb.2012.0021
   Batty EM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066129
   Baylis SA, 2017, TRANSFUSION, V57, P748, DOI 10.1111/trf.14026
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Brown JR, 2015, J CLIN VIROL, V70, pS12, DOI 10.1016/j.jcv.2015.07.037
   Brown JR, 2016, J CLIN MICROBIOL, V54, P2530, DOI 10.1128/JCM.01052-16
   Carrillo C, 2007, J VIROL, V81, P11341, DOI 10.1128/JVI.00930-07
   Carroll MW, 2015, NATURE, V524, P97, DOI 10.1038/nature14594
   Chan M, 2016, J APPL LAB MED, V1, P25, DOI 10.1373/jalm.2016.020131
   Connor TR, 2016, MICROB GENOMICS, V2, DOI 10.1099/mgen.0.000086
   Dudas G, 2017, NATURE, V544, P309, DOI 10.1038/nature22040
   Eckert SE, 2016, MICROB GENOMICS, V2, DOI 10.1099/mgen.0.000087
   Faria N. R., 2017, NATURE
   Faria NR, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0356-2
   Gardner Shea N., 2014, Advances in Bioinformatics, V2014, P101894, DOI 10.1155/2014/101894
   Gardy J, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0726-x
   Gire SK, 2014, SCIENCE, V345, P1369, DOI 10.1126/science.1259657
   Goodwin S, 2016, NAT REV GENET, V17, P333, DOI 10.1038/nrg.2016.49
   Greninger AL, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0220-9
   Grubaugh N. D., 2017, NATURE
   Guerbois M, 2016, J INFECT DIS, V214, P1349, DOI 10.1093/infdis/jiw302
   Hoenen T, 2016, EMERG INFECT DIS, V22, P331, DOI 10.3201/eid2202.151796
   Holmes EC, 2016, NATURE, V538, P193, DOI 10.1038/nature19790
   Houldcroft CJ, 2017, NAT REV MICROBIOL, V15, P183, DOI 10.1038/nrmicro.2016.182
   Hysom DA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034560
   Kilianski A, 2016, EMERG INFECT DIS, V22, P1448, DOI 10.3201/eid2208.160270
   Kilianski A, 2015, GIGASCIENCE, V4, DOI 10.1186/s13742-015-0051-z
   Koster J, 2012, BIOINFORMATICS, V28, P2520, DOI 10.1093/bioinformatics/bts480
   KWOK S, 1990, NUCLEIC ACIDS RES, V18, P999, DOI 10.1093/nar/18.4.999
   KWOK S, 1994, PCR METH APPL, V3, pS39
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li K, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-261
   Loman NJ, 2012, NAT BIOTECHNOL, V30, P434, DOI 10.1038/nbt.2198
   Mamanova L, 2010, NAT METHODS, V7, P111, DOI 10.1038/nmeth.1419
   Marquez S, 2017, MICROBIOL RESOUR ANN, V5, DOI [10.1128/genomeA.01673-16, 10.1128/genomea.01673-16]
   Matranga CB, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0519-7
   Metsky HC, 2017, NATURE
   Metzker ML, 2010, NAT REV GENET, V11, P31, DOI 10.1038/nrg2626
   Milne I, 2010, BIOINFORMATICS, V26, P401, DOI 10.1093/bioinformatics/btp666
   Misencik MJ, 2016, VECTOR-BORNE ZOONOT, V16, P181, DOI 10.1089/vbz.2015.1889
   Naccache SN, 2016, EMERG INFECT DIS, V22, P1788, DOI 10.3201/eid2210.160663
   Nakamura S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004219
   Palacios G, 2008, NEW ENGL J MED, V358, P991, DOI 10.1056/NEJMoa073785
   Quick J, 2016, NATURE, V530, P228, DOI 10.1038/nature16996
   Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Salzberg SL, 2007, EMERG INFECT DIS, V13, P713, DOI 10.3201/eid1305.070013
   Scotto-Lavino E, 2006, NAT PROTOC, V1, P2555, DOI 10.1038/nprot.2006.480
   Sipos B., 2016, BIORXIV
   Thomson E, 2016, J CLIN MICROBIOL, V54, P2470, DOI 10.1128/JCM.00330-16
   Trosemeier J-H, 2016, GENOME ANNOUNC, V4
   Wang J, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00766
   Wilson MR, 2014, NEW ENGL J MED, V370, P2408, DOI 10.1056/NEJMoa1401268
   Worobey M, 2016, NATURE, V539, P98, DOI 10.1038/nature19827
   Yu Q, 2011, BIOINFORMATICS, V27, P266, DOI 10.1093/bioinformatics/btq624
   Yuste E, 2000, J VIROL, V74, P9546, DOI 10.1128/JVI.74.20.9546-9552.2000
NR 59
TC 191
Z9 194
U1 9
U2 106
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1754-2189
EI 1750-2799
J9 NAT PROTOC
JI Nat. Protoc.
PD JUN
PY 2017
VL 12
IS 6
BP 1261
EP 1276
DI 10.1038/nprot.2017.066
PG 16
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA EV9RK
UT WOS:000402122900001
PM 28538739
OA Green Accepted, Green Published, Bronze
DA 2020-11-30
ER

PT J
AU Cruz, HM
   Scalioni, LD
   de Paula, VS
   Miguel, JC
   do O, KMR
   Milagres, FAP
   Cruz, MS
   Bastos, FI
   Flores, PP
   Leal, E
   Motta-Castro, ARC
   Lewis-Ximenez, LL
   Lampe, E
   Villar, LM
AF Cruz, Helena Medina
   Scalioni, Leticia de Paula
   de Paula, Vanessa Salete
   Miguel, Juliana Custodio
   Rodrigues do O, Kycia Maria
   Padua Milagres, Flavio Augusto
   Cruz, Marcelo Santos
   Bastos, Francisco Inacio
   Flores, Priscila Pollo
   Leal, Erotildes
   Coimbra Motta-Castro, Ana Rita
   Lewis-Ximenez, Lia Laura
   Lampe, Elisabeth
   Villar, Livia Melo
TI Poor sensitivity of rapid tests for the detection of antibodies to the
   hepatitis B virus: implications for field studies
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE hepatitis B virus; antibodies; rapid tests; performance
AB Rapid tests (RTs) can be used as an alternative method for the conventional diagnosis of hepatitis B virus (HBV). This study aims to evaluate antibodies to HBsAg (anti-HBs) and antibodies to HBeAg (anti-HBe) RTs under different Brazilian settings. The following three groups were included: GI: viral hepatitis outpatient services; GII: low resource areas; and GIII: crack users and beauticians. Imuno-rapido anti-HBsAg (TM) and Imuno-rapido anti-HBeAg (TM) RTs were evaluated and showed specificities greater than 95% in all groups. The sensitivity values to anti-HBs were 50.38%, 51.05% and 46.73% and the sensitivity values to anti-HBe were 76.99%, 10.34% and 11.76% in the GI, GII and GIII groups, respectively. The assays had a low sensitivity and high specificity, which indicated their use for screening in regions endemic for HBV.
C1 [Cruz, Helena Medina; Scalioni, Leticia de Paula; Miguel, Juliana Custodio; Lewis-Ximenez, Lia Laura; Lampe, Elisabeth; Villar, Livia Melo] Fundacao Oswaldo Cruz Fiocruz, Inst Oswaldo Cruz, Lab Hepatites Virais, Rio De Janeiro, RJ, Brazil.
   [de Paula, Vanessa Salete] Fundacao Oswaldo Cruz Fiocruz, Inst Oswaldo Cruz, Lab Desenvolvimento Tecnol Virol, Rio De Janeiro, RJ, Brazil.
   [Rodrigues do O, Kycia Maria] Hosp Sao Lucas, Petropolis, RJ, Brazil.
   [Padua Milagres, Flavio Augusto] Univ Fed Tocantins, Fac Med, Palmas, TO, Brazil.
   [Cruz, Marcelo Santos] Univ Fed Rio de Janeiro, Inst Psiquiatria, Rio De Janeiro, RJ, Brazil.
   [Bastos, Francisco Inacio] Fundacao Oswaldo Cruz Fiocruz, Inst Comunicacao & Informacao Cient & Tecnol Saud, Rio De Janeiro, RJ, Brazil.
   [Flores, Priscila Pollo] Univ Brasilia, Brasilia, DF, Brazil.
   [Leal, Erotildes] Univ Fed Rio de Janeiro, Campus Macae, Macae, RJ, Brazil.
   [Coimbra Motta-Castro, Ana Rita] Univ Fed Mato Grosso do Sul, Dept Bioquim & Farm, Grande, MS, Brazil.
RP Villar, LM (corresponding author), Fundacao Oswaldo Cruz Fiocruz, Inst Oswaldo Cruz, Lab Hepatites Virais, Rio De Janeiro, RJ, Brazil.
EM lvillar@ioc.fiocruz.br
RI Cruz, Helena Medina/U-4780-2019; Cruz, Marcelo Santos/AAH-5963-2020;
   VILLAR, LIVIA M/F-7811-2012; motta-castro, ana rita c/O-2075-2017;
   milagres, flavio/Q-2403-2019; Cruz, Marcelo Santos/I-5890-2014; de
   Paula, Vanessa S/I-8037-2016
OI Cruz, Helena Medina/0000-0003-2088-7705; Cruz, Marcelo
   Santos/0000-0003-0057-2095; VILLAR, LIVIA M/0000-0001-7644-8969; de
   Paula, Vanessa S/0000-0002-6314-754X; Motta-Castro, Ana
   Rita/0000-0003-3070-1337; Bastos, Francisco/0000-0001-5970-8896;
   Milagres, Flavio/0000-0002-6889-8772
FU FAPERJCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); CNPqNational Council for Scientific and
   Technological Development (CNPq); CAPESCAPES; FIOCRUZ
FX FAPERJ, CNPq, CAPES, FIOCRUZ.
CR BMH - Brazilian Ministry of Health, 2015, EP B VIR HEP
   BMH - Brazilian Ministry of Health, 2011, CLIN PROT THER GUID
   Bottero J, 2016, EUR J GASTROEN HEPAT, V28, P633, DOI 10.1097/MEG.0000000000000620
   Bottero J, 2013, J HEPATOL, V58, P473, DOI 10.1016/j.jhep.2012.11.016
   Cha Young Joo, 2006, Korean J Lab Med, V26, P52, DOI 10.3343/kjlm.2006.26.1.52
   Cruz MS, 2013, INT J DRUG POLICY, V24, P432, DOI 10.1016/j.drugpo.2013.03.012
   EI-Ghitany EM, 2013, J VIROL METHODS, V194, P190, DOI 10.1016/j.jviromet.2013.08.026
   Gerlich WH, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-239
   Kwon So Young, 2011, Korean J Hepatol, V17, P87, DOI 10.3350/kjhep.2011.17.2.87
   Oh J, 1999, KOREAN J CLIN PATHOL, V19, P114
   Shivkumar S, 2012, AM J GASTROENTEROL, V107, P1306, DOI 10.1038/ajg.2012.141
   Soeung SC, 2009, AM J TROP MED HYG, V81, P252, DOI 10.4269/ajtmh.2009.81.252
   Villar Livia Melo, 2015, World J Virol, V4, P323, DOI 10.5501/wjv.v4.i4.323
   Villar LM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/324638
   Villar LM, 2014, J MED VIROL, V86, P1515, DOI 10.1002/jmv.23993
   Whang DongHee, 2005, Korean Journal of Laboratory Medicine, V25, P186
   World Health Organization WHO, 2015, HEP B
   Wu FY, 2016, PEDIATR NEONATOL, V57, P219, DOI 10.1016/j.pedneo.2015.07.003
NR 18
TC 7
Z9 7
U1 0
U2 3
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD MAR
PY 2017
VL 112
IS 3
BP 209
EP 213
DI 10.1590/0074-02760160394
PG 5
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA EL3JW
UT WOS:000394516400007
PM 28146158
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Melgaco, JG
   Soriani, FM
   Sucupira, PHF
   Pinheiro, LA
   Vieira, YR
   de Oliveira, JM
   Lewis-Ximenez, LL
   Araujo, CCV
   Pacheco-Moreira, LF
   Menezes, GB
   Cruz, OG
   Vitral, CL
   Pinto, MA
AF Melgaco, Juliana Gil
   Soriani, Frederico Marianetti
   Ferreira Sucupira, Pedro Henrique
   Pinheiro, Leonardo Assaf
   Vieira, Yasmine Rangel
   de Oliveira, Jaqueline Mendes
   Lewis-Ximenez, Lia Laura
   Vianna Araujo, Cristina Carvalho
   Pacheco-Moreira, Lucio Filgueiras
   Menezes, Gustavo Batista
   Cruz, Oswaldo Goncalves
   Vitral, Claudia Lamarca
   Pinto, Marcelo Alves
TI Changes in cellular proliferation and plasma products are associated
   with liver failure
SO WORLD JOURNAL OF HEPATOLOGY
LA English
DT Article
DE Acute liver failure; Cytokines; Mitochondrial DNA; Cellular immune
   response; Hepatitis A virus
AB AIM
   To study the differences in immune response and cytokine profile between acute liver failure and self-limited acute hepatitis.
   METHODS
   Forty-six patients with self-limited acute hepatitis (AH), sixteen patients with acute liver failure (ALF), and twenty-two healthy subjects were involved in this study. The inflammatory and anti-inflammatory products in plasma samples were quantified using commercial enzyme-linked immunoassays and quantitative real-time PCR. The cellular immune responses were measured by proliferation assay using flow cytometry. The groups were divided into viral- and non-viral-induced self-limited AH and ALF. Thus, we worked with five groups: Hepatitis A virus (HAV)-induced self-limited acute hepatitis (HAV-AH), HAV-induced ALF (HAV-ALF), non-viral-induced self-limited acute hepatitis (non-viral AH), non-viral-induced acute liver failure (non-viral ALF), and healthy subjects (HC). Comparisons among HAV and non-viral-induced AH and ALF were performed.
   RESULTS
   The levels of mitochondrial DNA (mtDNA) and the cytokines investigated [interleukin (IL)-6, IL-8, IL-10, interferon gamma, and tumor necrosis factor] were significantly increased in ALF patients, independently of etiology (P < 0.05). High plasma mtDNA and IL-10 were the best markers associated with ALF [mtDNA: OR = 320.5 (95%CI: 14.42-7123.33), P < 0.0001; and IL-10: OR = 18.8 (95%CI: 1.38-257.94), P = 0.028] and death [mtDNA: OR = 12.1 (95%CI: 2.57-57.07), P = 0.002; and IL-10: OR = 8.01 (95%CI: 1.26-50.97), P = 0.027]. In the cellular proliferation assay, NKbright, NKT and regulatory T cells (TReg) predominated in virus-specific stimulation in HAV-induced ALF patients with an anergic behavior in the cellular response to mitotic stimulation. Therefore, in non-viral-induced ALF, anergic behavior of activated T cells was not observed after mitotic stimulation, as expected and as described by the literature.
   CONCLUSION
   mtDNA and IL-10 may be predictors of ALF and death. TReg cells are involved in immunological disturbance in HAV-induced ALF.
C1 [Melgaco, Juliana Gil; Pinheiro, Leonardo Assaf; Vitral, Claudia Lamarca] Univ Fed Fluminense, Dept Microbiol & Parasitol, BR-20550013 Niteroi, RJ, Brazil.
   [Melgaco, Juliana Gil; Vieira, Yasmine Rangel; de Oliveira, Jaqueline Mendes; Pinto, Marcelo Alves] Inst Oswaldo Cruz, FIOCRUZ, Lab Desenvolvimento Tecnol Virol, BR-21040900 Rio De Janeiro, Brazil.
   [Soriani, Frederico Marianetti; Ferreira Sucupira, Pedro Henrique] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Biol Geral, BR-31270901 Belo Horizonte, MG, Brazil.
   [Lewis-Ximenez, Lia Laura] Inst Oswaldo Cruz, FIOCRUZ, Ambulatorio Hepatites Virais, BR-21040900 Rio De Janeiro, Brazil.
   [Vianna Araujo, Cristina Carvalho; Pacheco-Moreira, Lucio Filgueiras] Hosp Fed Bonsucesso, BR-21041030 Rio De Janeiro, Brazil.
   [Menezes, Gustavo Batista] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, Lab Imunofarmacol, BR-31270901 Belo Horizonte, MG, Brazil.
   [Cruz, Oswaldo Goncalves] Fundacao Oswaldo Cruz, Programa Comp Cient, BR-21040900 Rio De Janeiro, Brazil.
RP Melgaco, JG (corresponding author), Fundacao Oswaldo Cruz, FIOCRUZ, Lab Desenvolvimento Tecnol Virol, Inst Oswaldo Cruz, Ave Brasil 4365, BR-21040900 Rio De Janeiro, Brazil.
EM juliana.melgaco@gmail.com
RI Melgaco, Juliana/AAQ-6084-2020; Pinto, Marcelo Alves/ABA-3312-2020;
   Pinto, Marcelo/G-7503-2012
OI Melgaco, Juliana/0000-0003-0087-6531; Pinto,
   Marcelo/0000-0003-3462-7277; Sucupira, Pedro/0000-0002-1997-1590
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico -
   CNPqNational Council for Scientific and Technological Development (CNPq)
   [308951/2010-7]; Fundacao de Amparo a Pesquisas no Rio de Janeiro -
   Faperj [E-26/110.848/2013]
FX Supported by Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico - CNPq, No. 308951/2010-7; and the Fundacao de Amparo a
   Pesquisas no Rio de Janeiro - Faperj, No. E-26/110.848/2013.
CR Akdogan M, 2006, J CLIN APHERESIS, V21, P96, DOI 10.1002/jca.20064
   Antoniades CG, 2012, HEPATOLOGY, V56, P735, DOI 10.1002/hep.25657
   Ash SR, 2001, THER APHER, V5, P404, DOI 10.1046/j.1526-0968.2001.00384.x
   Azeredo EL, 2010, IMMUNOLOGY, V130, P202, DOI 10.1111/j.1365-2567.2009.03224.x
   Azhar N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078202
   Baquerizo A, 2003, TRANSPLANTATION, V75, P2007, DOI 10.1097/01.TP.0000063219.21313.32
   Best DH, 2010, EXP MOL PATHOL, V88, P7, DOI 10.1016/j.yexmp.2009.10.009
   Bjorkstrom NK, 2010, TRENDS IMMUNOL, V31, P401, DOI 10.1016/j.it.2010.08.003
   Bonorino P, 2009, J HEPATOL, V51, P458, DOI 10.1016/j.jhep.2009.05.030
   Brenndorfer ED, 2010, HEPATOLOGY, V52, P1553, DOI 10.1002/hep.23870
   Bucuvalas J, 2013, J PEDIATR GASTR NUTR, V56, P311, DOI 10.1097/MPG.0b013e31827a78b2
   Carollo M, 2012, VACCINE, V30, P1667, DOI 10.1016/j.vaccine.2011.12.104
   Castro-Garcia FP, 2014, IMMUNOLOGY, V143, P578, DOI 10.1111/imm.12336
   Cho H, 2013, J MICROBIOL, V51, P247, DOI 10.1007/s12275-013-2522-1
   Cisneros-Garza LE, 2014, ANN HEPATOL, V13, P240, DOI 10.1016/S1665-2681(19)30887-7
   Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9
   Dalgaard TS, 2010, VET IMMUNOL IMMUNOP, V138, P85, DOI 10.1016/j.vetimm.2010.07.010
   Ding L, 2013, J HUAZHONG U SCI-MED, V33, P505, DOI 10.1007/s11596-013-1150-7
   Dong XJ, 2013, LIVER INT, V33, P1517, DOI 10.1111/liv.12248
   dos Santos DCM, 2012, LIVER INT, V32, P147, DOI 10.1111/j.1478-3231.2011.02654.x
   Dunn C, 2009, GASTROENTEROLOGY, V137, P1289, DOI 10.1053/j.gastro.2009.06.054
   Fierro NA, 2015, MEM I OSWALDO CRUZ, V110, P263, DOI 10.1590/0074-02760140309
   Foureau DM, 2015, CLIN EXP IMMUNOL, V180, P40, DOI 10.1111/cei.12558
   GASPAR AMC, 1992, BRAZ J MED BIOL RES, V25, P697
   Golden-Mason L, 2007, J VIROL, V81, P9292, DOI 10.1128/JVI.00834-07
   Jayakumar S, 2013, CRIT CARE CLIN, V29, P677, DOI 10.1016/j.ccc.2013.03.013
   Jia BS, 2015, J VIROL, V89, P2041, DOI 10.1128/JVI.03106-14
   Kasztelan-Szczerbinska B, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/673032
   Laszikova E, 2014, NEUROENDOCRINOL LETT, V35, P280
   Lee HS, 2013, TRANSPL P, V45, P2992, DOI 10.1016/j.transproceed.2013.08.036
   Leifeld L, 2002, HEPATOLOGY, V36, P1001, DOI 10.1053/jhep.2002.35532
   Liang XS, 2014, WORLD J GASTROENTERO, V20, P8558, DOI 10.3748/wjg.v20.i26.8558
   Liaskou E, 2013, HEPATOLOGY, V57, P385, DOI 10.1002/hep.26016
   Lima LR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102925
   Llovet JM, 2012, CLIN CANCER RES, V18, P2290, DOI 10.1158/1078-0432.CCR-11-2175
   Lugli E, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00390
   Marques PE, 2012, HEPATOLOGY, V56, P1971, DOI 10.1002/hep.25801
   Masubuchi Y, 2009, CHEM-BIOL INTERACT, V179, P273, DOI 10.1016/j.cbi.2008.10.028
   McGill MR, 2014, HEPATOLOGY, V60, P1336, DOI 10.1002/hep.27265
   McGill MR, 2012, J CLIN INVEST, V122, P1574, DOI 10.1172/JCI59755
   Meier UC, 2005, J VIROL, V79, P12365, DOI 10.1128/JVI.79.19.12365-12374.2005
   Moore SM, 2006, J CLIN IMMUNOL, V26, P533, DOI 10.1007/s10875-006-9044-0
   dos Santos DCM, 2009, BRAZ J INFECT DIS, V13, P323, DOI 10.1590/S1413-86702009000500002
   dos Santos DCM, 2009, LIVER INT, V29, P544, DOI 10.1111/j.1478-3231.2008.01872.x
   Motta-Castro ARC, 2003, MEM I OSWALDO CRUZ, V98, P13, DOI 10.1590/S0074-02762003000100002
   Perrella A, 2008, J GASTROEN HEPATOL, V23, pE105, DOI 10.1111/j.1440-1746.2007.05008.x
   Roy AK, 2004, J BIOL CHEM, V279, P28345, DOI 10.1074/jbc.M400457200
   SEKIYAMA KD, 1994, CLIN EXP IMMUNOL, V98, P71
   Soundravally R, 2010, INDIAN J PEDIATR, V77, P435, DOI 10.1007/s12098-010-0027-z
   Srivastava R, 2011, J GASTROEN HEPATOL, V26, P306, DOI 10.1111/j.1440-1746.2010.06356.x
   Srivastava R, 2007, VIRAL IMMUNOL, V20, P56, DOI 10.1089/vim.2006.0053
   Steuerwald NM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081974
   Sugawara K, 2012, J GASTROENTEROL, V47, P849, DOI 10.1007/s00535-012-0624-x
   Thornton AM, 2000, J IMMUNOL, V164, P183, DOI 10.4049/jimmunol.164.1.183
   Tiberio GAM, 2008, CYTOKINE, V42, P372, DOI 10.1016/j.cyto.2008.03.012
   Topuria D, 2006, Georgian Med News, P111
   Vitral CL, 2008, J VIRAL HEPATITIS, V15, P22, DOI 10.1111/j.1365-2893.2008.01024.x
   Vitral CL, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-458
   Wang DW, 2013, WORLD J GASTROENTERO, V19, P7069, DOI 10.3748/wjg.v19.i41.7069
   Wang JY, 1999, WORLD J GASTROENTERO, V5, P38
   Wang QH, 2011, BMC IMMUNOL, V12, DOI 10.1186/1471-2172-12-25
   Wang XZ, 2015, J APPL TOXICOL, V35, P695, DOI 10.1002/jat.3115
   Wang XZ, 2014, FITOTERAPIA, V93, P245, DOI 10.1016/j.fitote.2014.01.006
   Weidmann M, 2008, J CLIN VIROL, V42, P326, DOI 10.1016/j.jcv.2008.03.005
   Xu DP, 2006, J IMMUNOL, V177, P739, DOI 10.4049/jimmunol.177.1.739
   Yamada K, 2008, TOHOKU J EXP MED, V214, P1, DOI 10.1620/tjem.214.1
   Ye YF, 2010, J CLIN IMMUNOL, V30, P546, DOI 10.1007/s10875-010-9416-3
   Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780
   Zhou Y, 2012, J EXP MED, V209, P1481, DOI 10.1084/jem.20111906
   Zimmermann HW, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00056
NR 70
TC 4
Z9 4
U1 2
U2 3
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1948-5182
J9 WORLD J HEPATOL
JI World J. Hepatol.
PD NOV 18
PY 2016
VL 8
IS 32
BP 1370
EP 1383
DI 10.4254/wjh.v8.i32.1370
PG 14
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA VE3ZH
UT WOS:000439249800003
PM 27917263
OA Green Published, Other Gold
DA 2020-11-30
ER

PT J
AU Scheurich, C
   zur Wiesch, JS
   Kim, AY
   Lewis-Ximenez, L
   Meyer, T
   Polywka, S
   Chung, RT
   Lauer, GM
AF Scheurich, C.
   zur Wiesch, J. Schulze
   Kim, A. Y.
   Lewis-Ximenez, L.
   Meyer, T.
   Polywka, S.
   Chung, R. T.
   Lauer, G. M.
TI Breadth of the HCV-specific CD4+T-cell response in spontaneous resolvers
   is independent of the IL-28 haplotype
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Letter
ID HEPATITIS-C VIRUS; GENETIC-VARIATION; INFECTION; IL28B
C1 [Scheurich, C.; zur Wiesch, J. Schulze] Univ Med Ctr Hamburg Eppendorf, Dept Med, Hamburg, Germany.
   [Kim, A. Y.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
   [Kim, A. Y.; Chung, R. T.; Lauer, G. M.] Harvard Med Sch, Boston, MA USA.
   [Lewis-Ximenez, L.] Fiocruz MS, Inst Oswaldo Cruz, Lab Viral Hepatitis, Rio De Janeiro, Brazil.
   [Meyer, T.; Polywka, S.] Univ Med Ctr Hamburg Eppendorf, Inst Med Microbiol & Virol, Hamburg, Germany.
   [Chung, R. T.; Lauer, G. M.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
RP zur Wiesch, JS (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Med, Hamburg, Germany.
EM julianszw@gmail.com
RI Lauer, Georg/J-1467-2018
OI Lauer, Georg/0000-0002-9792-4271
CR Bes M, 2012, J VIRAL HEPATITIS, V19, P867, DOI 10.1111/j.1365-2893.2012.01631.x
   Duggal P, 2013, ANN INTERN MED, V158, P235, DOI 10.7326/0003-4819-158-4-201302190-00003
   Fitzmaurice K, 2015, GUT, V64, P813, DOI 10.1136/gutjnl-2013-306287
   Thomas DL, 2009, NATURE, V461, P798, DOI 10.1038/nature08463
   zur Wiesch JS, 2005, J IMMUNOL, V175, P3603, DOI 10.4049/jimmunol.175.6.3603
NR 5
TC 1
Z9 1
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
EI 1365-2893
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD OCT
PY 2016
VL 23
IS 10
BP 831
EP 832
DI 10.1111/jvh.12560
PG 2
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA DX8GF
UT WOS:000384625400011
PM 27346754
DA 2020-11-30
ER

PT J
AU Marques, BL
   do Espirito-Santo, MP
   Marques, VA
   Miguel, JC
   da Silva, EF
   Villela-Nogueira, CA
   Lewis-Ximenez, LL
   Lampe, E
   Villar, LM
AF Crespo Marques, Brunna Lemos
   do Espirito-Santo, Marcia Paschoal
   Marques, Vanessa Alves
   Miguel, Juliana Custodio
   da Silva, Elisangela Ferreira
   Villela-Nogueira, Cristiane Alves
   Lewis-Ximenez, Lia Laura
   Lampe, Elisabeth
   Villar, Livia Melo
TI Evaluation of dried blood spot samples for hepatitis C virus detection
   and quantification
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE Hepatitis C virus; Dried blood spot (DBS); Quantitative methods;
   Genotyping; Optimization
ID ANTIBODY DETECTION; HCV RNA; SEQUENCE; STORAGE
AB Background: Dried blood spots (DBS) could be an excellent alternative for HCV diagnosis, since it is less invasive and can be stored and transported without refrigeration.
   Objectives: The aim of this study was to optimize quantitative and qualitative methods for HCV detection in DBS.
   Study design: DBS and serum samples were collected from 99 subjects (59 anti-HCV/HCV RNA positive and 40 seronegative samples). Seven extraction methods and different PCR parameters were evaluated in DBS samples in the quantitative RT-PCR (qRT-PCR) developed to amplify the 5' noncoding region of HCV. A qualitative PCR for amplification of NS5B region of HCV was also valued and the nested-PCR sequenced.
   Results: The qRT-PCR showed good correlation to commercial assay for HCV viral measurement in serum. To quantify HCV RNA in DBS, it was necessary to increase reverse transcriptase and cDNA concentration. HCV RNA quantification in DBS demonstrated sensitivity of 65.9%, 100% of specificity and kappa statistic of 0.65. The median viral load of DBS samples was 5.38 log10 copies/ml (minimum value = 1.76 and maximum value = 10.48 log10 copies/ml). HCV RNA was detected in NS5B regions and nucleotide sequences obtained in 43 serum and 11 DBS samples. The presence of the same subtype was observed in paired serum and DBS samples.
   Conclusions: In this study, it was possible to demonstrate that, despite the low sensitivity, the optimized protocol was able to determine the viral load, as well as, the infecting HCV genotype, validating the usefulness of DBS for viral load determination and molecular epidemiology studies of HCV. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Crespo Marques, Brunna Lemos; do Espirito-Santo, Marcia Paschoal; Marques, Vanessa Alves; Miguel, Juliana Custodio; da Silva, Elisangela Ferreira; Lewis-Ximenez, Lia Laura; Lampe, Elisabeth; Villar, Livia Melo] Fiocruz MS, Inst Oswaldo Cruz, Lab Viral Hepatitis, Rio De Janeiro, Brazil.
   [Villela-Nogueira, Cristiane Alves] Univ Fed Rio de Janeiro, Clementino Fraga Filho Univ Hosp, Hepatol Div, Rio De Janeiro, Brazil.
RP Villar, LM (corresponding author), Viral Hepatitis Lab, Helio & Peggy Pereira Pavill,Ground Floor, BR-4365 Rio De Janeiro, RJ, Brazil.
EM lvillar@ioc.fiocruz.br
RI VILLAR, LIVIA M/F-7811-2012
OI VILLAR, LIVIA M/0000-0001-7644-8969
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Brazilian National Council of Technological and
   Scientific Development (CNPq)National Council for Scientific and
   Technological Development (CNPq); Brazilian Ministry of Health;
   Coordination of Improvement of Higher Education Personnel (CAPES)CAPES;
   Oswaldo Cruz Foundation (FIOCRUZ)
FX This research was supported by the Fundacao de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ), the Brazilian National Council of
   Technological and Scientific Development (CNPq), Brazilian Ministry of
   Health, the Coordination of Improvement of Higher Education Personnel
   (CAPES) and the Oswaldo Cruz Foundation (FIOCRUZ).
CR Bennett S, 2012, J CLIN VIROL, V54, P106, DOI 10.1016/j.jcv.2012.02.004
   Bereczky S, 2005, AM J TROP MED HYG, V72, P249, DOI 10.4269/ajtmh.2005.72.249
   Brandao CPU, 2013, J CLIN VIROL, V57, P98, DOI 10.1016/j.jcv.2013.02.014
   Brown B.S., 2009, J CLIN VIROL S1, V44, pS27
   De Crignis E, 2010, J VIROL METHODS, V165, P51, DOI 10.1016/j.jviromet.2009.12.017
   Dokubo EK, 2014, J CLIN VIROL, V59, P223, DOI 10.1016/j.jcv.2014.01.014
   Greenman J, 2015, J VIRAL HEPATITIS, V22, P353, DOI 10.1111/jvh.12345
   Hope VD, 2011, J VIRAL HEPATITIS, V18, P262, DOI 10.1111/j.1365-2893.2010.01297.x
   Lampe E, 2013, ANTIVIR THER, V18, P435, DOI 10.3851/IMP2606
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Marques BLC, 2012, J MED VIROL, V84, P1600, DOI 10.1002/jmv.23379
   Martins PP, 2013, CLIN LAB, V59, P1031, DOI 10.7754/Clin.Lab.2013.120903
   Ndiaye O., 2015, J MED VIROL      DEC
   Otto TD, 2008, GENET MOL RES, V7, P861, DOI 10.4238/vol7-3X-Meeting04
   Sambrook J., 1989, MOL CLONING LAB MANU
   Sandres-Saune K, 2003, J VIROL METHODS, V109, P187, DOI 10.1016/S0166-0934(03)00070-3
   Santos C, 2012, J VIROL METHODS, V179, P17, DOI 10.1016/j.jviromet.2011.06.012
   Soulier A., 2015, J INFECT DIS
   TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]
   Tejada-Strop A, 2015, J VIROL METHODS, V212, P66, DOI 10.1016/j.jviromet.2014.10.018
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Tuaillon E, 2010, HEPATOLOGY, V51, P752, DOI 10.1002/hep.23407
   Zhang EZ, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-53
NR 23
TC 12
Z9 13
U1 0
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD SEP
PY 2016
VL 82
BP 139
EP 144
DI 10.1016/j.jcv.2016.07.009
PG 6
WC Virology
SC Virology
GA DZ7DP
UT WOS:000386024900025
PM 27497191
DA 2020-11-30
ER

PT J
AU Flores, GL
   de Almeida, AJ
   Miguel, JC
   Cruz, HM
   Portilho, MM
   Scalioni, LD
   Marques, VA
   Lewis-Ximenez, LL
   Lampe, E
   Villar, LM
AF Flores, Geane L.
   de Almeida, Adilson J.
   Miguel, Juliana C.
   Cruz, Helena M.
   Portilho, Moyra M.
   Scalioni, Leticia de P.
   Marques, Vanessa A.
   Lewis-Ximenez, Lia Laura
   Lampe, Elisabeth
   Villar, Livia Melo
TI A Cross Section Study to Determine the Prevalence of Antibodies against
   HIV Infection among Hepatitis B and C Infected Individuals
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE hepatitis C virus; hepatitis B virus; prevalence; human immunodeficiency
   virus
ID HUMAN-IMMUNODEFICIENCY-VIRUS; RISK-FACTORS; LATIN-AMERICA; COINFECTION;
   SEROPREVALENCE; POPULATION; KNOWLEDGE; MEN; SEX
AB (1) Background: There are limited data regarding human immunodeficiency virus (HIV) prevalence among hepatitis B virus (HBV) or hepatitis C virus (HCV) infected individuals. The aim of this cross-sectional study is to determine the prevalence of HBV and HCV infection among HIV individuals; (2) Methods: A total of 409 patients (126 HBV+ and 283 HCV+) referred to the Brazilian Reference Laboratory for Viral Hepatitis from 2010 to 2013 donated serum samples. Anti-HIV, HBsAg, anti-HBc, anti-HBs, anti-HBcIgM, anti-HBe, HBeAg, and anti-HCV antibodies were measured, and anti-HCV positive samples were tested for viral RNA and genotype; (3) Results: The anti-HIV antibody prevalence was 10.31% and 4.59% among HBV+ and HCV+ patients, respectively. The HCV mean (SD) viral load was log 5.14 +/- 1.64 IU/mL, and genotype I was most prevalent (163/283). Anti-HBs and anti-HBc were detected in 40% and 26% of HCV+ individuals, respectively. Among the HBV+ population, the presence of anti-HIV antibodies was associated with male gender, marital status (married), tattoo, sexual orientation, sexual practices (oral sex and anal sex), history of sexually transmitted diseases (STDs), history of viral hepatitis treatment, and a sexual partner with hepatitis or HIV. For the HCV+ group, the presence of anti-HIV antibodies was associated with female gender, marital status (married), anal intercourse, previous history of STDs, and number of sexual partners; (4) Conclusion: A high prevalence of anti-HIV antibodies was found among individuals with HBV and HCV, showing the importance of education programmes towards HIV infection among HBV- and HCV-infected individuals.
C1 [Flores, Geane L.; de Almeida, Adilson J.; Miguel, Juliana C.; Cruz, Helena M.; Portilho, Moyra M.; Scalioni, Leticia de P.; Marques, Vanessa A.; Lewis-Ximenez, Lia Laura; Lampe, Elisabeth; Villar, Livia Melo] Oswaldo Cruz Fdn FIOCRUZ, Viral Hepatitis Lab, Inst Oswaldo Cruz, BR-21036004 Rio De Janeiro, Brazil.
RP Villar, LM (corresponding author), Oswaldo Cruz Fdn FIOCRUZ, Viral Hepatitis Lab, Inst Oswaldo Cruz, BR-21036004 Rio De Janeiro, Brazil.
EM geane@ioc.fiocruz.br; adilsonjoal@ioc.fiocruz.br; julicm@ioc.fiocruz.br;
   h.medina@ioc.fiocruz.br; moyramp@ioc.fiocruz.br; lescali@ioc.fiocruz.br;
   vmarques@ioc.fiocruz.br; llewis@ioc.fiocruz.br; elampe@ioc.fiocruz.br;
   lvillar@ioc.fiocruz.br
RI Cruz, Helena Medina/U-4780-2019
OI Cruz, Helena Medina/0000-0003-2088-7705
FU Foundation for Supporting the Research of Rio de Janeiro State (FAPERJ);
   Coordination for Improvement of Personnel of superior level
   (CAPES)CAPES; Brazilian National Counsel of Technological and Scientific
   Development (CNPq)National Council for Scientific and Technological
   Development (CNPq); Oswaldo Cruz Foundation (FIOCRUZ)
FX The authors would like to thank the technicians of the Viral Hepatitis
   Laboratory for technical assistance in blood sampling. This research was
   supported by the Foundation for Supporting the Research of Rio de
   Janeiro State (FAPERJ), the Coordination for Improvement of Personnel of
   superior level (CAPES), the Brazilian National Counsel of Technological
   and Scientific Development (CNPq), and the Oswaldo Cruz Foundation
   (FIOCRUZ).
CR Alonso M, 2015, INT J PUBLIC HEALTH, V60, P789, DOI 10.1007/s00038-015-0708-5
   Alvarado-Mora MV, 2013, ANTIVIR THER, V18, P429, DOI 10.3851/IMP2595
   Alvarado-Mora MV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018888
   Attia KA, 2012, WORLD J HEPATOL, V4, P218, DOI 10.4254/wjh.v4.i7.218
   Basso M, 2014, AIDS RES THER, V11, DOI 10.1186/1742-6405-11-21
   Brazilian Health Ministry, NOT JOINT TECHN 02
   Brazilian Health Ministry, BRAZ PORT
   Brazilian Health Ministry, EP B HIV AIDS 2014
   Chen X, 2013, ARCH VIROL, V158, P1889, DOI 10.1007/s00705-013-1681-z
   de Oliveira SB, 2014, CAD SAUDE PUBLICA, V30, P433, DOI 10.1590/0102-311X00010413
   TÁVORA Lara Gurgel Fernandes, 2013, Arq. Gastroenterol., V50, P277, DOI 10.1590/S0004-28032013000400007
   Freitas SZ, 2014, REV INST MED TROP SP, V56, P517, DOI 10.1590/S0036-46652014000600011
   Garcia PJ, 2014, CURR HIV-AIDS REP, V11, P146, DOI 10.1007/s11904-014-0204-1
   Guilamo-Ramos V, 2015, GLOB PUBLIC HEALTH, V10, P318, DOI 10.1080/17441692.2014.966250
   Harania RS, 2008, AIDS, V22, P1221, DOI 10.1097/QAD.0b013e32830162a8
   Hoyos-Orrego Alvaro, 2006, Rev. Inst. Med. trop. S. Paulo, V48, P321, DOI 10.1590/S0036-46652006000600004
   Jobarteh M, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-230
   Kapembwa KC, 2011, J GLOB INFECT DIS, V3, P269, DOI 10.4103/0974-777X.83534
   Lacombe K, 2012, GUT, V61, P47, DOI 10.1136/gutjnl-2012-302062
   Lepretre A, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.19888
   Maan MA, 2014, PAK J MED SCI, V30, P32, DOI 10.12669/pjms.301.4176
   Mallet V, 2011, LIVER INT, V31, P135, DOI 10.1111/j.1478-3231.2010.02394.x
   Matsuda EM, 2014, AIDS RES HUM RETROV, V30, P1150, DOI 10.1089/aid.2014.0264
   Silva ACM, 2006, REV SAUDE PUBL, V40, P482, DOI 10.1590/S0034-89102006000300017
   Muriuki Beatrice Mukami, 2013, BMC Res Notes, V6, P363, DOI 10.1186/1756-0500-6-363
   Nagu TJ, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-416
   Oyekale AS, 2014, INT J ENV RES PUB HE, V11, P12726, DOI 10.3390/ijerph111212726
   Pereira LMMB, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-60
   Pereira LMMB, 2009, AM J TROP MED HYG, V81, P240
   Raizada A, 2011, TROP DOCT, V41, P154, DOI 10.1258/td.2011.100440
   Stuyver L, 1996, J CLIN MICROBIOL, V34, P2259, DOI 10.1128/JCM.34.9.2259-2266.1996
   Teixeira LB, 2013, CAD SAUDE PUBLICA, V29, P609, DOI 10.1590/S0102-311X2013000300018
   Tremeau-Bravard A, 2012, AFR HEALTH SCI, V12, P312, DOI 10.4314/ahs.v12i3.10
   Vaughan AS, 2014, AIDS RES HUM RETROV, V30, P740, DOI [10.1089/aid.2014.0144, 10.1089/AID.2014.0144]
   Villar LM, 2015, BRAZ J INFECT DIS, V19, P285, DOI 10.1016/j.bjid.2015.02.002
   Villar LM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/324638
   Villar LM, 2014, J MED VIROL, V86, P1515, DOI 10.1002/jmv.23993
   WHO, HEP C
   World Health Organization, HEP B
   World Health Organization, 2020, HIV AIDS
NR 40
TC 6
Z9 6
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD MAR
PY 2016
VL 13
IS 3
DI 10.3390/ijerph13030314
PG 10
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA DI5HD
UT WOS:000373528600087
PM 26978383
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Bottecchia, M
   Barcaiu, HS
   Lewis-Ximenez, LL
   Mouta, SDE
   de Moraes, MTB
AF Bottecchia, Marcelle
   Barcaiu, Halime Silva
   Lewis-Ximenez, Lia Laura
   da Silva e Mouta Junior, Sergio
   Baroni de Moraes, Marcia Terezinha
TI Monitoring the emergence of HBV resistance mutations by HBV-RNA
   pyrosequencing
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Letter
ID HEPATITIS-B; INFECTED PATIENTS
C1 [Bottecchia, Marcelle; da Silva e Mouta Junior, Sergio; Baroni de Moraes, Marcia Terezinha] Fundacao Oswaldo Cruz FIOCRUZ, Inst Oswaldo Cruz, Lab Virol Comparada & Ambiental, Rio De Janeiro, RJ, Brazil.
   [Barcaiu, Halime Silva] HSE, DIP Doencas Infectoparasitarias, Rio De Janeiro, RJ, Brazil.
   [Lewis-Ximenez, Lia Laura] Fundacao Oswaldo Cruz FIOCRUZ, Inst Oswaldo Cruz, Lab Hepatites Virais, Rio De Janeiro, RJ, Brazil.
RP de Moraes, MTB (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ, Inst Oswaldo Cruz, Lab Virol Comparada & Ambiental, Rio De Janeiro, RJ, Brazil.
EM baroni@ioc.fiocruz.br
CR BOTTECCHIA M, 2008, BMC MICROBIOL, V22, P8
   GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.bi.56.070187.003251
   Mello FCA, 2012, BMC MICROBIOL, V12, DOI 10.1186/1471-2180-12-96
   Moraes MTB, 1999, BRAZ J MED BIOL RES, V32, P45, DOI 10.1590/S0100-879X1999000100006
   Soriano V, 2013, CLIN LIVER DIS, V17, P489, DOI 10.1016/j.cld.2013.05.008
NR 5
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD MAR-APR
PY 2016
VL 20
IS 2
BP 216
EP 217
DI 10.1016/j.bjid.2015.11.004
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA DH5GD
UT WOS:000372813300017
PM 26748231
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Villar, LM
   Marques, BLC
   Espirito-Santos, MP
   Marques, VA
   Villela-Nogueira, CA
   Lewis-Ximenez, LL
   Lampe, E
AF Villar, L. M.
   Marques, B. L. C.
   Espirito-Santos, M. P.
   Marques, V. A.
   Villela-Nogueira, C. A.
   Lewis-Ximenez, L. L.
   Lampe, E.
TI APPLICABILITY OF DRIED BLOOD SAMPLES FOR HEPATITIS C VIRUS DETECTION AND
   QUANTIFICATION
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT EASL International Liver Congress
CY APR 13-17, 2016
CL Barcelona, SPAIN
SP EASL
C1 [Villar, L. M.; Marques, B. L. C.; Espirito-Santos, M. P.; Marques, V. A.; Lewis-Ximenez, L. L.; Lampe, E.] Fiocruz MS, Viral Hepatitis Lab, Rio De Janeiro, Brazil.
   [Villela-Nogueira, C. A.] Univ Fed Rio de Janeiro, Clementino Fraga Filho Univ Hosp, Rio De Janeiro, Brazil.
EM liviafiocruz@gmail.com
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PY 2016
VL 64
SU 2
MA THU-260
BP S418
EP S418
DI 10.1016/S0168-8278(16)00673-5
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA ER3QE
UT WOS:000398711700666
DA 2020-11-30
ER

PT J
AU Villar, LM
   Lampe, E
   de Almeida, AJ
   Scalioni, LD
   Lewis-Ximenez, LL
   Miguel, JC
   Del Campo, JA
   Ranchal, I
   Villela-Nogueira, CA
   Romero-Gomez, M
AF Villar, Livia M.
   Lampe, Elisabeth
   de Almeida, Adilson Jose
   Scalioni, Leticia de Paula
   Lewis-Ximenez, Lia Laura
   Miguel, Juliana Custodio
   Antonio Del Campo, Jose
   Ranchal, Isidore
   Villela-Nogueira, Cristiane Alves
   Romero-Gomez, Manuel
TI Reply to contribution on the topic of hypovitaminosis D in chronic
   hepatitis C
SO ANNALS OF HEPATOLOGY
LA English
DT Letter
ID VITAMIN-D; METAANALYSIS
C1 [Villar, Livia M.; Lampe, Elisabeth; de Almeida, Adilson Jose; Scalioni, Leticia de Paula; Lewis-Ximenez, Lia Laura; Miguel, Juliana Custodio] Fiocruz MS, Lab Viral Hepatitis, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil.
   [Antonio Del Campo, Jose; Ranchal, Isidore; Romero-Gomez, Manuel] Hosp Univ Valme, Unit Clin Management Digest Dis, Seville, Spain.
   [Antonio Del Campo, Jose; Ranchal, Isidore; Romero-Gomez, Manuel] Hosp Univ Valme, CIBERehd, Seville, Spain.
   [Villela-Nogueira, Cristiane Alves] Univ Fed Rio de Janeiro, Dept Clin Med, Hepatol Unit, Clementino Fraga Filho Univ Hosp, Rio de Janeiro, Brazil.
RP Villar, LM (corresponding author), Fiocruz MS, Viral Hepatitis Lab, Helio & Peggy Pereira Pavill,Ground Floor, BR-21036004 Rio De Janeiro, RJ, Brazil.
EM lvillar@ioc.fiocruz.br
RI VILLAR, LIVIA M/F-7811-2012; Romero-Gomez, Manuel/L-8030-2014
OI VILLAR, LIVIA M/0000-0001-7644-8969; Romero-Gomez,
   Manuel/0000-0001-8494-8947; Ranchal, Isidora/0000-0001-7870-7768
CR Bitetto D, 2011, TRANSPL INT, V24, P43, DOI 10.1111/j.1432-2277.2010.01141.x
   El Husseiny NM, 2012, WORLD J HEPATOL, V4, P242, DOI 10.4254/wjh.v4.i8.242
   Falleti E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080764
   Kitson MT, 2014, J HEPATOL, V61, P1247, DOI 10.1016/j.jhep.2014.08.004
   Lange CM, 2011, J HEPATOL, V54, P887, DOI 10.1016/j.jhep.2010.08.036
   Rahman AH, 2013, J HEPATOL, V58, P184, DOI 10.1016/j.jhep.2012.07.026
   Villar LM, 2013, WORLD J GASTROENTERO, V19, P5917, DOI 10.3748/wjg.v19.i35.5917
NR 7
TC 0
Z9 0
U1 0
U2 3
PU MEXICAN ASSOC HEPATOLOGY
PI MEXICO
PA PUNTE DE PIEDRA 150, COLONIA TORIELLO GUERRA, MEXICO, DF CP 14040,
   MEXICO
SN 1665-2681
J9 ANN HEPATOL
JI Ann. Hepatol.
PD JAN-FEB
PY 2016
VL 15
IS 1
BP 139
EP 140
DI 10.5604/16652681.1184297
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DL8KD
UT WOS:000375890000020
PM 31320161
OA Other Gold
DA 2020-11-30
ER

PT J
AU Leon, LAA
   de Almeida, AJ
   de Paula, VS
   Tourinho, RS
   Villela, DAM
   Gaspar, AMC
   Lewis-Ximenez, LL
   Pinto, MA
AF Amado Leon, Luciane Almeida
   de Almeida, Adilson Jose
   de Paula, Vanessa Salete
   Tourinho, Renata Santos
   Maciel Villela, Daniel Antunes
   Coimbra Gaspar, Ana Maria
   Lewis-Ximenez, Lia Laura
   Pinto, Marcelo Alves
TI Longitudinal Study of Hepatitis A Infection by Saliva Sampling: The
   Kinetics of HAV Markers in Saliva Revealed the Application of Saliva
   Tests for Hepatitis A Study
SO PLOS ONE
LA English
DT Article
ID TIME RT-PCR; ORAL FLUID; RAPID TEST; VIRUS; VIREMIA; QUANTIFICATION;
   ANTIBODIES; DURATION; BLOOD; SERUM
AB Despite the increasing numbers of studies investigating hepatitis A diagnostic through saliva, the frequency and the pattern of hepatitis A virus (HAV) markers in this fluid still remains unknown. To address this issue, we carried on a longitudinal study to examine the kinetics of HAV markers in saliva, in comparison with serum samples. The present study followed-up ten patients with acute hepatitis A infection during 180 days post diagnosis (dpd). Total anti-HAV was detected in paired serum and saliva samples until the end of the follow-up, showing a peak titer at 90th. However, total anti-HAV level was higher in serum than in saliva samples. This HAV marker showed a probability of 100% to be detected in both serum and saliva during 180 dpd. The IgM anti-HAV could be detected in saliva up to 150 dpd, showing the highest frequency at 30th, when it was detected in all individuals. During the first month of HAV infection, this acute HAV marker showed a detection probability of 100% in paired samples. The detection of IgM anti-HAV in saliva was not dependent on its level in serum, HAV-RNA detection and/or viral load, since no association was found between IgM anti-HAV positivity in saliva and any of these parameter (p > 0.05). Most of the patients (80%) were found to contain HAV-RNA in saliva, mainly at early acute phase (30th day). However, it was possible to demonstrate the HAV RNA presence in paired samples for more than 90 days, even after seroconversion. No significant relationship was observed between salivary HAV-RNA positivity and serum viral load, demonstrating that serum viral load is not predictive of HAV-RNA detection in saliva. Similar viral load was seen in paired samples (on average 104 copies/mL). These data demonstrate that the best diagnostic coverage can be achieved by salivary anti-HAV antibodies and HAV-RNA tests during 30-90 dpd. The long detection and high probability of specific-HAV antibodies positivity in saliva samples make the assessment of salivary antibodies a useful tool for diagnosis and epidemiological studies. The high frequency of HAV-RNA in saliva and the probability of detection of about 50%, during the first 30 dpd, demonstrate that saliva is also useful for molecular investigation of hepatitis A cases, mainly during the early course of infection. Therefore, the collection of saliva may provide a simple, cheap and non-invasive means of diagnosis, epidemiological surveys and monitoring of hepatitis A infection purposes.
C1 [Amado Leon, Luciane Almeida; de Paula, Vanessa Salete; Tourinho, Renata Santos; Coimbra Gaspar, Ana Maria; Pinto, Marcelo Alves] Oswaldo Cruz Inst Fdn, Lab Technol Dev Virol, Rio De Janeiro, RJ, Brazil.
   [de Almeida, Adilson Jose; Lewis-Ximenez, Lia Laura] Oswaldo Cruz Inst Fdn, Lab Viral Hepatitis, Rio De Janeiro, RJ, Brazil.
   [Maciel Villela, Daniel Antunes] Oswaldo Cruz Inst Fdn, Sci Comp Program Dept, PROCC, Rio De Janeiro, RJ, Brazil.
RP Leon, LAA (corresponding author), Oswaldo Cruz Inst Fdn, Lab Technol Dev Virol, Rio De Janeiro, RJ, Brazil.
EM l_amado@ioc.fiocruz
RI Villela, Daniel/AAG-6445-2019; Pinto, Marcelo Alves/ABA-3312-2020;
   Pinto, Marcelo/G-7503-2012; de Paula, Vanessa S/I-8037-2016
OI Villela, Daniel/0000-0001-8371-2959; Pinto, Marcelo/0000-0003-3462-7277;
   de Paula, Vanessa S/0000-0002-6314-754X
FU Fundacao de Amparo a pesquisa do Estado do Rio de JaneiroCarlos Chagas
   Filho Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ) [E-26/112.097/2013]
FX Support was provided by the Fundacao de Amparo a pesquisa do Estado do
   Rio de Janeiro [www.faperj.br], grant number: E-26/112.097/2013 to
   author: LAAL.
CR Ahmed M, 2011, INDIAN J MED MICROBI, V29, P72, DOI 10.4103/0255-0857.76532
   Amado LA, 2006, MEM I OSWALDO CRUZ, V101, P149, DOI 10.1590/S0074-02762006000200006
   Amado LA, 2010, INT J EXP PATHOL, V91, P87, DOI 10.1111/j.1365-2613.2009.00699.x
   Arnado LA, 2008, J VIROL METHODS, V148, P74, DOI 10.1016/j.jviromet.2007.10.020
   Belza MJ, 2012, SEX TRANSM INFECT, V88, P218, DOI 10.1136/sextrans-2011-050131
   Bower WA, 2000, J INFECT DIS, V182, P12, DOI 10.1086/315701
   BRANDTZAEG P, 1970, SCAND J HAEMAT     S, V12, P1
   Costa-Mattioli M, 2002, J VIRAL HEPATITIS, V9, P101, DOI 10.1046/j.1365-2893.2002.00336.x
   Cruz HM, 2011, J CLIN LAB ANAL, V25, P134, DOI 10.1002/jcla.20447
   Ximenes RAD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094622
   De Paula VS, 2007, WATER RES, V41, P1169, DOI 10.1016/j.watres.2006.11.029
   Donnell-Fink LA, 2012, JAIDS-J ACQ IMM DEF, V61, P588, DOI [10.1097/QAI.0b013e31826a6d67, 10.1097/QAI.0b013e31826a6d67.]
   Drobnik A, 2011, AM J PUBLIC HEALTH, V101, P2151, DOI 10.2105/AJPH.2011.300251
   FitzSimons David, 2010, Vaccine, V28, P583, DOI 10.1016/j.vaccine.2009.10.136
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   Hussain Z, 2006, WORLD J GASTROENTERO, V12, P4683, DOI 10.3748/wjg.v12.i29.4683
   Joshi MS, 2014, DIAGN MICR INFEC DIS, V78, P379, DOI 10.1016/j.diagmicrobio.2013.12.013
   Kwon OS, 2000, J GASTROEN HEPATOL, V15, P1043, DOI 10.1046/j.1440-1746.2000.02291.x
   Lackner A, 2010, J MED VIROL, V82, P1582, DOI 10.1002/jmv.21849
   Lima LR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102925
   Menezes GBL, 2012, MEM I OSWALDO CRUZ, V107, P680, DOI 10.1590/S0074-02762012000500016
   Mackiewicz V, 2004, J CLIN MICROBIOL, V42, P4329, DOI 10.1128/JCM.42.9.4329-4331.2004
   Matheson K, 2010, VACCINE, V28, P8105, DOI 10.1016/j.vaccine.2010.09.107
   Morris-Cunnington MC, 2004, AM J EPIDEMIOL, V159, P786, DOI 10.1093/aje/kwh107
   Mortimer P P, 1994, Clin Diagn Virol, V2, P231, DOI 10.1016/0928-0197(94)90048-5
   Normann A, 2004, J MED VIROL, V72, P10, DOI 10.1002/jmv.10532
   Oba Isabel Takano, 2000, Revista do Instituto de Medicina Tropical de Sao Paulo, V42, P197, DOI 10.1590/S0036-46652000000400004
   Ochnio JJ, 1997, J CLIN MICROBIOL, V35, P98, DOI 10.1128/JCM.35.1.98-101.1997
   PARRY JV, 1989, J MED VIROL, V28, P255, DOI 10.1002/jmv.1890280410
   Poovorawan Y, 2005, J CLIN VIROL, V32, P24, DOI 10.1016/j.jcv.2004.04.008
   R Core Team, 2015, R LANG ENV STAT COMP
   Soderling E, 1989, HUMAN SALIVA CLIN CH, P1
   Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9
   Tourinho RS, 2012, VACCINE, V30, P6421, DOI 10.1016/j.vaccine.2012.08.015
   Tourinho RS, 2011, J VIROL METHODS, V173, P169, DOI 10.1016/j.jviromet.2011.01.014
   Vitral CL, 2012, MEM I OSWALDO CRUZ, V107, P652, DOI 10.1590/S0074-02762012000500012
   Wood S, 2013, GAMMA4 GEN ADDITIVE
NR 37
TC 11
Z9 11
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 21
PY 2015
VL 10
IS 12
AR e0145454
DI 10.1371/journal.pone.0145454
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CZ4SF
UT WOS:000367092300077
PM 26690904
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Cruz, HM
   Scalioni, LD
   de Paula, VS
   da Silva, EF
   do O, KMR
   Milagres, FAP
   Cruz, MS
   Bastos, FI
   Pollo-Flores, P
   Leal, E
   Motta-Castro, ARC
   Pilotto, JH
   Lewis-Ximenez, LL
   Lampe, E
   Villar, LM
AF Cruz, Helena Medina
   Scalioni, Leticia de Paula
   de Paula, Vanessa Salete
   da Silva, Elisangela Ferreira
   Rodrigues do O, Kycia Maria
   Padua Milagres, Flavio Augusto
   Cruz, Marcelo Santos
   Bastos, Francisco Inacio
   Pollo-Flores, Priscila
   Leal, Erotildes
   Coimbra Motta-Castro, Ana Rita
   Pilotto, Jose Henrique
   Lewis-Ximenez, Lia Laura
   Lampe, Elisabeth
   Villar, Livia Melo
TI Evaluating HBsAg rapid test performance for different biological samples
   from low and high infection rate settings & populations
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Hepatitis B virus; Rapid tests; Performance of tests; Diagnostic
   procedures
ID HEPATITIS-B SURFACE; ANTIGEN; SALIVA; ASSAYS
AB Background: Rapid tests (RTs) might have several advantages over standard laboratory procedures, increasing access to diagnosis, especially among vulnerable populations and/or those living in remote areas. The aim of this study was to evaluate the performance of RTs for the detection of hepatitis B virus surface antigen (HBsAg) in samples from different populations/settings.
   Methods: Three RTs for HBsAg detection (Vikia (R) HBsAg, HBsAg Teste Rapido (R), and Imuno-Rapido HBsAg (R)) and different biological specimens (serum, whole blood, and saliva) were evaluated. Analyses comprised a reference panel and samples from field studies targeting suspected cases of hepatitis B virus (HBV) (G I), individuals living in deprived areas (G II), and highly vulnerable individuals (G III). Enzyme immunoassay (EIA) was defined as the gold standard in this study. Reproducibility, repeatability, and cross reactivity with other infectious agents such as dengue, immunodeficiency (HIV), and hepatitis C (HCV) viruses and T. pallidum were determined.
   Results: For the reference panel, the sensitivity and specificity of all HBsAg RTs were higher than 93.00 %. G I presented the highest kappa values for all rapid assays using sera samples. When using serum, the sensitivity values were higher than 9340 for G I. 60.00 % for G II and 66.77 % for G III, and the specificity values were higher than 9930 for GI, 97.20 for G II and 99.10 % for G III for all tests. For whole blood samples & the Vikie (R) HBsAg assay, the best performance was achieved for GIII (k = 79.75 %). For saliva samples, the Imuno-Rapido HBsAg (R) assay showed the highest concordance values with EIA for G I (40.68 %) and G II (32.20 %). The reproducibility and repeatability of all RTs for serum and saliva were excellent, and the concordance between HBsAg ElAs and RTs using samples reactive with other infectious agents varied from 70.10 % to 100.00 %
   Conclusions: The overall performance of RTs for HBsAg in serum was high/moderately high for all groups, thereby promoting increased access to HBV diagnosis among vulnerable populations as well as samples from individuals in emergency settings or remote areas. Rapid tests for HBsAg using whole blood could be used in prevalence studies, though these assays should not be used for saliva samples.
C1 [Cruz, Helena Medina; Scalioni, Leticia de Paula; da Silva, Elisangela Ferreira; Lewis-Ximenez, Lia Laura; Lampe, Elisabeth; Villar, Livia Melo] Fiocruz MS, Inst Oswaldo Cruz, Lab Viral Hepatitis, BR-21045900 Rio De Janeiro, Brazil.
   [de Paula, Vanessa Salete] Fiocruz MS, Inst Oswaldo Cruz, Lab Technol Dev Virol, BR-21045900 Rio De Janeiro, Brazil.
   [Rodrigues do O, Kycia Maria] Sao Lucas Hosp, Rio De Janeiro, Brazil.
   [Padua Milagres, Flavio Augusto] Fed Univ Tocantins, Med Fac, Palmas, Brazil.
   [Cruz, Marcelo Santos] Univ Fed Rio de Janeiro, Inst Psychiat, Rio De Janeiro, Brazil.
   [Bastos, Francisco Inacio] Fundacao Oswaldo Cruz, Inst Commun & Sci Informat & Technol Hlth, Rio De Janeiro, Brazil.
   [Pollo-Flores, Priscila] Univ Fed Fluminense, Antonio Pedro Univ Hosp, Rio De Janeiro, Brazil.
   [Leal, Erotildes] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil.
   [Coimbra Motta-Castro, Ana Rita] Univ Fed Mato Grosso do Sul, Campo Grande, MS, Brazil.
   [Coimbra Motta-Castro, Ana Rita] FIOCRUZ MS, Campo Grande, MS, Brazil.
   [Pilotto, Jose Henrique] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Mol Immunol, BR-21045900 Rio De Janeiro, Brazil.
RP Villar, LM (corresponding author), Viral Hepatitis Lab, Hello & Peggy Pereira Pavil Ground,Floor Room BO9, BR-21036004 Rio De Janeiro, RJ, Brazil.
EM livaflocruz@gmail.com
RI Cruz, Marcelo Santos/AAH-5963-2020; Pilotto, Jose
   Henrique/AAD-9773-2019; Cruz, Helena Medina/U-4780-2019; milagres,
   flavio/Q-2403-2019; motta-castro, ana rita c/O-2075-2017; de Paula,
   Vanessa S/I-8037-2016; Cruz, Marcelo Santos/I-5890-2014; VILLAR, LIVIA
   M/F-7811-2012
OI Cruz, Marcelo Santos/0000-0003-0057-2095; Pilotto, Jose
   Henrique/0000-0003-0521-8597; Cruz, Helena Medina/0000-0003-2088-7705;
   de Paula, Vanessa S/0000-0002-6314-754X; VILLAR, LIVIA
   M/0000-0001-7644-8969; Motta-Castro, Ana Rita/0000-0003-3070-1337;
   Milagres, Flavio/0000-0002-6889-8772; Bastos,
   Francisco/0000-0001-5970-8896
FU Support Foundation for Research in Rio de Janeiro State (FAPERJ);
   Brazilian National Council of Technological and Scientific Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Oswaldo Cruz Foundation (FIOCRUZ)
FX This research was supported by the Support Foundation for Research in
   Rio de Janeiro State (FAPERJ), Brazilian National Council of
   Technological and Scientific Development (CNPq) and the Oswaldo Cruz
   Foundation (FIOCRUZ).
CR Altman D.G., 1991, PRACTICAL STAT MED R
   Bottero J, 2013, J HEPATOL, V58, P473, DOI 10.1016/j.jhep.2012.11.016
   Brazilian Health Ministry, 2012, EP B VIR HEP
   Brazilian Health Ministry, 2014, TECHN MAN DIAGN HIV
   Chevaliez S, 2014, J CLIN VIROL, V59, P89, DOI 10.1016/j.jcv.2013.11.010
   Cruz HM, 2011, J CLIN LAB ANAL, V25, P134, DOI 10.1002/jcla.20447
   Cruz MS, 2013, INT J DRUG POLICY, V24, P432, DOI 10.1016/j.drugpo.2013.03.012
   Davies J, 2010, T ROY SOC TROP MED H, V104, P162, DOI 10.1016/j.trstmh.2009.10.010
   Franzeck FC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058468
   Gerlich WH, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-239
   Khuroo MS, 2014, J CLIN EXP HEPATOL, V4, P226, DOI 10.1016/j.jceh.2014.07.008
   Lien TX, 2000, AM J TROP MED HYG, V62, P301, DOI 10.4269/ajtmh.2000.62.301
   Martinez-Lamas L, 2011, REV ESP QUIM, V24, P164
   PARRY JV, 1987, LANCET, V2, P72, DOI 10.1016/S0140-6736(87)92737-1
   Randrianirina F, 2008, J VIROL METHODS, V151, P294, DOI 10.1016/j.jviromet.2008.03.019
   Scalioni LD, 2014, J CLIN VIROL, V60, P200, DOI 10.1016/j.jcv.2014.04.001
   Seremba E, 2010, J MED VIROL, V82, P1334, DOI 10.1002/jmv.21813
   Shivkumar S, 2012, AM J GASTROENTEROL, DOI [10.1038/ajg2012.141, DOI 10.1038/AJG2012.141]
   Villar LM, 2014, J MED VIROL, V86, P1515, DOI 10.1002/jmv.23993
   World Health Organization, 2014, HEP B
NR 20
TC 15
Z9 15
U1 0
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD NOV 30
PY 2015
VL 15
AR 548
DI 10.1186/s12879-015-1249-5
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA CX2CX
UT WOS:000365503700001
PM 26619906
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Portilho, MM
   Baptista, ML
   da Silva, M
   de Sousa, PSF
   Lewis-Ximenez, LL
   Lampe, E
   Villar, LM
AF Portilho, Moyra Machado
   Baptista, Marcia Leite
   da Silva, Messias
   Fonseca de Sousa, Paulo Sergio
   Lewis-Ximenez, Lia Laura
   Lampe, Elisabeth
   Villar, Livia Melo
TI Usefulness of in-house PCR methods for hepatitis B virus DNA detection
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE HBV DNA; Molecular diagnosis; In-house PCR; Commercial methods
ID ABBOTT REALTIME HBV; MONITOR TEST; ASSAY; QUANTIFICATION; QUANTITATION
AB The aim of the present study was to evaluate the performance of three in-house PCR techniques for HBV DNA detection and compare it with commercial quantitative methods to evaluate the usefulness of in-house methods for HBV diagnosis. Three panels of HBsAg reactive sera samples were evaluated: (i) 50 samples were examined using three methods for in-house qualitative PCR and the Cobas Amplicor HBV Monitor Assay; (ii) 87 samples were assayed using in-house semi-nested PCR and the Cobas TaqMan HBV test; (iii) 11 serial samples obtained from 2 HBV-infected individuals were assayed using the Cobas Amplicor HBV test and semi-nested PCR. In panel I, HBV DNA was detected in 44 samples using the Cobas Amplicor HBV test, 42 samples using semi-nested PCR (90% concordance with Cobas Amplicor), 22 samples using PCR for the core gene (63.6% concordance) and 29 samples using single-round PCR for the pre-S/S gene (75% concordance). In panel II, HBV DNA was quantified in 78 of the 87 HBsAg reactive samples using Cobas TaqMan but 52 samples using semi-nested PCR (67.8% concordance). HBV DNA was detected in serial samples until the 17th and 26th week after first donation using in-house semi-nested PCR and the Cobas Amplicor HBV test, respectively. In-house semi-nested PCR presented adequate concordance with commercial methods as an alternative method for HBV molecular diagnosis in low-resource settings. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Portilho, Moyra Machado; Fonseca de Sousa, Paulo Sergio; Lewis-Ximenez, Lia Laura; Lampe, Elisabeth; Villar, Livia Melo] Oswaldo Cruz Fdn FIOCRUZ, Inst Oswaldo Cruz, Lab Viral Hepatitis, Rio De Janeiro, Brazil.
   [Baptista, Marcia Leite] Oswaldo Cruz Fdn FIOCRUZ, Inst Oswaldo Cruz, Lab Enteroviruses, Rio De Janeiro, Brazil.
   [da Silva, Messias] Oswaldo Cruz Fdn FIOCRUZ, Inst Oswaldo Cruz, Dept Tech & Technol Support, Rio De Janeiro, Brazil.
RP Villar, LM (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab Viral Hepatitis, Pavil Helio & Peggy Pereira,Ground Floor,Room B09, BR-21041210 Rio De Janeiro, RJ, Brazil.
EM liviaflocruz@gmail.com
RI VILLAR, LIVIA M/F-7811-2012
OI VILLAR, LIVIA M/0000-0001-7644-8969
FU Foundation for Supporting Research at Rio de Janeiro State
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); Brazilian National Counsel of Technological
   and Scientific Development (CNPq)National Council for Scientific and
   Technological Development (CNPq); Oswaldo Cruz Foundation (FIOCRUZ)
FX The authors would like to thank Juliana Custodio Miguel and Elisangela
   Ferreira da Silva for technical assistance with blood processing. This
   research was financially supported through grants from the Foundation
   for Supporting Research at Rio de Janeiro State (FAPERJ), Brazilian
   National Counsel of Technological and Scientific Development (CNPq) and
   the Oswaldo Cruz Foundation (FIOCRUZ).
CR Alexopoulou A, 2014, WORLD J GASTROENTERO, V20, P7644, DOI 10.3748/wjg.v20.i24.7644
   Ciotti M, 2008, J CLIN MICROBIOL, V46, P1517, DOI 10.1128/JCM.02046-07
   dos Santos AD, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-16
   Enjalbert F, 2014, TRANSFUSION, V54, P2485, DOI 10.1111/trf.12653
   Gerlich WH, 2010, DIGEST DIS, V28, P116, DOI 10.1159/000282074
   Kania D, 2014, J VIROL METHODS, V201, P24, DOI 10.1016/j.jviromet.2014.01.015
   Konnick EQ, 2005, J CLIN MICROBIOL, V43, P596, DOI 10.1128/JCM.43.2.596-603.2005
   Lopez VA, 2002, J CLIN MICROBIOL, V40, P1972, DOI 10.1128/JCM.40.6.1972-1976.2002
   Morris CJ, 2013, J VIROL METHODS, V193, P391, DOI 10.1016/j.jviromet.2013.06.036
   Motta JS, 2010, J GASTROEN HEPATOL, V25, P101, DOI 10.1111/j.1440-1746.2009.05972.x
   Naito H, 2001, J CLIN MICROBIOL, V39, P362, DOI 10.1128/JCM.39.1.362-364.2001
   NIEL C, 1994, J MED VIROL, V44, P180, DOI 10.1002/jmv.1890440212
   Papatheodoridis G, 2012, J HEPATOL, V57, P167, DOI 10.1016/j.jhep.2012.02.010
   Pas SD, 2000, J CLIN MICROBIOL, V38, P2897, DOI 10.1128/JCM.38.8.2897-2901.2000
   Shi M, 2008, WORLD J GASTROENTERO, V14, P479, DOI 10.3748/wjg.14.479
   TAKAHASHI T, 1976, J IMMUNOL, V117, P1392
   Valsamakis A, 2007, CLIN MICROBIOL REV, V20, P426, DOI 10.1128/CMR.00009-07
   Yao JDC, 2004, J CLIN MICROBIOL, V42, P800, DOI 10.1128/JCM.42.2.800-806.2004
   Yeh ML, 2014, J CLIN VIROL, V60, P206, DOI 10.1016/j.jcv.2014.04.008
   Yuan HJ, 2004, J CLIN MICROBIOL, V42, P3513, DOI 10.1128/JCM.42.8.3513-3517.2004
NR 20
TC 4
Z9 4
U1 0
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD OCT
PY 2015
VL 223
BP 40
EP 44
DI 10.1016/j.jviromet.2015.07.010
PG 5
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA CR3UN
UT WOS:000361258700008
PM 26215428
DA 2020-11-30
ER

PT J
AU Melgaco, JG
   Morgado, LN
   Santiago, MA
   de Oliveira, JM
   Lewis-Ximenez, LL
   Hasselmann, B
   Cruz, OG
   Pinto, MA
   Vitral, CL
AF Melgaco, Juliana Gil
   Morgado, Lucas Nobrega
   Santiago, Marta Almeida
   de Oliveira, Jaqueline Mendes
   Lewis-Ximenez, Lia Laura
   Hasselmann, Barbara
   Cruz, Oswaldo Goncalves
   Pinto, Marcelo Alves
   Vitral, Claudia Lamarca
TI A single dose of inactivated hepatitis A vaccine promotes HAV-specific
   memory cellular response similar to that induced by a natural infection
SO VACCINE
LA English
DT Article
DE Hepatitis A vaccine; Single dose; Central memory cells; Effector memory
   cells; Cellular response
ID T-CELL; IMMUNE-RESPONSES; VIRUS-INFECTION; B VACCINATION;
   DIFFERENTIATION; IMMUNIZATION; CHILDHOOD; ADULTS; IMMUNOGENICITY;
   EPIDEMIOLOGY
AB Based on current studies on the effects of single dose vaccines on antibody production, Latin American countries have adopted a single dose vaccine program. However, no data are available on the activation of cellular response to a single dose of hepatitis A. Our study investigated the functional reactivity of the memory cell phenotype after hepatitis A virus (HAV) stimulation through administration of the first or second dose of HAV vaccine and compared the response to that of a baseline group to an initial natural infection. Proliferation assays showed that the first vaccine dose induced HAV-specific cellular response; this response was similar to that induced by a second dose or an initial natural infection. Thus, from the first dose to the second dose, increase in the frequencies of classical memory B cells, TCD8 cells, and central memory TCD4 and TCD8 cells were observed. Regarding cytokine production, increased IL-6, IL-10, TNF, and IFN gamma levels were observed after vaccination. Our findings suggest that a single dose of HAV vaccine promotes HAV-specific memory cell response similar to that induced by a natural infection. The HAV-specific T cell immunity induced by primary vaccination persisted independently of the protective plasma antibody level. In addition, our results suggest that a single dose immunization system could serve as an alternative strategy for the prevention of hepatitis A in developing countries. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Melgaco, Juliana Gil; Morgado, Lucas Nobrega; Vitral, Claudia Lamarca] Univ Fed Fluminense, Dept Microbiol & Parasitol, Niteroi, RJ, Brazil.
   [Melgaco, Juliana Gil; de Oliveira, Jaqueline Mendes; Pinto, Marcelo Alves] Inst Oswaldo Cruz, Lab Desenvolvimento Tecnol Virol, FIOCRUZ, BR-21040900 Rio De Janeiro, Brazil.
   [Santiago, Marta Almeida] Biomanguinhos, Lab Tecnol Diagnost, Rio De Janeiro, Brazil.
   [Lewis-Ximenez, Lia Laura; Hasselmann, Barbara] Inst Oswaldo Cruz, Ambulatorio Hepatites Virais, FIOCRUZ, BR-21040900 Rio De Janeiro, Brazil.
   [Cruz, Oswaldo Goncalves] Fundacao Oswaldo Cruz, Programa Comp Cient, Rio De Janeiro, Brazil.
RP Melgaco, JG (corresponding author), Inst Oswaldo Cruz, Lab Desenvolvimento Tecnol Virol, Fundacao Oswaldo Cruz Ave Brasil 4365, BR-21040900 Rio De Janeiro, Brazil.
EM juliana.melgaco@gmail.com; morgadobiomed@yahoo.com.br;
   msantiago@bio.fiocruz.br; jackie@ioc.fiocruz.br;
   lialewis.fiocruz@gmail.com; barbarahasselmann@gmail.com;
   ogcruz@gmail.com; marcelop@ioc.fiocruz.br; clvitral@id.uff.br
RI Melgaco, Juliana/AAQ-6084-2020; Pinto, Marcelo Alves/ABA-3312-2020;
   Pinto, Marcelo/G-7503-2012
OI Melgaco, Juliana/0000-0003-0087-6531; Pinto, Marcelo/0000-0003-3462-7277
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [308951/2010-7]; FaperjCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ) [65 26/110.848/2013]
FX We thank the graduate students of the Faculty of Medicine from
   Universidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil who
   participated as subjects in this study. We thank Luzia M. O. Pinto,
   Paulo S. F. Sousa and Leena Raza for providing technical support. We
   thank American Journal Experts (AJE) for English language editing. All
   authors have contributed significantly to the work. In summary, J.G.
   Melgaco conceived the study, performed the experiments, analyzed the
   data and wrote the manuscript. L.N. Morgado performed the in vitro
   assay. M. Santiago performed the flow cytometric data acquisition. C.L.
   Vitral and J.M. de Oliveira performed data acquisition for the
   serological assay. C.L. Vitral also reviewed the data analysis and wrote
   the manuscript. B. Hasselmann and L.L. Lewis-Ximenez collected the
   clinical data and samples from the self-limited acute hepatitis
   patients. O.G. Cruz performed the statistical analysis. C.L. Vitral and
   M.A. Pinto participated in the study design and coordination. M.A. Pinto
   also participated in the data analysis and manuscript preparation. This
   work was supported by CNPq (Grant number 308951/2010-7) and Faperj
   (Grant number 65 26/110.848/2013).
CR Andre FE, 2006, CURR TOP MICROBIOL, V304, P95
   [Anonymous], 2012, Wkly Epidemiol Rec, V87
   Bauer T, 2006, VACCINE, V24, P572, DOI 10.1016/j.vaccine.2005.08.058
   Beck BR, 2004, J TRAVEL MED, V11, P201, DOI 10.2310/7060.2004.19002
   Carollo M, 2013, VACCINE, V31, P506, DOI 10.1016/j.vaccine.2012.11.029
   Carollo M, 2012, VACCINE, V30, P1667, DOI 10.1016/j.vaccine.2011.12.104
   Cederna JB, 1999, VACCINE, V18, P892, DOI 10.1016/S0264-410X(99)00342-4
   Cox MA, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/159152
   Dalgaard TS, 2010, VET IMMUNOL IMMUNOP, V138, P85, DOI 10.1016/j.vetimm.2010.07.010
   Espul C, 2012, HEPATIC MED-EVID RES, V4, P53, DOI 10.2147/HMER.S33847
   FEINSTONE SM, 1973, SCIENCE, V182, P1026, DOI 10.1126/science.182.4116.1026
   Garner-Spitzer E, 2009, VACCINE, V27, P197, DOI 10.1016/j.vaccine.2008.10.045
   GASPAR AM, 1992, MEM I OSWALDO CRUZ, V87, P449, DOI 10.1590/S0074-02761992000300020
   Hatz C, 2011, CLIN VACCINE IMMUNOL, V18, P885, DOI 10.1128/CVI.00358-10
   Hendrickx G, 2008, J VIRAL HEPATITIS, V15, P1, DOI 10.1111/j.1365-2893.2008.01022.x
   Hens N, 2014, VACCINE, V32, P1507, DOI 10.1016/j.vaccine.2013.10.088
   Hohler T, 2007, VACCINE, V25, P1503, DOI 10.1016/j.vaccine.2006.10.024
   INNIS BL, 1994, JAMA-J AM MED ASSOC, V271, P1328, DOI 10.1001/jama.271.17.1328
   Iwarson S, 2004, J TRAVEL MED, V11, P120, DOI 10.2310/7060.2004.17079
   Lefrancois L, 2006, IMMUNOL REV, V211, P93, DOI 10.1111/j.0105-2896.2006.00393.x
   Lima LR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102925
   Markus JR, 2011, J PEDIAT-BRAZIL, V87, P419, DOI [10.2223/JPED.2119, 10.1590/S0021-75572011000500009]
   Melgaco JG, 2011, J MED VIROL, V83, P208, DOI 10.1002/jmv.21973
   Moore SM, 2006, J CLIN IMMUNOL, V26, P533, DOI 10.1007/s10875-006-9044-0
   NALIN D, 1993, VACCINE, V11, pS15, DOI 10.1016/0264-410X(93)90152-N
   NALIN DR, 1993, J HEPATOL, V18, pS51, DOI 10.1016/S0168-8278(05)80379-4
   Orr N, 2006, VACCINE, V24, P4328, DOI 10.1016/j.vaccine.2006.03.010
   Ott JJ, 2013, INT J INFECT DIS, V17, pE939, DOI 10.1016/j.ijid.2013.04.012
   Perrella A, 2008, J GASTROEN HEPATOL, V23, pE105, DOI 10.1111/j.1440-1746.2007.05008.x
   Raczniak GA, 2013, J INFECT DIS, V207, P493, DOI 10.1093/infdis/jis710
   Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702
   Sartori AMC, 2012, VACCINE, V30, P7489, DOI 10.1016/j.vaccine.2012.10.056
   Schmidtke P, 2005, VACCINE, V23, P5127, DOI 10.1016/j.vaccine.2005.06.022
   Srivastava R, 2007, VIRAL IMMUNOL, V20, P56, DOI 10.1089/vim.2006.0053
   Stockinger B, 2006, IMMUNOL REV, V211, P39, DOI 10.1111/j.0105-2896.2006.00381.x
   Silva ALT, 2013, MICROBES INFECT, V15, P837, DOI 10.1016/j.micinf.2013.07.009
   Tourinho RS, 2012, VACCINE, V30, P6421, DOI 10.1016/j.vaccine.2012.08.015
   Van Damme Pierre, 2007, Travel Med Infect Dis, V5, P79, DOI 10.1016/j.tmaid.2006.04.004
   Vaughan G, 2014, INFECT GENET EVOL, V21, P227, DOI 10.1016/j.meegid.2013.10.023
   Vizzotti C, 2014, PEDIATR INFECT DIS J, V33, P84, DOI 10.1097/INF.0000000000000042
   Weinberg A, 2009, JAIDS-J ACQ IMM DEF, V52, P17, DOI 10.1097/QAI.0b013e3181b011f6
   Wiesel M, 2009, APMIS, V117, P356, DOI 10.1111/j.1600-0463.2009.02459.x
   Youngblood B, 2013, IMMUNOLOGY, V139, P277, DOI 10.1111/imm.12074
   Zhou Y, 2012, J EXP MED, V209, P1481, DOI 10.1084/jem.20111906
NR 44
TC 18
Z9 18
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 31
PY 2015
VL 33
IS 32
BP 3813
EP 3820
DI 10.1016/j.vaccine.2015.06.099
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA CN5HN
UT WOS:000358460500006
PM 26144899
OA Green Published
DA 2020-11-30
ER

PT J
AU Melo-Villar, L
   Lampe, E
   de Almeida, AJ
   Scalioni, LD
   Lewis-Ximenez, LL
   Miguel, JC
   Del Campo, JA
   Ranchal, I
   Villela-Nogueira, CA
   Romero-Gomez, M
AF Melo-Villar, Livia
   Lampe, Elisabeth
   de Almeida, Adilson J.
   Scalioni, Leticia de P.
   Lewis-Ximenez, Lia L.
   Miguel, Juliana C.
   Del Campo, Jose A.
   Ranchal, Isidora
   Villela-Nogueira, Cristiane A.
   Romero-Gomez, Manuel
TI Hypovitaminosis D and its relation to demographic and laboratory data
   among hepatitis C patients
SO ANNALS OF HEPATOLOGY
LA English
DT Article
DE Vitamin D; Hepatitis C virus; Virological response; Treatment
ID VITAMIN-D DEFICIENCY; SUSTAINED VIROLOGICAL RESPONSE; D SERUM-LEVELS;
   FIBROSIS; ASSOCIATION; INTERFERON; SEVERITY; THERAPY
AB Background. The relationship between 25-hydroxyvitamin D [25(OH)D] serum levels and response to antiviral therapy and laboratory data in HCV infection remains unclear. The aim of this study was to determine pre-treatment 25(OH)D serum level among HCV infected individuals and to evaluate the association between vitamin D status, virological response, and laboratory data. Material and methods. Baseline serum 25(OH)D levels were measured in 237 chronic HCV infected patients (139 female, age 53.7 11.2 years) using chemiluminescence immunoassay. Correlations between serum 25(OH)D levels, virological and laboratory data regarding HCV infection as well as sustained virological response (SVR) to antiviral therapy were evaluated. Results. Mean serum values of 25(OH)D was 26.2 12 ng/mL and prevalence of vitamin D deficiency (< 30 ng/mL) was 66.2%. Advanced age (> 55 years), high mean values of LDL, total cholesterol, HDL and low mean values of alkaline phosphatase and hemoglobin were statistically associated to vitamin D deficiency. Antiviral treatment was underwent by 133 HCV patients and 44.3% of them achieved SVR. Most of individuals that presented SVR also presented 25(OH)D level higher than 30ng/mL (55.9%). SVR was associated to low mean values of LDL, total cholesterol and platelets; high mean values of ALT, AST and low fibrosis grade. Conclusions: In conclusion, low vitamin D levels were observed among HCV infected patients and was associated to laboratory findings, however baseline 25(OH)D level is not independently associated with SVR.
C1 [Melo-Villar, Livia; Lampe, Elisabeth; de Almeida, Adilson J.; Scalioni, Leticia de P.; Lewis-Ximenez, Lia L.; Miguel, Juliana C.] Fiocruz MS, Inst Oswaldo Cruz, Lab Viral Hepatitis, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Del Campo, Jose A.; Ranchal, Isidora; Romero-Gomez, Manuel] Hosp Univ Valme, Unit Clin Management Digest Dis, Seville, Spain.
   [Del Campo, Jose A.; Ranchal, Isidora; Romero-Gomez, Manuel] Hosp Univ Valme, CIBERehd, Seville, Spain.
   [Villela-Nogueira, Cristiane A.] Univ Fed Rio de Janeiro, Clementino Fraga Filho Univ Hosp, Dept Clin Med, Hepatol Unit, Rio de Janeiro, RJ, Brazil.
RP Melo-Villar, L (corresponding author), Viral Hepatitis Lab, Helio & Peggy Pereira Pavillion Ground Floor Roo, BR-21036004 Rio De Janeiro, RJ, Brazil.
EM lvillar@ioc.fiocruz.br
RI IBIS, DIGESTIVAS/O-1913-2015; VILLAR, LIVIA M/F-7811-2012; Romero-Gomez,
   Manuel/L-8030-2014
OI VILLAR, LIVIA M/0000-0001-7644-8969; Ranchal,
   Isidora/0000-0001-7870-7768; Romero-Gomez, Manuel/0000-0001-8494-8947
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Brazilian National Counsel of Technological and
   Scientific Development (CNPq)National Council for Scientific and
   Technological Development (CNPq); Coordination of Improvement of Higher
   Education Personnel (CAPES)CAPES; Oswaldo Cruz Foundation (FIOCRUZ)
FX This research was supported by Fundacao de Amparo a Pesquisa do Estado
   do Rio de Janeiro (FAPERJ), Brazilian National Counsel of Technological
   and Scientific Development (CNPq), Coordination of Improvement of Higher
   Education Personnel (CAPES) and Oswaldo Cruz Foundation (FIOCRUZ).
CR Abu-Mouch S, 2011, WORLD J GASTROENTERO, V17, P5184, DOI 10.3748/wjg.v17.i47.5184
   Baur K, 2012, LIVER INT, V32, P635, DOI 10.1111/j.1478-3231.2011.02674.x
   Berg T, 2014, LIVER INT
   Bitetto D, 2011, HEPATOLOGY, V53, P1118, DOI 10.1002/hep.24201
   Eslam M, 2011, J VIRAL HEPATITIS, V18, P675, DOI 10.1111/j.1365-2893.2011.01474.x
   Eslam M, 2011, ALIMENT PHARM THER, V34, P297, DOI 10.1111/j.1365-2036.2011.04716.x
   Ferreira PR, 2014, BRAZ J INFECT DIS
   Fleet JC, 2012, BIOCHEM J, V441, P61, DOI 10.1042/BJ20110744
   Guzman-Fulgencio M, 2014, J INFECTION, V68, P176, DOI 10.1016/j.jinf.2013.10.011
   Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4
   Idrees M, 2008, J VIROL METHODS, V150, P50, DOI 10.1016/j.jviromet.2008.03.001
   Kitson MT, 2013, J HEPATOL, V58, P467, DOI 10.1016/j.jhep.2012.11.017
   Klenerman P, 2012, QJM-INT J MED, V105, P29, DOI 10.1093/qjmed/hcr231
   Ladero JM, 2013, ANN HEPATOL, V12, P199, DOI 10.1016/S1665-2681(19)31357-2
   Lavanchy D, 2011, CLIN MICROBIOL INFEC, V17, P107, DOI 10.1111/j.1469-0691.2010.03432.x
   Martinez SM, 2011, HEPATOLOGY, V53, P325, DOI 10.1002/hep.24013
   de Rueda PM, 2011, AM J GASTROENTEROL, V106, P1246, DOI 10.1038/ajg.2011.82
   Niederau C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107592
   Nimer A, 2012, WORLD J GASTROENTERO, V18, P800, DOI 10.3748/wjg.v18.i8.800
   O'Brien MA, 2012, VET J, V194, P27, DOI 10.1016/j.tvjl.2012.05.022
   Petta S, 2013, J VIRAL HEPATITIS, V20, P486, DOI 10.1111/jvh.12072
   Petta S, 2010, HEPATOLOGY, V51, P1158, DOI 10.1002/hep.23489
   Steinvil A, 2011, EUR J CLIN INVEST, V41, P263, DOI 10.1111/j.1365-2362.2010.02403.x
   Stokes CS, 2014, EUR J CLIN INVEST, V44, P176, DOI 10.1111/eci.12205
   Sung CC, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/634195
   Terrier B, 2012, RHEUMATOLOGY, V51, P2083, DOI 10.1093/rheumatology/kes209
   Villar LM, 2013, WORLD J GASTROENTERO, V19, P5917, DOI 10.3748/wjg.v19.i35.5917
NR 27
TC 10
Z9 10
U1 0
U2 4
PU ELSEVIER ESPANA
PI MADRID
PA CALLE DE ZURBANO, 76-4TH FLR LEFT, MADRID, 28010, SPAIN
SN 1665-2681
J9 ANN HEPATOL
JI Ann. Hepatol.
PD JUL-AUG
PY 2015
VL 14
IS 4
BP 457
EP 463
DI 10.1016/S1665-2681(19)31166-4
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CQ8OE
UT WOS:000360866900003
PM 26019031
OA Other Gold
DA 2020-11-30
ER

PT J
AU Espirito-Santo, MP
   Mello, FCDA
   da Cruz, JNM
   Lewis-Ximenez, LL
   Lampe, E
AF Espirito-Santo, M. P.
   Mello, F. C. D. A.
   da Cruz, J. N. M.
   Lewis-Ximenez, L. L.
   Lampe, E.
TI An update on hepatitis B virus genotypes circulating in two Brazilian
   regions
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Meeting Abstract
CT 15th International Symposium on Viral Hepatitis and Liver Diseases
   (ISVHLD)
CY JUN 26-28, 2015
CL Berlin, GERMANY
C1 [Espirito-Santo, M. P.; Mello, F. C. D. A.; Lewis-Ximenez, L. L.; Lampe, E.] Fiocruz MS, Inst Oswaldo Cruz, Lab Viral Hepatitis, BR-21045900 Rio De Janeiro, Brazil.
   [da Cruz, J. N. M.] Lacen CE, Lab Cent Saude Publ, Fortaleza, Ceara, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
EI 1365-2893
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD JUN
PY 2015
VL 22
SU 2
SI SI
MA P035
BP 36
EP +
DI 10.1111/jvh.33_12425
PG 2
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA CL3XB
UT WOS:000356884200065
OA Bronze
DA 2020-11-30
ER

PT J
AU de Almeida, RW
   Espirito-Santo, MP
   Sousa, PSF
   de Almeida, AJ
   Lampe, E
   Lewis-Ximenez, LL
AF de Almeida, R. W.
   Espirito-Santo, M. P.
   Sousa, P. S. F.
   de Almeida, A. J.
   Lampe, E.
   Lewis-Ximenez, L. L.
TI Hepatitis B virus DNA stability in plasma samples under short-term
   storage at 42 degrees C
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE HBV; Stability studies; Real-time PCR
ID HUMAN-IMMUNODEFICIENCY-VIRUS; C VIRUS; NUCLEIC-ACIDS; RNA; BLOOD;
   QUANTIFICATION; ASSAY; NAT
AB We evaluated the stability of hepatitis B virus (HBV) DNA in plasma samples stored at 42 degrees C for external quality assessment (EQA) panels of viral load. To assess the stability of plasma samples containing different concentrations of HBV DNA, serial dilutions of HBV-infected samples with a viral load of 6.40 log((10)) IU/mL were made to yield viral loads of 5, 4, and 3 log((10)) IU/mL. These were incubated at 42 degrees C for up to 7 days and then frozen at -70 degrees C. Viral load testing for HBV DNA was performed for all samples using COBAS (R) AmpliPrep/COBAS (R) TaqMan (R) HBV Test (v.2.0, Roche, Switzerland). Results were compared with fresh frozen plasma samples as a benchmark to establish acceptable measurements on the days following sample collection. Although the results of this study demonstrated a decrease in HBV DNA viral load ranging from 0.005 to 0.30 log((10)) IU/mL after storage at 42 degrees C for up to 7 days, these values did not exceed 0.5 log((10)), which is the estimated intra-assay variation for molecular tests. Thus, the insignificant decrease in viral load suggests that shipment of HBV in plasma samples at temperatures of up to 42 degrees C is permissible if they are frozen within 7 days.
C1 [de Almeida, R. W.; Espirito-Santo, M. P.; Sousa, P. S. F.; de Almeida, A. J.; Lampe, E.; Lewis-Ximenez, L. L.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Hepatites Virais, Rio De Janeiro, RJ, Brazil.
RP de Almeida, RW (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Hepatites Virais, Rio De Janeiro, RJ, Brazil.
EM ricardo.almeida@ioc.fiocruz.br
FU Fundacao Oswaldo Cruz (FIOCRUZ); Departamento de DST, Aids e Hepatites
   Virais do Ministerio da Saude, Brazil
FX This research was supported by Fundacao Oswaldo Cruz (FIOCRUZ) and
   Departamento de DST, Aids e Hepatites Virais do Ministerio da Saude,
   Brazil.
CR Baleriola C, 2011, J CLIN MICROBIOL, V49, P3163, DOI 10.1128/JCM.02447-10
   Berger A, 1998, INTERVIROLOGY, V41, P24, DOI 10.1159/000024912
   BUSCH MP, 1992, TRANSFUSION, V32, P420, DOI 10.1046/j.1537-2995.1992.32592327714.x
   CARMAN WF, 1991, HEPATOLOGY, V14, P219, DOI 10.1016/0270-9139(91)91406-Q
   Chevaliez S, 2010, J CLIN MICROBIOL, V48, P3641, DOI 10.1128/JCM.01306-10
   Ehrlich GD, 1994, PCR BASED DIAGNOSTIC, V2
   Gerlich WH, 1995, VIRAL HEP, V1, P53
   Gessoni G, 2004, TRANSFUS APHER SCI, V30, P197, DOI 10.1016/j.transci.2003.11.010
   Ginocchio CC, 1997, J CLIN MICROBIOL, V35, P2886, DOI 10.1128/JCM.35.11.2886-2893.1997
   Grant PR, 2000, VOX SANG, V78, P137
   Jose M, 2005, BIOLOGICALS, V33, P9, DOI 10.1016/j.biologicals.2004.10.003
   Krajden M, 1999, J CLIN MICROBIOL, V37, P1683, DOI 10.1128/JCM.37.6.1683-1686.1999
   Lee DH, 2002, TRANSFUSION, V42, P409, DOI 10.1046/j.1525-1438.2002.00068.x
   Lira R, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-153
   Ministerio da Saude, 2011, PROT CLIN DIR TER TR
   Mohamed S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061077
   Noborg U, 1999, J CLIN MICROBIOL, V37, P2793, DOI 10.1128/JCM.37.9.2793-2797.1999
   Pawlotsky JM, 1997, HEPATOLOGY, V26, P1
   Sebire K, 1998, J CLIN MICROBIOL, V36, P493, DOI 10.1128/JCM.36.2.493-498.1998
   Villar LM, 2011, J MED VIROL, V83, P1522, DOI 10.1002/jmv.22138
NR 20
TC 1
Z9 1
U1 0
U2 4
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, 00, BRAZIL
SN 0100-879X
EI 1678-4510
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD JUN
PY 2015
VL 48
IS 6
BP 553
EP 556
DI 10.1590/1414-431X20144040
PG 4
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA CK9DQ
UT WOS:000356541200010
PM 25790101
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU de Barros, JF
   Peres, LR
   de Sousa, PSF
   Mello, FCD
   de Araujo, NM
   Gomes, SD
   Niel, C
   Lewis-Ximenez, LL
AF Franca de Barros, Jose Junior
   Peres, Luciana Rego
   Fonseca de Sousa, Paulo Sergio
   do Amaral Mello, Francisco Campello
   de Araujo, Natalia Motta
   Gomes, Selma de Andrade
   Niel, Christian
   Lewis-Ximenez, Lia Laura
TI Occult infection with HBV intergenotypic A2/G recombinant following
   acute hepatitis B caused by an HBV/A2 isolate
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE Brazil; Genotype A; Genotype G; HBsAg loss; Occult hepatitis B;
   Recombinant virus
ID VIRUS GENOTYPE-G; BLOOD-DONORS; RESISTANCE MUTATIONS; BRAZIL;
   PERSISTENCE; RECOVERY; GENOMES
AB Viral and host factors leading to occult hepatitis B virus (HBV) infection (OBI) are not fully understood. Whether HBV genotype may influence the occurrence and course of OBIs is unknown. Here, we describe the case of a patient infected with HBV genotype A2 who developed symptomatic acute hepatitis and did not seroconvert after loss of HBsAg and HBeAg. The acute phase of hepatitis B was followed by a period of more than 2 years during which the DNA of an intergenotypic HBV/A2/G recombinant was intermittently detected in serum. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Franca de Barros, Jose Junior; do Amaral Mello, Francisco Campello; de Araujo, Natalia Motta; Gomes, Selma de Andrade; Niel, Christian] Fiocruz MS, Inst Oswaldo Cruz, Mol Virol Lab, BR-21040360 Rio De Janeiro, RJ, Brazil.
   [Peres, Luciana Rego; Fonseca de Sousa, Paulo Sergio; Lewis-Ximenez, Lia Laura] Fiocruz MS, Inst Oswaldo Cruz, Lab Referencia Nacl Hepatites Virais, BR-21045900 Rio De Janeiro, RJ, Brazil.
RP Niel, C (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Mol Virol Lab, Av Brasil 4365, BR-21040360 Rio De Janeiro, RJ, Brazil.
EM niel@ioc.fiocruz.br
RI Araujo, Natalia M/B-6596-2013; Niel, Christian/G-3712-2013
OI Barros, Jose/0000-0002-4288-8680
FU CNPqNational Council for Scientific and Technological Development (CNPq)
FX This work was supported by CNPq.
CR Araujo NM, 2013, J GEN VIROL, V94, P150, DOI 10.1099/vir.0.047324-0
   BHAT RA, 1990, HEPATOLOGY, V11, P271, DOI 10.1002/hep.1840110218
   Bottecchia M, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-11
   Chudy M, 2006, HEPATOLOGY, V44, P99, DOI 10.1002/hep.21220
   da Silva AC, 2010, MEM I OSWALDO CRUZ, V105, P770, DOI 10.1590/S0074-02762010000600007
   Kato H, 2004, HEPATOL RES, V30, P199, DOI 10.1016/j.hepres.2004.09.004
   Kiely P, 2014, TRANSFUSION, V54, P2084, DOI 10.1111/trf.12556
   Lieshout-Krikke RW, 2014, EUR J CLIN MICROBIOL, V33, P69, DOI 10.1007/s10096-013-1930-9
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Loriot MA, 1997, J HEPATOL, V27, P251, DOI 10.1016/S0168-8278(97)80168-7
   MICHALAK TI, 1994, J CLIN INVEST, V93, P230, DOI 10.1172/JCI116950
   Osiowy C, 2008, J GEN VIROL, V89, P3009, DOI 10.1099/vir.0.2008/005124-0
   Pereira JSF, 2006, BRAZ J MED BIOL RES, V39, P525, DOI 10.1590/S0100-879X2006000400013
   Raimondo G, 2013, SEMIN IMMUNOPATHOL, V35, P39, DOI 10.1007/s00281-012-0327-7
   Schultz AK, 2012, NUCLEIC ACIDS RES, V40, pW193, DOI 10.1093/nar/gks414
   Stuyver L, 2000, J GEN VIROL, V81, P67, DOI 10.1099/0022-1317-81-1-67
   Yotsuyanagi H, 1998, HEPATOLOGY, V27, P1377, DOI 10.1002/hep.510270526
NR 17
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD JUN
PY 2015
VL 67
BP 31
EP 35
DI 10.1016/j.jcv.2015.03.019
PG 5
WC Virology
SC Virology
GA CH6CW
UT WOS:000354124400007
PM 25959154
DA 2020-11-30
ER

PT J
AU Scalioni, LD
   Cruz, HM
   de Paula, VS
   Miguel, JC
   Marques, VA
   Villela-Nogueira, CA
   Milagres, FAP
   Cruz, MS
   Bastos, FI
   Andrade, TM
   Motta-Castro, ARC
   Lewis-Ximenez, LL
   Lampe, E
   Villar, LM
AF Scalioni, Leticia de Paula
   Cruz, Helena Medina
   de Paula, Vanessa Salete
   Miguel, Juliana Custodio
   Marques, Vanessa Alves
   Villela-Nogueira, Cristiane Alves
   Padua Milagres, Flavio Augusto
   Cruz, Marcelo Santos
   Bastos, Francisco Inacio
   Andrade, Tarcisio Matos
   Coimbra Motta-Castro, Ana Rita
   Lewis-Ximenez, Lia Laura
   Lampe, Elisabeth
   Villar, Livia Melo
TI Performance of rapid hepatitis C virus antibody assays among high- and
   low-risk populations
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE Hepatitis C virus; Diagnosis; Rapid test; Endemicity; Prevalence
ID ANTIGEN; USERS; DONORS; HEALTH
AB Background: Rapid tests for the detection of antibodies to hepatitis C virus (anti-HCV) can facilitate access to diagnosis.
   Objectives: This study aimed to evaluate the performance of rapid tests for anti-HCV detection in the sera, whole blood, and oral fluid samples from individuals with different endemicity profiles and risk behaviors.
   Study design: Three groups donated biological samples that were tested using three anti-HCV rapid tests(WAMA, Bioeasy and OraSure): (I) suspected cases of hepatitis C, (II) individuals who were living in remote areas in Brazil and (III) crack users and beauty professionals. Reproducibility, repeatability and cross-reactivity to other infectious agents (dengue, HIV, malaria, and syphilis) were also evaluated.
   Results: In group I, specificities varied from 93.75% to 100% and sensitivities varied from 76.03% to 93.84% according to the EIA results. When anti-HCV/HCV RNA-reactive sera samples were considered true-positive HCV cases, the sensitivities and specificities varied from 86.3% to 99.09% and 93.75% to 100%, respectively. In group II, the OraSure rapid test presented the best performance. In group III, the Bioeasy assay performed best using saliva and whole blood and the OraSure assay performed best using oral fluid samples. The reproducibility and repeatability of the WAMA and Bioeasy tests were excellent. The level of concordance between the HCV EIAs and the rapid tests using samples that were reactive for other infectious agents varied from 82.35% to 100% for the WAMA assay and 94.11% to 100% for the Bioeasy assay.
   Conclusion: All of the rapid tests could be used to identify active HCV infection among individuals with different endemicity profiles and risk behaviors. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Scalioni, Leticia de Paula; Cruz, Helena Medina; Miguel, Juliana Custodio; Marques, Vanessa Alves; Lewis-Ximenez, Lia Laura; Lampe, Elisabeth; Villar, Livia Melo] Fiocruz MS, Inst Oswaldo Cruz, Lab Viral Hepatitis, BR-21045900 Rio De Janeiro, Brazil.
   [de Paula, Vanessa Salete] Fiocruz MS, Inst Oswaldo Cruz, Lab Tecnhol Dev Virol, BR-21045900 Rio De Janeiro, Brazil.
   [Villela-Nogueira, Cristiane Alves] Univ Fed Rio de Janeiro, Clementino Fraga Filho Univ Hosp, Hepatol Div, Rio De Janeiro, Brazil.
   [Padua Milagres, Flavio Augusto] Fed Univ Tocantins, Fac Med, Palmas, Brazil.
   [Cruz, Marcelo Santos] Univ Fed Rio de Janeiro, Inst Psychiat, Rio De Janeiro, Brazil.
   [Bastos, Francisco Inacio] Fundacao Oswaldo Cruz, Inst Commun & Sci Informat & Technol Hlth, Rio De Janeiro, Brazil.
   [Andrade, Tarcisio Matos] Univ Fed Bahia, Dept Community & Family Hlth, Salvador, BA, Brazil.
   [Coimbra Motta-Castro, Ana Rita] Univ Fed Mato Grosso do Sul, Dept Biochem & Pharm, Campo Grande, MS USA.
RP Villar, LM (corresponding author), Viral Hepatitis Lab, Helio & Peggy Pereira Pavill,Ground Floor, BR-21036004 Rio De Janeiro, RJ, Brazil.
EM lvillar@ioc.fiocruz.br
RI de Paula, Vanessa S/I-8037-2016; Cruz, Marcelo Santos/AAH-5963-2020;
   motta-castro, ana rita c/O-2075-2017; VILLAR, LIVIA M/F-7811-2012; Cruz,
   Helena Medina/U-4780-2019; Cruz, Marcelo Santos/I-5890-2014; milagres,
   flavio/Q-2403-2019
OI de Paula, Vanessa S/0000-0002-6314-754X; Cruz, Marcelo
   Santos/0000-0003-0057-2095; VILLAR, LIVIA M/0000-0001-7644-8969; Cruz,
   Helena Medina/0000-0003-2088-7705; Bastos,
   Francisco/0000-0001-5970-8896; Motta-Castro, Ana
   Rita/0000-0003-3070-1337; Milagres, Flavio/0000-0002-6889-8772
FU Fundacao de Amparoa Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Brazilian National Counsel of Technological and
   Scientific Development(CNPq)National Council for Scientific and
   Technological Development (CNPq); Coordination of Improvement of Higher
   Education Personnel (CAPES)CAPES; Oswaldo Cruz Foundation (FIOCRUZ)
FX This research was supported by the Fundacao de Amparoa Pesquisa do
   Estado do Rio de Janeiro (FAPERJ), the Brazilian National Counsel of
   Technological and Scientific Development(CNPq), the Coordination of
   Improvement of Higher Education Personnel (CAPES) and the Oswaldo Cruz
   Foundation (FIOCRUZ).
CR ACETI A, 1990, LANCET, V336, P1442, DOI 10.1016/0140-6736(90)93139-G
   Alzahrani AJ, 2008, J MED VIROL, V80, P603, DOI 10.1002/jmv.21075
   Brandao CPU, 2013, J CLIN VIROL, V57, P98, DOI 10.1016/j.jcv.2013.02.014
   Brazilian Ministry of Health, 2010, VIR HEP EP B
   Centers for Disease Control and Prevention, 2013, TEST HCV INF UPD GUI
   Centers for Disease Control Prevention, 1998, AM J MANAG CARE, V47, P1
   Cha YJ, 2013, ANN LAB MED, V33, P184, DOI 10.3343/alm.2013.33.3.184
   Cruz HM, 2012, J ORAL PATHOL MED, V41, P793, DOI 10.1111/j.1600-0714.2012.01176.x
   Cruz HM, 2011, J CLIN LAB ANAL, V25, P134, DOI 10.1002/jcla.20447
   Cruz MS, 2013, INT J DRUG POLICY, V24, P432, DOI 10.1016/j.drugpo.2013.03.012
   da Rosa L, 2013, HEPAT MON, V13, DOI 10.5812/hepatmon.12274
   de Oliveira ACDS, 2010, BRAZ J INFECT DIS, V14, P502, DOI 10.1590/S1413-86702010000500013
   Drobnik A, 2011, AM J PUBLIC HEALTH, V101, P2151, DOI 10.2105/AJPH.2011.300251
   KLEINMAN S, 1992, TRANSFUSION, V32, P805, DOI 10.1046/j.1537-2995.1992.32993110750.x
   Lavanchy D, 2011, CLIN MICROBIOL INFEC, V17, P107, DOI 10.1111/j.1469-0691.2010.03432.x
   Lee SR, 2010, J CLIN VIROL, V48, P15, DOI 10.1016/j.jcv.2010.02.018
   LEE SR, 1995, TRANSFUSION, V35, P845, DOI 10.1046/j.1537-2995.1995.351096026366.x
   Lee SR, 2011, J VIROL METHODS, V172, P27, DOI 10.1016/j.jviromet.2010.12.009
   Nunes CLX, 2007, BRAZ J INFECT DIS, V11, P561, DOI 10.1590/S1413-86702007000600007
   Smith BD, 2011, CLIN INFECT DIS, V53, P780, DOI 10.1093/cid/cir499
   Smith BD, 2011, J INFECT DIS, V204, P825, DOI 10.1093/infdis/jir422
   Southern WN, 2011, J VIRAL HEPATITIS, V18, P474, DOI 10.1111/j.1365-2893.2010.01327.x
   Visseaux B, 2013, J CLIN VIROL, V58, P385, DOI 10.1016/j.jcv.2013.07.015
   von Diemen L, 2010, ARCH WOMEN MENT HLTH, V13, P185, DOI 10.1007/s00737-009-0089-y
NR 24
TC 22
Z9 23
U1 0
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD JUL
PY 2014
VL 60
IS 3
BP 200
EP 205
DI 10.1016/j.jcv.2014.04.001
PG 6
WC Virology
SC Virology
GA AL7BF
UT WOS:000339287200004
PM 24794796
DA 2020-11-30
ER

PT J
AU Chen, DY
   Robilotti, B
   Matsubara, LK
   Brown, J
   Aneja, J
   Kulaga, S
   Lewis-Ximenez, L
   James, EA
   Kwok, WW
   Kim, AY
   Lauer, GM
AF Chen, Diana Y.
   Robilotti, Brandon
   Matsubara, Lyndon K.
   Brown, Joelle
   Aneja, Jasneet
   Kulaga, Stephanie
   Lewis-Ximenez, Lia
   James, Eddie A.
   Kwok, William W.
   Kim, Arthur Y.
   Lauer, Georg M.
TI Increased Frequency of CD39+HCV-Specific CD4 T cells Correlates with
   Progression to Chronic Hepatitis C
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases
CY NOV 07-11, 2014
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Chen, Diana Y.; Robilotti, Brandon; Matsubara, Lyndon K.; Brown, Joelle; Lauer, Georg M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA USA.
   [Aneja, Jasneet; Kulaga, Stephanie; Kim, Arthur Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA USA.
   [Lewis-Ximenez, Lia] Inst Oswaldo Cruz, Dept Virol, BR-20001 Rio De Janeiro, Brazil.
   [James, Eddie A.; Kwok, William W.] Virginia Mason, Benaroya Res Inst, Seattle, WA USA.
RI James, Eddie/V-4929-2019
OI James, Eddie/0000-0002-7217-5729
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PY 2014
VL 60
SU 1
SI SI
MA 1833
BP 1080A
EP 1080A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AS8EW
UT WOS:000344483804395
DA 2020-11-30
ER

PT J
AU Villar, LM
   Amado, LA
   de Almeida, AJ
   de Paula, VS
   Lewis-Ximenez, LL
   Lampe, E
AF Villar, Livia Melo
   Amado, Luciane Almeida
   de Almeida, Adilson Jose
   de Paula, Vanessa Salete
   Lewis-Ximenez, Lia Laura
   Lampe, Elisabeth
TI Low Prevalence of Hepatitis B and C Virus Markers among Children and
   Adolescents
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID SEROLOGICAL MARKERS; RISK-FACTORS; INFECTION; SEROPREVALENCE;
   VACCINATION; GENOTYPES; EXPOSURE; IMPACT; BRAZIL; AREAS
AB This study aimed to determine the prevalence of HBV and HCV among children and adolescents attending schools and daycare centres in Rio de Janeiro State, located in southern Brazil. Serum samples from 1,217 individuals aged 0 to 18 years were collected from 1999 to 2012 and tested for HBsAg, total anti-HBc, anti-HBs, and anti-HCV by ELISA. Reactive HBsAg and anti-HBc samples were tested for HBV DNA. Reactive anti-HCV samples were tested for HCV RNA and genotyped by RFLP. HBsAg was detected in 1.8% of individuals, and total anti-HBc was detected among 3.6% of individuals. Anti-HBs reactivity was found among 25.3% (322/1,217) of the individuals and increased from 6.28% in the years 1999-2000 to 76.2% in the years 2001-2012 (P < 0.0001). HBV DNA was detected in 18 of 51 individuals who presented with HBsAg or isolated anti-HBc, and nine were considered occult hepatitis B cases. Three individuals were anti-HCV- and HCV RNA-positive: two of them were infected with genotype 1, and the other was infected with genotype 3. Low levels of HBV and HCV markers were observed in children and adolescents. HBV immunity increased during the period of study, indicating that childhood universal HBV vaccination has been effective for controlling HBV infection in Brazil.
C1 [Villar, Livia Melo; de Almeida, Adilson Jose; Lewis-Ximenez, Lia Laura; Lampe, Elisabeth] Fiocruz MS, Inst Oswaldo Cruz, Lab Viral Hepatitis, BR-21040360 Rio De Janeiro, RJ, Brazil.
   [Amado, Luciane Almeida; de Paula, Vanessa Salete] Fiocruz MS, Inst Oswaldo Cruz, Lab Technol Dev Virol, BR-21040360 Rio De Janeiro, RJ, Brazil.
RP Villar, LM (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab Viral Hepatitis, BR-21040360 Rio De Janeiro, RJ, Brazil.
EM lvillar@ioc.fiocruz.br
RI de Paula, Vanessa S/I-8037-2016; VILLAR, LIVIA M/F-7811-2012
OI de Paula, Vanessa S/0000-0002-6314-754X; VILLAR, LIVIA
   M/0000-0001-7644-8969
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Brazilian National Counsel of Technological and
   Scientific Development (CNPq)National Council for Scientific and
   Technological Development (CNPq); Oswaldo Cruz Foundation (FIOCRUZ)
FX The authors wish to thank Juliana Custodio Miguel, Elisangela Ferreira
   da Silva, and Rosane Vieira de Oliveira for technical assistance with
   the collection and processing of blood samples. This research was
   supported by the Fundacao de Amparo a Pesquisa do Estado do Rio de
   Janeiro (FAPERJ), the Brazilian National Counsel of Technological and
   Scientific Development (CNPq), and the Oswaldo Cruz Foundation
   (FIOCRUZ).
CR Aghakhani A, 2011, WORLD J PEDIATR, V7, P358, DOI 10.1007/s12519-011-0286-4
   de Almeida AJ, 2009, HEPATO-GASTROENTEROL, V56, P429
   do Livramento A, 2011, REV INST MED TROP SP, V53, P13, DOI 10.1590/S0036-46652011000100003
   Escobedo-Melendez G, 2012, ANN HEPATOL, V11, P194, DOI 10.1016/S1665-2681(19)31024-5
   Jonas MM, 2002, HEPATOLOGY, V36, pS173, DOI 10.1053/jhep.2002.36799
   Luo ZB, 2012, INT J INFECT DIS, V16, pE82, DOI 10.1016/j.ijid.2011.10.009
   Meheus A, 2000, VACCINE, V18, pS26, DOI 10.1016/S0264-410X(99)00458-2
   Ministry of Health Brazil, 2008, INSTR MAT TRAIN SURV
   Nascimento MC, 2008, J MED VIROL, V80, P53, DOI 10.1002/jmv.21046
   Nelson PK, 2011, LANCET, V378, P571, DOI 10.1016/S0140-6736(11)61097-0
   Oliveira MLA, 1999, BRAZ J MED BIOL RES, V32, P279, DOI 10.1590/S0100-879X1999000300005
   Pereira LMMB, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-60
   Pereira LMMB, 2009, AM J TROP MED HYG, V81, P240
   Portilho MM, 2012, J MED MICROBIOL, V61, P844, DOI 10.1099/jmm.0.040238-0
   Porto AF, 2012, CURR OPIN PEDIATR, V24, P113, DOI 10.1097/MOP.0b013e32834eb73f
   Qamer Sheeba, 2004, Indian Journal of Pediatrics, V71, P965
   Paraboni MLR, 2012, SCI WORLD J, DOI 10.1100/2012/946954
   Said ZNA, 2009, LIVER INT, V29, P518, DOI 10.1111/j.1478-3231.2009.01975.x
   Scaraveli NG, 2011, CAD SAUDE PUBLICA, V27, P753, DOI 10.1590/S0102-311X2011000400014
   Shen LP, 2012, VACCINE, V30, P6623, DOI 10.1016/j.vaccine.2012.08.067
   Tan YJ, 2011, WORLD J GASTROENTERO, V17, P4853, DOI 10.3748/wjg.v17.i44.4853
   Utsumi T, 2010, AM J TROP MED HYG, V83, P189, DOI 10.4269/ajtmh.2010.09-0589
   Voigt AR, 2010, BRAZ J INFECT DIS, V14, P60, DOI 10.1590/S1413-86702010000100012
   World Health Organization, 2014, HEP B
   World Health Organization, 2014, HEP C
   Wu TC, 2008, T ROY SOC TROP MED H, V102, P935, DOI 10.1016/j.trstmh.2008.06.012
   Xiao JP, 2012, INT J INFECT DIS, V16, pE692, DOI 10.1016/j.ijid.2012.05.1027
NR 27
TC 13
Z9 14
U1 1
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2014
VL 2014
AR 324638
DI 10.1155/2014/324638
PG 5
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AL1AX
UT WOS:000338859300001
PM 25093164
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Brandao, CPU
   Marques, BLC
   Marques, VA
   Villela-Nogueira, CA
   Do O, KMR
   de Paula, MT
   Lewis-Ximenez, LL
   Lampe, E
   Ferreira, JAS
   Villar, LM
AF Brandao, C. P. U.
   Marques, B. L. C.
   Marques, V. A.
   Villela-Nogueira, C. A.
   Do O, K. M. R.
   de Paula, M. T.
   Lewis-Ximenez, L. L.
   Lampe, E.
   Sa Ferreira, J. A.
   Villar, L. M.
TI Simultaneous detection of hepatitis c virus antigen and antibodies in
   dried blood spots
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE Hepatitis C virus; Dried blood spot; Enzyme immunoassay; HCV AgAb
ID CORE ANTIGEN; SAMPLES; RNA
AB Background: Enzyme immunoassays (EIA) designed to detect hepatitis C virus (HCV) core antigen and anti-HCV antibodies (HCV AgAb) simultaneously can improve the early detection of HCV infection when molecular diagnostic methods are not widely available.
   Objectives: To evaluate the suitability of dried blood spot (DBS) samples for detecting HCV AgAb using commercial EIAs.
   Study design: Paired serum and DBS samples were assayed using two commercial EIAs for HCV AgAb (Monolisa (TM) HCV AgAb ULTRA and Murex HCV AgAb). Manufacturer's recommendations were followed for sera while sample volume, incubation time and cut-off (CO) determination were evaluated for the DBS samples. The values of sensitivity, specificity, inter-rater agreement, detection limit, assay precision and stability of DBS samples at different conditions (22-26 degrees C, 2-8 degrees C and -20 degrees C) were determined.
   Results: It was necessary to increase the DBS sample volume fourfold compared to the sera samples to approximate the DBS Optical Density (OD) values to the sera OD values. Using ROC curve to recalculate CO values for the DBS samples, sensitivity was 97.5% for both EIAs, while the specificity was 99.71% for Monolisa (TM) HCV AgAb ULTRA and 95.95% for Murex HCV AgAb. Accurate testing results were obtained with DBS samples for 60 days at all conditions evaluated; storage at -20 degrees C resulted in low OD variation. Both EIAs demonstrated the same limit of detection among DBS samples [ estimated viral load of 3.1 International Units per millilitre (IU/mL)] and low OD value variability in repetitivity and reproducibility studies.
   Conclusion: DBS samples can be used for the detection of HCV AgAb by EIA as they present comparable performance characteristics and excellent stability among various storage conditions. (c) 2013 Elsevier B.V. All rights reserved.
C1 [Brandao, C. P. U.; de Paula, M. T.] Fed Hosp Servers State Rio de Janeiro, Rio De Janeiro, Brazil.
   [Marques, B. L. C.; Marques, V. A.; Lewis-Ximenez, L. L.; Lampe, E.; Villar, L. M.] Fiocruz MS, Inst Oswaldo Cruz, Lab Viral Hepatitis, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Villela-Nogueira, C. A.] Univ Fed Rio de Janeiro, Clementino Fraga Filho Univ Hosp, Hepatol Div, BR-21941 Rio De Janeiro, RJ, Brazil.
   [Do O, K. M. R.] Unimed Hosp, Petropolis, RJ, Brazil.
   [Sa Ferreira, J. A.] Fiocruz MS, Immunobiol Technol Inst Bio Manguinhos, BR-21045900 Rio De Janeiro, RJ, Brazil.
RP Villar, LM (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab Hepatites Virais Pavilhao Helio & Peggy Perei, Av Brazil,4365 Manguinhos RJ, BR-21045900 Rio De Janeiro, Brazil.
EM lvillar@ioc.fiocruz.br
RI VILLAR, LIVIA M/F-7811-2012
OI VILLAR, LIVIA M/0000-0001-7644-8969
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Oswaldo Cruz Foundation (FIOCRUZ)
FX This research was supported by the Fundacao de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ) and Oswaldo Cruz Foundation (FIOCRUZ).
CR Abe K, 1998, J CLIN MICROBIOL, V36, P3070, DOI 10.1128/JCM.36.10.3070-3072.1998
   Bazzigaluppi E, 1999, DIABETES CARE, V22, P275, DOI 10.2337/diacare.22.2.275
   Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude. Departamento de DST, 2011, B EP HEP VIR, V1
   Cao J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018477
   Clinical and Laboratory Standards Institute (CLSI), 2004, APPR GUID EP A2 EV P
   Croom HA, 2006, J CLIN VIROL, V36, P68, DOI 10.1016/j.jcv.2005.12.002
   CROWTHER JR, 2001, ELISA GUIDEBOOK METH
   Laperche S, 2005, TRANSFUSION, V45, P1965, DOI 10.1111/j.1537-2995.2005.00648.x
   Marques BLC, 2012, J MED VIROL, V84, P1600, DOI 10.1002/jmv.23379
   McCarron B, 1999, J VIRAL HEPATITIS, V6, P453, DOI 10.1046/j.1365-2893.1999.00197.x
   Mcdade TW, 2007, DEMOGRAPHY, V44, P899, DOI 10.1353/dem.2007.0038
   Melgaco JG, 2011, J MED VIROL, V83, P208, DOI 10.1002/jmv.21973
   Montebugnoli L, 1999, CLIN CHIM ACTA, V288, P91, DOI 10.1016/S0009-8981(99)00146-1
   Nastouli E, 2009, J CLIN VIROL, V44, P78, DOI 10.1016/j.jcv.2008.09.008
   Obuchowski NA, 2005, AM J ROENTGENOL, V184, P364, DOI 10.2214/ajr.184.2.01840364
   Oliveira CA, 2010, GESTAO FASE ANALITIC, P144
   Parker SP, 1999, J CLIN MICROBIOL, V37, P2061, DOI 10.1128/JCM.37.6.2061-2063.1999
   Parker SP, 1997, J VIROL METHODS, V68, P199, DOI 10.1016/S0166-0934(97)00127-4
   Santos C, 2012, J VIROL METHODS, V179, P17, DOI 10.1016/j.jviromet.2011.06.012
   Solmone M, 2002, J CLIN MICROBIOL, V40, P3512, DOI 10.1128/JCM.40.9.3512-3514.2002
   Tuaillon E, 2010, HEPATOLOGY, V51, P752, DOI 10.1002/hep.23407
   Villar LM, 2011, J MED VIROL, V83, P1522, DOI 10.1002/jmv.22138
   Yang JF, 2011, KAOHSIUNG J MED SCI, V27, P258, DOI 10.1016/j.kjms.2010.11.007
NR 23
TC 25
Z9 25
U1 0
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD JUN
PY 2013
VL 57
IS 2
BP 98
EP 102
DI 10.1016/j.jcv.2013.02.014
PG 5
WC Virology
SC Virology
GA 139EH
UT WOS:000318563900002
PM 23518440
DA 2020-11-30
ER

PT J
AU Echevarria, JM
   Gonzalez, JE
   Lewis-Ximenez, LL
   dos Santos, DRL
   Munne, MS
   Pinto, MA
   Pujol, FH
   Rodriguez-Lay, LA
AF Echevarria, J. M.
   Gonzalez, J. E.
   Lewis-Ximenez, L. L.
   Lopes dos Santos, D. R.
   Munne, M. S.
   Pinto, M. A.
   Pujol, F. H.
   Rodriguez-Lay, L. A.
TI Hepatitis E virus infection in Latin America: A review
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE hepatitis E; hepatitis E virus; hepatitis E virus genotypes; Latin
   America; epidemiology
ID ACUTE VIRAL-HEPATITIS; TRANSMITTED NON-A; NON-B-HEPATITIS; MOLECULAR
   CHARACTERIZATION; SEQUENCES ANALYSIS; RURAL POPULATIONS; HEV INFECTION;
   BLOOD-DONORS; ANTIBODIES; PREVALENCE
AB Data reported during recent years reveal the complex picture of the epidemiology of hepatitis E virus (HEV) infection in Latin America. Whereas in countries like Argentina and Brazil is almost identical to the characteristic of most countries from North America and Europe, HEV in the Caribbean and Mexico involves the water-borne, non-zoonotic viral genotypes responsible for epidemics in Asia and Africa. Nevertheless, Latin America has been considered a highly endemic region for hepatitis E in the scientific literature, a generalization that ignores the above complexity. In addition, reports from isolated Amerindian communities, which display well known, important and very specific epidemiological features for hepatitis B and D virus infections are neither taken into account when considering the epidemiology of hepatitis E in the region. This review updates compilation of the available information for the HEV infection, both among humans and other mammals, in Latin America, discusses the strengths and the weaknesses of our current knowledge, and identifies future areas of research. J. Med. Virol. 85: 10371045, 2013. (c) 2013 Wiley Periodicals, Inc.
C1 [Echevarria, J. M.] Carlos III Hlth Inst, Madrid, Spain.
   [Gonzalez, J. E.; Munne, M. S.] Natl Inst Infect Dis, Buenos Aires, DF, Argentina.
   [Lewis-Ximenez, L. L.; Pinto, M. A.] Fiocruz MS, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil.
   [Lopes dos Santos, D. R.] Rural Fed Univ Rio de Janeiro, Inst Vet, Seropedica, Brazil.
   [Pujol, F. H.] Venezuelan Inst Sci Res, Caracas, Venezuela.
   [Rodriguez-Lay, L. A.] Inst Trop Med Pedro Kouri, Havana, Cuba.
RP Echevarria, JM (corresponding author), Inst Salud Carlos III, Dept Virol, Ctr Nacl Microbiol, Madrid 28220, Spain.
EM jmecheva@isciii.es
RI Pinto, Marcelo/G-7503-2012; Pinto, Marcelo Alves/ABA-3312-2020; Pujol,
   Flor H/E-5687-2010
OI Pinto, Marcelo/0000-0003-3462-7277; Pujol, Flor H/0000-0001-6086-6883
FU Oswaldo Cruz Institute Foundation, Rio de Janeiro
FX Grant sponsor: Oswaldo Cruz Institute Foundation, Rio de Janeiro.
CR Aggarwal R, 2011, VIRUS RES, V161, P15, DOI 10.1016/j.virusres.2011.03.017
   Ahmad I, 2011, VIRUS RES, V161, P47, DOI 10.1016/j.virusres.2011.02.011
   Alvarez-Munoz MT, 1999, ARCH MED RES, V30, P251, DOI 10.1016/S0188-0128(99)00019-6
   Assis Sandra Breder, 2002, Rev. Soc. Bras. Med. Trop., V35, P155, DOI 10.1590/S0037-86822002000200005
   Bartoloni A, 1999, TROP MED INT HEALTH, V4, P596, DOI 10.1046/j.1365-3156.1999.00457.x
   Bendall R, 2008, J MED VIROL, V80, P95, DOI 10.1002/jmv.21033
   Bendall R, 2010, J MED VIROL, V82, P799, DOI 10.1002/jmv.21656
   Bernal Reyes R, 1996, Rev Gastroenterol Mex, V61, P233
   BlitzDorfman L, 1996, ANN TROP MED PARASIT, V90, P655, DOI 10.1080/00034983.1996.11813098
   Bortoliero André Luiz, 2006, Rev. Inst. Med. trop. S. Paulo, V48, P87, DOI 10.1590/S0036-46652006000200006
   BRYAN JP, 1994, J INFECT DIS, V170, P517, DOI 10.1093/infdis/170.3.517
   Carrilho F J, 2005, Gastroenterol Hepatol, V28, P118, DOI 10.1157/13072011
   Cooper K, 2005, J CLIN MICROBIOL, V43, P1684, DOI 10.1128/JCM.43.4.1684-1688.2005
   Cossaboom CM, 2012, J VIROL, V86, P13124, DOI 10.1128/JVI.02414-12
   Cruells M R, 1997, Gastroenterol Hepatol, V20, P295
   Dell'Amico MC, 2011, EMERG INFECT DIS, V17, P1488, DOI 10.3201/eid1708.100769
   dos Santos DCM, 2002, MEM I OSWALDO CRUZ, V97, P637, DOI 10.1590/S0074-02762002000500007
   Drobeniuc J, 2009, 13 INT S VIR HEP LIV
   Drobeniuc J, 2010, CLIN INFECT DIS, V51, pE24, DOI 10.1086/654801
   Echevarria JM, 2011, J CLIN VIROL, V50, P69, DOI 10.1016/j.jcv.2010.09.016
   Fainboim H, 1999, J VIRAL HEPATITIS, V6, P53, DOI 10.1046/j.1365-2893.1999.t01-1-6120135.x
   Fogeda M, 2012, J MED VIROL, V84, P71, DOI 10.1002/jmv.22270
   Fogeda M, 2009, J MED VIROL, V81, P1743, DOI 10.1002/jmv.21564
   Fogeda M, 2009, J CLIN VIROL, V45, P259, DOI 10.1016/j.jcv.2009.05.022
   Gambel JM, 1998, AM J TROP MED HYG, V58, P731, DOI 10.4269/ajtmh.1998.58.731
   Gardinali NR, 2012, RES VET SCI, V93, P1515, DOI 10.1016/j.rvsc.2012.06.003
   Gardinali NR, 2012, MEM I OSWALDO CRUZ, V107, P935, DOI 10.1590/S0074-02762012000700016
   GOLDSMITH R, 1992, LANCET, V339, P328, DOI 10.1016/0140-6736(92)91647-Q
   Goncales NSL, 2000, CLIN DIAGN LAB IMMUN, V7, P813, DOI 10.1128/CDLI.7.5.813-816.2000
   Garcia CG, 2012, J MED VIROL, V84, P1025, DOI 10.1002/jmv.23277
   Haagsma EB, 2008, LIVER TRANSPLANT, V14, P547, DOI 10.1002/lt.21480
   Hakze-van der Honing RW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022673
   Hu Guang-dong, 2010, Chinese Journal of Virology, V26, P27
   Huang F, 2011, HEPAT MON, V11, P745, DOI 10.5812/kowsar.1735143X.730
   Hurtado C, 2005, REV MED CHILE, V133, P645, DOI 10.4067/S0034-98872005000600004
   Hyams KC, 1996, CLIN INFECT DIS, V22, P719, DOI 10.1093/clinids/22.4.719
   Ibarra H, 2001, REV MED CHILE, V129, P523
   Ibarra H, 1997, REV MED CHILE, V125, P257
   Ibarra H, 2007, REV MED CHILE, V135, P997, DOI 10.4067/S0034-98872007000800006
   Kamar N, 2008, AM J TRANSPLANT, V8, P1744, DOI 10.1111/j.1600-6143.2008.02286.x
   Kamar N, 2008, NEW ENGL J MED, V358, P811, DOI 10.1056/NEJMoa0706992
   Kase JA, 2008, INT J ENVIRON HEAL R, V18, P165, DOI 10.1080/09603120701498311
   Khudyakov Y, 2011, VIRUS RES, V161, P84, DOI 10.1016/j.virusres.2011.06.006
   Khuroo MS, 2011, VIRUS RES, V161, P3, DOI 10.1016/j.virusres.2011.02.007
   KHUROO MS, 1993, LANCET, V341, P1355
   Khuroo MS, 2003, J VIRAL HEPATITIS, V10, P61, DOI 10.1046/j.1365-2893.2003.00398.x
   Kim Hee Sup, 2011, Korean J Hepatol, V17, P323, DOI 10.3350/kjhep.2011.17.4.323
   Konomi N, 1999, J CLIN MICROBIOL, V37, P3291, DOI 10.1128/JCM.37.10.3291-3295.1999
   Koshy A, 1996, SCAND J INFECT DIS, V28, P439, DOI 10.3109/00365549609037935
   Lemos G, 2000, J CLIN VIROL, V16, P71, DOI 10.1016/S1386-6532(99)00062-1
   Leon P, 1999, Rev Panam Salud Publica, V5, P144, DOI 10.1590/S1020-49891999000300002
   dos Santos DRL, 2011, VET MICROBIOL, V149, P236, DOI 10.1016/j.vetmic.2010.10.024
   dos Santos DRL, 2010, J CLIN VIROL, V47, P276, DOI 10.1016/j.jcv.2009.12.021
   dos Santos DRL, 2009, VET J, V182, P474, DOI 10.1016/j.tvjl.2008.08.001
   Lyra AC, 2005, BRAZ J MED BIOL RES, V38, P767, DOI 10.1590/S0100-879X2005000500015
   Mansuy JM, 2011, EMERG INFECT DIS, V17, P2309, DOI 10.3201/eid1712.110371
   Marek A, 2010, VET MICROBIOL, V145, P54, DOI 10.1016/j.vetmic.2010.03.014
   Meky FA, 2006, CLIN INFECT DIS, V42, P628, DOI 10.1086/500133
   Meng XJ, 2010, VET MICROBIOL, V140, P256, DOI 10.1016/j.vetmic.2009.03.017
   Meng XJ, 2011, VIRUS RES, V161, P23, DOI 10.1016/j.virusres.2011.01.016
   Mirazo S, 2011, ARCH VIROL, V156, P1451, DOI 10.1007/s00705-011-0991-2
   Villalba MCM, 2010, T ROY SOC TROP MED H, V104, P772, DOI 10.1016/j.trstmh.2010.08.006
   Villallba MDM, 2008, EMERG INFECT DIS, V14, P1320, DOI 10.3201/eid1408.080049
   Munne MS, 2006, J MED VIROL, V78, P1579, DOI 10.1002/jmv.20741
   Munne Maria Silvina, 2006, Acta Gastroenterol Latinoam, V36, P125
   Nakamura S, 2012, J VET MED SCI, V74, P279, DOI 10.1292/jvms.11-0394
   Nishizawa T, 2003, J GEN VIROL, V84, P1245, DOI 10.1099/vir.0.19052-0
   Paiva HH, 2007, BRAZ J MICROBIOL, V38, P693, DOI 10.1590/S1517-83822007000400020
   Parana R, 1997, AM J TROP MED HYG, V57, P60, DOI 10.4269/ajtmh.1997.57.60
   Perez OM, 1996, AM J TROP MED HYG, V55, P17
   PUJOL FH, 1994, J MED VIROL, V42, P234, DOI 10.1002/jmv.1890420305
   Purcell RH, 2008, J HEPATOL, V48, P494, DOI 10.1016/j.jhep.2007.12.008
   Purdy MA, 2012, EMERG INFECT DIS, V18, P339, DOI 10.3201/eid1802.111453
   Purdy MA, 2011, VIRUS RES, V161, P31, DOI 10.1016/j.virusres.2011.04.030
   Quintana A, 2005, J MED VIROL, V76, P69, DOI 10.1002/jmv.20324
   Raj VS, 2012, EMERG INFECT DIS, V18, P1369, DOI 10.3201/eid1808.111659
   Redlinger T, 1998, Tex Med, V94, P68
   Rey, 1997, J Travel Med, V4, P100, DOI 10.1111/j.1708-8305.1997.tb00788.x
   REYES GR, 1990, SCIENCE, V247, P1335, DOI 10.1126/science.2107574
   Lay LDLAR, 2008, J MED VIROL, V80, P798, DOI 10.1002/jmv.21147
   Schlauder GG, 2000, J INFECT DIS, V182, P294, DOI 10.1086/315651
   Munne MS, 2011, J CLIN VIROL, V52, P138, DOI 10.1016/j.jcv.2011.06.015
   de Souza AJS, 2012, COMP IMMUNOL MICROB, V35, P477, DOI 10.1016/j.cimid.2012.04.004
   Tavitian S, 2010, J CLIN VIROL, V49, P141, DOI 10.1016/j.jcv.2010.06.016
   Tesse S, 2012, J CLIN VIROL, V54, P197, DOI 10.1016/j.jcv.2012.02.007
   Thomas DL, 1997, J CLIN MICROBIOL, V35, P1244, DOI 10.1128/JCM.35.5.1244-1247.1997
   Trinta KS, 2001, MEM I OSWALDO CRUZ, V96, P25, DOI 10.1590/S0074-02762001000100004
   Vasickova P, 2012, J VIROL METHODS, V180, P38, DOI 10.1016/j.jviromet.2011.12.007
   VELAZQUEZ O, 1990, JAMA-J AM MED ASSOC, V263, P3281, DOI 10.1001/jama.263.24.3281
   Vildosola H, 2000, REV GASTROENTEROL PE, V20, P111
   Villalba MD, 2005, INT J INFECT DIS, V9, P286, DOI 10.1016/j.ijid.2004.10.003
   Vitral CL, 2005, MEM I OSWALDO CRUZ, V100, P117, DOI 10.1590/S0074-02762005000200003
   Wang Yongxia, 2010, Weishengwu Xuebao, V50, P937
   Wichmann Ole, 2008, J Infect Dis, V198, P1732, DOI 10.1086/593211
   Xing L, 2010, J BIOL CHEM, V285, P33175, DOI 10.1074/jbc.M110.106336
   Yamamoto H, 2012, EMERG INFECT DIS, V18, P2032, DOI 10.3201/eid1812.120884
NR 96
TC 61
Z9 65
U1 0
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD JUN
PY 2013
VL 85
IS 6
BP 1037
EP 1045
DI 10.1002/jmv.23526
PG 9
WC Virology
SC Virology
GA 130IE
UT WOS:000317906300013
PM 23588729
DA 2020-11-30
ER

PT J
AU Scalioni, LD
   Cruz, HM
   de Paula, VS
   Oliveira, JC
   dos Santos, RT
   Motta-Castro, ARC
   Murat, PG
   Villela-Nogueira, CA
   Lewis-Ximenez, LL
   Lampe, E
   Villar, LM
AF Scalioni, Leticia de Paula
   Cruz, Helena Medina
   de Paula, Vanessa Salete
   Oliveira, Jaqueline Correia
   dos Santos, Renata Tourinho
   Coimbra Motta-Castro, Ana Rita
   Murat, Paula Guerra
   Villela-Nogueira, Cristiane Alves
   Lewis-Ximenez, Lia Laura
   Lampe, Elisabeth
   Villar, Livia Melo
TI Importance of Collection Methods and Stability of Oral Fluid Samples for
   Hepatitis B Surface Antigen Detection
SO JOURNAL OF CLINICAL LABORATORY ANALYSIS
LA English
DT Article
DE hepatitis B virus; oral fluid; diagnosis; stability study; collection
   device
ID C VIRUS; SALIVARY ANTIBODIES; INFECTION; SERUM; EPIDEMIOLOGY; DIAGNOSIS;
   SPECIMEN; ASSAY; HBSAG; TIME
AB BackgroundOral fluid (OF) sample collection and stability for HBsAg detection are not fully established. This study aims to investigate the applicability of OF collectors and sample stability for Hepatitis B virus surface antigen detection.
   MethodsPaired serum and OF samples were obtained from 191 individuals, and Chembio (Chembio Diagnostic System, USA) and Salivette (Sarstedt, Germany) devices were used for OF collection. Two HBsAg enzyme immunoassays (EIAs) were used (HBsAg One kit, Radim, Rome, Italy and ETI-MAK-4, DiaSorin, Vercelli, Italy) to determine the most efficient method according OF collector. Sample volume, incubation time, and cutoff (CO) value were evaluated. The stability of OF samples was determined under different environmental conditions.
   ResultsChembio samples analyzed using DiaSorin EIA without modification of the manufacturer's instructions, demonstrated a sensitivity of 95.24% and a specificity of 100%. Salivette samples analyzed with Radim EIA with receiver operating characteristic (ROC) curve for calculating the CO showed a sensitivity of 78.26% and a specificity of 89.88%. HBsAg was detected in Chembio and Salivette samples under different environmental conditions, but the Chembio samples were the most stable.
   ConclusionsBoth collectors can be used for HBsAg detection in OF samples, but some modifications of commercial EIAs should be incorporated for Salivette device. OF samples were reliably stable and could be stored for up to 90 days at 2-8 degrees C. (C) 2013 Wiley Periodicals, Inc.
C1 [Scalioni, Leticia de Paula; Cruz, Helena Medina; Oliveira, Jaqueline Correia; Lewis-Ximenez, Lia Laura; Lampe, Elisabeth; Villar, Livia Melo] Fiocruz MS, Lab Viral Hepatitis, Inst Oswaldo Cruz, BR-21036004 Rio De Janeiro, Brazil.
   [de Paula, Vanessa Salete; dos Santos, Renata Tourinho] Fiocruz MS, Lab Technol Dev Virol, Inst Oswaldo Cruz, BR-21036004 Rio De Janeiro, Brazil.
   [Coimbra Motta-Castro, Ana Rita; Murat, Paula Guerra] Univ Fed Mato Grosso do Sul, Lab Clin Immunol, Campo Grande, MS, Brazil.
   [Villela-Nogueira, Cristiane Alves] Univ Fed Rio de Janeiro, Hepatol Div, Clementino Fraga Filho Univ Hosp, Rio De Janeiro, Brazil.
RP Villar, LM (corresponding author), Fiocruz MS, Viral Hepatitis Lab, Helio & Peggy Pereira Pavill,Ground Floor, BR-21036004 Rio De Janeiro, Brazil.
EM lvillar@ioc.fiocruz.br
RI de Paula, Vanessa S/I-8037-2016; Cruz, Helena Medina/U-4780-2019;
   motta-castro, ana rita c/O-2075-2017; VILLAR, LIVIA M/F-7811-2012
OI de Paula, Vanessa S/0000-0002-6314-754X; Cruz, Helena
   Medina/0000-0003-2088-7705; VILLAR, LIVIA M/0000-0001-7644-8969;
   Motta-Castro, Ana Rita/0000-0003-3070-1337
FU Fundacao Oswaldo Cruz (FIOCRUZ); Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq)National Council for Scientific and
   Technological Development (CNPq); Fundacao de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ)
FX Grant sponsor: Fundacao Oswaldo Cruz (FIOCRUZ); Grant sponsor: Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Grant
   sponsor: Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro
   (FAPERJ).
CR Altman D.G., 1991, PRACTICAL STAT MED R
   Amado LA, 2006, MEM I OSWALDO CRUZ, V101, P149, DOI 10.1590/S0074-02762006000200006
   ARCHIBALD DW, 1986, J CLIN MICROBIOL, V24, P873, DOI 10.1128/JCM.24.5.873-875.1986
   Aspinall EJ, 2011, OCCUP MED-OXFORD, V61, P531, DOI 10.1093/occmed/kqr136
   Bello PY, 1998, EUR J CLIN MICROBIOL, V17, P570, DOI 10.1007/BF01708621
   Chiappin S, 2007, CLIN CHIM ACTA, V383, P30, DOI 10.1016/j.cca.2007.04.011
   CROFTS N, 1991, AIDS, V5, P561, DOI 10.1097/00002030-199105000-00013
   CROWTHER JR, 2000, ELISA GUIDEBOOK METH
   Cruz HM, 2011, J CLIN LAB ANAL, V25, P134, DOI 10.1002/jcla.20447
   Elgolihari HM, 2008, CLEV CLIN J MED, V75, P881, DOI 10.3949/ccjm.75a.07019
   FRIEDMAN MG, 1993, CLIN EXP IMMUNOL, V92, P194, DOI 10.1111/j.1365-2249.1993.tb03379.x
   Fung J, 2011, J MED VIROL, V83, P1900, DOI 10.1002/jmv.22171
   Hutse V, 2005, J MED VIROL, V77, P53, DOI 10.1002/jmv.20413
   Judd A, 2003, J MED VIROL, V71, P49, DOI 10.1002/jmv.10463
   Krajden M, 1999, J CLIN MICROBIOL, V37, P1683, DOI 10.1128/JCM.37.6.1683-1686.1999
   MAJOR CJ, 1991, J INFECT DIS, V163, P699, DOI 10.1093/infdis/163.4.699
   Morris M, 2002, J IMMUNOL METHODS, V266, P111, DOI 10.1016/S0022-1759(02)00114-X
   Ott JJ, 2012, VACCINE, V30, P2212, DOI 10.1016/j.vaccine.2011.12.116
   Roy KM, 1999, ORAL DIS, V5, P123
   Sanlidag T, 2005, J VIROL METHODS, V123, P49, DOI 10.1016/j.jviromet.2004.09.006
   Sarid O, 2001, J MED VIROL, V64, P149, DOI 10.1002/jmv.1030
   SHERMAN KE, 1994, AM J GASTROENTEROL, V89, P2025
   THIEME T, 1992, J CLIN MICROBIOL, V30, P1076, DOI 10.1128/JCM.30.5.1076-1079.1992
   Tourinho RS, 2011, J VIROL METHODS, V173, P169, DOI 10.1016/j.jviromet.2011.01.014
   VANDENAKKER R, 1992, AIDS, V6, P953, DOI 10.1097/00002030-199209000-00007
   Vyse AJ, 2001, PUBLIC HEALTH, V115, P201, DOI 10.1016/S0033-3506(01)00444-9
   WARD RL, 1992, J MED VIROL, V36, P222, DOI 10.1002/jmv.1890360313
   World Health Organization, 2011, HEP B
   ZAMAN S, 1991, ACTA PAEDIATR SCAND, V80, P1166, DOI 10.1111/j.1651-2227.1991.tb11805.x
   Zhevachevsky NG, 2000, J MED VIROL, V61, P433, DOI 10.1002/1096-9071(200008)61:4&lt;433::AID-JMV4&gt;3.0.CO;2-5
NR 30
TC 4
Z9 4
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0887-8013
EI 1098-2825
J9 J CLIN LAB ANAL
JI J. Clin. Lab. Anal.
PD MAY
PY 2013
VL 27
IS 3
BP 186
EP 194
DI 10.1002/jcla.21582
PG 9
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 291EU
UT WOS:000329811500004
PM 23440736
OA Green Published
DA 2020-11-30
ER

PT J
AU Villar, LM
   Brandao, CPU
   Marques, BLC
   da Silva, EF
   Marques, VA
   Villela-Nogueira, CA
   do O, KMR
   de Paula, MT
   Lewis-Ximenez, LL
   Ferreira, JAS
   Lampe, E
AF Villar, L. M.
   Brandao, C. P. U.
   Marques, B. L. C.
   da Silva, E. F.
   Marques, V. A.
   Villela-Nogueira, C. A.
   do O, K. M. R.
   de Paula, M. T.
   Lewis-Ximenez, L. L.
   Sa Ferreira, J. A.
   Lampe, E.
TI SIMULTANEOUS DETECTION OF HEPATITIS C VIRUS ANTIGEN AND ANTIBODIES USING
   DRIED BLOOD SPOTS SAMPLES
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress / 48th Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver (EASL)
CY APR 24-28, 2013
CL Amsterdam, NETHERLANDS
SP European Assoc Study Liver (EASL)
C1 [Villar, L. M.; Marques, B. L. C.; da Silva, E. F.; Marques, V. A.; Lewis-Ximenez, L. L.; Lampe, E.] Fiocruz MS, Inst Oswaldo Cruz, Viral Hepatitis Lab, BR-21045900 Rio De Janeiro, Brazil.
   [Brandao, C. P. U.] Federal Hosp Servers State Rio de Janeiro, Rio De Janeiro, Brazil.
   [Villela-Nogueira, C. A.] Univ Fed Rio de Janeiro, Hepatol Unit, Rio de Janeiro, Brazil.
   [do O, K. M. R.] Unimed Hosp, Petropolis, Brazil.
   [Sa Ferreira, J. A.] Immunobiol Technol Inst Biomanguinhos, Rio De Janeiro, Brazil.
EM liviafiocruz@gmail.com
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2013
VL 58
SU 1
MA 507
BP S208
EP S208
DI 10.1016/S0168-8278(13)60509-7
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 199GQ
UT WOS:000322983000508
DA 2020-11-30
ER

PT J
AU Lampe, E
   Lewis-Ximenez, L
   Espirito-Santo, MP
   Delvaux, NM
   Pereira, SA
   Peres-da-Silva, A
   Martins, RMB
   Soares, MA
   Santos, AF
   Vidal, LL
   Germano, FN
   de Martinez, AMB
   Basso, R
   Pinho, JRR
   Malta, FM
   Gomes-Gouvea, M
   Moliterno, RA
   Bertolini, DA
   Fujishima, MAT
   Bello, G
AF Lampe, Elisabeth
   Lewis-Ximenez, Lia
   Espirito-Santo, Marcia P.
   Delvaux, Nathalia M.
   Pereira, Sergio A.
   Peres-da-Silva, Allan
   Martins, Regina M. B.
   Soares, Marcelo A.
   Santos, Andre F.
   Vidal, Luanna L.
   Germano, Fabiana N.
   de Martinez, Ana Maria B.
   Basso, Rossana
   Rebello Pinho, Joao R.
   Malta, Fernanda M.
   Gomes-Gouvea, Michele
   Moliterno, Ricardo A.
   Bertolini, Dennis A.
   Fujishima, Mayara A. T.
   Bello, Gonzalo
TI Genetic diversity of HCV in Brazil
SO ANTIVIRAL THERAPY
LA English
DT Article
ID HEPATITIS-C-VIRUS; INJECTING DRUG-USERS; HEMODIALYSIS-PATIENTS;
   RISK-FACTORS; GENOTYPES; INFECTION; PREVALENCE; PROTEASE; TRANSMISSION;
   ACCURATE
AB Background: Many studies have documented the molecular epidemiological scenario of HCV within individual Brazilian states, but we still have an incomplete understanding of the dispersion dynamics of the virus in different regions throughout the country.
   Methods: A total of 676 HCV NS5B gene sequences of subtypes 1a (n=321), 1b (n=170) and 3a (n=185), isolated from seven different Brazilian states covering four out of five regions were analysed in the present study. We also analysed 22 HCV NS5B gene sequences of minor genetic variants including genotype 2 (n=13), genotype 4 (n=6) and subtype 5a (n=3). Brazilian HCV sequences were aligned with sequences of non-Brazilian origin and subjected to maximum likelihood phylogenetic analyses.
   Results: These analyses revealed that the Brazilian HCV epidemic resulted from multiple introductions and autochthonous transmission of subtypes 1a, 1b, 3a and genotypes 2, 4 and 5. Brazilian HCV subtype 1a epidemic is dominated by the dissemination of one major clade; while Brazilian HCV subtypes 1b and 3a epidemics are characterized by concurrent dissemination of several independent HCV lineages. Some HCV Brazilian lineages of subtypes 1a, 1b, 2b and 3a were successful in becoming established and disseminated through several regions in the country. Despite significant phylogenetic intermixing of Brazilian sequences, the distribution of HCV strains from different states across lineages was not completely homogeneous.
   Conclusions: These results demonstrate the existence of multiple introductions and local propagation of both prevalent and uncommon HCV genetic variants in Brazil and identify some major Brazilian HCV clades with nationwide dissemination. This study also suggests that the observed HCV diversity in Brazil has been shaped by both frequent viral migration among regions and in situ viral dissemination.
C1 [Lampe, Elisabeth; Lewis-Ximenez, Lia; Espirito-Santo, Marcia P.; Delvaux, Nathalia M.; Pereira, Sergio A.; Peres-da-Silva, Allan] Fiocruz MS, Inst Oswaldo Cruz, Lab Hepatites Virais, BR-21045900 Rio De Janeiro, Brazil.
   [Martins, Regina M. B.] Univ Fed Goias, Inst Patol Trop & Saude Publ, Goiania, Go, Brazil.
   [Soares, Marcelo A.; Santos, Andre F.; Vidal, Luanna L.; Germano, Fabiana N.] Univ Fed Rio de Janeiro, Dept Genet, Rio De Janeiro, Brazil.
   [de Martinez, Ana Maria B.; Basso, Rossana] Univ Fed Rio Grande, Fac Med, Rio Grande, Brazil.
   [Rebello Pinho, Joao R.; Malta, Fernanda M.; Gomes-Gouvea, Michele] Univ Sao Paulo, Fac Med, Dept Gastroenterol, BR-09500900 Sao Paulo, Brazil.
   [Moliterno, Ricardo A.; Bertolini, Dennis A.; Fujishima, Mayara A. T.] Univ Estadual Maringa, Dept Ciencias Basicas Saude, Maringa, Parana, Brazil.
   [Moliterno, Ricardo A.; Bertolini, Dennis A.; Fujishima, Mayara A. T.] Univ Estadual Maringa, Dept Anal Clin & Biomed, Maringa, Parana, Brazil.
   [Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
RP Lampe, E (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab Hepatites Virais, BR-21045900 Rio De Janeiro, Brazil.
EM elampe@ioc.fiocruz.br
RI Pinho, Joao R. R./G-2850-2012; Bentancor, Gonzalo Jose
   Bello/N-7377-2019; Santos, Andre FA/I-5734-2016; Soares, Marcelo
   A/G-5662-2010; Malta, Fernanda/B-1316-2013; Bello, Gonzalo/E-6842-2013
OI Pinho, Joao R. R./0000-0003-3999-0489; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793; Malta, Fernanda/0000-0001-8887-5060; ,
   Germano, FN/0000-0002-3474-0643
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Fundacao Carlos Chagas Filho de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ); Programa de
   Excelencia em Pesquisa - PROEP/FIOCRUZ
FX This work was supported by grants from the `Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico' (CNPq) the `Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior' (CAPES) the `Fundacao
   Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro'
   (FAPERJ) and `Programa de Excelencia em Pesquisa - PROEP/FIOCRUZ'. The
   authors wish also to thank `Plataforma Genomica de Sequenciamento de
   DNA/PDTIS-FIOCRUZ' for DNA sequencing.
CR Oliveira MDA, 2009, J CLIN VIROL, V44, P200, DOI 10.1016/j.jcv.2008.12.008
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Bae A, 2010, ANTIMICROB AGENTS CH, V54, P5288, DOI 10.1128/AAC.00777-10
   Brazil Health Ministry, VIR HEP NUMB
   Campiotto S, 2005, BRAZ J MED BIOL RES, V38, P41, DOI 10.1590/S0100-879X2005000100007
   Carneiro MAS, 2007, J MED VIROL, V79, P1325, DOI 10.1002/jmv.20932
   Freitas SZ, 2008, MEM I OSWALDO CRUZ, V103, P405, DOI 10.1590/S0074-02762008000400016
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Halfon P, 2011, J HEPATOL, V55, P192, DOI 10.1016/j.jhep.2011.01.011
   Hauri AM, 2004, INT J STD AIDS, V15, P7, DOI 10.1258/095646204322637182
   Holland PV, 1996, J CLIN MICROBIOL, V34, P2372, DOI 10.1128/JCM.34.10.2372-2378.1996
   Kuiken C, 2005, BIOINFORMATICS, V21, P379, DOI 10.1093/bioinformatics/bth485
   Lampe E, 2010, INFECT GENET EVOL, V10, P886, DOI 10.1016/j.meegid.2010.05.010
   Lavanchy D, 2011, CLIN MICROBIOL INFEC, V17, P107, DOI 10.1111/j.1469-0691.2010.03432.x
   Lenz O, 2012, J HEPATOL, V56, pS5, DOI 10.1016/S0168-8278(12)60023-3
   Lopes Carmen L R, 2009, Rev. Saúde Pública, V43, P43, DOI 10.1590/S0034-89102009000800008
   Martins Regina M.B., 2006, Rev. Inst. Med. trop. S. Paulo, V48, P53, DOI 10.1590/S0036-46652006000100012
   Martins RMB, 1998, MEM I OSWALDO CRUZ, V93, P299, DOI 10.1590/S0074-02761998000300004
   Oliveira MLA, 2009, EPIDEMIOL INFECT, V137, P970, DOI 10.1017/S0950268808001970
   Oliveira MLA, 1999, BRAZ J MED BIOL RES, V32, P279, DOI 10.1590/S0100-879X1999000300005
   Pereira LMMB, 2002, J MED VIROL, V67, P27, DOI 10.1002/jmv.2188
   Peres-da-Silva A, 2012, MEM I OSWALDO CRUZ, V107, P254, DOI 10.1590/S0074-02762012000200016
   Perez RM, 2003, J MED VIROL, V69, P489, DOI 10.1002/jmv.10336
   Pickett BE, 2011, J VIRAL HEPATITIS, V18, P608, DOI 10.1111/j.1365-2893.2010.01342.x
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Pybus Oliver G, 2005, Infect Genet Evol, V5, P131, DOI 10.1016/j.meegid.2004.08.001
   Ribeiro LC, 2009, ARCH VIROL, V154, P665, DOI 10.1007/s00705-008-0279-3
   RODRIGUEZ F, 1990, J THEOR BIOL, V142, P485, DOI 10.1016/S0022-5193(05)80104-3
   Romano CM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011170
   Silva LK, 2000, AM J TROP MED HYG, V62, P257, DOI 10.4269/ajtmh.2000.62.257
   Simmonds P, 2005, HEPATOLOGY, V42, P962, DOI 10.1002/hep.20819
   STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093
   Tanaka Y, 2005, J HEPATOL, V42, P47, DOI 10.1016/j.jhep.2004.09.023
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Vieira DS, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-165
   Zarife MAS, 2006, T ROY SOC TROP MED H, V100, P663, DOI 10.1016/j.trstmh.2005.09.009
NR 37
TC 19
Z9 19
U1 0
U2 2
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
J9 ANTIVIR THER
JI Antivir. Ther.
PY 2013
VL 18
IS 3
BP 435
EP 444
DI 10.3851/IMP2606
PN B
PG 10
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA AG2FM
UT WOS:000335231500003
PM 23792792
DA 2020-11-30
ER

PT J
AU Martins, PP
   Lampe, E
   Lewis-Ximenez, LL
   de Souza, PSF
   Fernandes, CA
   Villar, LM
AF Martins, Patricia Pais
   Lampe, Elisabeth
   Lewis-Ximenez, Lia Laura
   de Souza, Paulo Sergio Fonseca
   Fernandes, Carlos Augusto
   Villar, Livia Melo
TI Performance of Molecular Methods for Hepatitis C Virus Diagnosis:
   Usefulness among Chronic Cases and during the Course of Infection
SO CLINICAL LABORATORY
LA English
DT Article
DE hepatitis C; molecular diagnosis; performance
ID TRANSCRIPTION-MEDIATED AMPLIFICATION; INJECTING DRUG-USERS; TEST VERSION
   2.0; RIO-DE-JANEIRO; HCV RNA; CLINICAL-PERFORMANCE; VIROLOGICAL TOOLS;
   ASSAYS; QUANTIFICATION; PLATELETS
AB Background: Molecular methods are essential to define hepatitis C virus (HCV) infection. This study was conducted to evaluate the performance of molecular qualitative and quantitative methods for HCV RNA among chronic patients and individuals during the course of HCV infection.
   Methods: Single serum samples were obtained from 82 HCV infected individuals where six of them donated serial serum samples (n = 52) during the course of HCV infection. Qualitative (in-house RT-nested PCR and COBAS (R) AMPLICOR HCV Test v2.0 and TMA) and quantitative (COBAS (R) AMPLICOR HCV Monitor Test v2.0 and bDNA) techniques were employed.
   Results: TMA presented the highest rate (87.8%) of HCV detection among qualitative tests and it was the most sensitive for HCV RNA detection during the early and late phases of HCV infection. HCV RNA was quantified among 56 samples and significant correlation was observed between the two assays (r 0.92; p < 0.0001).
   Conclusions: It is concluded that both quantitative methods can be used among chronic and acute HCV cases, but TMA was the most efficient for HCV qualitative detection among chronic cases and in the early and late phases of HCV infection.
C1 [Martins, Patricia Pais; Lampe, Elisabeth; Lewis-Ximenez, Lia Laura; de Souza, Paulo Sergio Fonseca; Villar, Livia Melo] Fiocruz MS, Oswald Cruz Inst, Viral Hepatitis Lab, BR-21045900 Rio De Janeiro, Brazil.
   [Fernandes, Carlos Augusto] Cent Publ Hlth Lab Noel Nutels, Hepatitis Div, Rio De Janeiro, Brazil.
RP Villar, LM (corresponding author), Viral Hepatitis Lab, Helio & Peggy Pereira Pavill,Ground Floor Room B0, BR-21036004 Rio De Janeiro, RJ, Brazil.
EM lvillar@ioc.fiocruz.br
RI VILLAR, LIVIA M/F-7811-2012
OI VILLAR, LIVIA M/0000-0001-7644-8969
FU Brazilian National Counsel of Technological and Scientific Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Oswaldo Cruz Foundation (FIOCRUZ)
FX This research was supported by the Brazilian National Counsel of
   Technological and Scientific Development (CNPq) and the Oswaldo Cruz
   Foundation (FIOCRUZ).
CR Oliveira MDA, 2009, J CLIN VIROL, V44, P200, DOI 10.1016/j.jcv.2008.12.008
   Aguilera A, 2010, ENFERM INFEC MICR CL, V28, P62, DOI 10.1016/S0213-005X(10)70011-2
   Al Olaby RR, 2011, EXPERT REV MOL DIAGN, V11, P53, DOI [10.1586/erm.10.101, 10.1586/ERM.10.101]
   Ashfaq UA, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-161
   Bortoletto G, 2011, J CLIN VIROL, V50, P217, DOI 10.1016/j.jcv.2010.11.010
   Chevaliez S, 2011, CLIN MICROBIOL INFEC, V17, P116, DOI 10.1111/j.1469-0691.2010.03418.x
   Chevaliez S, 2012, GASTROENTEROLOGY, V142, P1303, DOI 10.1053/j.gastro.2012.02.027
   de Almeida AJ, 2009, HEPATO-GASTROENTEROL, V56, P429
   de Almeidal AJ, 2007, HEPATO-GASTROENTEROL, V54, P964
   Desombere I, 2005, J CLIN MICROBIOL, V43, P2590, DOI 10.1128/JCM.43.6.2590-2597.2005
   DRIESEL G, 1994, ARCH VIROL, V139, P379, DOI 10.1007/BF01310799
   Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047
   Hadziyannis SJ, 2004, ANN INTERN MED, V140, P346, DOI 10.7326/0003-4819-140-5-200403020-00010
   Hsieh MY, 2007, KAOHSIUNG J MED SCI, V23, P332, DOI 10.1016/S1607-551X(09)70418-8
   Krajden M, 2002, J CLIN MICROBIOL, V40, P2903, DOI 10.1128/JCM.40.8.2903-2907.2002
   KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0
   Lavanchy D, 2011, CLIN MICROBIOL INFEC, V17, P107, DOI 10.1111/j.1469-0691.2010.03432.x
   Lee SC, 2000, J CLIN MICROBIOL, V38, P4171, DOI 10.1128/JCM.38.11.4171-4179.2000
   Ministerio da Saude (Brasil), 2007, DIARIO OFICIAL UNIAO
   Morishima C, 2008, HEPATOLOGY, V48, P1412, DOI 10.1002/hep.22487
   Oliveira MLA, 1999, BRAZ J MED BIOL RES, V32, P1107, DOI 10.1590/S0100-879X1999000900009
   Oliveira MLA, 1999, BRAZ J MED BIOL RES, V32, P279, DOI 10.1590/S0100-879X1999000300005
   Pawlotsky JM, 2002, HEPATOLOGY, V36, pS65, DOI 10.1053/jhep.2002.36815
   Rao V, 2010, RENAL FAILURE, V32, P721, DOI 10.3109/0886022X.2010.486499
   Sarrazin C, 2000, HEPATOLOGY, V32, P818, DOI 10.1053/jhep.2000.17709
   Sarrazin C, 2006, J CLIN MICROBIOL, V44, P729, DOI 10.1128/JCM.44.3.729-737.2006
   Scott JD, 2007, JAMA-J AM MED ASSOC, V297, P724, DOI 10.1001/jama.297.7.724
   Sherman KE, 2002, CLIN INFECT DIS, V35, P482, DOI 10.1086/341976
   SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391
   Trabaud MA, 1997, J MED VIROL, V52, P105, DOI 10.1002/(SICI)1096-9071(199705)52:1&lt;105::AID-JMV17&gt;3.0.CO;2-L
NR 30
TC 2
Z9 4
U1 0
U2 1
PU CLIN LAB PUBL
PI HEIDELBERG
PA IM BREITSPIEL 15, HEIDELBERG, D-69126, GERMANY
SN 1433-6510
J9 CLIN LAB
JI Clin. Lab.
PY 2013
VL 59
IS 9-10
BP 1031
EP 1039
DI 10.7754/Clin.Lab.2013.120903
PG 9
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 278TT
UT WOS:000328913400011
PM 24273925
DA 2020-11-30
ER

PT J
AU Cruz, HM
   Marques, VA
   Villela-Nogueira, CA
   do O, KMR
   Lewis-Ximenez, LL
   Lampe, E
   Villar, LM
AF Cruz, H. M.
   Marques, V. A.
   Villela-Nogueira, C. A.
   do O, K. M. R.
   Lewis-Ximenez, L. L.
   Lampe, E.
   Villar, L. M.
TI An evaluation of different saliva collection methods for detection of
   antibodies against hepatitis C virus (anti-HCV)
SO JOURNAL OF ORAL PATHOLOGY & MEDICINE
LA English
DT Article
DE diagnosis; enzyme immunoassay; hepatitis C virus; saliva
ID ORAL FLUID SAMPLES; BLOOD; SPECIMENS; HIV-1; ASSAY; RNA; INFECTION;
   DIAGNOSIS; PLASMA; SERUM
AB BACKGROUND: Saliva samples can be used as an alternative fluid for against hepatitis C virus (anti-HCV) detection owing to the ease of collection and excellent acceptability. This study was conducted to optimize a commercial enzyme immunoassay (EIA) to detect anti-HCV in saliva samples.
   METHODS: Ninety-six individuals donated paired serum and saliva samples that were obtained, using a commercial device (Salivette) and spitting into a sterile container. Initially, elution buffer for the Salivette samples, sample volume, incubation time and temperature, and two different anti-HCV EIAs were evaluated. Using the optimized assay, three methods for cut-off calculation were also evaluated.
   RESULTS: A 20-fold increase in the sample volume for both collection methods was needed. Moreover, the Radim assay was the most appropriate assay for anti-HCV detection in saliva samples, and the quality parameters were increased when a ROC curve was used to determine the cut-off value. Using this optimized assay, the sensitivities, specificities, accuracies, positive and negative predictive values were above 90% for saliva obtained using both the Salivette and spitting methods. Using this assay, discordant false-negative results were obtained for only two Salivette samples and five spitting samples. The concordance kappa was 93% for the Salivette method and 86.1% for the spitting method, demonstrating excellent performance.
   CONCLUSIONS: Saliva samples obtained for both methods can be employed for anti-HCV detection among HCV-infected or HCV-suspected cases, but several modifications must be performed on commercial EIAs to obtain good results. Moreover, samples obtained with commercial devices are more appropriate for anti-HCV detection in saliva samples. J Oral Pathol Med (2012) 41: 793-800
C1 [Cruz, H. M.; Marques, V. A.; Lewis-Ximenez, L. L.; Lampe, E.; Villar, L. M.] Fiocruz MS, Inst Oswaldo Cruz, Viral Hepatitis Lab, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Villela-Nogueira, C. A.; do O, K. M. R.] Univ Fed Rio de Janeiro, Clementino Fraga Filho Univ Hosp, Hepatol Div, Rio De Janeiro, Brazil.
RP Villar, LM (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Viral Hepatitis Lab, Ground Floor,Room B09,Av Brasil 4365 Manguinhos R, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM lvillar@ioc.fiocruz.br
RI Cruz, Helena Medina/U-4780-2019; VILLAR, LIVIA M/F-7811-2012
OI Cruz, Helena Medina/0000-0003-2088-7705; VILLAR, LIVIA
   M/0000-0001-7644-8969
FU Rio de Janeiro State Research Supporting Foundation (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); National Counsel of Technological and Scientific
   Development(CNPq)National Council for Scientific and Technological
   Development (CNPq); Oswaldo Cruz Foundation (FIOCRUZ)
FX We thank the technicians of the Viral Hepatitis Laboratory for their
   technical assistance. This research was supported by the Rio de Janeiro
   State Research Supporting Foundation (FAPERJ), the National Counsel of
   Technological and Scientific Development(CNPq) and the Oswaldo Cruz
   Foundation (FIOCRUZ).
CR Altman D.G., 1991, PRACTICAL STAT MED R
   Amado LA, 2006, MEM I OSWALDO CRUZ, V101, P149, DOI 10.1590/S0074-02762006000200006
   Ayele W, 2007, J CLIN MICROBIOL, V45, P891, DOI 10.1128/JCM.01919-06
   Bello PY, 1998, EUR J CLIN MICROBIOL, V17, P570, DOI 10.1007/BF01708621
   Bourlet T, 2001, AIDS, V15, P284, DOI 10.1097/00002030-200101260-00025
   Cameron SO, 1999, J VIRAL HEPATITIS, V6, P141, DOI 10.1046/j.1365-2893.1999.00142.x
   Chiappin S, 2007, CLIN CHIM ACTA, V383, P30, DOI 10.1016/j.cca.2007.04.011
   CROWTHER JR, 2001, ELISA GUIDEBOOK METH
   Cruz HM, 2011, J CLIN LAB ANAL, V25, P134, DOI 10.1002/jcla.20447
   De Cock L, 2004, J VIROL METHODS, V122, P179, DOI 10.1016/j.jviromet.2004.09.001
   Elsana S, 1998, J MED VIROL, V55, P24, DOI 10.1002/(SICI)1096-9071(199805)55:1&lt;24::AID-JMV5&gt;3.0.CO;2-Q
   Gonzalez V, 2008, EUR J CLIN MICROBIOL, V27, P121, DOI 10.1007/s10096-007-0408-z
   Judd A, 2003, J MED VIROL, V71, P49, DOI 10.1002/jmv.10463
   Lee JM, 2009, ORTHOD CRANIOFAC RES, V12, P206, DOI 10.1111/j.1601-6343.2009.01454.x
   Lee SR, 2010, J CLIN VIROL, V48, P15, DOI 10.1016/j.jcv.2010.02.018
   Lee SR, 2011, J VIROL METHODS, V172, P27, DOI 10.1016/j.jviromet.2010.12.009
   Lee YH, 2009, AM J DENT, V22, P241
   Lucidarme D, 2003, GASTROEN CLIN BIOL, V27, P159
   Mahboobi N, 2012, J ORAL PATHOL MED, V41, P505, DOI 10.1111/j.1600-0714.2011.01123.x
   McIntyre PG, 1996, EUR J CLIN MICROBIOL, V15, P882, DOI 10.1007/BF01691223
   Monti LD, 2000, METABOLISM, V49, P73, DOI 10.1016/S0026-0495(00)90763-7
   Moorthy M, 2008, INDIAN J MED MICROBI, V26, P327
   Nugent CT, 2009, J VIROL METHODS, V159, P10, DOI 10.1016/j.jviromet.2009.02.015
   Obuchowski NA, 2005, AM J ROENTGENOL, V184, P364, DOI 10.2214/ajr.184.2.01840364
   PARRY JV, 1987, LANCET, V2, P72, DOI 10.1016/S0140-6736(87)92737-1
   Pilcher CD, 2007, AIDS, V21, P1723, DOI 10.1097/QAD.0b013e3281532c82
   Pink R, 2009, BIOMED PAP, V153, P103, DOI 10.5507/bp.2009.017
   Portilho MM, 2012, J MED MICROBIOL, V61, P844, DOI 10.1099/jmm.0.040238-0
   Sambrook J., 1989, MOL CLONING LAB MANU, V3, pE3
   Shepard RN, 2000, J CLIN MICROBIOL, V38, P1414, DOI 10.1128/JCM.38.4.1414-1418.2000
   SHERMAN KE, 1994, AM J GASTROENTEROL, V89, P2025
   THIEME T, 1992, J CLIN MICROBIOL, V30, P1076, DOI 10.1128/JCM.30.5.1076-1079.1992
   Tourinho RS, 2011, J VIROL METHODS, V173, P169, DOI 10.1016/j.jviromet.2011.01.014
   Van Doornum GJJ, 2001, J MED VIROL, V64, P13, DOI 10.1002/jmv.1011
NR 34
TC 13
Z9 13
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0904-2512
EI 1600-0714
J9 J ORAL PATHOL MED
JI J. Oral Pathol. Med.
PD NOV
PY 2012
VL 41
IS 10
BP 793
EP 800
DI 10.1111/j.1600-0714.2012.01176.x
PG 8
WC Dentistry, Oral Surgery & Medicine; Pathology
SC Dentistry, Oral Surgery & Medicine; Pathology
GA 030WH
UT WOS:000310600300011
PM 22690929
DA 2020-11-30
ER

PT J
AU Marques, BLC
   Brandao, CU
   Silva, EF
   Marques, VA
   Villela-Nogueira, CA
   Do, KMR
   de Paula, MT
   Lewis-Ximenez, LL
   Lampe, E
   Villar, LM
AF Marques, B. L. C.
   Brandao, C. U.
   Silva, E. F.
   Marques, V. A.
   Villela-Nogueira, C. A.
   Do O, K. M. R.
   de Paula, M. T.
   Lewis-Ximenez, L. L.
   Lampe, E.
   Villar, L. M.
TI Dried blood spot samples: Optimization of commercial EIAs for hepatitis
   C antibody detection and stability under different storage conditions
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE hepatitis C virus; diagnosis; dried blood spot; enzyme immunoassay;
   stability studies
ID HUMAN-IMMUNODEFICIENCY-VIRUS; FILTER-PAPER; RISK-FACTORS; PREVALENCE;
   WOMEN; HIV; RNA
AB This study was undertaken to optimize and compare the efficiency of two commercial EIAs for anti-HCV detection (HCV Ab Radim, Pomezzia, Italy and ETI-AB-HCVK-4 DiaSorin, Vercelli, Italy), in dried blood spot (DBS) samples. The long-term stability of anti-HCV on DBS samples stored at three environmental conditions was also evaluated at: 28 degrees C, 2025 degrees C, and -20 degrees C. Paired DBS and serum samples were obtained from individuals with or without anti-HCV. The type of elution buffer, sample and conjugate volume, sample incubation time and cut-off values were evaluated. For both EIAs, a larger sample volume was used, and the cut-off value determined by the manufacturer was employed for Radim EIA; however, ROC curve analysis was used for the DiaSorin EIA. The sensitivity and specificity of Radim EIA on DBS were 97.5% and 99.5%, respectively, and of DiaSorin EIA were 88.9% and 98.9%, respectively. Accurate results were obtained for a period of 117 days using DBS samples stored at all storage conditions, but storage at -20 degrees C resulted in the lowest variation among the absorbance values. Both EIAs demonstrated the same limit of detection (until dilution of 1:104 with estimated viral load of 3.1?x?10-1?UI/ml), but the Radim EIA was associated with the best performance because a low coefficient of variation was observed in the repetition and reproducibility studies. In conclusion, commercial EIAs can be optimized for anti-HCV detection in DBS samples that are extremely stable at different conditions for more than 100 days. J. Med. Virol. 84:16001607, 2012. (c) 2012 Wiley Periodicals, Inc.
C1 [Marques, B. L. C.; Silva, E. F.; Marques, V. A.; Lewis-Ximenez, L. L.; Lampe, E.; Villar, L. M.] Fiocruz MS, Inst Oswaldo Cruz, Lab Viral Hepatitis, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Brandao, C. U.; de Paula, M. T.] Fed Hosp Servers State Rio de Janeiro, Rio De Janeiro, RJ, Brazil.
   [Villela-Nogueira, C. A.] Univ Fed Rio de Janeiro, Clementino Fraga Filho Univ Hosp, Hepatol Div, Rio De Janeiro, RJ, Brazil.
   [Do O, K. M. R.] Unimed Hosp, Rio De Janeiro, RJ, Brazil.
RP Villar, LM (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab Viral Hepatitis, Pavilhao Helio & Peggy Pereira Terreo,Sala B09,Av, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM lvillar@ioc.fiocruz.br
RI VILLAR, LIVIA M/F-7811-2012
OI VILLAR, LIVIA M/0000-0001-7644-8969
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Oswaldo Cruz Foundation (FIOCRUZ)
FX Grant sponsor: Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro
   (FAPERJ); Grant sponsor: Oswaldo Cruz Foundation (FIOCRUZ)..
CR Abe K, 1998, J CLIN MICROBIOL, V36, P3070, DOI 10.1128/JCM.36.10.3070-3072.1998
   Ashfaq UA, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-161
   Bazzigaluppi E, 1999, DIABETES CARE, V22, P275, DOI 10.2337/diacare.22.2.275
   Biggar RJ, 1997, J ACQ IMMUN DEF SYND, V14, P368, DOI 10.1097/00042560-199704010-00010
   Bruns T, 2009, J CLIN MICROBIOL, V47, P3231, DOI 10.1128/JCM.00925-09
   Chevaliez S, 2011, CLIN MICROBIOL INFEC, V17, P116, DOI 10.1111/j.1469-0691.2010.03418.x
   Costa ZB, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-116
   Croom HA, 2006, J CLIN VIROL, V36, P68, DOI 10.1016/j.jcv.2005.12.002
   Crowther JR, 2009, ELISA GUIDEBOOK METH
   Cruz HM, 2011, J CLIN LAB ANAL, V25, P134, DOI 10.1002/jcla.20447
   GUTHRIE R, 1963, PEDIATRICS, V32, P338
   Hutchinson SJ, 2004, GUT, V53, P593, DOI 10.1136/gut.2003.027383
   International Committee on Taxonomy of Viruses (ICTV), 2011, HEP C VIR
   IRIE M, 1975, LANCET, V2, P1233
   Judd A, 2003, J MED VIROL, V71, P49, DOI 10.1002/jmv.10463
   Lavanchy D, 2011, CLIN MICROBIOL INFEC, V17, P107, DOI 10.1111/j.1469-0691.2010.03432.x
   Mahfoud Z, 2010, J INFECT DEV COUNTR, V4, P144, DOI 10.3855/jidc.517
   McCarron B, 1999, J VIRAL HEPATITIS, V6, P453, DOI 10.1046/j.1365-2893.1999.00197.x
   Melgaco JG, 2011, J MED VIROL, V83, P208, DOI 10.1002/jmv.21973
   Mendy M, 2005, J VIRAL HEPATITIS, V12, P642, DOI 10.1111/j.1365-2893.2005.00641.x
   Montebugnoli L, 1999, CLIN CHIM ACTA, V288, P91, DOI 10.1016/S0009-8981(99)00146-1
   Neto EC, 2004, EMERG INFECT DIS, V10, P1069, DOI 10.3201/eid1006.030830
   Obuchowski NA, 2005, AM J ROENTGENOL, V184, P364, DOI 10.2214/ajr.184.2.01840364
   Parker SP, 1999, J CLIN MICROBIOL, V37, P2061, DOI 10.1128/JCM.37.6.2061-2063.1999
   Parker SP, 1997, J VIROL METHODS, V68, P199, DOI 10.1016/S0166-0934(97)00127-4
   Pawlotsky JM, 2002, HEPATOLOGY, V36, pS65, DOI 10.1053/jhep.2002.36815
   Sambrook J., 1989, MOL CLONING LAB MANU, V3, pE3
   Solmone M, 2002, J CLIN MICROBIOL, V40, P3512, DOI 10.1128/JCM.40.9.3512-3514.2002
   Tappin DM, 1998, EPIDEMIOL INFECT, V121, P387, DOI 10.1017/S0950268898001393
   Toledo ACD, 2005, MEM I OSWALDO CRUZ, V100, P365
   Tourinho RS, 2011, J VIROL METHODS, V173, P169, DOI 10.1016/j.jviromet.2011.01.014
   Tuaillon E, 2010, HEPATOLOGY, V51, P752, DOI 10.1002/hep.23407
   Universidade de Pernambuco, 2010, NUCL POS GRAD EST PR
   Villar LM, 2011, J MED VIROL, V83, P1522, DOI 10.1002/jmv.22138
NR 34
TC 20
Z9 21
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD OCT
PY 2012
VL 84
IS 10
BP 1600
EP 1607
DI 10.1002/jmv.23379
PG 8
WC Virology
SC Virology
GA 996QF
UT WOS:000308106500014
PM 22930508
DA 2020-11-30
ER

PT J
AU Mello, FCA
   Lago, BV
   Lewis-Ximenez, LL
   Fernandes, CA
   Gomes, SA
AF Mello, Francisco C. A.
   Lago, Barbara V.
   Lewis-Ximenez, Lia L.
   Fernandes, Carlos A.
   Gomes, Selma A.
TI Detection of mixed populations of wild-type and YMDD hepatitis B
   variants by pyrosequencing in acutely and chronically infected patients
SO BMC MICROBIOLOGY
LA English
DT Article
ID MONITORING DRUG-RESISTANCE; REAL-TIME PCR; LAMIVUDINE THERAPY; VIRUS
   POLYMERASE; ANTIVIRAL THERAPY; MUTATIONS; IDENTIFICATION; PREVALENCE;
   GENOTYPES; ASSAY
AB Background: Lamivudine (LAM) is associated with the highest known rate of resistance mutations among nucleotide analogs used to treat chronic hepatitis B virus (HBV) infection. Despite this, LAM continues in widespread use, especially in combination therapies. The primary LAM resistance mutation (rtM204V/I) occurs in the YMDD motif of HBV polymerase. The aim of this study was to characterize Brazilian HBV isolates from acute and chronic cases by direct sequencing, and to identify HBV quasispecies in the YMDD motif using a pyrosequencing method capable of detecting single-nucleotide polymorphisms. HBV DNA from serum samples of 20 individuals with acute HBV infection and 44 with chronic infection undergoing antiviral therapies containing LAM were analyzed by direct sequencing and pyrosequencing methods.
   Results: Phylogenic analyses of direct-sequenced isolates showed the expected genotypes (A, D and F) for the Brazilian population in both acute and chronic infections. However, within genotype A isolates, subgenotype A2 was more frequently detected in acute cases than in chronic cases (P = 0.012). As expected, none of the individuals with acute hepatitis B had LAM-resistant isolates as a dominant virus population, whether detected by direct sequencing or pyrosequencing. However, pyrosequencing analyses showed that 45% of isolates (9/20) had minor subpopulations (4-17%) of LAM-resistant isolates. Among chronic patients undergoing LAM treatment, YMDD mutants were frequently found as a dominant virus population. In cases where wild-type virus was the dominant population, subpopulations of YMDD variants were usually found, demonstrating the complexity of HBV quasispecies.
   Conclusions: YMDD variants were frequently detected as a minor population in acute HBV infection. The occurrence of pre-existing variants may lead to a high frequency of resistant mutants during antiviral therapy in the chronic phase. In chronic infection, detection of YMDD variants before virological or biochemical breakthrough might contribute to making better therapy choices and thus improving treatment outcome.
C1 [Mello, Francisco C. A.; Lago, Barbara V.; Gomes, Selma A.] Fiocruz MS, Inst Oswaldo Cruz, Mol Virol Lab, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Lewis-Ximenez, Lia L.] Fiocruz MS, Inst Oswaldo Cruz, Lab Referencia Nacl Hepatites Virais, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Fernandes, Carlos A.] Lab Cent Saude Publ Noel Nutels, BR-20231092 Rio De Janeiro, RJ, Brazil.
RP Gomes, SA (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Mol Virol Lab, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM selma@ioc.fiocruz.br
RI gomes, selma A/D-2762-2015
OI Fernandes, Carlos/0000-0003-2941-4744; Gomes, Selma/0000-0003-0233-3370
FU PAPES/CNPqNational Council for Scientific and Technological Development
   (CNPq)
FX The authors thank the Plataforma Genomica - Sequenciamento de
   DNA/PDTIS-FIOCRUZ for performing the DNA sequencing. Financial support:
   PAPES/CNPq.
CR Ahmed SNS, 2000, HEPATOLOGY, V32, P1078, DOI 10.1053/jhep.2000.19619
   Allen MI, 1999, J CLIN MICROBIOL, V37, P3338, DOI 10.1128/JCM.37.10.3338-3347.1999
   Allen MI, 1998, HEPATOLOGY, V27, P1670, DOI 10.1002/hep.510270628
   Cane PA, 1999, ANTIMICROB AGENTS CH, V43, P1600, DOI 10.1128/AAC.43.7.1600
   Chayama K, 1998, HEPATOLOGY, V27, P1711, DOI 10.1002/hep.510270634
   Dienstag JL, 1999, NEW ENGL J MED, V341, P1256, DOI 10.1056/NEJM199910213411702
   Mello FCD, 2012, MEM I OSWALDO CRUZ, V107, P317, DOI 10.1590/S0074-02762012000300005
   Ijaz S, 2008, J MED VIROL, V80, P1160, DOI 10.1002/jmv.21206
   Jardi R, 1999, J VIROL METHODS, V83, P181, DOI 10.1016/S0166-0934(99)00125-1
   Kim HS, 2005, ANTIVIR THER, V10, P441
   Lai CL, 2003, CLIN INFECT DIS, V36, P687, DOI 10.1086/368083
   Lindstrom A, 2004, J CLIN MICROBIOL, V42, P4788, DOI 10.1128/JCM.42.10.4788-4795.2004
   Ling R, 1996, HEPATOLOGY, V24, P711, DOI 10.1053/jhep.1996.v24.pm0008781347
   Malmstrom S, 2007, J VIROL METHODS, V143, P147, DOI 10.1016/j.jviromet.2007.03.001
   Margeridon-Thermet S, 2009, J INFECT DIS, V199, P1275, DOI 10.1086/597808
   Moraes MTB, 1999, BRAZ J MED BIOL RES, V32, P45, DOI 10.1590/S0100-879X1999000100006
   Shamliyan TA, 2011, J GEN INTERN MED, V26, P326, DOI 10.1007/s11606-010-1569-5
   Shaw T, 2006, J HEPATOL, V44, P593, DOI 10.1016/j.jhep.2006.01.001
   Solmone M, 2009, J VIROL, V83, P1718, DOI 10.1128/JVI.02011-08
   Stuyver L, 2000, J CLIN MICROBIOL, V38, P702, DOI 10.1128/JCM.38.2.702-707.2000
   Sucupira MVF, 2006, MEM I OSWALDO CRUZ, V101, P655, DOI 10.1590/S0074-02762006000600013
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Tran N, 2006, J CLIN MICROBIOL, V44, P2792, DOI 10.1128/JCM.00295-06
   Wang RS, 2006, WORLD J GASTROENTERO, V12, P1308, DOI 10.3748/wjg.v12.i8.1308
   Yuen LKW, 2009, J HEPATOL, V50, P445, DOI 10.1016/j.jhep.2008.12.005
   Yuen MF, 2001, HEPATOLOGY, V34, P785, DOI 10.1053/jhep.2001.27563
   Zoulim F, 2009, GASTROENTEROLOGY, V137, P1593, DOI 10.1053/j.gastro.2009.08.063
NR 28
TC 17
Z9 20
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2180
J9 BMC MICROBIOL
JI BMC Microbiol.
PD JUN 6
PY 2012
VL 12
AR 96
DI 10.1186/1471-2180-12-96
PG 9
WC Microbiology
SC Microbiology
GA 973EV
UT WOS:000306340900001
PM 22672436
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Villar, LM
   Cruz, HM
   Scalioni, LP
   de Paula, VS
   Miguel, JC
   da Silva, EF
   Oliveira, JC
   Marques, VA
   Portilho, MM
   Marques, BLC
   Villela-Nogueira, CA
   Milagres, FAP
   Lewis-Ximenez, LL
   Lampe, E
AF Villar, L. M.
   Cruz, H. M.
   Scalioni, L. P.
   de Paula, V. S.
   Miguel, J. C.
   da Silva, E. F.
   Oliveira, J. C.
   Marques, V. A.
   Portilho, M. M.
   Marques, B. L. C.
   Villela-Nogueira, C. A.
   Milagres, F. A. P.
   Lewis-Ximenez, L. L.
   Lampe, E.
TI CAN RAPID TESTS BE APPLIED FOR HEPATITIS C VIRUS DIAGNOSIS IN DEVELOPING
   COUNTRIES?
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 47th Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver (EASL)
CY APR 18-22, 2012
CL Barcelona, SPAIN
SP European Assoc Study Liver (EASL)
C1 [Villar, L. M.; Cruz, H. M.; Scalioni, L. P.; Miguel, J. C.; da Silva, E. F.; Oliveira, J. C.; Marques, V. A.; Portilho, M. M.; Marques, B. L. C.; Lewis-Ximenez, L. L.; Lampe, E.] Oswaldo Cruz Inst Fiocruz, Viral Hepatitis Lab, Rio De Janeiro, Brazil.
   [de Paula, V. S.] Oswaldo Cruz Inst Fiocruz, Lab Technol Dev Virol, Rio De Janeiro, Brazil.
   [Villela-Nogueira, C. A.] Univ Fed Rio de Janeiro, Clementino Fraga Filho Hosp, Rio De Janeiro, Brazil.
   [Milagres, F. A. P.] Fed Univ Tocantis, Fac Med, Palmas, Brazil.
EM lvillar@ioc.fiocruz.br
RI milagres, flavio/Q-2403-2019; de Paula, Vanessa S/I-8037-2016; VILLAR,
   LIVIA M/F-7811-2012
OI de Paula, Vanessa S/0000-0002-6314-754X; VILLAR, LIVIA
   M/0000-0001-7644-8969
NR 0
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2012
VL 56
SU 2
MA 157
BP S68
EP S68
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 931TD
UT WOS:000303241300157
DA 2020-11-30
ER

PT J
AU zur Wiesch, JS
   Ciuffreda, D
   Lewis-Ximenez, L
   Kasprowicz, V
   Nolan, BE
   Streeck, H
   Aneja, J
   Reyor, LL
   Allen, TM
   Lohse, AW
   McGovern, B
   Chung, RT
   Kwok, WW
   Kim, AY
   Lauer, GM
AF zur Wiesch, Julian Schulze
   Ciuffreda, Donatella
   Lewis-Ximenez, Lia
   Kasprowicz, Victoria
   Nolan, Brian E.
   Streeck, Hendrik
   Aneja, Jasneet
   Reyor, Laura L.
   Allen, Todd M.
   Lohse, Ansgar W.
   McGovern, Barbara
   Chung, Raymond T.
   Kwok, William W.
   Kim, Arthur Y.
   Lauer, Georg M.
TI Broadly directed virus-specific CD4(+) T cell responses are primed
   during acute hepatitis C infection, but rapidly disappear from human
   blood with viral persistence
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
ID INTERFERON-ALPHA THERAPY; ACUTE HCV INFECTION; EX-VIVO ANALYSIS;
   IMMUNE-RESPONSES; NONSTRUCTURAL PROTEIN-3; SPONTANEOUS-RECOVERY;
   ANTIVIRAL TREATMENT; PD-1 EXPRESSION; CD4+T CELLS; CD8(+)
AB Vigorous proliferative CD4(+) T cell responses are the hallmark of spontaneous clearance of acute hepatitis C virus (HCV) infection, whereas comparable responses are absent in chronically evolving infection. Here, we comprehensively characterized the breadth, specificity, and quality of the HCV-specific CD4(+) T cell response in 31 patients with acute HCV infection and varying clinical outcomes. We analyzed in vitro T cell expansion in the presence of interleukin-2, and ex vivo staining with HCV peptide-loaded MHC class II tetramers. Surprisingly, broadly directed HCV-specific CD4(+) T cell responses were universally detectable at early stages of infection, regardless of the clinical outcome. However, persistent viremia was associated with early proliferative defects of the HCV-specific CD4(+) T cells, followed by rapid deletion of the HCV-specific response. Only early initiation of antiviral therapy was able to preserve CD4(+) T cell responses in acute, chronically evolving infection. Our results challenge the paradigm that HCV persistence is the result of a failure to prime HCV-specific CD4(+) T cells. Instead, broadly directed HCV-specific CD4(+) T cell responses are usually generated, but rapid exhaustion and deletion of these cells occurs in the majority of patients. The data further suggest a short window of opportunity to prevent the loss of CD4(+) T cell responses through antiviral therapy.
C1 [zur Wiesch, Julian Schulze; Ciuffreda, Donatella; Nolan, Brian E.; Aneja, Jasneet; Reyor, Laura L.; Chung, Raymond T.; Lauer, Georg M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
   [Aneja, Jasneet; Reyor, Laura L.; Kim, Arthur Y.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
   [Kasprowicz, Victoria; Streeck, Hendrik; Allen, Todd M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ragon Inst MGH MIT & Harvard, Boston, MA 02114 USA.
   [zur Wiesch, Julian Schulze; Lohse, Ansgar W.] Univ Klinikum Hamburg Eppendorf, Med Klin 1, D-20246 Hamburg, Germany.
   [zur Wiesch, Julian Schulze] Leibniz Inst Expt Virol, Heinrich Pette Inst, D-20251 Hamburg, Germany.
   [McGovern, Barbara] Tufts Univ, Sch Med, Lemuel Shattuck Hosp, Jamaica Plain, MA 02130 USA.
   [Kwok, William W.] Benaroya Res Inst Virginia Mason, Seattle, WA 98101 USA.
   [Lewis-Ximenez, Lia] Fundacao Oswaldo Cruz, Lab Hepatites Virais, Inst Oswaldo Cruz, BR-21040 Rio De Janeiro, RJ, Brazil.
RP Lauer, GM (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
EM glauer@helix.mgh.harvard.edu
RI Allen, Todd/F-5473-2011; Lauer, Georg/J-1467-2018
OI Allen, Todd/0000-0002-6609-1318; Lauer, Georg/0000-0002-9792-4271
FU Howard Hughes Medical InstituteHoward Hughes Medical Institute; Deutsche
   ForschungsgemeinschaftGerman Research Foundation (DFG) [Schu 2482/1-1,
   SFB 841 A6]; Swiss National Science FoundationSwiss National Science
   Foundation (SNSF); National Institutes of HealthUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USA
   [U19-AI066345, U19-AI082630, R01-AI067926-01]; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [P30AI060354,
   U19AI066345, U19AI082630, P30AI060354, U19AI082630, U19AI066345,
   P30AI060354, U19AI082630, P30AI060354, U19AI066345, U19AI082630,
   U19AI082630, U19AI082630, P30AI060354, U19AI066345, U19AI066345,
   U19AI066345, P30AI060354, U19AI082630, P30AI060354, U19AI082630,
   U19AI082630, U19AI082630, U19AI082630, U19AI066345, U19AI082630,
   U19AI066345, P30AI060354, U19AI082630, P30AI060354, P30AI060354,
   R01AI091450, P30AI060354, P30AI060354, P30AI060354, U19AI082630,
   U19AI066345, U19AI082630, U19AI066345, P30AI060354, U19AI082630,
   U19AI066345, U19AI082630, P30AI060354, U19AI082630, U19AI066345,
   P30AI060354, U19AI066345, U19AI082630, U19AI082630, U19AI082630,
   P30AI060354, P30AI060354, P30AI060354, P30AI060354, P30AI060354,
   P30AI060354, P30AI060354, U19AI066345, U19AI082630, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI082630, P30AI060354,
   U19AI066345, U19AI082630, P30AI060354, U19AI082630, U19AI082630,
   U19AI082630, P30AI060354, U19AI082630, P30AI060354, U19AI082630,
   U19AI082630, U19AI066345, U19AI082630, U19AI082630, P30AI060354,
   U19AI066345, P30AI060354, U19AI066345, U19AI082630, U19AI066345,
   P30AI060354, P30AI060354, P30AI060354, P30AI060354, U19AI082630,
   U19AI066345, P30AI060354, U19AI082630, U19AI082630, U19AI082630,
   U19AI066345, U19AI066345, U19AI082630, U19AI066345, P30AI060354,
   P30AI060354, P30AI060354, U19AI066345, P30AI060354, P30AI060354,
   U19AI082630, R01AI067926, R01AI067926, P30AI060354, U19AI082630,
   U19AI082630, P30AI060354, P30AI060354, U19AI082630, U19AI082630,
   U19AI082630, U19AI066345, P30AI060354, P30AI060354, U19AI082630,
   U19AI082630, P30AI060354, P30AI060354, P30AI060354, U19AI082630,
   R01AI091450, U19AI066345, U19AI066345, U19AI066345, U19AI082630,
   P30AI060354, U19AI066345, U19AI082630, U19AI082630, P30AI060354,
   U19AI082630, U19AI066345, U19AI082630, U19AI082630, U19AI082630,
   U19AI066345, P30AI060354, U19AI066345, U19AI082630, U19AI082630,
   U19AI066345, U19AI066345, P30AI060354, U19AI066345, U19AI082630,
   U19AI082630, P30AI060354, U19AI066345, P30AI060354, U19AI066345,
   U19AI082630, P30AI060354, P30AI060354, U19AI082630, U19AI066345,
   U19AI082630, U19AI082630, U19AI066345, U19AI082630, U19AI082630,
   U19AI082630, P30AI060354, U19AI066345, P30AI060354, P30AI060354,
   U19AI066345, U19AI066345, R01AI091450, U19AI082630, U19AI082630,
   U19AI082630, P30AI060354, P30AI060354, U19AI082630, U19AI082630,
   U19AI066345, U19AI082630, P30AI060354, U19AI082630, U19AI082630,
   P30AI060354, P30AI060354, P30AI060354, U19AI066345, U19AI066345,
   P30AI060354, P30AI060354, P30AI060354, U19AI082630, U19AI082630,
   U19AI082630, P30AI060354, P30AI060354, R01AI091450, P30AI060354,
   U19AI082630, R01AI067926, U19AI082630, U19AI066345, U19AI066345,
   P30AI060354, U19AI066345, U19AI082630, U19AI082630, U19AI082630,
   P30AI060354, U19AI082630, P30AI060354, P30AI060354, P30AI060354,
   U19AI066345, R01AI091450, U19AI066345, U19AI082630, U19AI082630,
   U19AI066345, P30AI060354, P30AI060354, U19AI082630, P30AI060354,
   P30AI060354, U19AI066345, P30AI060354, P30AI060354, U19AI082630,
   P30AI060354, U19AI066345, P30AI060354, U19AI066345, P30AI060354,
   P30AI060354, P30AI060354, U19AI082630, P30AI060354, U19AI082630,
   U19AI082630, U19AI082630, P30AI060354, U19AI082630, U19AI082630,
   R01AI067926, P30AI060354, U19AI082630, U19AI082630, P30AI060354,
   U19AI066345, U19AI066345, P30AI060354, U19AI082630, U19AI082630,
   U19AI082630, U19AI066345, P30AI060354, U19AI082630, U19AI082630,
   U19AI066345, U19AI082630, U19AI066345, U19AI082630, U19AI082630,
   U19AI082630, P30AI060354, P30AI060354] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK) [P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351, P30DK043351, P30DK043351, P30DK043351,
   P30DK043351, P30DK043351] Funding Source: NIH RePORTER
FX This study was supported by the Howard Hughes Medical Institute (J.
   Schulze zur Wiesch), Deutsche Forschungsgemeinschaft Schu 2482/1-1, SFB
   841 A6 (J. Schulze zur Wiesch), Swiss National Science Foundation (D.
   Ciuffreda), and National Institutes of Health grants U19-AI066345 (L.
   Lewis-Ximenez, T.M. Allen, A.Y. Kim, and G.M. Lauer), U19-AI082630 (R.
   T. Chung and G. M. Lauer), and R01-AI067926-01 (T.M. Allen).
CR Alter HJ, 2000, SEMIN LIVER DIS, V20, P17, DOI 10.1055/s-2000-9505
   Badr G, 2008, J VIROL, V82, P10017, DOI 10.1128/JVI.01083-08
   Barnes E, 2009, J INFECT DIS, V199, P819, DOI 10.1086/597072
   Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x
   Chang KM, 2001, HEPATOLOGY, V33, P267, DOI 10.1053/jhep.2001.21162
   Chang KM, 2007, HEPATOL RES, V37, pS327, DOI 10.1111/j.1872-034X.2007.00220.x
   Corey KE, 2006, CLIN GASTROENTEROL H, V4, P1278, DOI 10.1016/j.cgh.2006.06.026
   Cox AL, 2005, J EXP MED, V201, P1741, DOI 10.1084/jem.20050121
   Cox AL, 2005, HEPATOLOGY, V42, P104, DOI 10.1002/hep.20749
   Cox AL, 2009, GASTROENTEROLOGY, V136, P26, DOI 10.1053/j.gastro.2008.11.049
   Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115
   Day CL, 2003, J CLIN INVEST, V112, P831, DOI 10.1172/JCI200318509
   Day CL, 2002, J VIROL, V76, P12584, DOI 10.1128/JVI.76.24.12584-12595.2002
   Diepolder HM, 2009, ANTIVIR RES, V82, P103, DOI 10.1016/j.antiviral.2009.02.203
   Diepolder HM, 1996, J MOL MED-JMM, V74, P583, DOI 10.1007/s001090050062
   Diepolder HM, 1997, J VIROL, V71, P6011, DOI 10.1128/JVI.71.8.6011-6019.1997
   DIEPOLDER HM, 1995, LANCET, V346, P1006, DOI 10.1016/S0140-6736(95)91691-1
   Folgori A, 2006, GUT, V55, P1012, DOI 10.1136/gut.2005.080077
   Fuller MJ, 2010, HEPATOLOGY, V51, P378, DOI 10.1002/hep.23319
   Gerlach JT, 2005, J VIROL, V79, P12425, DOI 10.1128/JVI.79.19.12425-12433.2005
   Gerlach JT, 1999, GASTROENTEROLOGY, V117, P933, DOI 10.1016/S0016-5085(99)70353-7
   Golden-Mason L, 2009, J VIROL, V83, P9122, DOI 10.1128/JVI.00639-09
   Grakoui A, 2003, SCIENCE, V302, P659, DOI 10.1126/science.1088774
   Iyasere C, 2003, J VIROL, V77, P10900, DOI 10.1128/JVI.77.20.10900-10909.2003
   Kamal SM, 2004, HEPATOLOGY, V39, P1721, DOI 10.1002/hep.20266
   Kaplan DE, 2007, GASTROENTEROLOGY, V132, P654, DOI 10.1053/j.gastro.2006.11.044
   Kasprowicz V, 2008, J VIROL, V82, P3154, DOI 10.1128/JVI.02474-07
   Kasprowicz V, 2010, J VIROL, V84, P1656, DOI 10.1128/JVI.01499-09
   Klenerman P, 2005, NAT IMMUNOL, V6, P873, DOI 10.1038/ni1241
   Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107
   Lauer GM, 2005, J VIROL, V79, P12979, DOI 10.1128/JVI.79.20.12979-12988.2005
   Lauer GM, 2002, J VIROL, V76, P2817, DOI 10.1128/JVI.76.6.2817-2826.2002
   Lauer GM, 2004, GASTROENTEROLOGY, V127, P924, DOI 10.1053/j.gastro.2004.06.015
   Lichterfeld M, 2004, J EXP MED, V200, P701, DOI 10.1084/jem.20041270
   Lucas M, 2004, J IMMUNOL, V172, P1744, DOI 10.4049/jimmunol.172.3.1744
   Lucas M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000649
   McGovern BH, 2006, CLIN INFECT DIS, V42, P1663, DOI 10.1086/504327
   McGovern BH, 2009, CLIN INFECT DIS, V49, P1051, DOI 10.1086/605561
   MINUTELLO MA, 1993, J EXP MED, V178, P17, DOI 10.1084/jem.178.1.17
   Missale G, 1996, J CLIN INVEST, V98, P706, DOI 10.1172/JCI118842
   Nakamoto N, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000313
   Nelson DR, 1998, HEPATOLOGY, V28, P225, DOI 10.1002/hep.510280129
   Neumann-Haefelin C, 2008, HEPATOLOGY, V47, P1824, DOI 10.1002/hep.22242
   Penna A, 2002, HEPATOLOGY, V35, P1225, DOI 10.1053/jhep.2002.33153
   Rahman F, 2004, HEPATOLOGY, V40, P87, DOI 10.1002/hep.20253
   Rehermann B, 2009, J CLIN INVEST, V119, P1745, DOI 10.1172/JCI39133
   Rosen HR, 2002, HEPATOLOGY, V35, P190, DOI 10.1053/jhep.2002.30293
   Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447
   Semmo N, 2005, HEPATOLOGY, V41, P1019, DOI 10.1002/hep.20669
   Semmo N, 2007, WORLD J GASTROENTERO, V13, P4831, DOI 10.3748/wjg.v13.i36.4831
   Shoukry NH, 2004, ANNU REV MICROBIOL, V58, P391, DOI 10.1146/annurev.micro.58.030603.123836
   Smyk-Pearson S, 2008, J VIROL, V82, P1827, DOI 10.1128/JVI.01581-07
   Smyk-Pearson S, 2006, J INFECT DIS, V194, P454, DOI 10.1086/505714
   Spangenberg HC, 2005, HEPATOLOGY, V42, P828, DOI 10.1002/hep.20856
   Takaki A, 2000, NAT MED, V6, P578
   Tester I, 2005, J EXP MED, V201, P1725, DOI 10.1084/jem.20042284
   Thimme R, 2001, J EXP MED, V194, P1395, DOI 10.1084/jem.194.10.1395
   Timm J, 2004, J EXP MED, V200, P1593, DOI 10.1084/jem.20041006
   Ulsenheimer A, 2006, J VIRAL HEPATITIS, V13, P708, DOI 10.1111/j.1365-2893.2006.00747.x
   Urbani S, 2008, J HEPATOL, V48, P548, DOI 10.1016/j.jhep.2007.12.014
   Urbani S, 2006, HEPATOLOGY, V44, P126, DOI 10.1002/hep.21242
   Wertheimer AM, 2003, HEPATOLOGY, V37, P577, DOI 10.1053/jhep.2003.50115
   Wong DKH, 1998, J IMMUNOL, V160, P1479
   zur Wiesch JS, 2005, J IMMUNOL, V175, P3603, DOI 10.4049/jimmunol.175.6.3603
   zur Wiesch JS, 2007, BLOOD, V110, P1559, DOI 10.1182/blood-2007-01-069583
   zur Wiesch JS, 2009, CLIN INFECT DIS, V49, P466, DOI 10.1086/600399
NR 66
TC 132
Z9 133
U1 0
U2 4
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0022-1007
J9 J EXP MED
JI J. Exp. Med.
PD JAN 16
PY 2012
VL 209
IS 1
BP 61
EP 75
DI 10.1084/jem.20100388
PG 15
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 885ZO
UT WOS:000299820200007
PM 22213804
OA Bronze, Green Published
DA 2020-11-30
ER

PT J
AU Ferreira, ADP
   Perez, RD
   Ferraz, MLG
   Lewis-Ximenez, LL
   Pereira, JL
   de Almeida, PRL
   de Mattos, AA
AF Paiva Ferreira, Adalgisa de Souza
   Perez, Renata de Mello
   Gomes Ferraz, Maria Lucia
   Lewis-Ximenez, Lia Laura
   Pereira, Joao Luis
   Lerias de Almeida, Paulo Roberto
   de Mattos, Angelo Alves
CA Acute Hepatitis C Study Grp Brazil
TI Acute Hepatitis C in Brazil: Results of a National Survey
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE acute hepatitis C; Brazil; epidemiology; HCV; risk factors
ID SPONTANEOUS VIRAL CLEARANCE; PEGYLATED INTERFERON-ALPHA;
   VIRUS-INFECTION; HEMODIALYSIS-PATIENTS; THERAPY; MONOTHERAPY; RESPONSES;
   EFFICACY; FAILURE
AB The incidence of acute hepatitis C has decreased in the world. However, new cases are still reported. The objective of this study was to obtain data of acute hepatitis C in Brazil and to identify risk factors of transmission, diagnostic criteria, clinical presentation, evolution, and treatment. A questionnaire was sent to all members of the Brazilian Society of Hepatology. Sixteen centers participated with a total of 170 cases between 2000 and 2008. Among them, 37 had chronic renal failure on hemodialysis and were evaluated separately. The main diagnostic criterion in non-uremic patients was ALT (alanine aminotransferase) elevation associated with risk factors. In patients with chronic renal failure, anti-hepatitis C virus (HCV) sero-conversion was the most frequent criterion. Among the 133 non-uremic patients the main risk factors were hospital procedures, whereas in hemodialysis patients, dialysis was the single risk factor in 95% of the cases. Jaundice was more frequent in non-uremic patients (82% vs. 13%; P < 0.001) and ALT levels were higher in these individuals (P < 0.001). Spontaneous clearance was more frequent in non-uremic patients (51% vs. 3%; P < 0.001). Sixty-five patients were treated: 39 non-urennic patients and 26 on dialysis. Sustained virological response rates were 60% for non-uremic and 58% for uremic patients (P = 0.98). There was no association of these rates with the study variables. These findings show that cases of acute hepatitis C are still occurring and have been related predominantly to hospital procedures. Measures to prevent nosocomial transmission should be adopted rigorously and followed to minimize this important source of infection observed in this survey. J. Med. Virol. 83:1738-1743, 2011. (C) 2011 Wiley-Liss, Inc. J. Med.
C1 [Paiva Ferreira, Adalgisa de Souza] Univ Fed Maranhao, Sao Luis, MA, Brazil.
   [Perez, Renata de Mello] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil.
   [Gomes Ferraz, Maria Lucia] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Lewis-Ximenez, Lia Laura] Osvaldo Cruz Fdn, Rio De Janeiro, Brazil.
   [Pereira, Joao Luis] Gen Hosp Bonsucesso, Rio De Janeiro, Brazil.
   [Lerias de Almeida, Paulo Roberto] Nossa Senhora Conceicao Hosp, Porto Alegre, RS, Brazil.
   [de Mattos, Angelo Alves] Fed Fdn Sch Med Sci, Porto Alegre, RS, Brazil.
RP Ferreira, ADP (corresponding author), Rua Mitra,200 Apart,1101,Renascenca 2, BR-65075770 Sao Paulo, Maranhao, Brazil.
EM adalgisaf@terra.com.br
RI ferreira, adalgisa S P/G-8169-2016
CR Al-Harbi ASB, 2005, SAUDI J KIDNEY DIS T, V16, P293
   Alberti A, 2002, HEPATOLOGY, V36, pS195, DOI 10.1053/jhep.2002.36808
   Calleri G, 2007, J VIRAL HEPATITIS, V14, P116, DOI 10.1111/j.1365-2893.2006.00802.x
   Cox AL, 2009, GASTROENTEROLOGY, V136, P26, DOI 10.1053/j.gastro.2008.11.049
   Eldin NS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004085
   Engel M, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-50
   Fabrizi F, 2008, INT J ARTIF ORGANS, V31, P1004
   Gerlach JT, 2003, GASTROENTEROLOGY, V125, P80, DOI 10.1016/S0016-5085(03)00668-1
   Heller T, 2005, SEMIN LIVER DIS, V25, P7, DOI 10.1055/s-2005-864778
   Hussein MM, 2007, SAUDI J KIDNEY DIS T, V18, P107
   IRVING WL, 2008, EUROSURVEILLANCE, V13, P1
   Ishii S, 2008, CLIN IMMUNOL, V128, P133, DOI 10.1016/j.clim.2008.03.525
   Jaeckel E, 2001, NEW ENGL J MED, V345, P1452, DOI 10.1056/NEJMoa011232
   Kalantar-Zadeh K, 2005, AM J KIDNEY DIS, V46, P290, DOI 10.1053/j.ajkd.2005.05.006
   Kamal SM, 2008, AM J GASTROENTEROL, V103, P1283, DOI 10.1111/j.1572-0241.2008.01825.x
   Kamal SM, 2006, HEPATOLOGY, V43, P923, DOI 10.1002/hep.21197
   Kamal SM, 2006, GASTROENTEROLOGY, V130, P632, DOI 10.1053/j.gastro.2006.01.034
   Kamal SM, 2004, HEPATOLOGY, V39, P1721, DOI 10.1002/hep.20266
   Lechner F, 2000, EUR J IMMUNOL, V30, P2479, DOI 10.1002/1521-4141(200009)30:9<2479::AID-IMMU2479>3.0.CO;2-B
   Licata A, 2003, J HEPATOL, V39, P1056, DOI 10.1016/S0168-8278(03)00461-6
   Martinez-Bauer E, 2008, J HEPATOL, V48, P20, DOI 10.1016/j.jhep.2007.07.031
   Micallef JM, 2006, J VIRAL HEPATITIS, V13, P34, DOI 10.1111/j.1365-2893.2005.00651.x
   Moreira R, 2003, CAN J MICROBIOL, V49, P503, DOI [10.1139/w03-065, 10.1139/W03-065]
   Okuda K, 1998, J GASTROEN HEPATOL, V13, P62, DOI 10.1111/j.1440-1746.1998.tb00547.x
   Rocha CM, 2007, EUR J GASTROEN HEPAT, V19, P119, DOI 10.1097/01.meg.0000252626.73172.f3
   Santantonio T, 2006, CLIN INFECT DIS, V43, P1154, DOI 10.1086/507640
   Santantonio T, 2005, J HEPATOL, V42, P329, DOI 10.1016/j.jhep.2004.11.021
   Santantonio T, 2008, J HEPATOL, V49, P625, DOI 10.1016/j.jhep.2008.07.005
   Wasley Annemarie, 2008, Morbidity and Mortality Weekly Report, V57, P1
   Wiegand J, 2006, HEPATOLOGY, V43, P250, DOI 10.1002/hep.21043
NR 30
TC 7
Z9 7
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0146-6615
J9 J MED VIROL
JI J. Med. Virol.
PD OCT
PY 2011
VL 83
IS 10
BP 1738
EP 1743
DI 10.1002/jmv.22175
PG 6
WC Virology
SC Virology
GA 808NO
UT WOS:000293985900009
PM 21837789
DA 2020-11-30
ER

PT J
AU Villar, LM
   de Oliveira, JC
   Cruz, HM
   Yoshida, CFT
   Lampe, E
   Lewis-Ximenez, LL
AF Villar, Livia Melo
   de Oliveira, Jaqueline Correia
   Cruz, Helena Medina
   Tachibana Yoshida, Clara Fumiko
   Lampe, Elisabeth
   Lewis-Ximenez, Lia Laura
TI Assessment of Dried Blood Spot Samples as a Simple Method for Detection
   of Hepatitis B Virus Markers
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE HBV; filter paper; DBS; stability studies; ELISA
ID C VIRUS; HBV INFECTION; PREVALENCE; DIAGNOSIS; SERUM; EPIDEMIOLOGY;
   VACCINATION; SETTINGS; SEROLOGY; INFANTS
AB Detection of hepatitis B virus (HBV) serological markers in dried blood spot (DBS) samples by enzyme immunoassay (ELISA) has not yet been fully optimized. In this study, the ability to detect three HBV markers (HBsAg, anti-HBc, and anti-HBs) was evaluated in DBS samples using a modified commercial ELISA. Matched serum and DBS samples were obtained from individuals with or without a past history of HBV infection. Sera samples were tested according to the manufacturer's instructions, but for DBS testing, paper diameters, elution buffer, volume of input sample, and cut-off values were evaluated to optimize the assay. Stability studies were done on DBS stored at for up to 180 days at different temperatures. The absorbance values that yielded the maximum sensitivity and specificity were determined based on the area under the ROC curve (AUROC) and chosen as the cut-off value. Using this parameter, sensitivity was 90.5%, 97.6%, and 78% for anti-HBc, HBsAg, anti-HBs assays, respectively. Specificity was 92.6%, 96.7%, and 97.3% for anti-HBc, HBsAg, and anti-HBs assays, respectively. HBV markers could be detected in DBS samples until 63 days after sample collection at most temperatures, but storage at -20 degrees C yielded more consistent results. These results indicate that modified ELISA can be used to detect HBV markers in DBS samples, particularly if the samples are stored appropriately. J. Med. Virol. 83: 1522-1529, 2011. (C) 2011 Wiley-Liss, Inc.
C1 [Villar, Livia Melo; de Oliveira, Jaqueline Correia; Cruz, Helena Medina; Tachibana Yoshida, Clara Fumiko; Lampe, Elisabeth; Lewis-Ximenez, Lia Laura] Fiocruz MS, Inst Oswaldo Cruz, Viral Hepatitis Lab, BR-21045900 Rio De Janeiro, Brazil.
RP Villar, LM (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Viral Hepatitis Lab, Helio & Peggy Ground Flooor,Room B09,FIOCRUZ Av B, BR-21045900 Rio De Janeiro, Brazil.
EM lvillar@ioc.fiocruz.br
RI VILLAR, LIVIA M/F-7811-2012; Cruz, Helena Medina/U-4780-2019
OI VILLAR, LIVIA M/0000-0001-7644-8969; Cruz, Helena
   Medina/0000-0003-2088-7705
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Oswaldo Cruz Foundation (FIOCRUZ)
FX Grant sponsor: Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro
   (FAPERJ); Grant sponsor: Oswaldo Cruz Foundation (FIOCRUZ).
CR Barin F, 2006, J MED VIROL, V78, pS13, DOI 10.1002/jmv.20600
   Brasil, 2010, B EP HEP VIR
   Catalan-Soares B C, 2000, Rev Soc Bras Med Trop, V33, P27, DOI 10.1590/S0037-86822000000100004
   Croom HA, 2006, J CLIN VIROL, V36, P68, DOI 10.1016/j.jcv.2005.12.002
   CROWTHER JR, 2001, ELISA GUIDEBOOK METH
   Elgolihari HM, 2008, CLEV CLIN J MED, V75, P881, DOI 10.3949/ccjm.75a.07019
   Forbi JC, 2008, REV INST MED TROP SP, V50, P219, DOI 10.1590/S0036-46652008000400006
   Forbi JC, 2010, ANN AFR MED, V9, P44, DOI 10.4103/1596-3519.62625
   GUTHRIE R, 1963, PEDIATRICS, V32, P338
   Hickman M, 2008, J VIRAL HEPATITIS, V15, P250, DOI 10.1111/j.1365-2893.2007.00937.x
   Jardi R, 2004, HEPATOLOGY, V40, P133, DOI 10.1002/hep.20275
   Komas NP, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-226
   Lakshmi V, 2007, CLIN MICROBIOL INFEC, V13, P1134, DOI 10.1111/j.1469-0691.2007.01809.x
   Lira R, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-153
   Mahfoud Z, 2010, J INFECT DEV COUNTR, V4, P144, DOI 10.3855/jidc.517
   Melgaco JG, 2011, J MED VIROL, V83, P208, DOI 10.1002/jmv.21973
   Mendy M, 2005, J VIRAL HEPATITIS, V12, P642, DOI 10.1111/j.1365-2893.2005.00641.x
   Mercader S, 2006, J VIROL METHODS, V137, P140, DOI 10.1016/j.jviromet.2006.06.018
   Obuchowski NA, 2005, AM J ROENTGENOL, V184, P364, DOI 10.2214/ajr.184.2.01840364
   PORTO SOB, 1994, J ADOLESCENT HEALTH, V15, P577, DOI 10.1016/1054-139X(94)90142-P
   Sambrook J, 1989, MOL CLONING LAB MANU, VIII, P1647
   Shepard CW, 2006, EPIDEMIOL REV, V28, P112, DOI 10.1093/epirev/mxj009
   Sherman GG, 2005, JAIDS-J ACQ IMM DEF, V38, P615, DOI 10.1097/01.qai.0000143604.71857.5d
   SINGH J, 2001, INDIAN PEDIATR, V38, P1318
   Sorrell MF, 2009, ANN INTERN MED, V150, P104, DOI 10.7326/0003-4819-150-2-200901200-00100
   Tuaillon E, 2010, HEPATOLOGY, V51, P752, DOI 10.1002/hep.23407
   VILLA E, 1981, J CLIN PATHOL, V34, P809, DOI 10.1136/jcp.34.7.809
   Weber B, 2005, EXPERT REV MOL DIAGN, V5, P75, DOI 10.1586/14737159.5.1.75
   ZOULEK G, 1985, B WORLD HEALTH ORGAN, V63, P935
NR 29
TC 45
Z9 46
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD SEP
PY 2011
VL 83
IS 9
BP 1522
EP 1529
DI 10.1002/jmv.22138
PG 8
WC Virology
SC Virology
GA 790OW
UT WOS:000292600100005
PM 21739441
DA 2020-11-30
ER

PT J
AU Kasprowicz, V
   zur Wiesch, JS
   Kuntzen, T
   Nolan, BE
   Longworth, S
   Berical, A
   Blum, J
   McMahon, C
   Reyor, LL
   Elias, N
   Kwok, WW
   McGovern, BG
   Freeman, G
   Chung, RT
   Klenerman, P
   Lewis-Ximenez, L
   Walker, BD
   Allen, TM
   Kim, AY
   Lauer, GM
AF Kasprowicz, Victoria
   zur Wiesch, Julian Schulze
   Kuntzen, Thomas
   Nolan, Brian E.
   Longworth, Steven
   Berical, Andrew
   Blum, Jenna
   McMahon, Cory
   Reyor, Laura L.
   Elias, Nahel
   Kwok, William W.
   McGovern, Barbara G.
   Freeman, Gordon
   Chung, Raymond T.
   Klenerman, Paul
   Lewis-Ximenez, Lia
   Walker, Bruce D.
   Allen, Todd M.
   Kim, Arthur Y.
   Lauer, Georg M.
TI High Level of PD-1 Expression on Hepatitis C Virus (HCV)-Specific CD8(+)
   and CD4(+) T Cells during Acute HCV Infection, Irrespective of Clinical
   Outcome (vol 82, pg 3154, 2008)
SO JOURNAL OF VIROLOGY
LA English
DT Correction
C1 [Kasprowicz, Victoria] Harvard Univ, Partners AIDS Res Ctr, Massachusetts Gen Hosp, Sch Med, Charlestown, MA 02129 USA.
   Univ Hamburg, Med Klin 1, Hamburg, Germany.
   Massachusetts Gen Hosp, Transplantat Unit, Dept Surg, Boston, MA 02114 USA.
   Benaroya Res Inst Virginia Mason, Seattle, WA USA.
   Lemuel Shattuck Hosp, Boston, MA USA.
   Tufts Univ, Sch Med, Boston, MA 02111 USA.
   Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst,Dept Med, Boston, MA 02115 USA.
   Massachusetts Gen Hosp, Gastrointestinal Unit, Dept Med, Boston, MA 02114 USA.
   Univ Oxford, Nuffield Dept Med, Oxford OX1 3SY, England.
   Fiocruz MS, Inst Oswaldo Cruz, Dept Virol, BR-21045900 Rio De Janeiro, Brazil.
   Howard Hughes Med Inst, Chevy Chase, MD USA.
RP Kasprowicz, V (corresponding author), Harvard Univ, Partners AIDS Res Ctr, Massachusetts Gen Hosp, Sch Med, 149 13th St,6th Floor,Room 6001, Charlestown, MA 02129 USA.
RI Elias, Nahel/AAO-8344-2020; Allen, Todd/F-5473-2011; Freeman,
   Gordon/AAC-5380-2019
OI Elias, Nahel/0000-0001-6466-7347; Allen, Todd/0000-0002-6609-1318;
   Freeman, Gordon/0000-0002-7210-5616
CR Kasprowicz V, 2008, J VIROL, V82, P3154, DOI 10.1128/JVI.02474-07
NR 1
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD MAY
PY 2011
VL 85
IS 9
BP 4633
EP 4633
DI 10.1128/JVI.00376-11
PG 1
WC Virology
SC Virology
GA 751LG
UT WOS:000289618600061
OA Bronze, Green Accepted
DA 2020-11-30
ER

PT J
AU Kasprowicz, V
   Kang, YH
   Lucas, M
   zur Wiesch, JS
   Kuntzen, T
   Fleming, V
   Nolan, BE
   Longworth, S
   Berical, A
   Bengsch, B
   Thimme, R
   Lewis-Ximenez, L
   Allen, TM
   Kim, AY
   Klenerman, P
   Lauer, GM
AF Kasprowicz, Victoria
   Kang, Yu-Hoi
   Lucas, Michaela
   zur Wiesch, Julian Schulze
   Kuntzen, Thomas
   Fleming, Vicki
   Nolan, Brian E.
   Longworth, Steven
   Berical, Andrew
   Bengsch, Bertram
   Thimme, Robert
   Lewis-Ximenez, Lia
   Allen, Todd M.
   Kim, Arthur Y.
   Klenerman, Paul
   Lauer, Georg M.
TI Hepatitis C Virus (HCV) Sequence Variation Induces an HCV-Specific
   T-Cell Phenotype Analogous to Spontaneous Resolution (vol 84, pg 1656,
   2010)
SO JOURNAL OF VIROLOGY
LA English
DT Correction
C1 [Kasprowicz, Victoria] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ragon Inst Massachusetts Gen Hosp Massachusetts I, Boston, MA 02115 USA.
   Harvard Univ, Gastrointestinal Unit, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
   Univ Oxford, Nuffield Dept Med, Oxford, England.
   Univ Freiburg, Med Klin, D-7800 Freiburg, Germany.
   Fiocruz MS, Dept Virol, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil.
RP Kasprowicz, V (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ragon Inst Massachusetts Gen Hosp Massachusetts I, Boston, MA 02115 USA.
RI Allen, Todd/F-5473-2011
OI Allen, Todd/0000-0002-6609-1318; Lucas, Michaela/0000-0001-8881-9990
CR Kasprowicz V, 2010, J VIROL, V84, P1656, DOI 10.1128/JVI.01499-09
NR 1
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD MAY
PY 2011
VL 85
IS 9
BP 4636
EP 4636
DI 10.1128/JVI.00374-11
PG 1
WC Virology
SC Virology
GA 751LG
UT WOS:000289618600064
OA Green Accepted, Bronze
DA 2020-11-30
ER

PT J
AU Lampe, E
   Marques, VA
   Lewis-Ximenez, LL
   De Almeida, AJ
   Espirito-Santo, MP
AF Lampe, E.
   Marques, V. A.
   Lewis-Ximenez, L. L.
   De Almeida, A. J.
   Espirito-Santo, M. P.
TI SERIAL DETERMINATION OF HEPATITIS C VIRUS RNA LOAD IN PAIRED SERUM AND
   PLATELET SAMPLES FROM PATIENTS UNDER ANTIVIRAL THERAPY
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 46th Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver (EASL)
CY 2011
CL Berlin, GERMANY
SP European Assoc Study Liver (EASL)
C1 [Lampe, E.; Marques, V. A.; Lewis-Ximenez, L. L.; De Almeida, A. J.; Espirito-Santo, M. P.] Fiocruz MS, Viral Hepatitis Lab, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil.
   [De Almeida, A. J.] Fed Univ State Rio de Janeiro Sch Med & Surg UNIR, Gaffree & Guinle Univ Hosp, Rio De Janeiro, Brazil.
EM elampe@ioc.fiocruz.br
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD MAR
PY 2011
VL 54
SU 1
MA 442
BP S180
EP S180
DI 10.1016/S0168-8278(11)60444-3
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 856GC
UT WOS:000297625601022
DA 2020-11-30
ER

PT J
AU Kasprowicz, V
   Ward, SM
   Turner, A
   Grammatikos, A
   Nolan, BE
   Lewis-Ximenez, L
   Sharp, C
   Woodruff, J
   Fleming, VM
   Sims, S
   Walker, BD
   Sewell, AK
   Lauer, GM
   Klenerman, P
AF Kasprowicz, Victoria
   Ward, Scott M.
   Turner, Alison
   Grammatikos, Alexandros
   Nolan, Brian E.
   Lewis-Ximenez, Lia
   Sharp, Charles
   Woodruff, Jenny
   Fleming, Vicki M.
   Sims, Stuart
   Walker, Bruce D.
   Sewell, Andrew K.
   Lauer, Georg M.
   Klenerman, Paul
TI Defining the directionality and quality of influenza virus-specific
   CD8(+) T cell cross-reactivity in individuals infected with hepatitis C
   virus (vol 118, pg 1143, 2008)
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Correction
RI Grammatikos, Alexandros/A-5726-2011; Grammatikos, Alexandros/B-2804-2008
OI Grammatikos, Alexandros/0000-0001-6544-8218; Grammatikos,
   Alexandros/0000-0001-6544-8218; Sewell, Andrew/0000-0003-3194-3135
CR Kasprowicz V, 2008, J CLIN INVEST, V118, P1143, DOI 10.1172/JCI33082
NR 1
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD MAR
PY 2011
VL 121
IS 3
BP 1223
EP 1223
DI 10.1172/JCI57501
PG 1
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 729YQ
UT WOS:000287991000041
OA Green Accepted, Bronze, Green Published
DA 2020-11-30
ER

PT J
AU Strasak, AM
   Kim, AY
   Lauer, GM
   de Sousa, PS
   Ginuino, CF
   Fernandes, CA
   Velloso, CE
   de Almeida, AJ
   de Oliveira, JM
   Yoshida, CF
   zur Wiesch, JS
   Paranhos-Baccala, G
   Lang, S
   Brant, LJ
   Ulmer, H
   Strohmaier, S
   Kaltenbach, L
   Lampe, E
   Lewis-Ximenez, LL
AF Strasak, Alexander M.
   Kim, Arthur Y.
   Lauer, Georg M.
   de Sousa, Paulo S.
   Ginuino, Cleber F.
   Fernandes, Carlos A.
   Velloso, Carlos E.
   de Almeida, Adilson J.
   de Oliveira, Jaqueline M.
   Yoshida, Clara F.
   zur Wiesch, Julian Schulze
   Paranhos-Baccala, Glaucia
   Lang, Stefan
   Brant, Larry J.
   Ulmer, Hanno
   Strohmaier, Susanne
   Kaltenbach, Lalit
   Lampe, Elisabeth
   Lewis-Ximenez, Lia L.
TI Antibody dynamics and spontaneous viral clearance in patients with acute
   hepatitis C infection in Rio de Janeiro, Brazil
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID CELLULAR IMMUNE-RESPONSES; VIRUS-INFECTION; HCV; SEROCONVERSION;
   POPULATION; DISEASE; VIREMIA; COHORT; LOAD
AB Background: The anti-HCV antibody response has not been well characterized during the early phase of HCV infection and little is known about its relationship to the clinical course during this period.
   Methods: We analyzed serial anti-HCV antibodies longitudinally obtained from a prospective cohort of 65 patients with acute HCV infection by using a microparticle enzyme immunoassay AxSYM HCV 3.0 (Abbott Diagnostics) during the first 12 months from HCV acquisition in Rio de Janeiro, Brazil. Spontaneous viral clearance (SVC) was defined as undetectable HCV RNA in serum, in the absence of treatment, for three consecutive HCV PCR tests within 12-months of follow-up.
   Results: Baseline antibody values were similar among patient groups with self-limiting HCV evolution (n = 34) and persistent viremia (n = 31) [median (interquartile range) signal/cut-off ratio (s/co) 78.7 (60.7-93.8) vs. 93.9 (67.8-111.9), p = 0.26]. During 12-months follow-up, patients with acute spontaneous resolving HCV infection showed significantly lower serial antibody response in comparison to individuals progressing to chronic infection [median (interquartile range) s/co 62.7 (35.2-85.0) vs. 98.4 (70.4-127.4), p < 0.0001]. In addition, patients with self-limiting HCV evolution exhibited an expeditious, sharp decline of serial antibody values after SVC in comparison to those measured before SVC [median (interquartile range) s/co 56.0 (25.4-79.3) vs. 79.4 (66.3-103.0), p < 0.0001].
   Conclusion: Our findings indicate a rapid short-term decline of antibody values in patients with acute spontaneous resolving HCV infection.
C1 [de Sousa, Paulo S.; Ginuino, Cleber F.; Velloso, Carlos E.; de Almeida, Adilson J.; Yoshida, Clara F.; Lampe, Elisabeth; Lewis-Ximenez, Lia L.] Fiocruz MS, Inst Oswaldo Cruz, Viral Hepatitis Lab, BR-21045900 Rio De Janeiro, Brazil.
   [Strasak, Alexander M.; Ulmer, Hanno; Strohmaier, Susanne; Kaltenbach, Lalit] Innsbruck Med Univ, Dept Med Stat Informat & Hlth Econ, Innsbruck, Austria.
   [Kim, Arthur Y.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
   [Kim, Arthur Y.; Lauer, Georg M.] Harvard Univ, Sch Med, Boston, MA USA.
   [Lauer, Georg M.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
   [Fernandes, Carlos A.] Cent Publ Hlth Lab Noel Nutels, Hepatitis Div, Rio De Janeiro, Brazil.
   [de Almeida, Adilson J.] Fed Univ State Rio de Janeiro, Gaffree & Guinle Univ Hosp, Hematol Unit, Rio De Janeiro, Brazil.
   [de Oliveira, Jaqueline M.] Fiocruz MS, Inst Oswaldo Cruz, Viral Technol Lab, BR-21045900 Rio De Janeiro, Brazil.
   [zur Wiesch, Julian Schulze] Univ Klinikum Eppendorf, Med Klin 1, Hamburg, Germany.
   [Paranhos-Baccala, Glaucia] Fdn Merieux, Emerging Pathogens Lab, Lyon, France.
   [Lang, Stefan] Univ Innsbruck, Inst Stat, A-6020 Innsbruck, Austria.
   [Brant, Larry J.] NIA, Gerontol Res Ctr, Baltimore, MD 21224 USA.
RP Lewis-Ximenez, LL (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Viral Hepatitis Lab, BR-21045900 Rio De Janeiro, Brazil.
EM lialewis.fiocruz@gmail.com
RI Lang, Stefan/E-7500-2010; Ulmer, Hanno/S-6615-2019; Kaltenbach,
   Lalit/T-6261-2018; Lauer, Georg/J-1467-2018
OI Lang, Stefan/0000-0003-0739-3858; Ulmer, Hanno/0000-0001-5911-1002;
   Fernandes, Carlos/0000-0003-2941-4744; Kaltenbach,
   Lalit/0000-0002-8661-3750; Lauer, Georg/0000-0002-9792-4271
FU National Institute of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [AI066345-05];
   CGLAB/Ministry of Health, Brazil; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON
   AGINGUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)
   [ZICAG000638, ZICAG000638, ZICAG000638] Funding Source: NIH RePORTER
FX Our research was supported by National Institute of Health (NIH) grant
   AI066345-05, and CGLAB/Ministry of Health, Brazil.
CR Amin J, 2007, EPIDEMIOL INFECT, V135, P144, DOI 10.1017/S0950268806006388
   Blackard JT, 2008, HEPATOLOGY, V47, P321, DOI 10.1002/hep.21902
   Bossi V, 2004, J CLIN VIROL, V30, P45, DOI 10.1016/j.jcv.2003.08.007
   Chen M, 1999, GASTROENTEROLOGY, V116, P135, DOI 10.1016/S0016-5085(99)70237-4
   Corey KE, 2006, CLIN GASTROENTEROL H, V4, P1278, DOI 10.1016/j.cgh.2006.06.026
   Cox AL, 2005, CLIN INFECT DIS, V40, P951, DOI 10.1086/428578
   Cox AL, 2009, GASTROENTEROLOGY, V136, P26, DOI 10.1053/j.gastro.2008.11.049
   Eldin NS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004085
   Gerlach JT, 2003, GASTROENTEROLOGY, V125, P80, DOI 10.1016/S0016-5085(03)00668-1
   Heller T, 2005, SEMIN LIVER DIS, V25, P7, DOI 10.1055/s-2005-864778
   Hofer H, 2003, HEPATOLOGY, V37, P60, DOI 10.1053/jhep.2003.50019
   Hutin Y, 2004, J CLIN PHARMACOL, V44, P20, DOI 10.1177/0091270003258669
   Jaeckel E, 2001, NEW ENGL J MED, V345, P1452, DOI 10.1056/NEJMoa011232
   Lefrere JJ, 1997, J INFECT DIS, V175, P316, DOI 10.1093/infdis/175.2.316
   Lewis-Ximenez LL, 2010, CLIN INFECT DIS, V50, P1222, DOI 10.1086/651599
   Logvinoff C, 2004, P NATL ACAD SCI USA, V101, P10149, DOI 10.1073/pnas.0403519101
   Lu SN, 2004, J VIRAL HEPATITIS, V11, P563, DOI 10.1111/j.1365-2893.2004.00533.x
   Maheshwari A, 2008, LANCET, V372, P321, DOI 10.1016/S0140-6736(08)61116-2
   McGovern BH, 2009, CLIN INFECT DIS, V49, P1051, DOI 10.1086/605561
   Messick K, 2001, HAEMOPHILIA, V7, P568, DOI 10.1046/j.1365-2516.2001.00559.x
   Micallef JM, 2006, J VIRAL HEPATITIS, V13, P34, DOI 10.1111/j.1365-2893.2005.00651.x
   Netski DM, 2005, CLIN INFECT DIS, V41, P667, DOI 10.1086/432478
   Nikolaeva LI, 2002, J VIRAL HEPATITIS, V9, P429, DOI 10.1046/j.1365-2893.2002.00369.x
   Orland JR, 2001, HEPATOLOGY, V33, P321, DOI 10.1053/jhep.2001.22112
   Shata MT, 2003, VIROLOGY, V314, P601, DOI 10.1016/S0042-6822(03)00461-6
   Takaki A, 2000, NAT MED, V6, P578
   Thomas David L, 2005, Clin Liver Dis, V9, P383, DOI 10.1016/j.cld.2005.05.003
   Wang CC, 2007, J INFECT DIS, V196, P1474, DOI 10.1086/522608
NR 28
TC 8
Z9 8
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD JAN 12
PY 2011
VL 11
AR 15
DI 10.1186/1471-2334-11-15
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA 717YU
UT WOS:000287086000003
PM 21226945
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Cruz, HM
   da Silva, EF
   Villela-Nogueira, CA
   Nabuco, LC
   do O, KMR
   Lewis-Ximenez, LL
   Yoshida, CFT
   Lampe, E
   Villar, LM
AF Cruz, Helena Medina
   da Silva, Elisangela Ferreira
   Villela-Nogueira, Cristiane A.
   Nabuco, Leticia C.
   Rodrigues do O, Kycia Maria
   Lewis-Ximenez, Lia Laura
   Tachibana Yoshida, Clara Fumiko
   Lampe, Elisabeth
   Villar, Livia Melo
TI Evaluation of Saliva Specimens as an Alternative Sampling Method to
   Detect Hepatitis B Surface Antigen
SO JOURNAL OF CLINICAL LABORATORY ANALYSIS
LA English
DT Article
DE Hepatitis B; whole saliva; oral fluid; enzyme immunoassay
ID ORAL FLUID; C VIRUS; HCV ANTIBODIES; TRANSMISSION; DIAGNOSIS; SERUM;
   INFECTION; CHILDREN; ASSAY; DNA
AB In this study, a modified enzyme immunoassay (EIA) was evaluated for the Hepatitis B surface antigen (HBsAg) among whole saliva and oral fluid samples. Specimens were collected from 115 individuals who gave serum and oral fluid using Salivette (Sarstedt, Numbrecht, Germany) and whole saliva. Saliva specimens were tested following a modified ELISA, and the results were compared with paired serum specimens that were tested according to the supplier's instructions. Transport buffer for the oral fluids, sample volume for assay, incubation period of sample with conjugate as well as cut-off values were evaluated to optimize the assay. The highest sensitivity and specificity were obtained by increasing the incubation of sample and conjugate to 16 hr and using the area under the receiver operating characteristic curve to calculate cut-off values. HBsAg was detected in 40 oral fluids and 44 whole saliva samples out of 47 paired positive serum specimens and not detected in 64 oral fluids and 63 whole saliva samples out of 68 matched negative sera samples by the ELISA assay. There was excellent agreement between the results for the serum and saliva specimens kappa value (kappa): 0.80 for oral fluid and kappa: 0.87 for whole saliva and there was excellent reproducibility. Using an optimized protocol, the sensitivities of whole saliva and oral fluid were 93.6 and 85.1%, respectively, whereas specificities of whole saliva and oral fluid were 92.6 and 94.1%, respectively. Our data showed a significant promise for the use of whole saliva and oral fluid together with the modified commercial EIA for Hepatitis B virus infection surveillance. J. Clin. Lab. Anal. 25:134-141, 2011. (C) 2011 Wiley-Liss, Inc.
C1 [Cruz, Helena Medina; da Silva, Elisangela Ferreira; Lewis-Ximenez, Lia Laura; Tachibana Yoshida, Clara Fumiko; Lampe, Elisabeth; Villar, Livia Melo] Fiocruz MS, Lab Viral Hepatitis, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil.
   [Villela-Nogueira, Cristiane A.; Nabuco, Leticia C.; Rodrigues do O, Kycia Maria] Univ Fed Rio de Janeiro, Hepatol Div, Clementino Fraga Filho Univ Hosp, Rio De Janeiro, Brazil.
RP Villar, LM (corresponding author), Fiocruz MS, Lab Hepatites Virais Pavilhao Helio & Peggy Perei, Inst Oswaldo Cruz, Av Brazil,4365 Manguinhos RJ, BR-21045900 Rio De Janeiro, Brazil.
EM lvillar@ioc.fiocruz.br
RI Cruz, Helena Medina/U-4780-2019; VILLAR, LIVIA M/F-7811-2012
OI Cruz, Helena Medina/0000-0003-2088-7705; VILLAR, LIVIA
   M/0000-0001-7644-8969
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Oswaldo Cruz Foundation
FX Grant sponsors: Fundacao de Amparo a Pesquisa do Estado do Rio de
   Janeiro (FAPERJ); Oswaldo Cruz Foundation.
CR Amado LA, 2006, MEM I OSWALDO CRUZ, V101, P149, DOI 10.1590/S0074-02762006000200006
   Arnado LA, 2008, J VIROL METHODS, V148, P74, DOI 10.1016/j.jviromet.2007.10.020
   BANCROFT WH, 1977, J INFECT DIS, V135, P79, DOI 10.1093/infdis/135.1.79
   Bello PY, 1998, EUR J CLIN MICROBIOL, V17, P570, DOI 10.1007/BF01708621
   Chiappin S, 2007, CLIN CHIM ACTA, V383, P30, DOI 10.1016/j.cca.2007.04.011
   CROWTHER JR, 2001, METHODS MOL BIOL
   De Cock L, 2004, J VIROL METHODS, V122, P179, DOI 10.1016/j.jviromet.2004.09.001
   Elsana S, 1998, J MED VIROL, V55, P24, DOI 10.1002/(SICI)1096-9071(199805)55:1&lt;24::AID-JMV5&gt;3.0.CO;2-Q
   Granger DA, 2007, PHYSIOL BEHAV, V92, P583, DOI 10.1016/j.physbeh.2007.05.004
   Heiberg IL, 2010, PEDIATR INFECT DIS J, V29, P465, DOI 10.1097/INF.0b013e3181d8e009
   Hui AY, 2005, J CLIN VIROL, V33, P254, DOI 10.1016/j.jcv.2005.02.006
   Hutse V, 2005, J MED VIROL, V77, P53, DOI 10.1002/jmv.20413
   Judd A, 2003, J MED VIROL, V71, P49, DOI 10.1002/jmv.10463
   Kaufman E, 2002, CRIT REV ORAL BIOL M, V13, P197, DOI 10.1177/154411130201300209
   McIntyre PG, 1996, EUR J CLIN MICROBIOL, V15, P882, DOI 10.1007/BF01691223
   McKie A, 2002, LANCET INFECT DIS, V2, P18, DOI 10.1016/S1473-3099(01)00169-4
   MORTIMER PP, 1988, EPIDEMIOL INFECT, V101, P197, DOI 10.1017/S0950268800054108
   Nokes DJ, 2001, B WORLD HEALTH ORGAN, V79, P588
   Noppornpanth Suwanna, 2000, Southeast Asian Journal of Tropical Medicine and Public Health, V31, P419
   Oba IT, 2000, REV INST MED TROP SP, V42, P1
   Obuchowski NA, 2005, AM J ROENTGENOL, V184, P364, DOI 10.2214/ajr.184.2.01840364
   PARRY JV, 1993, ANN NY ACAD SCI, V694, P216, DOI 10.1111/j.1749-6632.1993.tb18355.x
   PARRY JV, 1989, J MED VIROL, V28, P255, DOI 10.1002/jmv.1890280410
   PIACENTINI SC, 1993, ANN NY ACAD SCI, V694, P334, DOI 10.1111/j.1749-6632.1993.tb18382.x
   Quoilin S, 2007, EUR J EPIDEMIOL, V22, P195, DOI 10.1007/s10654-007-9105-6
   RICHARDS AL, 1996, J TROP MED PUBLIC HL, V27, P80
   SAMBROOK FM, 1989, MOL CLONING LAB MANU, V3
   SCOTT RM, 1980, J INFECT DIS, V142, P67, DOI 10.1093/infdis/142.1.67
   THIEME T, 1992, J CLIN MICROBIOL, V30, P1076, DOI 10.1128/JCM.30.5.1076-1079.1992
   van der Eijk AA, 2004, J CLIN VIROL, V29, P92, DOI 10.1016/S1386-6532(03)00092-1
   Van Doornum GJJ, 2001, J MED VIROL, V64, P13, DOI 10.1002/jmv.1011
   Vyse AJ, 2001, PUBLIC HEALTH, V115, P201, DOI 10.1016/S0033-3506(01)00444-9
   Zhevachevsky NG, 2000, J MED VIROL, V61, P433, DOI 10.1002/1096-9071(200008)61:4&lt;433::AID-JMV4&gt;3.0.CO;2-5
   Zmuda JF, 2001, CLIN DIAGN LAB IMMUN, V8, P1267, DOI 10.1128/CDLI.8.6.1267-1270.2001
NR 34
TC 18
Z9 20
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0887-8013
EI 1098-2825
J9 J CLIN LAB ANAL
JI J. Clin. Lab. Anal.
PY 2011
VL 25
IS 2
BP 134
EP 141
DI 10.1002/jcla.20447
PG 8
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 735EZ
UT WOS:000288397500015
PM 21438008
OA Green Published
DA 2020-11-30
ER

PT J
AU Lewis-Ximenez, LL
   Lauer, GM
   zur Wiesch, JS
   de Sousa, PSF
   Ginuino, CF
   Paranhos-Baccala, G
   Ulmer, H
   Pfeiffer, KP
   Goebel, G
   Pereira, JL
   de Oliveira, JM
   Yoshida, CFT
   Lampe, E
   Velloso, CE
   Pinto, MA
   Coelho, HS
   Almeida, AJ
   Fernandes, CA
   Kim, AY
   Strasak, AM
AF Lewis-Ximenez, Lia L.
   Lauer, Georg M.
   zur Wiesch, Julian Schulze
   Fonseca de Sousa, Paulo Sergio
   Ginuino, Cleber F.
   Paranhos-Baccala, Glaucia
   Ulmer, Hanno
   Pfeiffer, Karl P.
   Goebel, Georg
   Pereira, Joao Luiz
   de Oliveira, Jaqueline Mendes
   Tachibana Yoshida, Clara Fumiko
   Lampe, Elisabeth
   Velloso, Carlos Eduardo
   Pinto, Marcelo Alves
   Coelho, Henrique Sergio
   Almeida, Adilson Jose
   Fernandes, Carlos Augusto
   Kim, Arthur Y.
   Strasak, Alexander M.
TI Prospective Follow-Up of Patients with Acute Hepatitis C Virus Infection
   in Brazil
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID SPONTANEOUS VIRAL CLEARANCE; CELLULAR IMMUNE-RESPONSES; HCV INFECTION;
   UNITED-STATES; DRUG-USERS; DIAGNOSIS; COHORT; SEROCONVERSION; DISEASE;
   VIREMIA
AB Background. The natural outcome of infection with hepatitis C virus (HCV) varies substantially among individuals. However, little is known about host and viral factors associated with a self-limiting or chronic evolution of HCV infection.
   Methods. From 1 January 2001 through 31 December 2008, a consecutive series of 65 patients from Rio de Janeiro, Brazil, with a well-documented diagnosis of acute HCV infection, acquired via various routes, were enrolled in this study. Patients were prospectively followed up for a median of 40 months after the estimated date of HCV infection with serial measurements of serum alanine aminotransferase, HCV RNA, and anti-HCV antibodies. Spontaneous viral clearance (SVC) was defined as undetectable levels of HCV RNA in serum, in the absence of treatment, for 3 consecutive HCV polymerase chain reaction tests within the first 6 months of follow-up. Cox proportional hazards regression was used to identify host and viral predictors of SVC.
   Results. The cumulative rate of SVC was 44.6% (95% confidence interval, 32.3%-57.5%). Compared with chronic HCV evolution, patients with self-limiting disease had significantly lower peak levels of anti-HCV antibodies (median, 109.0 vs 86.7 optical density-to-cutoff ratio [od/co]; P < .02), experienced disease symptoms more frequently (69.4% vs 100%; P < .001), and had lower viral load at first clinical presentation (median, 4.3 vs 0.0 log copies; P = .01). In multivariate analyses, low peak anti-HCV level (<93.5 od/co) was the only independent predictor for SVC; the hazard ratio compared with high anti-HCV levels (>= 93.5 od/co) was 2.62 (95% confidence interval, 1.11-6.19; P = .03).
   Conclusion. Our data suggest that low levels of anti-HCV antibodies during the acute phase of HCV infection are independently related to spontaneous viral clearance.
C1 [Lewis-Ximenez, Lia L.; Fonseca de Sousa, Paulo Sergio; Ginuino, Cleber F.; Tachibana Yoshida, Clara Fumiko; Lampe, Elisabeth; Velloso, Carlos Eduardo; Almeida, Adilson Jose] Fiocruz MS, Inst Oswaldo Cruz, Viral Hepatitis Lab, BR-21045900 Rio De Janeiro, Brazil.
   [de Oliveira, Jaqueline Mendes; Pinto, Marcelo Alves] Fiocruz MS, Inst Oswaldo Cruz, Viral Technol Lab, BR-21045900 Rio De Janeiro, Brazil.
   [Pereira, Joao Luiz] Fed Univ State Rio Janeiro, Bonsucesso Gen Hosp, Hepatol Clin, Rio De Janeiro, Brazil.
   [Coelho, Henrique Sergio] Fed Univ State Rio Janeiro, Liver Dis Clin, Clementino Fraga Filho Univ Hosp, Rio De Janeiro, Brazil.
   [Almeida, Adilson Jose] Fed Univ State Rio Janeiro, Gaffree & Guinle Univ Hosp, Hematol Unit, Rio De Janeiro, Brazil.
   [Fernandes, Carlos Augusto] Cent Publ Hlth Lab, Hepatitis Div, Rio De Janeiro, Brazil.
   [Lauer, Georg M.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
   [Kim, Arthur Y.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Boston, MA USA.
   [zur Wiesch, Julian Schulze] Univ Klinikum Eppendorf, Med Klin 1, Hamburg, Germany.
   [Paranhos-Baccala, Glaucia] Merieux Fdn, Lab Emerging Pathogens, Lyon, France.
   [Paranhos-Baccala, Glaucia] Merieux Fdn, Christoph Merieux Lab, Lyon, France.
   [Ulmer, Hanno; Pfeiffer, Karl P.; Goebel, Georg; Strasak, Alexander M.] Innsbruck Med Univ, Dept Med Stat Informat & Hlth Econ, Innsbruck, Austria.
RP Lewis-Ximenez, LL (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Viral Hepatitis Lab, Sala B09,Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM lialewis.fiocruz@gmail.com
RI Goebel, Georg/P-6909-2015; Pinto, Marcelo Alves/ABA-3312-2020; Coelho,
   Henrique Sergio Moraes/AAB-3973-2019; Ulmer, Hanno/S-6615-2019; Lauer,
   Georg/J-1467-2018
OI Ulmer, Hanno/0000-0001-5911-1002; Lauer, Georg/0000-0002-9792-4271;
   Fernandes, Carlos/0000-0003-2941-4744
FU National Institute of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AI066345-05];
   Coordenacao Geral de Laboratorios de Saude Publica/Ministry of Health in
   Brasilia, Brazil; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345] Funding
   Source: NIH RePORTER
FX Our research was supported by National Institute of Health grant
   AI066345-05 and Coordenacao Geral de Laboratorios de Saude
   Publica/Ministry of Health in Brasilia, Brazil.
CR Amin J, 2007, EPIDEMIOL INFECT, V135, P144, DOI 10.1017/S0950268806006388
   Armstrong GL, 2006, ANN INTERN MED, V144, P705, DOI 10.7326/0003-4819-144-10-200605160-00004
   Blackard JT, 2008, HEPATOLOGY, V47, P321, DOI 10.1002/hep.21902
   Chen M, 1999, GASTROENTEROLOGY, V116, P135, DOI 10.1016/S0016-5085(99)70237-4
   Chung RT, 2005, CLIN INFECT DIS, V41, pS14, DOI 10.1086/429490
   Corey KE, 2006, CLIN GASTROENTEROL H, V4, P1278, DOI 10.1016/j.cgh.2006.06.026
   Cox AL, 2005, CLIN INFECT DIS, V40, P951, DOI 10.1086/428578
   Eldin NS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004085
   Gerlach JT, 2003, GASTROENTEROLOGY, V125, P80, DOI 10.1016/S0016-5085(03)00668-1
   Heller T, 2005, SEMIN LIVER DIS, V25, P7, DOI 10.1055/s-2005-864778
   Hofer H, 2003, HEPATOLOGY, V37, P60, DOI 10.1053/jhep.2003.50019
   Huang WS, 2005, HEPATO-GASTROENTEROL, V52, P893
   Hutin Y, 2004, J CLIN PHARMACOL, V44, P20, DOI 10.1177/0091270003258669
   JEE LJ, 2004, GENES IMMUN, V5, P237
   Kamal SM, 2008, AM J GASTROENTEROL, V103, P1283, DOI 10.1111/j.1572-0241.2008.01825.x
   Komurian-Pradel F, 2001, J VIROL METHODS, V95, P111, DOI 10.1016/S0166-0934(01)00300-7
   Logvinoff C, 2004, P NATL ACAD SCI USA, V101, P10149, DOI 10.1073/pnas.0403519101
   Lu SN, 2004, J VIRAL HEPATITIS, V11, P563, DOI 10.1111/j.1365-2893.2004.00533.x
   Maheshwari A, 2008, LANCET, V372, P321, DOI 10.1016/S0140-6736(08)61116-2
   Mazzeo C, 2003, GUT, V52, P1030, DOI 10.1136/gut.52.7.1030
   McGovern BH, 2009, CLIN INFECT DIS, V49, P1051, DOI 10.1086/605561
   Micallef JM, 2006, J VIRAL HEPATITIS, V13, P34, DOI 10.1111/j.1365-2893.2005.00651.x
   Minola E, 2006, EUR J EPIDEMIOL, V21, P293, DOI 10.1007/s10654-006-0016-8
   Mondelli MU, 2005, J HEPATOL, V42, pS108, DOI 10.1016/j.jhep.2004.10.017
   Netski DM, 2005, CLIN INFECT DIS, V41, P667, DOI 10.1086/432478
   Nikolaeva LI, 2002, J VIRAL HEPATITIS, V9, P429, DOI 10.1046/j.1365-2893.2002.00369.x
   Orland JR, 2001, HEPATOLOGY, V33, P321, DOI 10.1053/jhep.2001.22112
   Page K, 2009, J INFECT DIS, V200, P1216, DOI 10.1086/605947
   Santantonio T, 2006, CLIN INFECT DIS, V43, P1154, DOI 10.1086/507640
   Santantonio T, 2003, DIGEST LIVER DIS, V35, P104, DOI 10.1016/S1590-8658(03)00007-0
   SCHULZE Z, 2007, BLOOD, V110, P1559
   Seeff Leonard B, 2003, Clin Liver Dis, V7, P261, DOI 10.1016/S1089-3261(02)00078-8
   Shata MT, 2003, VIROLOGY, V314, P601, DOI 10.1016/S0042-6822(03)00461-6
   Shepard CW, 2005, LANCET INFECT DIS, V5, P558, DOI 10.1016/S1473-3099(05)70216-4
   Singh R, 2007, WORLD J GASTROENTERO, V13, P1770, DOI 10.3748/wjg.v13.i12.1770
   Takaki A, 2000, NAT MED, V6, P578
   Thomas David L, 2005, Clin Liver Dis, V9, P383, DOI 10.1016/j.cld.2005.05.003
   Wang CC, 2007, J INFECT DIS, V196, P1474, DOI 10.1086/522608
NR 38
TC 17
Z9 17
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAY 1
PY 2010
VL 50
IS 9
BP 1222
EP 1230
DI 10.1086/651599
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 577UA
UT WOS:000276248300003
PM 20235831
OA Green Accepted, Bronze
DA 2020-11-30
ER

PT J
AU dos Santos, DRL
   Lewis-Ximenez, LL
   da Silva, MFM
   de Sousa, PSF
   Gaspar, AMC
   Pinto, MA
AF Lopes dos Santos, Debora Regina
   Lewis-Ximenez, Lia Laura
   Marques da Silva, Marcelle Figueira
   Fonseca de Sousa, Paulo Sergio
   Coimbra Gaspar, Ana Maria
   Pinto, Marcelo Alves
TI First report of a human autochthonous hepatitis E virus infection in
   Brazil
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE Hepatitis E; Autochthonous human case; Genotype 3; Zoonosis; Brazil
ID RIO-DE-JANEIRO; A VIRUS; SWINE; HEV; NETHERLANDS; IDENTIFICATION;
   POPULATIONS; GENOTYPE-1; ARGENTINA; VOLUNTEER
AB Background: Sporadic acute hepatitis E cases occurring in non-endemic areas have been associated to genotypes 3 and 4 of hepatitis E virus. Several studies have demonstrated the relationship among human and animals strains, mostly pigs and deers, from respective areas characterizing zoonosis. Circulation of genotype 3 of HEV in Brazilian swine herds have already been demonstrated. Nevertheless, no confirmed human cases have been reported to date in Brazil.
   Objectives: A study was developed to attempt the identification of hepatitis E acute cases in Brazil.
   Study design: A retrospective study carried out with 64 serum samples from patients with acute non-A-C hepatitis was performed to identify human cases of acute hepatitis E.
   Results: We could identify a confirmed case of acute hepatitis E. The patient seroconverted to hepatitis E virus-specific IgM and IgG antibody, HEV-RNA was amplified from serum, and the analysis of the sequence of a 242 nucleotide fragment from the ORF1 genome region classified the strain within genotype 3 and subgenotype 3b. Investigation of risk factors and results from phylogenetic analysis suggested a likely zoonotic origin for the infection.
   Conclusions: The first report of a human autochthonous in Brazil contributes with new information for hepatitis E epidemiology in Latin America and to considerate further broadly epidemiological studies. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Lopes dos Santos, Debora Regina; Coimbra Gaspar, Ana Maria; Pinto, Marcelo Alves] Fiocruz MS, IOC, Lab Desenvolvimento Tecnol Virol, BR-21045900 Rio De Janeiro, Brazil.
   [Lewis-Ximenez, Lia Laura; Fonseca de Sousa, Paulo Sergio] Fiocruz MS, IOC, Lab Hepatites Virais, BR-21045900 Rio De Janeiro, Brazil.
   [Marques da Silva, Marcelle Figueira] Fiocruz MS, IOC, Lab Virol Comparada & Ambiental, BR-21045900 Rio De Janeiro, Brazil.
RP dos Santos, DRL (corresponding author), Fiocruz MS, IOC, Lab Desenvolvimento Tecnol Virol, BR-21045900 Rio De Janeiro, Brazil.
EM santosdl@ioc.fiocruz.br
RI Pinto, Marcelo/G-7503-2012; Silva-Sales, Marcelle/D-9809-2015; Pinto,
   Marcelo Alves/ABA-3312-2020
OI Pinto, Marcelo/0000-0003-3462-7277; Silva-Sales,
   Marcelle/0000-0002-4275-9627; 
FU Brazilian agencies CAPESCAPES; CNPqNational Council for Scientific and
   Technological Development (CNPq)
FX We wish to thank Dr. Adilson Jose de Almeida, Dra. Elizabeth Lampe, Dra.
   Livia Melo Villar, Ilton Carlos Sant'ana and Dra. Clara Yoshida, from
   Laboratorio de Hepatites Virais/IOC, for collaboration and technical
   assistance, as well as the Brazilian agencies CAPES and CNPq for grant
   support. And special thanks to the "Red Iberoamericana para la
   Investigacion de la Hepatitis E (RIHEPE)" and to Dr. Jose Manuel
   Echevarr a for kindly reviewing the manuscript.
CR Ahmed A I A, 2008, Ned Tijdschr Geneeskd, V152, P2689
   Arnado LA, 2008, J VIROL METHODS, V148, P74, DOI 10.1016/j.jviromet.2007.10.020
   Borgen K, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-61
   Bortoliero André Luiz, 2006, Rev. Inst. Med. trop. S. Paulo, V48, P87, DOI 10.1590/S0036-46652006000200006
   CHAUHAN A, 1993, LANCET, V341, P149, DOI 10.1016/0140-6736(93)90008-5
   Cooper K, 2005, J CLIN MICROBIOL, V43, P1684, DOI 10.1128/JCM.43.4.1684-1688.2005
   Dalton HR, 2008, LANCET INFECT DIS, V8, P698, DOI 10.1016/S1473-3099(08)70255-X
   de Paula VS, 2002, J MED VIROL, V66, P22, DOI 10.1002/jmv.2106
   dos Santos DCM, 2002, MEM I OSWALDO CRUZ, V97, P637, DOI 10.1590/S0074-02762002000500007
   dos Santos DRL, 2008, MEM I OSWALDO CRUZ, V103, P254, DOI 10.1590/S0074-02762008000300005
   Fogeda M, 2009, J CLIN VIROL, V45, P259, DOI 10.1016/j.jcv.2009.05.022
   Jothikumar N, 2006, J VIROL METHODS, V131, P65, DOI 10.1016/j.jviromet.2005.07.004
   Kase JA, 2008, INT J ENVIRON HEAL R, V18, P165, DOI 10.1080/09603120701498311
   dos Santos DRL, 2009, VET J, V182, P474, DOI 10.1016/j.tvjl.2008.08.001
   Lu L, 2006, REV MED VIROL, V16, P5, DOI 10.1002/rmv.482
   Lyra AC, 2005, BRAZ J MED BIOL RES, V38, P767, DOI 10.1590/S0100-879X2005000500015
   Mateos Maria Luisa, 2006, Gastroenterol Hepatol, V29, P397
   Meng XJ, 1997, P NATL ACAD SCI USA, V94, P9860, DOI 10.1073/pnas.94.18.9860
   Villallba MDM, 2008, EMERG INFECT DIS, V14, P1320, DOI 10.3201/eid1408.080049
   Morais LM, 2006, MEM I OSWALDO CRUZ, V101, P401, DOI 10.1590/S0074-02762006000400010
   Munne MS, 2006, J MED VIROL, V78, P1579, DOI 10.1002/jmv.20741
   Munne Maria Silvina, 2006, Acta Gastroenterol Latinoam, V36, P125
   Perez-Gracia MT, 2007, AM J TROP MED HYG, V77, P893, DOI 10.4269/ajtmh.2007.77.893
   Pina S, 2000, J HEPATOL, V33, P826, DOI 10.1016/S0168-8278(00)80316-5
   Lay LDLAR, 2008, J MED VIROL, V80, P798, DOI 10.1002/jmv.21147
   Rutjes SA, 2009, EMERG INFECT DIS, V15, P381, DOI 10.3201/eid1503.071472
   Schlauder GG, 2000, J INFECT DIS, V182, P294, DOI 10.1086/315651
   Souto FJD, 1997, AM J TROP MED HYG, V57, P149, DOI 10.4269/ajtmh.1997.57.149
   Tei S, 2004, J MED VIROL, V74, P67, DOI 10.1002/jmv.20147
   Trinta KS, 2001, MEM I OSWALDO CRUZ, V96, P25, DOI 10.1590/S0074-02762001000100004
   van der Poel WHM, 2001, EMERG INFECT DIS, V7, P970, DOI 10.3201/eid0706.010608
   Villalba MD, 2005, INT J INFECT DIS, V9, P286, DOI 10.1016/j.ijid.2004.10.003
   Vitral CL, 2008, J VIRAL HEPATITIS, V15, P22, DOI 10.1111/j.1365-2893.2008.01024.x
   Vitral CL, 2005, MEM I OSWALDO CRUZ, V100, P117, DOI 10.1590/S0074-02762005000200003
   Wang D, 1999, J COMP PHYSIOL B, V169, P77, DOI 10.1007/s003600050196
NR 35
TC 50
Z9 50
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD MAR
PY 2010
VL 47
IS 3
BP 276
EP 279
DI 10.1016/j.jcv.2009.12.021
PG 4
WC Virology
SC Virology
GA 559XI
UT WOS:000274862700016
PM 20116328
DA 2020-11-30
ER

PT J
AU Kasprowicz, V
   Kang, YH
   Lucas, M
   zur Wiesch, JS
   Kuntzen, T
   Fleming, V
   Nolan, BE
   Longworth, S
   Berical, A
   Bengsch, B
   Thimme, R
   Lewis-Ximenez, L
   Allen, TM
   Kim, AY
   Klenerman, P
   Lauer, GM
AF Kasprowicz, Victoria
   Kang, Yu-Hoi
   Lucas, Michaela
   zur Wiesch, Julian Schulze
   Kuntzen, Thomas
   Fleming, Vicki
   Nolan, Brian E.
   Longworth, Steven
   Berical, Andrew
   Bengsch, Bertram
   Thimme, Robert
   Lewis-Ximenez, Lia
   Allen, Todd M.
   Kim, Arthur Y.
   Klenerman, Paul
   Lauer, Georg M.
TI Hepatitis C Virus (HCV) Sequence Variation Induces an HCV-Specific
   T-Cell Phenotype Analogous to Spontaneous Resolution
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID IL-7 RECEPTOR; EXPRESSION; INFECTION; MEMORY; EPITOPE; EXHAUSTION;
   RESPONSES; SUBSETS; VARIANT; ESCAPE
AB Hepatitis C virus (HCV)-specific CD8(+) T cells in persistent HCV infection are low in frequency and paradoxically show a phenotype associated with controlled infections, expressing the memory marker CD127. We addressed to what extent this phenotype is dependent on the presence of cognate antigen. We analyzed virus-specific responses in acute and chronic HCV infections and sequenced autologous virus. We show that CD127 expression is associated with decreased antigenic stimulation after either viral clearance or viral variation. Our data indicate that most CD8 T-cell responses in chronic HCV infection do not target the circulating virus and that the appearance of HCV-specific CD127(+) T cells is driven by viral variation.
C1 [Kasprowicz, Victoria; Kuntzen, Thomas; Berical, Andrew; Allen, Todd M.; Kim, Arthur Y.] MIT, Massachusetts Gen Hosp, Ragon Inst, Boston, MA USA.
   [zur Wiesch, Julian Schulze; Nolan, Brian E.; Longworth, Steven; Lauer, Georg M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA USA.
   [Kang, Yu-Hoi; Lucas, Michaela; Fleming, Vicki; Klenerman, Paul] Univ Oxford, Nuffield Dept Med, Oxford, England.
   [Bengsch, Bertram; Thimme, Robert] Univ Freiburg, Med Klin, D-7800 Freiburg, Germany.
   [Lewis-Ximenez, Lia] Fiocruz MS, Inst Oswaldo Cruz, Dept Virol, BR-21045900 Rio De Janeiro, Brazil.
RP Kasprowicz, V (corresponding author), MIT, Ragon Inst MGH, 149 13th St, Charlestown, MA 02129 USA.
EM vkasprowicz@partners.org; glauer@helix.mgh.harvard.edu
RI Allen, Todd/F-5473-2011; Lauer, Georg/J-1467-2018
OI Allen, Todd/0000-0002-6609-1318; Lauer, Georg/0000-0002-9792-4271;
   Fleming, Vicki/0000-0002-0460-3533; Lucas, Michaela/0000-0001-8881-9990
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [U19-AI066345,
   RO1-AI067926-01]; Deutsche Forschungsgemeinschaft (DFG)German Research
   Foundation (DFG) [SCHU 2482/1-1]; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, R01AI067926, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, R01AI067926,
   U19AI066345, U19AI066345, R01AI067926, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, R01AI067926, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345] Funding
   Source: NIH RePORTER
FX The work presented here was supported by the National Institutes of
   Health (U19-AI066345 to G. M. L., L. L.-X., T. M. A., and A. Y. K. and
   RO1-AI067926-01 to T. M. A.) and the Deutsche Forschungsgemeinschaft
   (DFG SCHU 2482/1-1 to J. S. Z. W.).
CR Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379
   Bengsch B, 2007, J VIROL, V81, P945, DOI 10.1128/JVI.01354-06
   BERTOLETTI A, 1994, J EXP MED, V180, P933, DOI 10.1084/jem.180.3.933
   Blattman JN, 2009, J VIROL, V83, P4386, DOI 10.1128/JVI.02524-08
   Boettler T, 2006, J VIROL, V80, P3532, DOI 10.1128/JVI.80.7.3532-3540.2006
   FOXWELL BMJ, 1992, INT IMMUNOL, V4, P277, DOI 10.1093/intimm/4.2.277
   Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407
   Kuntzen T, 2007, J VIROL, V81, P11658, DOI 10.1128/JVI.00995-07
   Lang KS, 2005, EUR J IMMUNOL, V35, P738, DOI 10.1002/eji.200425828
   Lauer GM, 2005, J VIROL, V79, P12979, DOI 10.1128/JVI.79.20.12979-12988.2005
   Lauer GM, 2004, GASTROENTEROLOGY, V127, P924, DOI 10.1053/j.gastro.2004.06.015
   Neumann-Haefelin C, 2008, J VIROL, V82, P3438, DOI 10.1128/JVI.01700-07
   van Leeuwen EMM, 2005, BLOOD, V106, P2091, DOI 10.1182/blood-2005-02-0449
   WEINER A, 1995, P NATL ACAD SCI USA, V92, P2755, DOI 10.1073/pnas.92.7.2755
   Wherry EJ, 2006, VIROLOGY, V353, P366, DOI 10.1016/j.virol.2006.06.017
NR 15
TC 56
Z9 56
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD FEB
PY 2010
VL 84
IS 3
BP 1656
EP 1663
DI 10.1128/JVI.01499-09
PG 8
WC Virology
SC Virology
GA 542XC
UT WOS:000273531600045
PM 19906915
OA Green Published, Bronze
DA 2020-11-30
ER

PT J
AU Villar, LM
   de Oliveira, JC
   Medina, H
   Yoshida, CFT
   Lampe, E
   Lewis-Ximenez, LL
AF Villar, L. M.
   de Oliveira, J. C.
   Medina, H.
   Yoshida, C. F. T.
   Lampe, E.
   Lewis-Ximenez, L. L.
TI USEFULNESS OF DRIED BLOOD SPOTS FOR HEPATITIS B VIRUS DIAGNOSIS
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver
CY APR 14-18, 2010
CL Vienna, AUSTRIA
SP European Assoc Study Liver
C1 [Villar, L. M.; de Oliveira, J. C.; Medina, H.; Yoshida, C. F. T.; Lampe, E.; Lewis-Ximenez, L. L.] Fiocruz MS, Viral Hepatitis Lab, BR-21045900 Rio De Janeiro, Brazil.
EM liviafiocruz@gmail.com
RI VILLAR, LIVIA M/F-7811-2012
OI VILLAR, LIVIA M/0000-0001-7644-8969
NR 0
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PY 2010
VL 52
SU 1
BP S249
EP S249
DI 10.1016/S0168-8278(10)60637-X
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 587UE
UT WOS:000277018001261
DA 2020-11-30
ER

PT J
AU Villar, LM
   Medina, H
   Villela-Nogueira, CA
   Nabuco, LC
   do O, KMR
   Da Silva, EF
   Lewis-Ximenez, LL
   Yoshida, CFT
   Lampe, E
AF Villar, L. M.
   Medina, H.
   Villela-Nogueira, C. A.
   Nabuco, L. C.
   Rodrigues do O, K. M.
   Da Silva, E. F.
   Lewis-Ximenez, L. L.
   Yoshida, C. F. T.
   Lampe, E.
TI SALIVA AS A SOURCE FOR HEPATITIS B VIRUS DIAGNOSIS
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver
CY APR 14-18, 2010
CL Vienna, AUSTRIA
SP European Assoc Study Liver
C1 [Villar, L. M.; Medina, H.; Da Silva, E. F.; Lewis-Ximenez, L. L.; Yoshida, C. F. T.; Lampe, E.] Fiocruz MS, Viral Hepatitis Lab, BR-21045900 Rio De Janeiro, Brazil.
   [Villela-Nogueira, C. A.; Nabuco, L. C.; Rodrigues do O, K. M.] Hosp Univ Clementino Fraga Filho UFRJ, Rio De Janeiro, Brazil.
EM liviafiocruz@gmail.com
RI VILLAR, LIVIA M/F-7811-2012
OI VILLAR, LIVIA M/0000-0001-7644-8969
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PY 2010
VL 52
SU 1
BP S248
EP S248
DI 10.1016/S0168-8278(10)60636-8
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 587UE
UT WOS:000277018001260
DA 2020-11-30
ER

PT J
AU zur Wiesch, JS
   Lewis-Ximenez, L
   Reyor, LL
   Kwok, WW
   McGovern, BH
   Lohse, AW
   Chung, R
   Allen, TM
   Kim, AY
   Lauer, GM
AF zur Wiesch, Julian Schulze
   Lewis-Ximenez, Lia
   Reyor, Laura L.
   Kwok, William W.
   McGovern, Barbara H.
   Lohse, Ansgar W.
   Chung, Raymond
   Allen, Todd M.
   Kim, Arthur Y.
   Lauer, Georg M.
TI PATTERNS OF HCV CDA plus T CELL IMMUNODOMINANCE IN A LARGE COHORT OF
   SUBJECTS WITH DIFFERENT STAGES AND OUTCOMES OF HCV INFECTION
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 60th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases
CY OCT 30-NOV 03, 2009
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [zur Wiesch, Julian Schulze; Lohse, Ansgar W.] Univ Klinikum Eppendorf, Med Klin, Hamburg, Germany.
   [Lewis-Ximenez, Lia] Fiocruz MS, Inst Oswaldo Cruz, Dept Virol, BR-21045900 Rio De Janeiro, Brazil.
   [Reyor, Laura L.; Chung, Raymond; Allen, Todd M.; Kim, Arthur Y.; Lauer, Georg M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
   [Kwok, William W.] Benaroya Res Inst, Seattle, WA USA.
   [McGovern, Barbara H.] Tufts Univ, Lemuel Shattuck Hosp, Boston, MA 02111 USA.
RI Allen, Todd/F-5473-2011
OI Allen, Todd/0000-0002-6609-1318
NR 0
TC 5
Z9 5
U1 0
U2 1
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2009
VL 50
IS 4
MA 1242
BP 880A
EP 881A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 502JV
UT WOS:000270456001239
PM 19937677
OA Bronze
DA 2020-11-30
ER

PT J
AU Wiesch, JSZ
   Kasprowicz, V
   Kuntzen, T
   Nolan, BE
   Longworth, S
   Reyor, LL
   McGovern, B
   Allen, TM
   Lohse, AW
   Lewis-Ximenez, L
   Kwok, WW
   Chung, RT
   Kim, AY
   Lauer, GM
AF Wiesch, Julian Schulze zur
   Kasprowicz, Victoria
   Kuntzen, Thomas
   Nolan, Brian E.
   Longworth, Steve
   Reyor, Laura L.
   McGovern, Barbara
   Allen, Todd M.
   Lohse, Ansgar W.
   Lewis-Ximenez, Lia
   Kwok, William W.
   Chung, Raymond T.
   Kim, Arthur Y.
   Lauer, Georg M.
TI EX VIVO ANALYSIS OF CD4+T HELPER CELL RESPONSES IN ACUTE HCV INFECTION
   AND EARLY TREATMENT. EARLY ANTIVIRAL THERAPY PRESERVES VIRUS SPECIFIC
   CD4+CELLS
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 59th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases
CY OCT 31-NOV 04, 2008
CL San Francisco, CA
SP Amer Assoc Study Liver Dis, Moscone West Convent Ctr
C1 [Wiesch, Julian Schulze zur; Lohse, Ansgar W.] Univ Hosp Hamburg Eppendorf, Dept Med, Hamburg, Germany.
   [Wiesch, Julian Schulze zur; Kasprowicz, Victoria; Kuntzen, Thomas; Nolan, Brian E.; Longworth, Steve; Reyor, Laura L.; Allen, Todd M.; Kim, Arthur Y.; Lauer, Georg M.] Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02114 USA.
   [McGovern, Barbara] Tufts Med Ctr, Boston, MA USA.
   [Lewis-Ximenez, Lia] Inst Oswaldo Cruz, Dept Virol, BR-20001 Rio De Janeiro, Brazil.
   [Nolan, Brian E.; Longworth, Steve; Reyor, Laura L.; Chung, Raymond T.; Lauer, Georg M.] Massachusetts Gen Hosp, Gl Div, Boston, MA 02114 USA.
   [Kwok, William W.] Benaroya Res Inst Virginia Mason, Seattle, WA USA.
RI Allen, Todd/F-5473-2011
OI Allen, Todd/0000-0002-6609-1318
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2008
VL 48
IS 4
SU S
MA 206
BP 401A
EP 401A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 356CX
UT WOS:000259757400203
DA 2020-11-30
ER

PT J
AU Lampe, E
   Yoshida, CFT
   De Oliveira, RV
   Lauer, GM
   Lewis-Ximenez, LL
AF Lampe, Elisabeth
   Tachibana Yoshida, Clara Fumiko
   De Oliveira, Rosane Vieira
   Lauer, Georg M.
   Lewis-Ximenez, Lia Laura
TI Molecular analysis and patterns of ALT and hepatitis C virus
   seroconversion in haemodialysis patients with acute hepatitis
SO NEPHROLOGY
LA English
DT Article
DE acute hepatitis; haemodialysis; hepatitis C virus; nosocomial
   transmission
ID ALANINE AMINOTRANSFERASE; INFECTION; HCV; TRANSMISSION; PREVALENCE;
   SPREAD; RANGE; UNIT
AB Background: Haemodialysis (HD) continues to carry the risk of hepatitis C virus (HCV) transmission, with delayed seroconversion and often normal alanine aminotransferase (ALT) values increasing the likelihood of undetected infection and thus uninterrupted spread of HCV. The aim of this study was to identify the characteristic patterns of ALT changes and seroconversion during an outbreak of HCV in a HD unit. We also wanted to establish the relationship between infecting viruses using molecular analysis.
   Methods: All patients (n = 72) and staff (n = 23) of the HD unit were prospectively followed for 14 months. Serial measurements for ALT, HCV antibody and HCV-RNA were performed besides HCV sequence analysis.
   Results: The initial screening for anti-HCV and HCV-RNA confirmed chronic infection in 16/72 (22%) subjects and identified three subjects with recent seroconversion. In addition, five cases were reverse transcription-polymerase chain reaction positive alone for a total of eight recent cases. The interval between the initial observation of ALT changes and seroconversion varied from 1 to 8 months, and in several individuals ALT fluctuations only below the upper limit of normal were detected. However, relating each subject's ALT values to ALT at baseline, ALT levels increased between 1.6- and 4.7-fold. Molecular analysis provided evidence for transmission from two chronically infected source patients, probably because of inappropriate infection control measures.
   Conclusion: Our data highlight the importance of well-implemented safety precautions and regular HCV-RNA testing to prevent the further spread of HCV in this population, and suggest the use of ALT baseline values to identify infections that may remain unnoticed otherwise.
C1 [Lampe, Elisabeth; Tachibana Yoshida, Clara Fumiko; De Oliveira, Rosane Vieira; Lewis-Ximenez, Lia Laura] Fiocruz MS, Inst Oswaldo Cruz, Lab Hepatitis Virais, BR-21040900 Rio De Janeiro, Brazil.
   [Lauer, Georg M.] Massachusetts Gen Hosp, Partners AIDS Res Ctr & Infect Dis Div, Boston, MA 02114 USA.
   [Lauer, Georg M.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Lampe, E (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab Hepatitis Virais, Avenida Brazil 4365, BR-21040900 Rio De Janeiro, Brazil.
EM elampe@ioc.fiocruz.br
RI Lauer, Georg/J-1467-2018
OI Lauer, Georg/0000-0002-9792-4271
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U19 AI066345] Funding Source: Medline;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345] Funding Source: NIH RePORTER
CR ALLANDER T, 1994, J MED VIROL, V43, P415, DOI 10.1002/jmv.1890430417
   Carneiro MAS, 2005, MEM I OSWALDO CRUZ, V100, P345, DOI 10.1590/S0074-02762005000400002
   Carneiro MAS, 2007, J MED VIROL, V79, P1325, DOI 10.1002/jmv.20932
   de Albuquerque ACC, 2005, MEM I OSWALDO CRUZ, V100, P467, DOI 10.1590/S0074-02762005000500003
   de Oliveira JM, 2001, J MED VIROL, V63, P265, DOI 10.1002/1096-9071(200104)63:4&lt;265::AID-JMV1000&gt;3.0.CO;2-V
   Di Lallo D, 1999, EUR J EPIDEMIOL, V15, P11, DOI 10.1023/A:1007592912010
   Espinosa M, 2000, CLIN NEPHROL, V54, P151
   Finelli L, 2005, SEMIN DIALYSIS, V18, P52, DOI 10.1111/j.1525-139X.2005.18108.x
   Fissell RB, 2004, KIDNEY INT, V65, P2335, DOI 10.1111/j.1523-1755.2004.00649.x
   GILLI P, 1990, INT J ARTIF ORGANS, V13, P737
   Jadoul M, 2000, NEPHROL DIAL TRANSPL, V15, P39, DOI 10.1093/ndt/15.suppl_8.39
   Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150
   Lopes EPA, 2006, J CLIN VIROL, V35, P298, DOI 10.1016/j.jcv.2005.09.010
   Milotic I, 2002, SCAND J UROL NEPHROL, V36, P447, DOI 10.1080/003655902762467611
   OKUDA K, 1995, J HEPATOL, V23, P28, DOI 10.1016/0168-8278(95)80307-6
   Santos MAM, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-32
   Saxena AK, 2004, J AM GERIATR SOC, V52, P242, DOI 10.1111/j.1532-5415.2004.52062.x
   Saxena AK, 2003, SWISS MED WKLY, V133, P611
   Seme K, 1997, NEPHRON, V77, P273, DOI 10.1159/000190287
   SIMON N, 1994, KIDNEY INT, V46, P504, DOI 10.1038/ki.1994.301
   Stuyver L, 1996, KIDNEY INT, V49, P889, DOI 10.1038/ki.1996.122
   [Anonymous], 2001, MMWR Recomm Rep, V50, P1
   Vanderborght B. O. M., 1995, Revista do Instituto de Medicina Tropical de Sao Paulo, V37, P75, DOI 10.1590/S0036-46651995000100012
   Viazov S, 1997, J MED VIROL, V53, P36, DOI 10.1002/(SICI)1096-9071(199709)53:1&lt;36::AID-JMV7&gt;3.0.CO;2-R
NR 24
TC 10
Z9 10
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1320-5358
EI 1440-1797
J9 NEPHROLOGY
JI Nephrology
PD APR
PY 2008
VL 13
IS 3
BP 186
EP 192
DI 10.1111/j.1440-1797.2008.00931.x
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA 282PA
UT WOS:000254578500002
PM 18315700
DA 2020-11-30
ER

PT J
AU Kasprowicz, V
   Ward, SM
   Turner, A
   Grammatikos, A
   Nolan, BE
   Lewis-Ximenez, L
   Sharp, C
   Woodruff, J
   Fleming, VM
   Sims, S
   Walker, BD
   Sewell, AK
   Lauer, GM
   Klenerman, P
AF Kasprowicz, Victoria
   Ward, Scott M.
   Turner, Alison
   Grammatikos, Alexandros
   Nolan, Brian E.
   Lewis-Ximenez, Lia
   Sharp, Charles
   Woodruff, Jenny
   Fleming, Vicki M.
   Sims, Stuart
   Walker, Bruce D.
   Sewell, Andrew K.
   Lauer, Georg M.
   Klenerman, Paul
TI Defining the directionality and quality of influenza virus-specific
   CD8(+) T cell cross-reactivity in individuals infected with hepatitis C
   virus
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID IMMUNE-RESPONSES; LYMPHOCYTE; BINDING; MEMORY; CORECEPTOR; CD4(+); CTL;
   ACTIVATION; MECHANISM; LIGANDS
AB Cross-reactivity of murine and recently human CD8(+) T cells between different viral peptides, i.e., heterologous immunity, has been well characterized. However, the directionality and quality of these cross-reactions is critical in determining their biological importance. Herein we analyzed the response of human CD8(+) T cells that recognize both a hepatitis C virus peptide (HCV-NS3) and a peptide derived from the influenza neuraminidase protein (Flu-NA). To detect the cross-reactive CD8(+) T cells, we used peptide-MHC class I complexes (pMHCs) containing a new mutant form of MHC class I able to bind CD8 more strongly than normal MHC class I complexes. T cell responses against HCV-NS3 and Flu-NA peptide were undetectable in normal donors. In contrast, some responses against the Flu-NA peptide were identified in HCV+ donors who showed strong HCV-NS3-specific reactivity. The Flu-NA peptide was a weak agonist for CD8(+) T cells in HCV+ individuals on the basis of novel pMHCs and functional assays. These data support the idea of cross-reactivity between the 2 peptides, but indicate that reactivity toward the Flu-NA peptide is highly CD8-dependent and occurs predominantly after priming during HCV infection. Our findings indicate the utility of the novel pMHCs in dissecting cross-reactivity and suggest that cross-reactivity between HCV and influenza is relatively weak. Further studies are needed to relate affinity and functionality of cross-reactive T cells.
C1 [Ward, Scott M.; Turner, Alison; Grammatikos, Alexandros; Sharp, Charles; Woodruff, Jenny; Fleming, Vicki M.; Sims, Stuart; Klenerman, Paul] Univ Oxford, Nuffield Dept Clin Med, Oxford OX1 1SY, England.
   [Kasprowicz, Victoria; Nolan, Brian E.; Walker, Bruce D.; Lauer, Georg M.] Massachusetts Gen Hosp, Partners AIDS Res Ctr, Charlestown, MA USA.
   [Kasprowicz, Victoria; Nolan, Brian E.; Walker, Bruce D.; Lauer, Georg M.] Massachusetts Gen Hosp, Div Infect Dis, Charlestown, MA USA.
   [Kasprowicz, Victoria; Nolan, Brian E.; Walker, Bruce D.; Lauer, Georg M.] Harvard Univ, Sch Med, Charlestown, MA USA.
   [Lewis-Ximenez, Lia] Inst Oswaldo Cruz Fiocruz, Dept Virol, Rio De Janeiro, Brazil.
   [Sewell, Andrew K.] Cardiff Univ, Dept Med Biochem & Immunol, Cardiff, S Glam, Wales.
RP Klenerman, P (corresponding author), Univ Oxford, Nuffield Dept Clin Med, Peter Medawar Bldg Pathogen Res,S Parks Rd, Oxford OX1 1SY, England.
EM paul.klenerman@ndm.ox.ac.uk
RI Grammatikos, Alexandros/B-2804-2008; Grammatikos,
   Alexandros/A-5726-2011; Lauer, Georg/J-1467-2018
OI Grammatikos, Alexandros/0000-0001-6544-8218; Grammatikos,
   Alexandros/0000-0001-6544-8218; Sharp, Charles/0000-0002-4063-3625;
   Lauer, Georg/0000-0002-9792-4271; Fleming, Vicki/0000-0002-0460-3533;
   Sewell, Andrew/0000-0003-3194-3135
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, R01AI031563,
   U19AI066345, R01AI031563, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, R01AI031563, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   R01AI031563, U19AI066345, U19AI066345, U19AI066345, R01AI031563,
   U19AI066345, R01AI031563, U19AI066345, U19AI066345, U19AI066345,
   R01AI031563, U19AI066345, U19AI066345, R01AI031563, U19AI066345,
   U19AI066345, R01AI031563, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   R01AI031563, U19AI066345, R01AI031563, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, R01AI031563, R01AI031563,
   U19AI066345] Funding Source: NIH RePORTER; Howard Hughes Medical
   InstituteHoward Hughes Medical Institute Funding Source: Medline; NIAID
   NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01 AI031563, U19 AI066345, AI31563]
   Funding Source: Medline; Wellcome TrustWellcome Trust Funding Source:
   Medline
CR Bachmann MF, 1998, EUR J IMMUNOL, V28, P3110
   Barnes E, 2004, EUR J IMMUNOL, V34, P1570, DOI 10.1002/eji.200424898
   BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0
   Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395
   Chang KM, 2001, HEPATOLOGY, V33, P267, DOI 10.1053/jhep.2001.21162
   Clute SC, 2005, J CLIN INVEST, V115, P3602, DOI 10.1172/JCI25078
   Cox AL, 2005, HEPATOLOGY, V42, P104, DOI 10.1002/hep.20749
   Day CL, 2003, J CLIN INVEST, V112, P831, DOI 10.1172/JCI200318509
   EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816
   Hampl J, 1997, IMMUNITY, V7, P379, DOI 10.1016/S1074-7613(00)80359-3
   Hillman MR, 2002, VACCINE, V20, P3068, DOI 10.1016/S0264-410X(02)00254-2
   Hutchinson SL, 2003, J BIOL CHEM, V278, P24285, DOI 10.1074/jbc.M300633200
   Kantzanou M, 2003, IMMUNOL LETT, V85, P165, DOI 10.1016/S0165-2478(02)00224-9
   Kennedy PTF, 2006, HEPATOLOGY, V43, P602, DOI 10.1002/hep.21081
   Kent SJ, 1997, J IMMUNOL, V158, P807
   Klenerman P, 1998, NATURE, V394, P482
   KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0
   Komatsu H, 2003, CLIN EXP IMMUNOL, V134, P9, DOI 10.1046/j.1365-2249.2003.02266.x
   Koziel MJ, 1997, J INFECT DIS, V176, P859, DOI 10.1086/516546
   Lauer GM, 2002, J VIROL, V76, P6104, DOI 10.1128/JVI.76.12.6104-6113.2002
   Lauer GM, 2004, GASTROENTEROLOGY, V127, P924, DOI 10.1053/j.gastro.2004.06.015
   Laugel B, 2007, J BIOL CHEM, V282, P23799, DOI 10.1074/jbc.M700976200
   Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499
   Li QJ, 2007, CELL, V129, P147, DOI 10.1016/j.cell.2007.03.008
   Lucas M, 2004, J IMMUNOL, V172, P1744, DOI 10.4049/jimmunol.172.3.1744
   Lyons DS, 1996, IMMUNITY, V5, P53, DOI 10.1016/S1074-7613(00)80309-X
   Macken C, 2001, INT CONGR SER, V1219, P103, DOI 10.1016/S0531-5131(01)00330-2
   PARKER KC, 1994, J IMMUNOL, V152, P163
   Scriba TJ, 2005, J IMMUNOL, V175, P6334, DOI 10.4049/jimmunol.175.10.6334
   Selin LK, 2006, IMMUNOL REV, V211, P164, DOI 10.1111/j.0105-2896.2006.00394.x
   Selin LK, 1998, J EXP MED, V188, P1705, DOI 10.1084/jem.188.9.1705
   SELIN LK, 1994, J EXP MED, V179, P1933, DOI 10.1084/jem.179.6.1933
   Urbani S, 2005, J EXP MED, V201, P675, DOI 10.1084/jem.20041058
   Wedemeyer H, 2001, J VIROL, V75, P11392, DOI 10.1128/JVI.75.23.11392-11400.2001
   Wills MR, 1996, J VIROL, V70, P7569, DOI 10.1128/JVI.70.11.7569-7579.1996
   Wooldridge L, 2005, J BIOL CHEM, V280, P27491, DOI 10.1074/jbc.M500555200
   Wooldridge L, 2003, J IMMUNOL, V171, P6650, DOI 10.4049/jimmunol.171.12.6650
   Wooldridge L, 2007, EUR J IMMUNOL, V37, P1323, DOI 10.1002/eji.200636765
NR 38
TC 30
Z9 30
U1 0
U2 3
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD MAR
PY 2008
VL 118
IS 3
BP 1143
EP 1153
DI 10.1172/JCI33082
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 269JX
UT WOS:000253646400038
PM 18246203
OA Green Published, Green Accepted, Bronze
DA 2020-11-30
ER

PT J
AU Kasprowicz, V
   Wiesch, JSZ
   Kuntzen, T
   Nolan, BE
   Longworth, S
   Berical, A
   Blum, J
   McMahon, C
   Reyor, LL
   Elias, N
   Kwok, WW
   McGovern, BG
   Freeman, G
   Chung, RT
   Klenerman, P
   Lewis-Ximenez, L
   Walker, BD
   Allen, TM
   Kim, AY
   Lauer, GM
AF Kasprowicz, Victoria
   Wiesch, Julian Schulze zur
   Kuntzen, Thomas
   Nolan, Brian E.
   Longworth, Steven
   Berical, Andrew
   Blum, Jenna
   McMahon, Cory
   Reyor, Laura L.
   Elias, Nahel
   Kwok, William W.
   McGovern, Barbara G.
   Freeman, Gordon
   Chung, Raymond T.
   Klenerman, Paul
   Lewis-Ximenez, Lia
   Walker, Bruce D.
   Allen, Todd M.
   Kim, Arthur Y.
   Lauer, Georg M.
TI High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8(+)
   and CD4(+) T cells during acute HCV infection, irrespective of clinical
   outcome
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID UP-REGULATION; EXHAUSTION
AB We monitored expression of PD-1 (a mediator of T-cell exhaustion and viral persistence) on hepatitis C virus (HCV)-specific CD8(+) and CD4(+) T cells from blood and liver during acute and chronic infections and after the resolved infection stage. PD-1 expression on HCV-specific T cells was high early in acute infection irrespective of clinical outcome, and most cells continued to express PD-1 in resolved and chronic stages of infection; intrahepatic expression levels were especially high. Our results suggest that an analysis of PD-1 expression alone is not sufficient to predict infection outcome or to determine T-cell functionality in HCV infection.
C1 [Kasprowicz, Victoria; Wiesch, Julian Schulze zur; Kuntzen, Thomas; Nolan, Brian E.; Longworth, Steven; Berical, Andrew; Blum, Jenna; McMahon, Cory; Reyor, Laura L.; Elias, Nahel; Walker, Bruce D.; Allen, Todd M.; Kim, Arthur Y.; Lauer, Georg M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Partners AIDS Res Ctr, Charlestown, MA 02129 USA.
   [Wiesch, Julian Schulze zur] Univ Hamburg, Med Klin 1, Hamburg, Germany.
   [Elias, Nahel] Massachusetts Gen Hosp, Dept Surg, Transplantat Unit, Boston, MA 02114 USA.
   [Kwok, William W.] Benaroya Res Inst Virginia Mason, Seattle, WA USA.
   [McGovern, Barbara G.] Lemuel Shattuck Hosp, Boston, MA USA.
   [McGovern, Barbara G.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
   [Freeman, Gordon] Harvard Univ, Sch Med, Dept Med, Dana Farber Canc Inst,Dept Med Oncol, Boston, MA 02115 USA.
   [Chung, Raymond T.] Massachusetts Gen Hosp, Dept Surg, Gastrointestinal Unit, Boston, MA 02114 USA.
   [Klenerman, Paul] Univ Oxford, Nuffield Dept Med, Oxford OX1 3SY, England.
   [Lewis-Ximenez, Lia] Fiocruz MS, Inst Oswaldo Cruz, Dept Virol, BR-21045900 Rio De Janeiro, Brazil.
   [Wiesch, Julian Schulze zur; Elias, Nahel; Chung, Raymond T.; Walker, Bruce D.] Howard Hughes Med Inst, Chevy Chase, MD USA.
RP Lauer, GM (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Partners AIDS Res Ctr, 149 13th St,6th Floor,Room 6001, Charlestown, MA 02129 USA.
EM glauer@partners.org
RI Elias, Nahel/AAO-8344-2020; Freeman, Gordon/AAC-5380-2019; Allen,
   Todd/F-5473-2011; Lauer, Georg/J-1467-2018
OI Elias, Nahel/0000-0001-6466-7347; Freeman, Gordon/0000-0002-7210-5616;
   Allen, Todd/0000-0002-6609-1318; Lauer, Georg/0000-0002-9792-4271
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U19AI066345, U19AI066345, K23AI054379, U19AI066345, U19AI066345,
   R01AI031563, U19AI066345, R01AI067926, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, R01AI031563, U19AI066345, U19AI066345,
   R01AI031563, U19AI066345, U19AI066345, U19AI066345, R01AI031563,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, K23AI054379,
   U19AI066345, U19AI066345, U19AI066345, R01AI031563, U19AI066345,
   U19AI066345, R01AI031563, R01AI067926, R01AI031563, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, R01AI031563,
   U19AI066345, R01AI031563, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, K23AI054379, K23AI054379, R01AI031563,
   U19AI066345, R01AI031563, U19AI066345, R01AI067926, R01AI067926,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, R01AI031563, U19AI066345,
   K23AI054379, U19AI066345, U19AI066345, R01AI031563, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345] Funding
   Source: NIH RePORTER; NIAID NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [R01-AI031563-13,
   U19-AI066345-02, K23-AI054379-05, R01 AI067926, K23 AI054379, R01
   AI031563, U19 AI066345, R01-AI067926-01] Funding Source: Medline;
   Wellcome TrustWellcome Trust Funding Source: Medline
CR Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444
   Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115
   Day CL, 2003, J CLIN INVEST, V112, P831, DOI 10.1172/JCI200318509
   Golden-Mason L, 2007, J VIROL, V81, P9249, DOI 10.1128/JVI.00409-07
   Kim AY, 2005, BLOOD, V105, P1170, DOI 10.1182/blood-2004-06-2336
   Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107
   Lucas M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000649
   Penna A, 2007, HEPATOLOGY, V45, P588, DOI 10.1002/hep.21541
   Petrovas C, 2006, J EXP MED, V203, P2281, DOI 10.1084/jem.20061496
   Radziewicz H, 2007, J VIROL, V81, P2545, DOI 10.1128/JVI.02021-06
   Sauce D, 2007, AIDS, V21, P2005, DOI 10.1097/QAD.0b013e3282eee548
   Trautmann L, 2006, NAT MED, V12, P1198, DOI 10.1038/nm1482
   Urbani S, 2006, J VIROL, V80, P11398, DOI 10.1128/JVI.01177-06
   Zhang JY, 2007, BLOOD, V109, P4671, DOI 10.1182/blood-2006-09-044826
NR 14
TC 137
Z9 147
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD MAR
PY 2008
VL 82
IS 6
BP 3154
EP 3160
DI 10.1128/JVI.02474-07
PG 7
WC Virology
SC Virology
GA 270AB
UT WOS:000253691000055
PM 18160439
OA Bronze, Green Published
DA 2020-11-30
ER

PT J
AU Wiesch, JS
   Listgarden, J
   Li, B
   Nawar, H
   Kasprowicz, V
   Nolan, B
   Bium, J
   Lewis-Ximenez, L
   McGovern, B
   Kuntzen, T
   Kwok, B
   Allen, T
   Sette, A
   Lohse, A
   Walker, B
   Chung, R
   Kim, A
   Lauer, G
AF zur Wiesch, J. Schulze
   Listgarden, J.
   Li, B.
   Nawar, H.
   Kasprowicz, V.
   Nolan, B.
   Bium, J.
   Lewis-Ximenez, L.
   McGovern, B.
   Kuntzen, T.
   Kwok, B.
   Allen, T.
   Sette, A.
   Lohse, A.
   Walker, B.
   Chung, R.
   Kim, A.
   Lauer, G.
TI Comprehensive assessment of HCVCD4+epitopes through conventional mapping
   combined with computational analysis
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT 43rd Annual Meeting of the
   European-Association-for-the-Study-of-the-Liver
CY APR 23-27, 2008
CL Milan, ITALY
SP European Assoc Study Liver
C1 [zur Wiesch, J. Schulze; Lohse, A.] Univ Klin Hamburg Eppendorf, Med Klin 1, Hamburg, Germany.
   [zur Wiesch, J. Schulze; Li, B.; Nawar, H.; Kasprowicz, V.; Nolan, B.; Bium, J.; Allen, T.; Walker, B.; Kim, A.; Lauer, G.] Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02114 USA.
   [Chung, R.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
   [Listgarden, J.] Microsoft Res, Redmond, WA USA.
   [Sette, A.] La Jolla Inst Allergy & Immunol, Boston, MA USA.
   [McGovern, B.] Tufts Univ, Lemuel Shattuck Hosp, Boston, MA 02111 USA.
   [Kwok, B.] Benaroya Res Inst, Seattle, WA USA.
   [Lewis-Ximenez, L.] Fiocruz MS, Inst Oswaldo Cruz, Dept Virol, BR-21045900 Rio De Janeiro, Brazil.
RI Allen, Todd/F-5473-2011
OI Allen, Todd/0000-0002-6609-1318
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PY 2008
VL 48
SU 2
MA 622
BP S231
EP S232
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 312PL
UT WOS:000256683201113
DA 2020-11-30
ER

PT J
AU Kuntzen, T
   Timm, J
   Berical, A
   Lewis-Ximenez, LL
   Jones, A
   Nolan, B
   Wiesch, JSZ
   Li, B
   Schneidewind, A
   Kim, AY
   Chung, RT
   Lauer, GM
   Allen, TM
AF Kuntzen, Thomas
   Timm, Joerg
   Berical, Andrew
   Lewis-Ximenez, Lia L.
   Jones, Andrea
   Nolan, Brian
   Wiesch, Julian Schulze zur
   Li, Bin
   Schneidewind, Arne
   Kim, Arthur Y.
   Chung, Raymond T.
   Lauer, Georg M.
   Allen, Todd M.
TI Viral sequence evolution in acute hepatitis C virus infection
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID CYTOTOXIC T-LYMPHOCYTES; CELLULAR IMMUNE-RESPONSES; ESCAPE MUTATIONS;
   FITNESS COST; LONG-TERM; IN-VIVO; TYPE-1; REVERSION; TRANSMISSION;
   SELECTION
AB CD8(+)-T-cell responses play an important role in the containment and clearance of hepatitis C virus (HCV) infection, and an association between viral persistence and development of viral escape mutations has been postulated. While escape from CD8(+)-T-cell responses has been identified as a major driving force for the evolution of human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV), a broader characterization of this relationship is needed in HCV infection. To determine the extent, kinetics, and driving forces of HCV sequence evolution, we sequenced the entire HCV genome longitudinally in four subjects monitored for up to 30 months after acute infection. For two subjects the transmission sources were also available. Of 53 total nonenvelope amino acid substitutions detected, a majority represented forward mutations away from the consensus sequence. In contrast to studies in HIV and SIV, however, only 11% of these were associated with detectable CD8(+) T-cell responses. Interestingly, 19% of nonenvelope mutations represented changes toward the consensus sequence, suggesting reversion in the absence of immune pressure upon transmission. Notably, the rate of evolution of forward and reverse mutations correlated with the conservation of each residue, which is indicative of structural constraints influencing the kinetics of viral evolution. Finally, the rate of sequence evolution was observed to decline over the course of infection, possibly reflective of diminishing selection pressure by dysfunctional CD8(+) T cells. Taken together, these data provide insight into the extent to which HCV is capable of evading early CD8(+) T-cell responses and support the hypothesis that dysfunction of CD8(+) T cells may be associated with failure to resolve HCV infections.
C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Infect Dis Div,Partners AIDS Res Ctr, Boston, MA USA.
   Univ Hosp Essen, Dept Virol, Essen, Germany.
   Inst Oswaldo Cruz Fiocruz, Dept Virol, Rio De Janeiro, Brazil.
   Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
RP Allen, TM (corresponding author), Massachusetts Gen Hosp, Boston, MA 02129 USA.
EM tallen2@partners.org
RI Timm, Jorg/P-7652-2019; Allen, Todd/F-5473-2011; Yang, Chen/G-1379-2010;
   Lauer, Georg/J-1467-2018
OI Timm, Jorg/0000-0001-7799-3045; Allen, Todd/0000-0002-6609-1318; Lauer,
   Georg/0000-0002-9792-4271
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U19 AI066345, U19 AI 066345-02, R01
   AI067926, R01 AI 067926-01] Funding Source: Medline; NATIONAL INSTITUTE
   OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   R01AI067926, U19AI066345, U19AI066345, R01AI067926, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, R01AI067926,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   R01AI067926] Funding Source: NIH RePORTER
CR Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124
   Allen TM, 2005, J VIROL, V79, P13239, DOI 10.1128/JVI.79.21.13239-13249.2005
   Allen TM, 2004, J VIROL, V78, P7069, DOI 10.1128/JVI.78.13.7069-7078.2004
   Bain C, 2001, GASTROENTEROLOGY, V120, P512, DOI 10.1053/gast.2001.21212
   Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a
   Bhattacharya T, 2007, SCIENCE, V315, P1583, DOI 10.1126/science.1131528
   Booth JCL, 1998, HEPATOLOGY, V27, P223, DOI 10.1002/hep.510270134
   BUKH J, 1995, SEMIN LIVER DIS, V15, P41, DOI 10.1055/s-2007-1007262
   Cabrera R, 2004, HEPATOLOGY, V40, P1062, DOI 10.1002/hep.20454
   Chang KM, 1997, J CLIN INVEST, V100, P2376, DOI 10.1172/JCI119778
   Cooper S, 1999, IMMUNITY, V10, P439, DOI 10.1016/S1074-7613(00)80044-8
   Cox AL, 2005, J EXP MED, V201, P1741, DOI 10.1084/jem.20050121
   Cox AL, 2005, CLIN INFECT DIS, V40, P951, DOI 10.1086/428578
   Cox AL, 2005, HEPATOLOGY, V42, P104, DOI 10.1002/hep.20749
   Erickson AL, 2001, IMMUNITY, V15, P883, DOI 10.1016/S1074-7613(01)00245-X
   FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205
   Fernandez CS, 2005, J VIROL, V79, P5721, DOI 10.1128/JVI.79.9.5721-5731.2005
   Fernandez J, 2004, J VIROL, V78, P9782, DOI 10.1128/JVI.78.18.9782-9789.2004
   Friedrich TC, 2004, NAT MED, V10, P275, DOI 10.1038/nm998
   Friedrich TC, 2004, J VIROL, V78, P2581, DOI 10.1128/JVI.78.5.2581-2585.2004
   Gaudieri S, 2006, J VIROL, V80, P11094, DOI 10.1128/JVI.00912-06
   Gerlach JT, 1999, GASTROENTEROLOGY, V117, P933, DOI 10.1016/S0016-5085(99)70353-7
   Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212
   Gruner NH, 2000, J INFECT DIS, V181, P1528, DOI 10.1086/315450
   Herbeck JT, 2006, J VIROL, V80, P1637, DOI 10.1128/JVI.80.4.1637-1644.2006
   Holmes EC, 1998, J VIROL, V72, P886
   Korber B, 2000, COMPUTATIONAL ANAL H, P55, DOI DOI 10.1007/B112102
   Lauer GM, 2002, J VIROL, V76, P6104, DOI 10.1128/JVI.76.12.6104-6113.2002
   Lauer GM, 2002, J VIROL, V76, P2817, DOI 10.1128/JVI.76.6.2817-2826.2002
   Lauer GM, 2004, GASTROENTEROLOGY, V127, P924, DOI 10.1053/j.gastro.2004.06.015
   Leslie AJ, 2004, NAT MED, V10, P282, DOI 10.1038/nm992
   Li B, 2007, J VIROL, V81, P193, DOI 10.1128/JVI.01231-06
   Limmer A, 2000, NAT MED, V6, P1348
   Liu CH, 2006, CLIN INFECT DIS, V42, P1254, DOI 10.1086/503040
   Martinez-Picado J, 2006, J VIROL, V80, P3617, DOI 10.1128/JVI.80.7.3617-3623.2006
   Moore CB, 2002, SCIENCE, V296, P1439, DOI 10.1126/science.1069660
   Netski DM, 2005, CLIN INFECT DIS, V41, P667, DOI 10.1086/432478
   O'Connor DH, 2004, J VIROL, V78, P14012, DOI 10.1128/JVI.78.24.14012-14022.2004
   Quer J, 2005, J VIROL, V79, P15131, DOI 10.1128/JVI.79.24.15131-15141.2005
   Ray SC, 2005, J EXP MED, V201, P1753, DOI 10.1084/jem.20050122
   Seeff LB, 2002, HEPATOLOGY, V36, pS1, DOI 10.1053/jhep.2002.36992
   Shannon C. E., 1949, MATH THEORY COMMUNIC
   Simmonds P, 2004, J GEN VIROL, V85, P3173, DOI 10.1099/vir.0.80401-0
   Soderholm J, 2006, GUT, V55, P266, DOI 10.1136/gut.2005.072231
   Tester I, 2005, J EXP MED, V201, P1725, DOI 10.1084/jem.20042284
   Thimme R, 2001, J EXP MED, V194, P1395, DOI 10.1084/jem.194.10.1395
   Timm J, 2004, J EXP MED, V200, P1593, DOI 10.1084/jem.20041006
   Urbani S, 2005, J IMMUNOL, V175, P7519, DOI 10.4049/jimmunol.175.11.7519
   Von Hahn T, 2007, GASTROENTEROLOGY, V132, P667, DOI 10.1053/j.gastro.2006.12.008
   Ward S, 2002, CLIN EXP IMMUNOL, V128, P195, DOI 10.1046/j.1365-2249.2002.01840.x
   Wedemeyer H, 2002, J IMMUNOL, V169, P3447, DOI 10.4049/jimmunol.169.6.3447
   Wong DKH, 2001, J VIROL, V75, P1229, DOI 10.1128/JVI.75.3.1229-1235.2001
   ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734
NR 53
TC 79
Z9 79
U1 0
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD NOV
PY 2007
VL 81
IS 21
BP 11658
EP 11668
DI 10.1128/JVI.00995-07
PG 11
WC Virology
SC Virology
GA 224AM
UT WOS:000250417400013
PM 17699568
OA Green Published, Bronze
DA 2020-11-30
ER

PT J
AU zur Wiesch, JS
   Lauer, GM
   Timm, J
   Kuntzen, T
   Neukamm, M
   Berical, A
   Jones, AM
   Nolan, BE
   Longworth, SA
   Kasprowicz, V
   McMahon, C
   Wurcel, A
   Lohse, AW
   Lewis-Ximenez, LL
   Chung, RT
   Kim, AY
   Allen, TM
   Walker, BD
AF zur Wiesch, Julian Schulze
   Lauer, Georg M.
   Timm, Joerg
   Kuntzen, Thomas
   Neukamm, Martin
   Berical, Andrew
   Jones, Andrea M.
   Nolan, Brian E.
   Longworth, Steve A.
   Kasprowicz, Victoria
   McMahon, Cory
   Wurcel, Alysse
   Lohse, Ansgar W.
   Lewis-Ximenez, Lia L.
   Chung, Raymond T.
   Kim, Arthur Y.
   Allen, Todd M.
   Walker, Bruce D.
TI Immunologic evidence for lack of heterologous protection following
   resolution of HCV in patients with non-genotype 1 infection
SO BLOOD
LA English
DT Article
ID HEPATITIS-C VIRUS; CD4(+) T-CELLS; PRIMERS PCR-SSP; VIRAL CLEARANCE;
   IMMUNE-RESPONSES; NONSTRUCTURAL PROTEIN-3; CD8-T-CELL MEMORY; CD4-T-CELL
   HELP; HLA-B; GENOTYPE
AB Chronic hepatitis C virus (HCV) infection is typically characterized by a lack of virus-specific CD4(+) T-cell-proliferative responses, but strong responses have been described in a subset of persons with persistent viremia. One possible explanation for these responses is that they were primed by an earlier resolved infection and do not recognize the current circulating virus. We defined all targeted epitopes using overlapping peptides corresponding to a genotype 1 a strain in 44 patients chronically infected with different HCV genotypes (GT). Surprisingly, more HCV-specific CD4(+) T-cell responses were detected in patients with chronic non-GT1 infection compared with patients with chronic GT1 infection (P =.017). Notably, we found serologic evidence of a previous exposure to GT1 in 4 patients with non-GT1 infection, and these persons also demonstrated significantly more responses than non-GT1 patients in whom genotype and HCV serotype were identical (P <.001). Comparison of recognition of GT1-specific peptides to peptides representing autologous virus revealed the absence of cross-recognition of the autologous circulating virus. These data indicate that persisent HCV infection can occur in the presence of an HCV-specific T-cell response primed against a heterologous HCV strain, and suggest that clearance of 1 GT does not necessarily protect against subsequent exposure to a second GT.
C1 Massachusetts Gen Hosp, Howard Hughes Med Inst, Partners AIDS Res Ctr, Infect Dis Div, Charlestown, MA 02129 USA.
   Harvard Univ, Sch Med, Boston, MA 02115 USA.
   Howard Hughes Med Inst, Chevy Chase, MD USA.
   Univ Klinikum Eppendorf, Med Klin 1, Hamburg, Germany.
   Heinrich Pette Inst Expt Virol & Immunol, Hamburg, Germany.
   Univ Essen Gesamthsch, Inst Virol, D-4300 Essen, Germany.
   Inst Oswaldo Cruz, Dept Virol, BR-20001 Rio De Janeiro, Brazil.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Walker, BD (corresponding author), Massachusetts Gen Hosp, Howard Hughes Med Inst, Partners AIDS Res Ctr, Infect Dis Div, 149 13th St,Rm 5212D, Charlestown, MA 02129 USA.
EM bwalker@partners.org
RI Timm, Jorg/P-7652-2019; Wurcel, Alysse/AAC-5372-2019; Allen,
   Todd/F-5473-2011; Wurcel, Alysse/AAZ-6132-2020; Lauer, Georg/J-1467-2018
OI Timm, Jorg/0000-0001-7799-3045; Wurcel, Alysse/0000-0002-8255-8387;
   Allen, Todd/0000-0002-6609-1318; Lauer, Georg/0000-0002-9792-4271
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U19AI066345, R01AI031563, U19AI066345, U19AI066345, R01AI031563,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, R01AI031563, U19AI066345, U19AI066345,
   R01AI031563, U19AI066345, U19AI066345, R01AI067926, U19AI066345,
   U19AI066345, U19AI066345, R01AI031563, U19AI066345, U19AI066345,
   U19AI066345, R01AI031563, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, R01AI067926, U19AI066345, R01AI031563, R01AI031563,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, R01AI067926, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   R01AI031563, R01AI031563, U19AI066345, U19AI066345, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, R01AI031563, U19AI066345,
   U19AI066345, U19AI066345, U19AI066345, U19AI066345, U19AI066345,
   R01AI031563, R01AI031563, R01AI067926, U19AI066345, U19AI066345] Funding
   Source: NIH RePORTER; NIAID NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [R01-AI067926-01, U19
   AI066345, R01 AI031563, R01 AI067926, U19-AI066345-02, R01-AI031563-13]
   Funding Source: Medline
CR BATTEGAY M, 1994, J VIROL, V68, P4700, DOI 10.1128/JVI.68.7.4700-4704.1994
   Bowen DG, 2005, NATURE, V436, P946, DOI 10.1038/nature04079
   BUNCE M, 1995, TISSUE ANTIGENS, V45, P81, DOI 10.1111/j.1399-0039.1995.tb02422.x
   Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x
   Chang KM, 2001, HEPATOLOGY, V33, P267, DOI 10.1053/jhep.2001.21162
   Chisari FV, 2005, NATURE, V436, P930, DOI 10.1038/nature04076
   Corey KE, 2006, CLIN GASTROENTEROL H, V4, P1278, DOI 10.1016/j.cgh.2006.06.026
   Day CL, 2003, J EXP MED, V198, P1773, DOI 10.1084/jem.20031947
   Day CL, 2002, J VIROL, V76, P12584, DOI 10.1128/JVI.76.24.12584-12595.2002
   Diepolder HM, 1998, CLIN EXP IMMUNOL, V113, P244
   Diepolder HM, 1997, J VIROL, V71, P6011, DOI 10.1128/JVI.71.8.6011-6019.1997
   Diepolder HM, 2004, J HEPATOL, V40, P1030, DOI 10.1016/j.jhep.2004.04.002
   DIEPOLDER HM, 1995, LANCET, V346, P1006, DOI 10.1016/S0140-6736(95)91691-1
   *EUR UN, EUR HCV DAT
   Folgori A, 2006, GUT, V55, P1012, DOI 10.1136/gut.2005.080077
   Folgori A, 2006, NAT MED, V12, P190, DOI 10.1038/nm1353
   Gerlach JT, 2005, J VIROL, V79, P12425, DOI 10.1128/JVI.79.19.12425-12433.2005
   Gerlach JT, 1999, GASTROENTEROLOGY, V117, P933, DOI 10.1016/S0016-5085(99)70353-7
   Gerlach JT, 2003, GASTROENTEROLOGY, V125, P80, DOI 10.1016/S0016-5085(03)00668-1
   Grebely J, 2006, HEPATOLOGY, V44, P1139, DOI 10.1002/hep.21376
   Hahn YS, 2003, CURR OPIN IMMUNOL, V15, P443, DOI 10.1016/S0952-7915(03)00076-1
   Harcourt GC, 2003, CLIN EXP IMMUNOL, V131, P122, DOI 10.1046/j.1365-2249.2003.02033.x
   Houghton M, 2005, NATURE, V436, P961, DOI 10.1038/nature04081
   Hultgren C, 2004, J HEPATOL, V40, P971, DOI [10.1016/j.jhep.2004.02.002, 10.1016/S0168-8278(04)00052-2]
   Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441
   Kaech SM, 2003, SCIENCE, V300, P263, DOI 10.1126/science.1084511
   KAO JH, 1993, GASTROENTEROLOGY, V105, P583, DOI 10.1016/0016-5085(93)90737-W
   Kao JH, 1996, J MED VIROL, V50, P303, DOI 10.1002/(SICI)1096-9071(199612)50:4&lt;303::AID-JMV4&gt;3.0.CO;2-C
   Kaplan DE, 2005, HEPATOLOGY, V41, P1365, DOI 10.1002/hep.20706
   Kuiken C, 2005, BIOINFORMATICS, V21, P379, DOI 10.1093/bioinformatics/bth485
   LAI ME, 1994, LANCET, V343, P388, DOI 10.1016/S0140-6736(94)91224-6
   Lamonaca V, 1999, HEPATOLOGY, V30, P1088, DOI 10.1002/hep.510300435
   Lanford RE, 2004, J VIROL, V78, P1575, DOI 10.1128/JVI.78.3.1575-1581.2004
   Lauer GM, 2005, J VIROL, V79, P12979, DOI 10.1128/JVI.79.20.12979-12988.2005
   Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499
   Mangada MM, 2005, J IMMUNOL, V175, P2676, DOI 10.4049/jimmunol.175.4.2676
   Mehta SH, 2002, LANCET, V359, P1478, DOI 10.1016/S0140-6736(02)08435-0
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   *NAT I ALL INF DIS, HCV VIR DAT PROJ
   OKAMOTO H, 1994, HEPATOLOGY, V20, P1131, DOI 10.1002/hep.1840200505
   Planz O, 1997, P NATL ACAD SCI USA, V94, P6874, DOI 10.1073/pnas.94.13.6874
   Prince AM, 2005, J INFECT DIS, V192, P1701, DOI 10.1086/496889
   Proust B, 2000, J CLIN MICROBIOL, V38, P3125, DOI 10.1128/JCM.38.8.3125-3127.2000
   Rehermann B, 2005, J EXP MED, V201, P667, DOI 10.1084/jem.20050220
   Rehermann B, 2005, NAT REV IMMUNOL, V5, P215, DOI 10.1038/nri1573
   Rothman AL, 2004, J CLIN INVEST, V113, P946, DOI 10.1172/JCI200421512
   Shedlock DJ, 2003, J IMMUNOL, V170, P2053, DOI 10.4049/jimmunol.170.4.2053
   Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305
   Shoukry NH, 2004, ANNU REV MICROBIOL, V58, P391, DOI 10.1146/annurev.micro.58.030603.123836
   Shoukry NH, 2004, J IMMUNOL, V172, P483, DOI 10.4049/jimmunol.172.1.483
   Simmonds P, 2004, J GEN VIROL, V85, P3173, DOI 10.1099/vir.0.80401-0
   Smyk-Pearson S, 2006, J INFECT DIS, V194, P454, DOI 10.1086/505714
   Sugimoto K, 2005, J VIROL, V79, P6976, DOI 10.1128/JVI.79.11.6976-6983.2005
   Sun JC, 2003, SCIENCE, V300, P339, DOI 10.1126/science.1083317
   Thimme R, 2001, J EXP MED, V194, P1395, DOI 10.1084/jem.194.10.1395
   Timm J, 2004, J EXP MED, V200, P1593, DOI 10.1084/jem.20041006
   Toyoda H, 1999, AM J GASTROENTEROL, V94, P2230, DOI 10.1111/j.1572-0241.1999.01298.x
   Ulsenheimer A, 2003, HEPATOLOGY, V37, P1189, DOI 10.1053/jhep.2003.50194
   vonHerrath MG, 1996, J VIROL, V70, P1072, DOI 10.1128/JVI.70.2.1072-1079.1996
   Yee LJ, 2004, GENES IMMUN, V5, P237, DOI 10.1038/sj.gene.6364090
   Zein NN, 2000, CLIN MICROBIOL REV, V13, P223, DOI 10.1128/CMR.13.2.223-235.2000
   zur Wiesch JS, 2005, J IMMUNOL, V175, P3603, DOI 10.4049/jimmunol.175.6.3603
NR 62
TC 21
Z9 21
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD SEP 1
PY 2007
VL 110
IS 5
BP 1559
EP 1569
DI 10.1182/blood-2007-01-069583
PG 11
WC Hematology
SC Hematology
GA 205YT
UT WOS:000249151800031
PM 17475911
OA Green Published
DA 2020-11-30
ER

PT J
AU Lewis-Ximenez, LL
   Espirito-Santo, MP
   Oliveira, JM
   Lauer, G
   Walker, B
   Yoshida, CFT
   Lampe, E
AF Lewis-Ximenez, L. L.
   Espirito-Santo, M. P.
   Oliveira, J. M.
   Lauer, G.
   Walker, B.
   Yoshida, C. F. T.
   Lampe, E.
TI Three cases of acute hepatitis C virus infection following dry sex
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Meeting Abstract
CT 12th International Symposium on Viral Hepatitis and Liver Disease
CY JUL 01-05, 2006
CL Paris, FRANCE
SP Pan Amer Soc Clin Virol, European Soc Clin Virol
C1 Fdn Oswaldo Cruz, Dept Virol, Rio De Janeiro, Brazil.
   Massachusetts Gen Hosp, Res Ctr, Boston, MA 02114 USA.
   Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
   Howard Hughes Med Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD JUL
PY 2006
VL 36
SU 2
BP S154
EP S154
DI 10.1016/S1386-6532(06)80476-2
PG 1
WC Virology
SC Virology
GA 064CR
UT WOS:000239067300466
DA 2020-11-30
ER

PT J
AU Nolan, B
   Kuntzen, T
   Jones, A
   Lewis-Ximenez, L
   Walker, BD
   Allen, TM
   Lauer, GM
AF Nolan, B.
   Kuntzen, T.
   Jones, A.
   Lewis-Ximenez, L.
   Walker, B. D.
   Allen, T. M.
   Lauer, G. M.
TI Dominant and subdominant T-cell responses and viral evolution in
   subjects with acute symptomatic HCV infection
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Meeting Abstract
CT 12th International Symposium on Viral Hepatitis and Liver Disease
CY JUL 01-05, 2006
CL Paris, FRANCE
SP Pan Amer Soc Clin Virol, European Soc Clin Virol
C1 Massachusetts Gen Hosp, Partners AIDS Res Ctr, Charlestown, MA USA.
   Massachusetts Gen Hosp, Howard Hughes Med Inst, Charlestown, MA USA.
   Harvard Univ, Sch Med, Charlestown, MA USA.
   Inst Oswaldo Cruz, BR-20001 Rio De Janeiro, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD JUL
PY 2006
VL 36
SU 2
BP S122
EP S122
DI 10.1016/S1386-6532(06)80379-3
PG 1
WC Virology
SC Virology
GA 064CR
UT WOS:000239067300370
DA 2020-11-30
ER

PT J
AU zur Wiesch, JS
   Lauer, GM
   Day, CL
   Kim, AY
   Ouchi, K
   Duncan, JE
   Wurcel, AG
   Timm, J
   Jones, AM
   Mothe, B
   Allen, TM
   McGovern, B
   Lewis-Ximenez, L
   Sidney, J
   Sette, A
   Chung, RT
   Walker, BD
AF zur Wiesch, JS
   Lauer, GM
   Day, CL
   Kim, AY
   Ouchi, K
   Duncan, JE
   Wurcel, AG
   Timm, J
   Jones, AM
   Mothe, B
   Allen, TM
   McGovern, B
   Lewis-Ximenez, L
   Sidney, J
   Sette, A
   Chung, RT
   Walker, BD
TI Broad repertoire of the CD4(+) th cell response in spontaneously
   controlled hepatitis C virus infection includes dominant and highly
   promiscuous epitopes
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID CLASS-II TETRAMERS; CHRONIC VIRAL-INFECTIONS; EX-VIVO ANALYSIS; PRIMERS
   PCR-SSP; LYMPHOCYTE EPITOPES; HLA-B; NONSTRUCTURAL PROTEIN-3;
   COMPREHENSIVE ANALYSIS; IMMUNE-RESPONSES; PEPTIDE BINDING
AB A vigorous hepatitis C virus (HCV)-specific Th cell response is regarded as essential to the immunological control of HCV viremia. The aim of this study was to comprehensively define the breadth and specificity of dominant HCV-specific CD4(+) T cell epitopes in large cohorts of subjects with chronic and spontaneously resolved HCV viremia. Following in vitro stimulation of PBMC, HCV-specific cell cultures from each subject were screened with an overlapping panel of synthetic 20-mer peptides spanning the entire HCV polyprotein. Of 22 subjects who spontaneously controlled HCV viremia, all recognized at least one of a group of six epitopes situated within the nonstructural (NS) proteins NS3, NS4, and NS5, each of which was detected by > 30% of subjects, but most subjects recognized additional, more heterogeneous specificities. In contrast, none of the most frequently targeted epitopes was detected by > 5% of persons with chronic infection. The most frequently recognized peptides showed promiscuous binding to multiple HLA-DR molecules in in vitro binding assays and were restricted by different HLA-DR molecules in functional assays in different persons. These data demonstrate that predominant CD4(+) T cell epitopes in persons with resolved HCV infection are preferentially located in the nonstructural proteins and are immunogenic in the context of multiple class 11 molecules. This comprehensive characterization of CD4(+) T cell epitopes in resolved HCV infection provides important information to facilitate studies of immunopathogenesis and HCV vaccine design and evaluation.
C1 Massachusetts Gen Hosp, Howard Hughes Med Inst, Partners AIDS Res Ctr, Boston, MA 02129 USA.
   Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02129 USA.
   Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02129 USA.
   Harvard Univ, Sch Med, Boston, MA 02115 USA.
   Calif State Univ, Dept Biol Sci, San Marcos, CA 92096 USA.
   Lemuel Shattuck Hosp, Jamaica Plain, MA 02108 USA.
   Inst Oswaldo Cruz, FIOCRUZ, Dept Virol, BR-20001 Rio De Janeiro, RJ, Brazil.
   La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA.
RP Walker, BD (corresponding author), Massachusetts Gen Hosp, Howard Hughes Med Inst, Partners AIDS Res Ctr, 149 13th St,Room 5212D, Boston, MA 02129 USA.
EM bwalker@partners.org
RI Timm, Jorg/P-7652-2019; Allen, Todd/F-5473-2011; Wurcel,
   Alysse/AAC-5372-2019; Day, Cheryl L/J-9844-2012; Wurcel,
   Alysse/AAZ-6132-2020; Lauer, Georg/J-1467-2018
OI Timm, Jorg/0000-0001-7799-3045; Allen, Todd/0000-0002-6609-1318; Wurcel,
   Alysse/0000-0002-8255-8387; Day, Cheryl L/0000-0002-6497-4846; Lauer,
   Georg/0000-0002-9792-4271
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [K23AI054379, R01AI031563, R01AI031563, K23AI054379, R01AI031563,
   R01AI031563, R01AI031563, R01AI031563, R01AI031563, K23AI054379,
   R01AI031563, R01AI031563, R01AI031563, R01AI031563, K23AI054379,
   R01AI031563, R01AI031563, K23AI054379] Funding Source: NIH RePORTER;
   NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [K23 AI054379, R01 AI031563, AI31563,
   AI054379] Funding Source: Medline
CR BARBER LD, 1993, ANNU REV CELL BIOL, V9, P163
   BATTEGAY M, 1994, J VIROL, V68, P4700, DOI 10.1128/JVI.68.7.4700-4704.1994
   Berzofsky JA, 2004, J CLIN INVEST, V114, P450, DOI 10.1172/JCI200422674
   Bitmansour AD, 2002, J IMMUNOL, V169, P1207, DOI 10.4049/jimmunol.169.3.1207
   BUNCE M, 1995, TISSUE ANTIGENS, V45, P81, DOI 10.1111/j.1399-0039.1995.tb02422.x
   Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x
   CARDIN RD, 1996, J EXP MED, V184, P363
   Chang GYN, 2001, EUR J NEUROL, V8, P267, DOI 10.1046/j.1468-1331.2001.00216.x
   Cheney IW, 2002, VIROLOGY, V297, P298, DOI 10.1006/viro.2002.1461
   Cohen J, 1999, SCIENCE, V285, P26, DOI 10.1126/science.285.5424.26
   Cooper S, 1999, IMMUNITY, V10, P439, DOI 10.1016/S1074-7613(00)80044-8
   Day CL, 2003, J EXP MED, V198, P1773, DOI 10.1084/jem.20031947
   Day CL, 2003, J CLIN INVEST, V112, P831, DOI 10.1172/JCI200318509
   Day CL, 2002, J VIROL, V76, P12584, DOI 10.1128/JVI.76.24.12584-12595.2002
   Diepolder HM, 1997, J VIROL, V71, P6011, DOI 10.1128/JVI.71.8.6011-6019.1997
   DIEPOLDER HM, 1995, LANCET, V346, P1006, DOI 10.1016/S0140-6736(95)91691-1
   Doolan DL, 2000, J IMMUNOL, V165, P1123, DOI 10.4049/jimmunol.165.2.1123
   Doolan DL, 1997, IMMUNITY, V7, P97, DOI 10.1016/S1074-7613(00)80513-0
   Eckels DD, 2000, IMMUNOL REV, V174, P90, DOI 10.1034/j.1600-0528.2002.017403.x
   Gerlach JT, 1999, GASTROENTEROLOGY, V117, P933, DOI 10.1016/S0016-5085(99)70353-7
   Gerlach JT, 2003, GASTROENTEROLOGY, V125, P80, DOI 10.1016/S0016-5085(03)00668-1
   Goulder PJR, 2001, J VIROL, V75, P1339, DOI 10.1128/JVI.75.3.1339-1347.2001
   Grakoui A, 2003, SCIENCE, V302, P659, DOI 10.1126/science.1088774
   Harcourt GC, 2004, J VIRAL HEPATITIS, V11, P324, DOI 10.1111/j.1365-2893.2004.00516.x
   Kaech SM, 2003, SCIENCE, V300, P263, DOI 10.1126/science.1084511
   KALAMS SA, 1999, J INFECT DIS, V179, P345
   Kaufmann DE, 2004, J VIROL, V78, P4463, DOI 10.1128/JVI.78.9.4463-4477.2004
   Kuiken C, 2005, BIOINFORMATICS, V21, P379, DOI 10.1093/bioinformatics/bth485
   Kwok WW, 2001, TRENDS IMMUNOL, V22, P583, DOI 10.1016/S1471-4906(01)02038-5
   Lamonaca V, 1999, HEPATOLOGY, V30, P1088, DOI 10.1002/hep.510300435
   Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107
   Lauer GM, 2002, J VIROL, V76, P6104, DOI 10.1128/JVI.76.12.6104-6113.2002
   Lauer GM, 2002, J VIROL, V76, P2817, DOI 10.1128/JVI.76.6.2817-2826.2002
   Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499
   Livingston B, 2002, J IMMUNOL, V168, P5499, DOI 10.4049/jimmunol.168.11.5499
   Lucas M, 2004, J VIROL, V78, P7284, DOI 10.1128/JVI.78.13.7284-7287.2004
   LUCAS M, 2004, 11 INT S HEP C VIR R, P46
   Mallone R, 2004, CLIN IMMUNOL, V110, P232, DOI 10.1016/j.clim.2003.11.004
   MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994
   Missale G, 1996, J CLIN INVEST, V98, P706, DOI 10.1172/JCI118842
   Nepom GT, 2002, ARTHRITIS RHEUM, V46, P5, DOI 10.1002/1529-0131(200201)46:1<5::AID-ART10063>3.0.CO;2-S
   Novak EJ, 2001, J IMMUNOL, V166, P6665, DOI 10.4049/jimmunol.166.11.6665
   Planz O, 1997, P NATL ACAD SCI USA, V94, P6874, DOI 10.1073/pnas.94.13.6874
   Qin WP, 2001, HEPATOLOGY, V33, P728, DOI 10.1053/jhep.2001.22765
   Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595
   Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447
   Sant'Angelo DB, 2002, EUR J IMMUNOL, V32, P2510, DOI 10.1002/1521-4141(200209)32:9<2510::AID-IMMU2510>3.0.CO;2-Q
   Sette A, 2003, CURR OPIN IMMUNOL, V15, P461, DOI 10.1016/S0952-7915(03)00083-9
   Shoukry NH, 2004, ANNU REV MICROBIOL, V58, P391, DOI 10.1146/annurev.micro.58.030603.123836
   Shoukry NH, 2004, J IMMUNOL, V172, P483, DOI 10.4049/jimmunol.172.1.483
   Simmonds P, 2004, J GEN VIROL, V85, P3173, DOI 10.1099/vir.0.80401-0
   Singh H, 2001, BIOINFORMATICS, V17, P1236, DOI 10.1093/bioinformatics/17.12.1236
   Southwood S, 1998, J IMMUNOL, V160, P3363
   Thimme R, 2001, J EXP MED, V194, P1395, DOI 10.1084/jem.194.10.1395
   WEINER AJ, 1991, VIROLOGY, V180, P842, DOI 10.1016/0042-6822(91)90104-J
   WEINER AJ, 1991, J HEPATOL, V13, pS6, DOI 10.1016/0168-8278(91)90015-4
   Wilson CC, 2001, J VIROL, V75, P4195, DOI 10.1128/JVI.75.9.4195-4207.2001
   zur Wiesch JS, 2003, ARCH VIROL, V148, P1247, DOI 10.1007/s00705-003-0115-8
NR 58
TC 139
Z9 143
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD SEP 15
PY 2005
VL 175
IS 6
BP 3603
EP 3613
DI 10.4049/jimmunol.175.6.3603
PG 11
WC Immunology
SC Immunology
GA 966HN
UT WOS:000232010800022
PM 16148104
OA Bronze
DA 2020-11-30
ER

PT J
AU Vitral, CL
   Pinto, MA
   Lewis-Ximenez, LL
   Khudyakov, YE
   dos Santos, DR
   Gaspar, AMC
AF Vitral, CL
   Pinto, MA
   Lewis-Ximenez, LL
   Khudyakov, YE
   dos Santos, DR
   Gaspar, AMC
TI Serological evidence of hepatitis E virus infection in different animal
   species from the Southeast of Brazil
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE anti-hepatitis E virus; animal reservoir; swine; Brazil
ID UNITED-STATES; BLOOD-DONORS; RISK-FACTORS; ANTI-HEV; SWINE; PREVALENCE;
   ANTIBODIES; PIGS; STRAINS; SEROREACTIVITY
AB Serological evidence of hepatitis E virus infection (HEV) has been observed in both humans and different animal species living in non-endemic areas, suggesting that animals could be important reservoir for virus transmission to man. Antibodies to HEV have been detected in some Brazilian population groups. Nevertheless, sporadic cases of acute HEV infection have never been reported We collected 271 serum samples from several domestic animals and also from pig handlers from Southeast of Brazil in order to investigate the seroprevalence of HEV infection. AntiHEVIgG was detected in cows (1.42%), dogs (6.97%), chickens (20%), swines (24.3%), and rodents (50%), as well as in pig handlers (6.3%). The recognition of swine HEV infections in pigs in many countries of the world led us to investigate a larger sample of pigs (n = 357)from the same Brazilian region with ages ranging from 1 to > 25 weeks. IgG anti-HE V was detected in 100% of 7-day old pigs. Following a gradual decline between weeks 2 and 8 (probably due to loss of maternal IgG), the prevalence then steady increased until it reached 97.3% of animals older than 25 weeks. Besides the detection of anti-REV antibodies in different animal species, the results showed that swine HEV infection seems to be almost universal within this Brazilian pig population. This is the first report that shows evidences of HE V circulation in Brazilian animal species and pig handlers.
C1 Univ Fed Fluminense, Inst Biomed, Dept Microbiol & Parasitol, Niteroi, RJ, Brazil.
   Inst Oswaldo Cruz, Dept Virol, BR-21040900 Rio De Janeiro, Brazil.
   Ctr Dis Control & Prevent, WHO, Collaborating Ctr Res & Reference Viral Hepatitis, Atlanta, GA USA.
RP Vitral, CL (corresponding author), Univ Fed Fluminense, Inst Biomed, Dept Microbiol & Parasitol, Niteroi, RJ, Brazil.
EM clvitral@ioc.fiocruz.br
CR Arankalle VA, 2001, J VIRAL HEPATITIS, V8, P223, DOI 10.1046/j.1365-2893.2001.00290.x
   Balayan MS, 1997, J VIRAL HEPATITIS, V4, P155, DOI 10.1046/j.1365-2893.1997.00145.x
   BALAYAN MS, 1990, J MED VIROL, V32, P58, DOI 10.1002/jmv.1890320110
   Choi IS, 2003, J CLIN MICROBIOL, V41, P3602, DOI 10.1128/JCM.41.8.3602-3608.2003
   CLAYSON ET, 1995, AM J TROP MED HYG, V53, P228, DOI 10.4269/ajtmh.1995.53.228
   dos Santos DCM, 2002, MEM I OSWALDO CRUZ, V97, P637, DOI 10.1590/S0074-02762002000500007
   Engle RE, 2002, J CLIN MICROBIOL, V40, P4576, DOI 10.1128/JCM.40.12.4576-4580.2002
   FAVOROV MO, 1998, AM J TROP MED HYG, V59, P242
   FOCACCIA R, 1995, LANCET, V346, P1165, DOI 10.1016/S0140-6736(95)91841-8
   Garkavenko O, 2001, J MED VIROL, V65, P525, DOI 10.1002/jmv.2067
   Harrison TJ, 1999, LIVER, V19, P171, DOI 10.1111/j.1478-3231.1999.tb00031.x
   Hirano M, 2003, JPN J INFECT DIS, V56, P8
   Hsieh SY, 1999, J CLIN MICROBIOL, V37, P3828, DOI 10.1128/JCM.37.12.3828-3834.1999
   Huang FF, 2002, J CLIN MICROBIOL, V40, P1326, DOI 10.1128/JCM.40.4.1326-1332.2002
   Kabrane-Lazizi Y, 1999, AM J TROP MED HYG, V61, P331, DOI 10.4269/ajtmh.1999.61.331
   KHUDYAKOV YE, 1994, VIROLOGY, V198, P390, DOI 10.1006/viro.1994.1048
   KHUDYAKOV YE, 1993, VIROLOGY, V194, P89, DOI 10.1006/viro.1993.1238
   Mast EE, 1997, J INFECT DIS, V176, P34, DOI 10.1086/514037
   Meng JH, 2001, VIROLOGY, V288, P203, DOI 10.1006/viro.2001.1093
   Meng X. J., 2000, INFECT DIS REV, V2, P35
   Meng XJ, 2000, J HEPATOL, V33, P842, DOI 10.1016/S0168-8278(00)80319-0
   Meng XJ, 1998, ARCH VIROL, V143, P1405, DOI 10.1007/s007050050384
   Meng XJ, 1999, J MED VIROL, V59, P297, DOI 10.1002/(SICI)1096-9071(199911)59:3&lt;297::AID-JMV6&gt;3.0.CO;2-3
   Meng XJ, 2002, J CLIN MICROBIOL, V40, P117, DOI 10.1128/JCM.40.1.117-122.2002
   Meng XJ, 1998, J VIROL, V72, P9714, DOI 10.1128/JVI.72.12.9714-9721.1998
   Meng XJ, 1997, P NATL ACAD SCI USA, V94, P9860, DOI 10.1073/pnas.94.18.9860
   Obriadina A, 2002, J Gastroenterol Hepatol, V17 Suppl 3, pS360, DOI 10.1046/j.1440-1746.17.s3.28.x
   Okamoto H, 2001, BIOCHEM BIOPH RES CO, V289, P929, DOI 10.1006/bbrc.2001.6088
   Oliveira MLA, 1999, BRAZ J MED BIOL RES, V32, P1107, DOI 10.1590/S0100-879X1999000900009
   PANG L, 1995, AM J TROP MED HYG, V52, P347, DOI 10.4269/ajtmh.1995.52.347
   Parana R, 1997, AM J TROP MED HYG, V57, P60, DOI 10.4269/ajtmh.1997.57.60
   Souto FJD, 1997, AM J TROP MED HYG, V57, P149, DOI 10.4269/ajtmh.1997.57.149
   Takahashi M, 2003, J GEN VIROL, V84, P851, DOI 10.1099/vir.0.18918-0
   Tei S, 2003, LANCET, V362, P371, DOI 10.1016/S0140-6736(03)14025-1
   Tei S, 2004, J MED VIROL, V74, P67, DOI 10.1002/jmv.20147
   Thomas DL, 1997, J CLIN MICROBIOL, V35, P1244, DOI 10.1128/JCM.35.5.1244-1247.1997
   TIEN NT, 1997, AM J TROP MED HYG, V57, P211
   Trinta KS, 2001, MEM I OSWALDO CRUZ, V96, P25, DOI 10.1590/S0074-02762001000100004
   TSAREV SA, 1998, AM J TROP MED HYG, V59, P242
   WU JC, 2000, J MED VIROL, V27, P1415
NR 40
TC 87
Z9 102
U1 0
U2 4
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD APR
PY 2005
VL 100
IS 2
BP 117
EP 122
DI 10.1590/S0074-02762005000200003
PG 6
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 920WP
UT WOS:000228726500003
PM 16021297
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU de Paula, VS
   Villar, LM
   Morais, LM
   Lewis-Ximenez, LL
   Niel, C
   Gaspar, AMC
AF de Paula, VS
   Villar, LM
   Morais, LM
   Lewis-Ximenez, LL
   Niel, C
   Gaspar, AMC
TI Detection of hepatitis A virus RNA in serum during the window period of
   infection
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE anti-HAV; early diagnosis; HAV RNA; non-A-C hepatitis; outbreaks;
   sporadic cases
ID VIRAL-RNA; DURATION; VIREMIA; TRANSMISSION; TRANSFUSION; CONCENTRATE;
   PREVALENCE; OUTBREAK; BLOOD
AB Background: Hepatitis A virus (HAV) infection is the leading cause of clinically apparent viral hepatitis in many parts of the world, including developed and developing countries. Only limited information is available regarding the seronegative viremic window that follows HAV infection, and no systematic search has been reported for HAV RNA positive, IgM anti-HAV negative serum samples during hepatitis A outbreaks. Objectives: To determine the proportion of HAV infected individuals among (i) children who were tested negative for anti-HAV antibodies during hepatitis A outbreaks which occur-red in a public school (n = 157) and a child care center (n = 38); (ii) subjects (n = 46) initially classified as acute non-A-C hepatitis patients after clinical examination and serological tests (sporadic cases). Study design: Reverse transcription (RT)-PCR was performed to detect the presence of HAV genome in serum samples collected from anti-HAV negative, susceptible subjects. Results: HAV RNA was detected in 19/157 (12%) and 5/38 (13%) anti-HAV negative children from the public school and child care center, respectively. Twelve (26%) out of the 46 acute hepatitis patients (sporadic cases) were also HAV RNA positive. From nine of these 12 patients, a second blood sample was obtained 18-34 days after the first one: all nine had seroconverted to IgM anti-HAV, and their serum transaminases had reached elevated levels (mean ALT, 418; mean AST, 241). Conclusions: Detection of HAV RNA before IgM anti-HAV seroconversion may be used as an early diagnosis method during hepatitis A outbreaks. HAV RNA testing should also help to elucidate acute hepatitis cases of unknown etiology. (C) 2003 Elsevier B.V. All rights reserved.
C1 Inst Oswaldo Cruz, Dept Virol, BR-21045900 Rio De Janeiro, RJ, Brazil.
RP Niel, C (corresponding author), Inst Oswaldo Cruz, Dept Virol, Avenida Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM niel@ioc.fiocruz.br
RI VILLAR, LIVIA M/F-7811-2012; de Paula, Vanessa S/I-8037-2016; Niel,
   Christian/G-3712-2013
OI VILLAR, LIVIA M/0000-0001-7644-8969; de Paula, Vanessa
   S/0000-0002-6314-754X; 
CR Allain JP, 2000, CLIN LAB HAEMATOL, V22, P1, DOI 10.1046/j.1365-2257.2000.00265.x
   Barzaga NG, 2000, VACCINE, V18, pS61, DOI 10.1016/S0264-410X(99)00467-3
   Benjamin RJ, 2001, SEMIN HEMATOL, V38, P11, DOI 10.1053/shem.2001.28829
   Bower WA, 2000, J INFECT DIS, V182, P12, DOI 10.1086/315701
   *CDCP, 1995, 56 CDCP
   Costa-Mattioli M, 2002, J VIRAL HEPATITIS, V9, P101, DOI 10.1046/j.1365-2893.2002.00336.x
   Costa-Mattioli M, 2002, J MED VIROL, V68, P7, DOI 10.1002/jmv.10163
   Fix AD, 2002, AM J TROP MED HYG, V66, P628, DOI 10.4269/ajtmh.2002.66.628
   Fujiwara K, 1997, HEPATOLOGY, V26, P1634, DOI 10.1002/hep.510260636
   KEDDA MA, 1995, HEPATOLOGY, V22, P1363, DOI 10.1016/0270-9139(95)90137-X
   Kolk DP, 2002, J CLIN MICROBIOL, V40, P1761, DOI 10.1128/JCM.40.5.1761-1766.2002
   Kwon OS, 2000, J GASTROEN HEPATOL, V15, P1043, DOI 10.1046/j.1440-1746.2000.02291.x
   Leino T, 1997, SCAND J INFECT DIS, V29, P213, DOI 10.3109/00365549709019029
   LEMON SM, 1994, VOX SANG, V67, P19, DOI 10.1111/j.1423-0410.1994.tb01293.x
   MOSLEY JW, 1994, VOX SANG, V67, P24
   OREN R, 1989, J MED VIROL, V28, P261, DOI 10.1002/jmv.1890280411
   Robertson BH, 1998, BIOLOGICALS, V26, P95, DOI 10.1006/biol.1998.0139
   ROBERTSON BH, 1992, J GEN VIROL, V73, P1365, DOI 10.1099/0022-1317-73-6-1365
   Roth WK, 2001, TRANSFUS CLIN BIOL, V8, P282, DOI 10.1016/S1246-7820(01)00115-X
   Soucie JM, 1998, TRANSFUSION, V38, P573, DOI 10.1046/j.1537-2995.1998.38698326337.x
   Stene-Johansen K, 1998, SCAND J INFECT DIS, V30, P35, DOI 10.1080/003655498750002277
   Tapia-Conyer R, 1999, AM J TROP MED HYG, V61, P825, DOI 10.4269/ajtmh.1999.61.825
   Weimer T, 2002, J MED VIROL, V67, P469, DOI 10.1002/jmv.10124
   YOTSUYANAGI H, 1993, J MED VIROL, V40, P35, DOI 10.1002/jmv.1890400108
NR 24
TC 21
Z9 21
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD APR
PY 2004
VL 29
IS 4
BP 254
EP 259
DI 10.1016/S1386-6532(03)00165-3
PG 6
WC Virology
SC Virology
GA 806QF
UT WOS:000220447700007
PM 15018853
DA 2020-11-30
ER

PT J
AU Timm, J
   Lauer, GM
   Lewis-Ximenez, LL
   Ouchi, K
   Kim, AY
   Walker, BD
   Allen, TM
AF Timm, J
   Lauer, GM
   Lewis-Ximenez, LL
   Ouchi, K
   Kim, AY
   Walker, BD
   Allen, TM
TI Longitudinal full genome sequencing to assess the extent of CD8+CTL
   escape in HCV.
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 54th Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases
CY OCT 24-28, 2003
CL BOSTON, MA
SP Amer Assoc Study Liver Dis
C1 Massachusetts Gen Hosp, Charlestown, MA USA.
   Inst Oswaldo Cruz, BR-20001 Rio De Janeiro, Brazil.
   Massachusetts Gen Hosp, Charlestown, MA USA.
RI Timm, Jorg/P-7652-2019
OI Timm, Jorg/0000-0001-7799-3045
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2003
VL 38
IS 4
SU 1
MA 400
BP 352A
EP 353A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 730ER
UT WOS:000185816700401
DA 2020-11-30
ER

PT J
AU Re, V
   Lampe, E
   Yoshida, CF
   De Oliveira, JM
   Lewis-Ximenez, L
   Spinsanti, L
   Elbarcha, O
   Contigiani, M
AF Re, V
   Lampe, E
   Yoshida, CF
   De Oliveira, JM
   Lewis-Ximenez, L
   Spinsanti, L
   Elbarcha, O
   Contigiani, M
TI Hepatitis C virus genotypes in Cordoba, Argentina - Unexpected high
   prevalence of genotype 2
SO MEDICINA-BUENOS AIRES
LA English
DT Article
DE hepatitis C virus; HCV genotyping; HCV genotype 2
ID INTERFERON-ALPHA; HEPATOCELLULAR-CARCINOMA; NUCLEOTIDE-SEQUENCE; HCV
   GENOTYPE; INFECTION; RISK; CIRRHOSIS; THERAPY; EPIDEMIOLOGY; POPULATION
AB To determine hepatitis C virus (HCV) genotypes circulating in the central region of Argentina, 96 consecutive anti-HCV positive subjects were studied. The presence of HCV RNA was detected in 60 samples by RT-nested PCR of the 5' noncoding region (5' NCR). Genotyping was performed by restriction fragment length polymorphism analysis of 5' NCR region combined with PCR using type-specific primers of the core region. The groups of individuals in this study included hemophilia and hemodialysis patients, injecting drug users, screened blood donors, and patients with acute or chronic liver disease, all from Cordoba, Argentina. Overall, genotype 2 was the most prevalent (55.0%), followed by genotypes 1 (38.3 %), and 3 (5.0%). Within genotype 1, subtype 1b was the most prevalent. An unexpected high prevalence of genotype 2 (61.9%) was found among patients with acute or chronic HCV infection (without known risk factors). These figures differ from other cohorts from East-Argentina where genotype 1 has been found as the most prevalent. This indicates that regional differences of genotype distribution might exist between Central and East Argentina.
C1 Univ Nacl Cordoba, Fac Ciencias Med, Inst Virol Dr JM Vanella, RA-5016 Cordoba, Argentina.
   Fundacao Oswaldo Cruz, Dept Virol, Lab Hepatites Virais, Rio De Janeiro, Brazil.
   Univ Catolica Cordoba, Fac Ciencias Quim, Catedra Virol, Cordoba, Argentina.
RP Re, V (corresponding author), Univ Nacl Cordoba, Fac Ciencias Med, Inst Virol Dr JM Vanella, Ciudad Univ, RA-5016 Cordoba, Argentina.
EM contigia@cmefcm.uncor.edu
CR Alfonso V, 2001, J CLIN MICROBIOL, V39, P1989, DOI 10.1128/JCM.39.5.1989-1992.2001
   Bjoro K, 2002, SCAND J GASTROENTERO, V37, P226, DOI 10.1080/003655202753416920
   Boyer N, 2000, J HEPATOL, V32, P98, DOI 10.1016/S0168-8278(00)80419-5
   Bruno S, 1997, HEPATOLOGY, V25, P754, DOI 10.1002/hep.510250344
   Chamberlain RW, 1997, J GEN VIROL, V78, P1341, DOI 10.1099/0022-1317-78-6-1341
   de Oliveira JM, 2001, J MED VIROL, V63, P265, DOI 10.1002/1096-9071(200104)63:4&lt;265::AID-JMV1000&gt;3.0.CO;2-V
   DRIESEL G, 1994, ARCH VIROL, V139, P379, DOI 10.1007/BF01310799
   Findor JA, 1999, MEDICINA-BUENOS AIRE, V59, P49
   Gismondi MI, 2001, MEDICINA-BUENOS AIRE, V61, P815
   Guadagnino V, 1997, HEPATOLOGY, V26, P1006, DOI 10.1002/hep.510260431
   KOHARA M, 1995, J INFECT DIS, V172, P934, DOI 10.1093/infdis/172.4.934
   Maggi G, 1999, LIVER, V19, P427, DOI 10.1111/j.1478-3231.1999.tb00073.x
   MARTINOTPEIGNOUX M, 1995, HEPATOLOGY, V22, P1050, DOI 10.1016/0270-9139(95)90608-8
   McHutchison JG, 2002, J GASTROEN HEPATOL, V17, P431, DOI 10.1046/j.1440-1746.2002.02777.x
   MCOMISH F, 1994, J CLIN MICROBIOL, V32, P884, DOI 10.1128/JCM.32.4.884-892.1994
   Nagayama K, 2000, HEPATOLOGY, V31, P745, DOI 10.1002/hep.510310327
   NOUSBAUM JB, 1995, ANN INTERN MED, V122, P161, DOI 10.7326/0003-4819-122-3-199502010-00001
   OKAMOTO H, 1991, J GEN VIROL, V72, P2697, DOI 10.1099/0022-1317-72-11-2697
   Osella AR, 2001, CLIN INFECT DIS, V33, P70, DOI 10.1086/320887
   Oubina JR, 2001, INTERVIROLOGY, V44, P215, DOI 10.1159/000050049
   OUBINA JR, 1995, J MED VIROL, V47, P97, DOI 10.1002/jmv.1890470118
   Picchio GR, 1997, J MED VIROL, V52, P219, DOI 10.1002/(SICI)1096-9071(199706)52:2&lt;219::AID-JMV17&gt;3.0.CO;2-F
   Poynard T, 1998, LANCET, V352, P1426, DOI 10.1016/S0140-6736(98)07124-4
   Quarleri JF, 1998, MEDICINA-BUENOS AIRE, V58, P153
   RAVAGGI A, 1994, J CLIN MICROBIOL, V32, P2280, DOI 10.1128/JCM.32.9.2280-2284.1994
   Silini E, 1996, GASTROENTEROLOGY, V111, P199, DOI 10.1053/gast.1996.v111.pm8698200
   Simmonds P, 1999, J HEPATOL, V31, P54, DOI 10.1016/S0168-8278(99)80375-4
   SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1016/0270-9139(94)90887-7
   Spada E, 1998, RES VIROLOGY, V149, P209, DOI 10.1016/S0923-2516(98)80002-2
   TAKADA N, 1993, J HEPATOL, V17, P277, DOI 10.1016/S0168-8278(05)80205-3
   Viazov S, 1997, J MED VIROL, V53, P36, DOI 10.1002/(SICI)1096-9071(199709)53:1&lt;36::AID-JMV7&gt;3.0.CO;2-R
   *WHO, 1999, WKLY EPIDEMIOL REC, V74, P421
   WIDELL A, 1994, J MED VIROL, V44, P272, DOI 10.1002/jmv.1890440311
   Yu ML, 2001, J MED VIROL, V65, P58, DOI 10.1002/jmv.2001
   Zein NN, 2000, CLIN MICROBIOL REV, V13, P223, DOI 10.1128/CMR.13.2.223-235.2000
   Zein NN, 1996, ANN INTERN MED, V125, P634, DOI 10.7326/0003-4819-125-8-199610150-00002
   Zeuzem S, 2001, GASTROENTEROLOGY, V120, P1438, DOI 10.1053/gast.2001.24006
NR 37
TC 18
Z9 20
U1 0
U2 1
PU MEDICINA (BUENOS AIRES)
PI BUENOS AIRES
PA DONATO ALVAREZ 3150, 1427 BUENOS AIRES, ARGENTINA
SN 0025-7680
EI 1669-9106
J9 MEDICINA-BUENOS AIRE
JI Med.-Buenos Aires
PY 2003
VL 63
IS 3
BP 205
EP 210
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 701BZ
UT WOS:000184148200003
PM 12876903
OA DOAJ Gold
DA 2020-11-30
ER

PT J
AU Motta-Castro, ARC
   Yoshida, CFT
   Lemos, ERS
   Oliveira, JM
   Cunha, RV
   Lewis-Ximenez, LL
   Cabello, PH
   Lima, KMB
   Martins, RMB
AF Motta-Castro, ARC
   Yoshida, CFT
   Lemos, ERS
   Oliveira, JM
   Cunha, RV
   Lewis-Ximenez, LL
   Cabello, PH
   Lima, KMB
   Martins, RMB
TI Seroprevalence of hepatitis B virus infection among an Afro-descendant
   community in Brazil
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE hepatitis B; Afro-descendants; seroprevalence; transmission; Brazil
ID HORIZONTAL TRANSMISSION; PROPHYLAXIS; PREVALENCE; VILLAGES; MARKERS;
   AFRICA
AB Furnas dos Dionisios is an Afro-Brazilian black community whose descendants were mainly fugitive slaves that established themselves in the State of Mato Grosso do Sul (US), Brazil. The population is comprised mainly of low socioeconomic individuals who are engaged in agricultural activities. The objective of this study was to investigate the prevalence of hepatitis B (HB) and its correlation with epidemiological data obtained from the community The studied population totaled 260 individuals with ages varying from 1 to 79 years (median 20). One hundred thirty-three (51.2%) were females and 127 (48.8%) were males. A high prevalence for anti-HBc was observed (42.7%), with present infection detected in 9.2% of the subjects who were also HB surface antigens (HBsAg)positive; 27.3% were anti-HBc and anti-HBs reactive, and 6.2% had anti-HBc as only marker. The prevalence for anti-HBc was proportional to age, reaching its highest peak in age categories greater than 50. No serological marker was detected in children under the age of 2,Years, however anti-HBc was present in 12 subjects with,ages between 2 and 14 years; of these 8 (7.4%) were HBsAg positive. Among individuals over the age of 15 Years, 99,were anti-HBc reactive, of these 16 (10.5%) were also HBsAg positive, thus suggesting an increased prevalence of HBV carriers among children and adolescents. The risk factors observed in this community that were significantly associated with anti-HBc positivity were age (over 20 years) and having an anti-HBc positive mother. Both HBeAg and anti-HBe were detected in 44.4% of the samples tested. HBsAg subtypes found in the studied population were adw(2) (77.7%) and ayw(2) (23.3%). While intrafamilial transmission was most likely responsible for HBV infection among children, other routes such as sexual contact might be considered for individuals with ages over 15 years.
C1 Fiocruz MS, Inst Oswaldo Cruz, Dept Virol, BR-21045900 Rio De Janeiro, Brazil.
   Fiocruz MS, Inst Oswaldo Cruz, Dept Genet, BR-21045900 Rio De Janeiro, Brazil.
   Univ Fed Mato Grosso Sul, Hemonucl Hosp Univ, Campo Grande, MS, Brazil.
   Estado Mato Grosso Sul, Secretaria Saude, Coordenadoria Imunizacoes, Campo Grande, MS, Brazil.
   Univ Fed Goiania, Inst Patol Trop & Saude Publ, Goiania, Go, Brazil.
RP Yoshida, CFT (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Dept Virol, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
RI motta-castro, ana rita c/O-2075-2017; Cunha, Rivaldo
   Venancio/I-7737-2014
OI Cunha, Rivaldo Venancio/0000-0002-6622-7043; Lemos,
   Elba/0000-0003-3761-0200; Motta-Castro, Ana Rita/0000-0003-3070-1337
CR ALTER MJ, 1986, JAMA-J AM MED ASSOC, V256, P1307, DOI 10.1001/jama.256.10.1307
   COUROUCEPAUTY AM, 1983, VOX SANG, V27, P533
   GASPAR A M C, 1987, Memorias do Instituto Oswaldo Cruz, V82, P253, DOI 10.1590/S0074-02761987000200013
   HADZIYANNIS SJ, 1975, AM J MED SCI, V270, P313
   HEATHCOTE J, 1974, LANCET, V4, P370
   Hilleman MR, 2001, VACCINE, V19, P1837, DOI 10.1016/S0264-410X(00)00364-9
   KARIM SSA, 1991, INT J EPIDEMIOL, V20, P495, DOI 10.1093/ije/20.2.495
   Kew MC, 1998, RES VIROLOGY, V149, P257, DOI 10.1016/S0923-2516(99)89003-7
   Kiire CF, 1996, GUT, V38, pS5, DOI 10.1136/gut.38.Suppl_2.S5
   KOFF RS, 1997, GASTROENTEROLOGY, V72, P297
   Martinson FEA, 1998, AM J EPIDEMIOL, V147, P478, DOI 10.1093/oxfordjournals.aje.a009474
   PASSOS ADC, 1993, REV SAUDE PUBL, V27, P30, DOI 10.1590/S0034-89101993000100005
   RICHARDLENOBLE D, 1995, AM J TROP MED HYG, V53, P338, DOI 10.4269/ajtmh.1995.53.338
   ROSENBLUM L, 1992, JAMA-J AM MED ASSOC, V267, P2477, DOI 10.1001/jama.267.18.2477
   SZMUNESS W, 1973, NEW ENGL J MED, V289, P1162, DOI 10.1056/NEJM197311292892203
   TABOR E, 1985, J MED VIROL, V15, P113, DOI 10.1002/jmv.1890150203
   Teles SA, 1999, ARTIF ORGANS, V23, P1074, DOI 10.1046/j.1525-1594.1999.06310.x
   Vall Mayans M., 1990, Lancet, V336, P1107
NR 18
TC 17
Z9 20
U1 0
U2 1
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD JAN
PY 2003
VL 98
IS 1
BP 13
EP 17
DI 10.1590/S0074-02762003000100002
PG 5
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 646MQ
UT WOS:000181039200002
PM 12700856
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Lewis-Ximenez, LL
   do O, KMR
   Ginuino, CF
   Silva, JC
   Schatzmayr, HG
   Stuver, S
   Yoshida, CFT
AF Lewis-Ximenez, LL
   do O, KMR
   Ginuino, CF
   Silva, JC
   Schatzmayr, HG
   Stuver, S
   Yoshida, CFT
TI Risk factors for hepatitis B virus infection in Rio de Janeiro, Brazil
SO BMC PUBLIC HEALTH
LA English
DT Article
ID VACCINATION
AB Background: Despite international efforts to prevent hepatitis B virus (HBV) infection through global vaccination programs, new cases are still being reported throughout the world.
   Methods: To supply data that might assist in improving preventive measures and national surveillance for HBV infection, a cross-sectional study was conducted among individuals referred to the Brazilian National Reference Center for Viral Hepatitis ( Rio de Janeiro) during a two-year period. Reported risk factors among infected subjects ("HBV-positive") were compared to those of subjects never exposed ("HBV-negative") to HBV. Two subgroups were further identified within the HBV-positive group, "acute" infection and "non-acute" infection.
   Results: A total of 1,539 subjects were tested for HBV, of which 616 were HBV-positive ( 79 acute infection and 537 non-acute infection). HBV-positive subjects were more likely to be of male gender (63% versus 47%); and to report multiple sexual partners (12% versus 6%) and illicit drug use (IDU and/or intranasal cocaine use) ( 6% versus 3%). Among the HBV-positive subgroups, age differed significantly, with 48% being under 30 years of age in subjects acutely infected compared to 17% in those with non-acute infection.
   Conclusions: The association of multiple sexual partners with past HBV infection and the age distribution of currently infected subjects suggest that sexual transmission played a major role in the transmission of HBV in this study population. Thus, vaccination during adolescence should be considered.
C1 Fiocruz MS, Minist Hlth, Inst Oswaldo Cruz,Dept Virol, Natl Reference Ctr Viral Hepatitis, BR-21045900 Rio De Janeiro, Brazil.
   Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
RP Lewis-Ximenez, LL (corresponding author), Fiocruz MS, Minist Hlth, Inst Oswaldo Cruz,Dept Virol, Natl Reference Ctr Viral Hepatitis, BR-21045900 Rio De Janeiro, Brazil.
EM lllewis@gene.dbbm.fiocruz.br; klr@compuland.com.br;
   deber@ioc.fiocruz.br; maracs@brfree.com.br; hermann@ioc.fiocruz.br;
   sstuver@hsph.harvard.edu; yoshida@ioc.fiocruz.br
OI Stuver, Sherri/0000-0002-4027-2663
FU FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [D43TW000918, D43TW000918, D43TW000918,
   D43TW000918, D43TW000918] Funding Source: NIH RePORTER; FIC NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [TW00918, D43 TW000918] Funding Source: Medline
CR Da Villa G, 2000, VACCINE, V18, pS31, DOI 10.1016/S0264-410X(99)00459-4
   FAVERO MS, 1974, J INFECT DIS, V129, P210, DOI 10.1093/infdis/129.2.210
   Huang KY, 2000, VACCINE, V18, pS35, DOI 10.1016/S0264-410X(99)00460-0
   JUAREZ E, 1991, PROG CLIN BIOL RES, V364, P343
   KNIGHT AH, 1970, BRIT MED J, V3, P603, DOI 10.1136/bmj.3.5723.603
   LAHAYE D, 1987, LANCET, V2, P441
   Lewis-Ximenez LL, 2001, NEPHRON, V87, P19, DOI 10.1159/000045880
   Martelli C M, 1999, Rev Panam Salud Publica, V6, P69, DOI 10.1590/S1020-49891999000600018
   MAYNARD JE, 1989, REV INFECT DIS, V11, pS574
   MULLEY AG, 1982, NEW ENGL J MED, V307, P644, DOI 10.1056/NEJM198209093071103
   NORDENFELT E, 1970, Acta Pathologica et Microbiologica Scandinavica Section B Microbiology and Immunology, V78, P692
   Seow S S, 1981, Aust Fam Physician, V10, P298
   SEOW SS, 1981, AUST FAM PHYSICIAN, V10, P296
   SEOW SS, 1981, AUST FAM PHYSICIAN, V10, P298
   Silveira T R, 1999, Rev Panam Salud Publica, V6, P378
   Skov T, 1998, INT J EPIDEMIOL, V27, P91, DOI 10.1093/ije/27.1.91
   SZMUNESS W, 1975, ANN INTERN MED, V83, P489, DOI 10.7326/0003-4819-83-4-489
   SZMUNESS W, 1978, VIRAL HEPATITIS, P279
   Wu JS, 1999, J INFECT DIS, V179, P1319, DOI 10.1086/314768
NR 19
TC 21
Z9 22
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD NOV 22
PY 2002
VL 2
AR 26
DI 10.1186/1471-2458-2-26
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 632XE
UT WOS:000180249500001
PM 12445329
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Lewis-Ximenez, LL
   Gaspar, AMC
   D'Oro, ACC
   Mercadante, LAC
   Ginuino, CF
   Yoshida, CFT
AF Lewis-Ximenez, LL
   Gaspar, AMC
   D'Oro, ACC
   Mercadante, LAC
   Ginuino, CF
   Yoshida, CFT
TI Viral hepatitis markers in antepartum and postpartum women in Rio de
   Janeiro, Brazil
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE seroprevalence; pregnant women; hepatitis; Rio de Janeiro; Brazil
ID PREVALENCE
AB A seroprevalence study was carried out among a group of women in Rio de Janeiro to determine the prevalence of different markers for viral hepatitis given the limited data among healthy populations. Blood samples collected and tested from 874 women before or after delivery in a public county maternity hospital demonstrated age to be directly related to markers for hepatitis A virus and hepatitis B virus (HBV) infection. The prevalence of HBV and hepatitis C virus infection were lower than that observed in the blood donor population and might be explained by the younger age group and gender.
C1 Fiocruz MS, Inst Oswaldo Cruz, Dept Virol, Ctr Referencia Nacl Hepatites, BR-21045900 Rio De Janeiro, Brazil.
   Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   Hosp Maternidade Carmela Dutra, Rio De Janeiro, RJ, Brazil.
RP Lewis-Ximenez, LL (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Dept Virol, Ctr Referencia Nacl Hepatites, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
CR Martelli C M, 1999, Rev Panam Salud Publica, V6, P69, DOI 10.1590/S1020-49891999000600018
   MARTINS RMB, 1995, MEM I OSWALDO CRUZ, V90, P11, DOI 10.1590/S0074-02761995000100004
   Parana R, 1997, AM J TROP MED HYG, V57, P60, DOI 10.4269/ajtmh.1997.57.60
   Silveira T R, 1999, Rev Panam Salud Publica, V6, P378
   Tapia-Conyer R, 1999, AM J TROP MED HYG, V61, P825, DOI 10.4269/ajtmh.1999.61.825
NR 5
TC 4
Z9 4
U1 0
U2 0
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD MAR
PY 2002
VL 97
IS 2
BP 203
EP 204
DI 10.1590/S0074-02762002000200011
PG 2
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 533NE
UT WOS:000174535900011
PM 12016444
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Lewis-Ximenez, LL
   Oliveira, JM
   Mercadante, LAC
   De Castro, L
   Santa Catharina, W
   Stuver, S
   Yoshida, CFT
AF Lewis-Ximenez, LL
   Oliveira, JM
   Mercadante, LAC
   De Castro, L
   Santa Catharina, W
   Stuver, S
   Yoshida, CFT
TI Serological and vaccination profile of hemodialysis patients during an
   outbreak of hepatitis B virus infection
SO NEPHRON
LA English
DT Article
DE hepatitis B virus, outbreak; hemodialysis unit; vaccination, Brazil
ID PATIENTS RECEIVING HEMODIALYSIS; CHRONIC LIVER-DISEASE;
   ANTIBODY-RESPONSE; SURFACE-ANTIGEN; DNA; STRATEGIES; SCHEDULES;
   EFFICACY; IMPACT
AB During an outbreak of hepatitis B virus (HBV) infection in a hemodialysis unit, patients were assessed for serological viral markers and vaccination status. HBV infection was identified in 26 patients. Twenty of these were positive for hepatitis B surface antigen (HBsAg), and 6 were negative for HBsAg but positive for IgM antibody to hepatitis B core (anti-HBc) and HBV DNA. The primary source of infection was not clearly identified, although 2 patients were suspected to be the index cases. A multiple logistic regression analysis revealed low anti-HBs titers and vaccination status to be independently associated with the risk of acquiring HBV infection. Both the high prevalence of HBV infection (31%) detected in this unit and the low vaccine response (53%) observed reinforce the importance of universal and preventive measures in controlling HBV infection. The detection of HBV DNA in HBsAg-negative/IgM anti-HBc-positive patients emphasizes the value of anti-HBc testing in the routine screening of HBV in hemodialysis units. Copyright (C) 2001 S. Karger AG, Basel.
C1 FIOCRUZ, Inst Oswaldo Cruz, Dept Virol, BR-21045900 Rio De Janeiro, Brazil.
   Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   Inst Doencas Renais, Sao Paulo, Brazil.
RP Lewis-Ximenez, LL (corresponding author), FIOCRUZ, Inst Oswaldo Cruz, Dept Virol, Ave Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
RI de Oliveira Junior, Jose Martins/I-4910-2013
OI de Oliveira Junior, Jose Martins/0000-0001-6435-1908; Stuver,
   Sherri/0000-0002-4027-2663
CR ALTER MJ, 1986, J INFECT DIS, V153, P1149, DOI 10.1093/infdis/153.6.1149
   BRECHOT C, 1985, NEW ENGL J MED, V312, P270, DOI 10.1056/NEJM198501313120503
   BRUGUERA M, 1990, VACCINE, V8, pS47, DOI 10.1016/0264-410X(90)90218-B
   Cabrerizo M, 1997, J AM SOC NEPHROL, V8, P1443
   CARMAN W, 1993, LANCET, V341, P349, DOI 10.1016/0140-6736(93)90146-8
   *CDC, 1996, MMWR-MORBID MORTAL W, V45, P285
   Cheng CH, 1997, VACCINE, V15, P1353, DOI 10.1016/S0264-410X(97)00037-6
   ELRESHAID K, 1994, VACCINE, V12, P223, DOI 10.1016/0264-410X(94)90198-8
   GASPAR A M C, 1987, Memorias do Instituto Oswaldo Cruz, V82, P253, DOI 10.1590/S0074-02761987000200013
   GERLICH WH, 1980, J INFECT DIS, V142, P95, DOI 10.1093/infdis/142.1.95
   Gomes SA, 1996, ACTA VIROL, V40, P133
   HOOFNAGLE JH, 1978, NEW ENGL J MED, V291, P11379
   JAISWAL SB, 1995, LANCET, V346, P317, DOI 10.1016/S0140-6736(95)92208-3
   Kroes ACM, 1998, INFECT CONT HOSP EP, V19, P508
   Lampe E, 1998, CLIN DIAGN VIROL, V9, P1, DOI 10.1016/S0928-0197(97)10017-4
   LIANG TJ, 1990, HEPATOLOGY, V12, P204, DOI 10.1002/hep.1840120205
   Miller ER, 1999, AM J KIDNEY DIS, V33, P356, DOI 10.1016/S0272-6386(99)70312-4
   Mitwalli A, 1996, NEPHRON, V73, P417
   Navarro JF, 1996, AM J NEPHROL, V16, P95, DOI 10.1159/000168977
   Peces R, 1997, AM J KIDNEY DIS, V29, P239, DOI 10.1016/S0272-6386(97)90036-6
   Propst T, 1998, AM J KIDNEY DIS, V32, P1041, DOI 10.1016/S0272-6386(98)70081-2
   QUIROGA JA, 1990, HEPATOLOGY, V12, P661, DOI 10.1002/hep.1840120407
   Radovic MM, 1997, CLIN NEPHROL, V47, P206
   RAULT R, 1995, ASAIO J, V41, pM717, DOI 10.1097/00002480-199507000-00106
   ROLL M, 1995, J HOSP INFECT, V30, P57, DOI 10.1016/0195-6701(95)90249-X
   STEVENS CE, 1984, NEW ENGL J MED, V311, P496, DOI 10.1056/NEJM198408233110803
   Swan AM, 1997, CLIN NEPHROL, V47, P207
   WAITE NM, 1995, J AM SOC NEPHROL, V5, P1930
   WOOD RC, 1993, JAMA-J AM MED ASSOC, V270, P2935, DOI 10.1001/jama.270.24.2935
   ZUCKERMAN AJ, 1994, LANCET, V343, P737, DOI 10.1016/S0140-6736(94)91622-5
NR 30
TC 31
Z9 33
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0028-2766
J9 NEPHRON
JI Nephron
PD JAN
PY 2001
VL 87
IS 1
BP 19
EP 26
DI 10.1159/000045880
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA 397HP
UT WOS:000166687500003
PM 11174022
DA 2020-11-30
ER

PT J
AU Saback, FL
   Gomes, SA
   de Paula, VS
   da Silva, RRS
   Lewis-Ximenez, LL
   Niel, C
AF Saback, FL
   Gomes, SA
   de Paula, VS
   da Silva, RRS
   Lewis-Ximenez, LL
   Niel, C
TI Age-specific prevalence and transmission of TT virus
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE parvoviridae; liver disease; vertical transmission; fecal-oral route;
   Brazil
ID HEPATITIS-G VIRUS; BLOOD-DONORS; POSTTRANSFUSION HEPATITIS;
   MOLECULAR-CLONING; UNKNOWN ETIOLOGY; LIVER-DISEASE; DNA; INFECTION
AB TT virus (TTV) is an unenveloped, single-stranded DNA virus that was discovered recently in the sera of Japanese patients with posttransfusion hepatitis of unknown etiology. A high prevalence of TTV infection in blood donors of several countries, including Brazil, has been demonstrated. To study the variation in TTV prevalence between different age groups, sera from 223 individuals without liver disease, aged 0-80 years, were tested by the polymerase chain reaction for the presence of TTV DNA. All subjects were inhabitants of the city of Rio de Janeiro, Brazil. The prevalence increased continuously with age (P < .001), from 17% among children under the age of 11 years, to 57% in people older than 50 years. To assess vertical transmission, sera from 105 unselected, consecutive parturient women attending a public maternity hospital were paired with cord bloods and examined for the presence of TTV DNA. Thirty-seven (35%) mothers were found to be TTV infected. Seven cord bloods were also positive, suggesting the possible transplacental transmission of the virus. Furthermore, a direct correlation between TTV viremia and presence of antibodies to the enterically transmissible hepatitis A virus (HAV) was observed in this group of women, with a relative risk of TTV infection of 5.09 (95% confidence interval 0.76-34.03) for women with anti-HAV, compared with women without. This finding suggested that the fecal-oral route might be an important route of TTV transmission. (C) 1999 Wiley-Liss, Inc.
C1 FIOCRUZ, Inst Oswaldo Cruz, Dept Virol, BR-21045900 Rio De Janeiro, Brazil.
RP Niel, C (corresponding author), FIOCRUZ, Inst Oswaldo Cruz, Dept Virol, Avenida Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
RI Niel, Christian/G-3712-2013; gomes, selma A/D-2762-2015; de Paula,
   Vanessa S/I-8037-2016
OI de Paula, Vanessa S/0000-0002-6314-754X; Gomes,
   Selma/0000-0003-0233-3370
CR Charlton M, 1998, HEPATOLOGY, V28, P839, DOI 10.1002/hep.510280335
   Cossart Y, 1998, LANCET, V352, P164, DOI 10.1016/S0140-6736(05)77802-8
   Lampe E, 1998, CLIN DIAGN VIROL, V9, P1, DOI 10.1016/S0928-0197(97)10017-4
   Lampe E, 1998, J MED VIROL, V56, P39, DOI 10.1002/(SICI)1096-9071(199809)56:1&lt;39::AID-JMV7&gt;3.0.CO;2-O
   Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505
   Mphahlele MJ, 1998, LIVER, V18, P143
   Naoumov NV, 1998, LANCET, V352, P195, DOI 10.1016/S0140-6736(98)04069-0
   Niel C, 1999, J MED VIROL, V57, P259, DOI 10.1002/(SICI)1096-9071(199903)57:3&lt;259::AID-JMV8&gt;3.0.CO;2-2
   Nishizawa T, 1997, BIOCHEM BIOPH RES CO, V241, P92, DOI 10.1006/bbrc.1997.7765
   Okamoto H, 1998, J MED VIROL, V56, P128, DOI 10.1002/(SICI)1096-9071(199810)56:2&lt;128::AID-JMV5&gt;3.0.CO;2-A
   Okamoto H, 1998, HEPATOL RES, V10, P1, DOI 10.1016/S1386-6346(97)00123-X
   Prescott LE, 1998, NEW ENGL J MED, V339, P776, DOI 10.1056/NEJM199809103391118
   Simmonds P, 1998, LANCET, V352, P191, DOI 10.1016/S0140-6736(98)03056-6
   SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564
   Tanaka H, 1998, J MED VIROL, V56, P234, DOI 10.1002/(SICI)1096-9071(199811)56:3&lt;234::AID-JMV10&gt;3.0.CO;2-E
   Viazov S, 1998, J CLIN VIROL, V11, P183, DOI 10.1016/S0928-0197(98)00060-9
   Vitral C L, 1991, Rev Soc Bras Med Trop, V24, P79
NR 17
TC 71
Z9 76
U1 0
U2 3
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0146-6615
J9 J MED VIROL
JI J. Med. Virol.
PD NOV
PY 1999
VL 59
IS 3
BP 318
EP 322
DI 10.1002/(SICI)1096-9071(199911)59:3<318::AID-JMV10>3.0.CO;2-Q
PG 5
WC Virology
SC Virology
GA 242HQ
UT WOS:000082934800010
PM 10502263
DA 2020-11-30
ER

PT J
AU MAHARAJ, D
   GOMEZMARIN, O
   LEWISXIMENEZ, LL
   RILEY, R
   ALBARRACIN, C
AF MAHARAJ, D
   GOMEZMARIN, O
   LEWISXIMENEZ, LL
   RILEY, R
   ALBARRACIN, C
TI SERUM G-CSF LEVELS IN PATIENTS UNDERGOING G-CSF CHEMOTHERAPY MOBILIZED
   PERIPHERAL STEM-CELL HARVEST AND PREDICTORS OF NEUTROPHIL AND PLATELET
   RECOVERY
SO LEUKEMIA
LA English
DT Article; Proceedings Paper
CT Symposium on Gene Therapy - New Frontiers
CY SEP 18-21, 1995
CL TRINITY COLL, DUBLIN, IRELAND
SP Int Assoc Comparat Res Leukemia & Related Dis, Leukemia Soc Amer, US NCI, Irish Assoc Canc Res, Stohlman Fdn
HO TRINITY COLL
ID COLONY-STIMULATING FACTOR; BLOOD PROGENITOR CELLS; HIGH-DOSE
   CHEMOTHERAPY; GRANULOCYTE; ACCELERATE
AB Granulocyte colony-stimulating factor (G-CSF)/Chemotherapy mobilized peripheral blood progenitors are an effective source of stem cells which affords rapid and complete hematopoietic engraftment after myeloablative chemotherapy regimens. The dose of G-CSF mast commonly used for mobilization is 5 mu/kg. We measured G-CSF levels in patients with chemosensitive malignancies undergoing peripheral stem cell harvest to determine whether there was a relationship between serum G-CSF levels end the yield of CD34(+) hematopoietic progenitors. Peripheral blood stem cells (PBSCs) were mobilized by chemotherapy followed by G-CSF (5 mu g/kg) started 24 hours after completion of chemotherapy, PBSCs were collected by daily leukapheresis during G-CSF stimulation once the WBC had recovered to 1.0 x 10(9)/L, with 10 liters of blood processed using a Fenwall CS 3000. G-CSF levels were monitored daily before and after leukapheresis. CD34(+) cells from daily leukapheresis collections were determined in II patients. Immunophenotyping analyses of CD34(+) and non-CD34(+) cells for surface antigens CD38(+), HLA-DR, CD71(+), CD61(+) and CD42a(+) were performed on these daily leukapheresis. The mean (SD) number of days to neutrophil recovery (NR: greater than or equal to 0.5 x 10(9)/L) after stem cell reinfusion was 9.2 (1.92). The corresponding values for platelet recovery (PR: greater than or equal to 20 x 10(9) L) were 8.1 (2.39) days. Using multiple regression analyses, the best predictors for NR were: last G-CSF (R(2) = 0.21); last G-CSF and CD34(+) (R(2) = 0.67); last G-CSF, CD34(+) and number of chemotherapy cycles (R(2) = 0.72), For PR: log G-CSF (R(2) = 0.35); log G-CSF and Ave CD34(+)/CD38(-)/DR(+) (R(2) = 0.41); log G-CSF, CD34(+)/CD38(-)/DR(+) and CD34(+)/CD38(+)/DR(-) (R(2) = 0.49). G-CSF levels are significantly related to the number of prior chemotherapy cycles. G-CSF, average CD34(+) cells and its subsets, and the number of chemotherapy cycles separately and jointly are important predictors of NR and PR.
C1 UNIV MIAMI,SCH MED,DEPT MED,FT LAUDERDALE,FL 33313.
   UNIV MIAMI,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,FT LAUDERDALE,FL 33313.
   UNIV MIAMI,SCH MED,DEPT PEDIAT,FT LAUDERDALE,FL 33313.
   UNIV MIAMI,SCH MED,DEPT MICROBIOL,FT LAUDERDALE,FL 33313.
   UNIV MIAMI,SCH MED,DEPT IMMUNOL,FT LAUDERDALE,FL 33313.
RP MAHARAJ, D (corresponding author), UNIV MIAMI,SCH MED,BONE MARROW STEM CELL TRANSPLANT INST,4850 W OAKLAND PK BLVD,FT LAUDERDALE,FL 33313, USA.
CR BRUGGER W, 1993, BRIT J HAEMATOL, V84, P402, DOI 10.1111/j.1365-2141.1993.tb03093.x
   CHAO NJ, 1993, BLOOD, V81, P2031
   COIFFIER B, 1994, J CLIN ONCOL, V12, P213
   ELIAS AD, 1992, BLOOD, V79, P3036
   HOHAUS S, 1993, EXP HEMATOL, V21, P508
   JUTTNER CA, 1988, TRANSPLANT P, V20, P40
   KERSINGER A, 1993, BLOOD, V71, P723
   KORBLING M, 1990, J CLIN ONCOL, V8, P978
   LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P28
   MAHARAJ D, 1993, BLOOD, V82, pA83
   METCALF D, 1986, BLOOD, V67, P257
   NICHOL JL, 1994, STEM CELLS, V12, P494, DOI 10.1002/stem.5530120505
   SHERIDAN WP, 1992, LANCET, V339, P640, DOI 10.1016/0140-6736(92)90795-5
   SHERIDAN WP, 1994, BONE MARROW TRANSPL, V14, P105
   TO LB, 1992, BONE MARROW TRANSPL, V9, P277
NR 15
TC 1
Z9 1
U1 0
U2 0
PU STOCKTON PRESS
PI BASINGSTOKE
PA HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS
SN 0887-6924
J9 LEUKEMIA
JI Leukemia
PD OCT
PY 1995
VL 9
SU 1
BP S113
EP S117
PG 5
WC Oncology; Hematology
SC Oncology; Hematology
GA TE568
UT WOS:A1995TE56800026
PM 7475301
DA 2020-11-30
ER

PT J
AU MAHARAJ, D
   LEWISXIMENEZ, L
   RILEY, R
   ALBARRACION, C
   GOMEZ, O
   ONEILL, JG
AF MAHARAJ, D
   LEWISXIMENEZ, L
   RILEY, R
   ALBARRACION, C
   GOMEZ, O
   ONEILL, JG
TI SERUM G-CSF LEVELS IN PATIENTS UNDERGOING G-CSF CHEMOTHERAPY MOBILIZED
   PERIPHERAL STEM-CELL HARVEST
SO BLOOD
LA English
DT Meeting Abstract
C1 UNIV MIAMI,SCH MED,MIAMI,FL 33152.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 15
PY 1994
VL 84
IS 10
SU 1
BP A349
EP A349
PG 1
WC Hematology
SC Hematology
GA PR754
UT WOS:A1994PR75401376
DA 2020-11-30
ER

EF